<!DOCTYPE html>
<html class="">

<head>
   <meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
   <title>Pulmonary embolism - Treatment algorithm | BMJ Best Practice</title>
   <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
   <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
   <meta name="description"
      content="Pulmonary embolism (PE) is a life-threatening condition resulting from dislodged thrombi occluding the pulmonary vasculature; right heart failure and cardiac arrest may ensue if not aggressively treated. Symptoms include chest pain, dyspnoea, and a sense of apprehension. Haemoptysis and syncope a...">
   <!-- Optimize Page Hiding Snippet -->
   <!-- <style>.async-hide
         { opacity: 0 !important}
      </style>
      <script async="" src="../js/adrum-ext.0086dbec5e8a6e717bf36d3a06b62042.js"></script><script src="../js/414393182248444" async=""></script><script async="" src="../js/fbevents.js"></script><script type="text/javascript" async="" src="../js/analytics.js"></script><script async="" src="../js/get-loader.js"></script><script type="text/javascript" async="" src="../js/insight.min.js"></script><script type="text/javascript" async="" src="../js/js"></script><script type="text/javascript" async="" src="../js/uwt.js"></script><script type="text/javascript" async="" src="../js/4896.js"></script><script type="text/javascript" async="" src="../js/analytics.js"></script><script async="" src="../js/gtm.js"></script><script>(function(a,s,y,n,c,h,i,d,e){s.className+=' '+y;h.start=1*new Date; h.end=i=function()
         {s.className=s.className.replace(RegExp(' ?'+y),'')}
         ; (a[n]=a[n]||[]).hide=h;setTimeout(function()
         
         {i();h.end=null}
         ,c);h.timeout=c;})(window,document.documentElement,'async-hide','dataLayer',3000,
         
         {'GTM-K3TZ3JV':true}
         );
      </script> -->
   <!-- end Optimize Page Hiding Snippet -->
   <!-- Google Tag Manager -->
   <!-- <script>
         /*<![CDATA[*/
         
          
         window.dataLayer = window.dataLayer || [];
         window.dataLayer.push({
                    'icsId': null,
                    'pi_icsId': "id82087",
                    'pi_icsName': "BMJ Group (Online access from BMA House)",
                    'access_rights': true,
                    'ics_groupings': [{"name":"Country Grouping"}],
                    'ics_countryName': "GB and ROW",
                    'siteLanguage': "en-gb",
                    'contentLanguage': "en-gb"
                 });
         		  
         /*]]>*/
            
      </script> -->
   <!-- <script>
         (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
         new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
         j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
         'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
         })(window,document,'script','dataLayer', 'GTM-K3TZ3JV');
      </script> -->
   <!-- End Google Tag Manager -->
   <!-- /* if user in China */ -->
   <link rel="stylesheet" type="text/css" media="screen" href="../css/material.css">
<link rel="stylesheet" type="text/css" media="screen" href="../css/styles.css">
<link rel="stylesheet" type="text/css" media="screen" href="../css/css-to-sass.css">
   <link rel="stylesheet" type="text/css" media="screen" href="../css/external.css">
   <link rel="shortcut icon" href="https://resources.bmj.com/repository/images/favicon.ico">
   
   <!-- TOGGLE  -->
   <script src="https://code.jquery.com/jquery-2.1.1.min.js"></script>
   <link href="../css/bootstrap-toggle.css" rel="stylesheet">
   <script src="../js/bootstrap-toggle.js"></script>   

   <!-- <link rel="canonical" href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm">
      <link rel="alternate" hreflang="uk-ua" href="https://bestpractice.bmj.com/topics/uk-ua/116/treatment-algorithm">
      <link rel="alternate" hreflang="en-ie" href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm">
      <link rel="alternate" hreflang="az-az" href="https://bestpractice.bmj.com/topics/az-az/116/treatment-algorithm">
      <link rel="alternate" hreflang="en-us" href="https://bestpractice.bmj.com/topics/en-us/116/treatment-algorithm">
      <link rel="alternate" hreflang="ru" href="https://bestpractice.bmj.com/topics/ru-ru/116/treatment-algorithm">
      <link rel="alternate" hreflang="pt" href="https://bestpractice.bmj.com/topics/pt-br/116/treatment-algorithm">
      <link rel="alternate" hreflang="ka-ge" href="https://bestpractice.bmj.com/topics/ka-ge/116/treatment-algorithm">
      <link rel="alternate" hreflang="pt-br" href="https://bestpractice.bmj.com/topics/pt-br/116/treatment-algorithm">
      <link rel="alternate" hreflang="en" href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm">
      <link rel="alternate" hreflang="es-es" href="https://bestpractice.bmj.com/topics/es-es/116/treatment-algorithm">
      <link rel="alternate" hreflang="zh-cn" href="https://bestpractice.bmj.com/topics/zh-cn/116/treatment-algorithm">
      <link rel="alternate" hreflang="es" href="https://bestpractice.bmj.com/topics/es-es/116/treatment-algorithm">
      <link rel="alternate" hreflang="zh" href="https://bestpractice.bmj.com/topics/zh-cn/116/treatment-algorithm">
      <link rel="alternate" hreflang="x-default" href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm">
      <link rel="alternate" hreflang="ru-ru" href="https://bestpractice.bmj.com/topics/ru-ru/116/treatment-algorithm">
      <link rel="alternate" hreflang="vi" href="https://bestpractice.bmj.com/topics/vi-vn/116/treatment-algorithm">
      <link rel="alternate" hreflang="uk" href="https://bestpractice.bmj.com/topics/uk-ua/116/treatment-algorithm">
      <link rel="alternate" hreflang="ka" href="https://bestpractice.bmj.com/topics/ka-ge/116/treatment-algorithm">
      <link rel="alternate" hreflang="az" href="https://bestpractice.bmj.com/topics/az-az/116/treatment-algorithm">
      <link rel="alternate" hreflang="vi-vn" href="https://bestpractice.bmj.com/topics/vi-vn/116/treatment-algorithm">
      <link rel="alternate" hreflang="en-gb" href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm"> -->
   <!--[if lte IE 9]>
      <link rel="stylesheet" type="text/css" media="screen" href="/gzip_1791a8687c5480ce19e791d0825e7a6b/css/lte-ie-9.css" >
      <![endif]-->
   <!-- <script>
         /*<![CDATA[*/
           var appdynamics_app_key="AD-AAB-AAF-RGR";
         /*]]>*/
           	window["adrum-app-key"] = appdynamics_app_key;
           	window['adrum-start-time'] = new Date().getTime();
           
      </script>
      <script type="text/javascript" src="../js/appdynamics.js"></script> -->
   <script type="application/ld+json">
      [

         {
            "@context": "http://schema.org",
            "@type": "MedicalCondition"
         }, {
            "isAccessibleForFree": "False",
            "hasPart":

            {
               "@type": "WebPageElement",
               "isAccessibleForFree": "False",
               "cssSelector": ".gpw"
            }
         }
      ]
   </script>
   <style></style>
</head>

<body class="gpw">
   <div role="dialog" aria-live="polite" aria-label="cookieconsent" aria-describedby="cookieconsent:desc"
      class="cc-window cc-banner cc-type-info cc-theme-classic cc-bottom cc-color-override--38786966 cc-invisible"
      style="display: none;">
      <!--googleoff: all--><span id="cookieconsent:desc" class="cc-message">We use cookies to improve our service and to
         tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To
         learn more about how we use cookies, please see our
         <a aria-label="learn more about cookies" role="button" tabindex="0" class="cc-link"
            href="https://www.bmj.com/company/your-privacy/cookies-policy/" target="_blank">cookies policy</a></span>
      <div class="cc-compliance"><a aria-label="dismiss cookie message" role="button" tabindex="0"
            class="cc-btn cc-dismiss">OK!</a></div>
      <!--googleon: all-->
   </div>
   <!-- Google Tag Manager (noscript) -->
   <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-K3TZ3JV" height="0" width="0"
         style="display:none;visibility:hidden"></iframe></noscript>
   <!-- End Google Tag Manager (noscript) -->
   <!-- /* if user in China */ -->
   <header id="header" role="banner">
      <a class="sr-only" href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#sr-content">Skip to
         main content</a>
      <div class="bg-info text-white">
      </div>
      <nav id="globalNav" class="logo-img-mob navbar navbar-toggleable-md">
         <div class="container">
            <a href="https://koba7c.axshare.com/#g=1&p=start_1&c=1" class="mobLogo"><span
                  class="remove"><abbr>BMJ</abbr> Best Practice</span></a>
            <button class="navbar-toggler navbar-toggler-right" type="button" data-toggle="collapse"
               data-target="#navbarNav" aria-controls="navbarNav" aria-expanded="false" aria-label="Toggle navigation">
               <span class="material-icons"></span>
            </button>
            <div id="navbarNav" class="collapse navbar-collapse">
               <ul id="globalNav-ul" class="navbar-nav" role="menubar">
                  <li id="globalNav-access" class="nav-item" role="presentation">
                     <span class="nav-link">
                        Access provided by:
                        BMJ Group (Online access from BMA House)
                     </span>
                  </li>
                  <li id="globalNav-help" class="nav-item dropdown" role="menuitem">
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                        id="navbarDropdownMenuLink02" class="nav-link dropdown-toggle" data-toggle="dropdown"
                        aria-haspopup="true" aria-expanded="false">
                        Help <span class="states">
                           <span class="material-icons"></span>
                           <span class="material-icons"></span>
                        </span>
                     </a>
                     <div id="globalNav-help-options" class="dropdown-menu dropdown-menu-right"
                        aria-labelledby="navbarDropdownMenuLink02">
                        <span class="material-icons"></span>
                        <ul role="menu">
                           <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/getting-started/"
                                 target="_blank">Getting started</a></li>
                           <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/faq/"
                                 target="_blank">FAQs</a></li>
                           <li class="dropdown-item"><a
                                 href="https://bestpractice.bmj.com/info/benefits-features/earn-cme-points/"
                                 target="_blank">About CME/CPD</a></li>
                           <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/contact-us/"
                                 target="_blank">Contact us</a></li>
                        </ul>
                     </div>
                  </li>
                  <li id="globalNav-register" class="nav-item">
                     <a href="https://bestpractice.bmj.com/registration" class="nav-link">Create account</a>
                  </li>
                  <li id="globalNav-login" class="nav-item">
                     <a href="https://bestpractice.bmj.com/login" class="nav-link">Log in</a>
                  </li>
                  <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link"
                        href="https://bestpractice.bmj.com/recent-updates"><span
                           class="icon icon-bp-icons-recent-updates"></span><span>Recent updates</span></a></li>
                  <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link"
                        href="https://bestpractice.bmj.com/specialties"><span
                           class="icon icon-bp-icons-specialties"></span><span>Specialties</span></a></li>
                  <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link"
                        href="https://bestpractice.bmj.com/calculators"><span
                           class="icon icon-bp-icons-calculators"></span><span>Calculators</span></a></li>
                  <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link"
                        href="https://bestpractice.bmj.com/patient-leaflets"><span
                           class="icon icon-bp-icons-patient-leaflets"></span><span>Patient leaflets</span></a></li>
                  <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link"
                        href="https://bestpractice.bmj.com/procedural-videos"><span
                           class="icon icon-bp-icons-procedural-videos"></span><span>Procedural videos</span></a></li>
                  <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link"
                        href="https://bestpractice.bmj.com/evidence"><span
                           class="icon icon-bp-icons-evidence"></span><span>Evidence</span></a></li>
                  <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link"
                        href="https://bestpractice.bmj.com/drugs"><span
                           class="icon icon-bp-icons-drugs"></span><span>Drugs</span></a></li>
               </ul>
            </div>
         </div>
      </nav>
      <div id="mainSearch" class="container">
         <div class="row">
            <div class="col-lg-7">
               <div class="logo-img"><a href="https://koba7c.axshare.com/#g=1&p=start_1&c=1"><span class="remove"><abbr
                           title="British Medical Journal">BMJ</abbr> Best Practice</span></a></div>
            </div>
            <div class="col-lg-5">
               <style type="text/css">
                  #searchBoxWrap .tt-open:before {
                     content: "Recently viewed topics:";
                  }

                  #searchBoxWrap .tt-label-override:before,
                  #searchBoxWrap .tt-suggested:before {
                     content: "Suggested topics:" !important;
                  }
               </style>
               <form id="searchBoxForm" action="https://bestpractice.bmj.com/search" role="search"
                  novalidate="novalidate">
                  <div class="input-group">
                     <div id="searchBoxWrap">
                        <label for="q" class="sr-only">Search</label>
                        <span class="twitter-typeahead" style="position: relative; display: inline-block;">
                           <input id="q" type="text" name="q" placeholder="Search conditions, symptoms..." value=""
                              class="tt-input" autocomplete="off" spellcheck="false" dir="auto"
                              style="position: relative; vertical-align: top;">
                           <pre aria-hidden="true"
                              style="position: absolute; visibility: hidden; white-space: pre; font-family: sans-serif; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; word-spacing: 0px; letter-spacing: 0px; text-indent: 0px; text-rendering: auto; text-transform: none;"></pre>
                           <div class="tt-menu"
                              style="position: absolute; top: 100%; left: 0px; z-index: 100; display: none;">
                              <div class="tt-dataset tt-dataset-0"></div>
                           </div>
                        </span>
                        <button id="mainSearchBtn" type="submit"><span class="material-icons"></span></button>
                     </div>
                  </div>
               </form>
               <script>
                  /*<![CDATA[*/

                  // These are required in completion, see BP-232 -->
                  var searchDefaultLanguageCode = "en-gb";
                  var regionName = "GB and ROW";
                  var regionAvailableLanguagesCodes = [{
                     "id": "1",
                     "code": "en-gb",
                     "displayName": "English"
                  }, {
                     "id": "3",
                     "code": "pt-br",
                     "displayName": "Portugu\u00EAs"
                  }, {
                     "id": "5",
                     "code": "es-es",
                     "displayName": "Espa\u00F1ol"
                  }, {
                     "id": "7",
                     "code": "ru-ru",
                     "displayName": "\u0420\u0443\u0441\u0441\u043A\u0438\u0439"
                  }];
                  var availableLanguages = [];

                  for (i = 0; i < regionAvailableLanguagesCodes.length; i++) {
                     availableLanguages.push(regionAvailableLanguagesCodes[i].code);
                  }
                  /*]]>*/
               </script>
            </div>
         </div>
      </div>
      <nav id="mainNav" class="navbar navbar-toggleable-md" role="navigation">
         <div class="container">
            <div id="mainNavbarNav">
               <ul class="navbar-nav" role="menubar">
                  <li class="nav-item main" role="menuitem"><a class="nav-link"
                        href="https://bestpractice.bmj.com/recent-updates"><span
                           class="icon icon-bp-icons-recent-updates"></span><span>Recent updates</span></a></li>
                  <li class="nav-item main" role="menuitem"><a class="nav-link"
                        href="https://bestpractice.bmj.com/specialties"><span
                           class="icon icon-bp-icons-specialties"></span><span>Specialties</span></a></li>
                  <li class="nav-item main" role="menuitem"><a class="nav-link"
                        href="https://bestpractice.bmj.com/calculators"><span
                           class="icon icon-bp-icons-calculators"></span><span>Calculators</span></a></li>
                  <li class="nav-item main" role="menuitem"><a class="nav-link"
                        href="https://bestpractice.bmj.com/patient-leaflets"><span
                           class="icon icon-bp-icons-patient-leaflets"></span><span>Patient leaflets</span></a></li>
                  <li class="nav-item main" role="menuitem"><a class="nav-link"
                        href="https://bestpractice.bmj.com/procedural-videos"><span
                           class="icon icon-bp-icons-procedural-videos"></span><span>Procedural videos</span></a></li>
                  <li class="nav-item main" role="menuitem"><a class="nav-link"
                        href="https://bestpractice.bmj.com/evidence"><span
                           class="icon icon-bp-icons-evidence"></span><span>Evidence</span></a></li>
                  <li class="nav-item main" role="menuitem"><a class="nav-link"
                        href="https://bestpractice.bmj.com/drugs"><span
                           class="icon icon-bp-icons-drugs"></span><span>Drugs</span></a></li>
               </ul>
            </div>
         </div>
      </nav>
   </header>
   <script type="text/javascript" id="">
      (function () {
         var f = google_tag_manager["GTM-K3TZ3JV"].macro(4),
            b = google_tag_manager["GTM-K3TZ3JV"].macro(5),
            a = function (a, b, d) {
               var e = "",
                  c = new Date;
               d && (c.setTime(c.getTime() + 864E5 * d), e = "; expires\x3d" + c.toGMTString());
               document.cookie = a + "\x3d" + b + e + "; path\x3d/; domain\x3dbmj.com"
            };
         f ? "true" != b && ("justLoggedIn" == b ? a("loggedIn", "true", 2) : a("loggedIn", "justLoggedIn", 2)) : a(
            "loggedIn", "false", 2)
      })();
   </script>
   <main id="tmp" class="container tmp treatment-table more-pops main-container" role="main">
      <script type="text/javascript">
         /*<![CDATA[*/
         var topicId = 116;
         var langCode = "en-gb";
         /*]]>*/
      </script>
      <div id="topicNav" class="container">
         <div class="lang">
            <ul role="menu">
               <li><a href="https://bestpractice.bmj.com/topics/en-gb/116" class="active">English</a></li>
               <li><a href="https://bestpractice.bmj.com/topics/pt-br/116">Português</a></li>
               <li><a href="https://bestpractice.bmj.com/topics/es-es/116">Español</a></li>
               <li><a href="https://bestpractice.bmj.com/topics/ru-ru/116">Русский</a></li>
            </ul>
         </div>
         <div id="topicMenuTopBg" style="height: 110px;"></div>
         <div id="topicMenuTopWrap" style="height: 110px;">
            <div id="topicMenuTop" style="height: 110px;">
               <h1>Pulmonary embolism</h1>
               <div class="pdf-links-nav">
                  <div class="pdf">
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/pdf/116.pdf" target="_blank">
                        <span class="icon icon-bp-icons-pdf-extra-small-on-white"></span> <span>View PDF</span>
                     </a>
                  </div>
               </div>
               <div id="mobileMenu" class="mUp">
                  <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="button">
                     <span><span class="material-icons"></span> Menu</span>
                     <span><span class="material-icons"></span> Close</span>
                  </a>
               </div>
               <ul id="menuLinks" role="menu">
                  <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#smenu-0"
                        aria-owns="menu-0">Overview <span class="material-icons"></span><span
                           class="material-icons"></span></a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#smenu-1"
                        aria-owns="menu-1">Theory <span class="material-icons"></span><span
                           class="material-icons"></span></a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#smenu-2"
                        aria-owns="menu-2">Diagnosis <span class="material-icons"></span><span
                           class="material-icons"></span></a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#smenu-3"
                        aria-owns="menu-3">Management <span class="material-icons"></span><span
                           class="material-icons"></span></a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#smenu-4"
                        aria-owns="menu-4">Follow up <span class="material-icons"></span><span
                           class="material-icons"></span></a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#smenu-5"
                        aria-owns="menu-5">Resources <span class="material-icons"></span><span
                           class="material-icons"></span></a></li>
               </ul>
            </div>
            <div id="como-2" class="card" style="display: none;">
               <div class="card-block">
                  <div class="row">
                     <div class="col-md-2 col-sm-12"> 
                        <span class="material-icons">
                        </span>
                        <b class="copy">omorbidities:</b>
                     </div>
                     
                     <div class="col-md-8 col-sm-12">
                        <div id="comoselected-2"></div>                      
                     </div>
                     <div class="col-md-2 col-sm-12">
                        <button class="btn" data-toggle="modal" data-target="#editComo">Edit</button>  
                        <!-- TOGGLE ON/OFF -->  
                        <div id="StickyToggle" class="como-toggle-on-off hide" style="float:right">
                           <input type="checkbox" checked data-toggle="toggle" data-style="ios" id="toggleSwitch" >                           
                        </div>

                     </div>
                  </div>
                  <!--- row --->

               </div>
            </div>
         </div>
         <div id="topicMenuBottomWrap" style="height: 176px;">
            <nav id="topicMenuBottom" class="mUp" role="navigation" style="height: 176px;">
               <ul id="menus" role="menubar">
                  <li>
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#"
                        class="parent"><span>Overview</span><span class="material-icons"></span><span
                           class="material-icons"></span></a>
                     <ul role="menu" id="menu-0">
                        <li><a href="116_overview_summary.html" id="Summary">Summary</a></li>
                     </ul>
                  </li>
                  <li>
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#"
                        class="parent"><span>Theory</span><span class="material-icons"></span><span
                           class="material-icons"></span></a>
                     <ul role="menu" id="menu-1">
                        <li><a href="116_theory_epidemiology.html" id="Epidemiology">Epidemiology</a></li>
                        <li><a href="116_theory_aetiology.html" id="Aetiology">Aetiology</a></li>
                        <li><a href="116_theory_case_history.html" id="Case history">Case history</a></li>
                     </ul>
                  </li>
                  <li>
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#"
                        class="parent"><span>Diagnosis</span><span class="material-icons"></span><span
                           class="material-icons"></span></a>
                     <ul role="menu" id="menu-2">
                        <li><a href="116_diagnosis_recommendations.html" id="Approach">Recommendations</a></li>
                        <li><a href="116_diagnosis_history-exam.html" id="History and exam">History and exam</a></li>
                        <li><a href="116_diagnosis_investigations.html" id="Investigations">Investigations</a></li>
                        <li><a href="116_diagnosis_differentials.html" id="Differentials">Differentials</a></li>
                        <li><a href="116_diagnosis_criteria.html" id="Criteria">Criteria</a></li>
                     </ul>
                  </li>
                  <li>
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#"
                        class="parent"><span>Management</span><span class="material-icons"></span><span
                           class="material-icons"></span></a>
                     <ul role="menu" id="menu-3">
                        <li><a href="116_management_recommendations.html" id="Approach">Recommendations</a></li>
                        <li><a href="116_management_treatment_algorithm.html" id="Treatment algorithm"
                              class="active">Treatment algorithm</a></li>
                        <li><a href="116_management_emerging.html" id="Emerging">Emerging</a></li>
                        <li><a href="116_management_prevention.html" id="Prevention">Prevention</a></li>
                        <li><a href="116_management_patient_discussions.html" id="Patient discussions">Patient
                              discussions</a></li>
                     </ul>
                  </li>
                  <li>
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#" class="parent"><span>Follow
                           up</span><span class="material-icons"></span><span class="material-icons"></span></a>
                     <ul role="menu" id="menu-4">
                        <li><a href="116_follow_up_monitoring.html" id="Monitoring">Monitoring</a></li>
                        <li><a href="116_follow_up_complications.html" id="Complications">Complications</a></li>
                        <li><a href="116_follow_up_prognosis.html" id="Prognosis">Prognosis</a></li>
                     </ul>
                  </li>
                  <li>
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#"
                        class="parent"><span>Resources</span><span class="material-icons"></span><span
                           class="material-icons"></span></a>
                     <ul role="menu" id="menu-5">
                        <li><a href="116_resources_guidelines.html" id="Guidelines">Guidelines</a></li>
                        <li><a href="116_resources_images_videos.html" id="Images and videos">Images and videos</a></li>
                        <li><a href="116_resources_references.html" id="References">References</a></li>
                        <li><a href="116_resources_patient_leaflets.html" id="Patient leaflets">Patient leaflets</a>
                        </li>
                        <li><a href="116_resources_evidence.html" id="Evidence">Evidence</a></li>
                     </ul>
                  </li>
                  <li class="mpdf"><a href="https://bestpractice.bmj.com/topics/en-gb/116/pdf/116.pdf"
                        target="_blank"><span class="icon icon-bp-icons-pdf-extra-small-on-white"></span> <span>View
                           PDF</span></a></li>
               </ul>
            </nav>
         </div>
      </div>
      <h2 id="sr-content">Treatment algorithm</h2>
      <p class="w-75">Please note that formulations/routes and doses may differ between drug names and brands, drug
         formularies, or locations. Treatment recommendations are specific to patient groups: </p>
      <div id="como-1" class="card">
         <div class="card-block">
            <div class="row">
               
               <div class="col-md-2">  
                  <div class="add-como-icon-and-text">
                     <span class="material-icons"></span>
                     <b class="add" data-toggle="modal" data-target="#editComo">omorbidities</b>
                     <b class="added unchecked">omorbidities</b>
                  </div>
               </div>

               <div class="col-md-9">
                  <div id="comoselected-1">
                     <button class="btn hide" data-toggle="modal" data-target="#editComo">Edit</button>
                  </div>
               </div>
               
               <div class="col-md-1">
                  <!-- TOGGLE ON/OFF -->
                  <div id="StaticToggle" class="como-toggle-on-off hide" style="float:right">
                     <input type="checkbox" checked data-toggle="toggle" data-style="ios" id="toggleSwitch">                           
                  </div>                        
                  
               </div>
            </div>
            <!--- row --->
         </div>
      </div>
      <div id="lookOutPopUp" class="card unchecked">
         <div class="row">
            <div class="col-md-12">

               <button type="button" class="close close-look-out" data-dismiss="modal" aria-label="Close">
                  <span aria-hidden="true" style="color: #333 !important; font-size: 28px;">×</span>
               </button>
               <p>Look out for this icon:
                  <span class="material-icons">
                     <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg"
                        xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30"
                        enable-background="new 0 0 30 30" xml:space="preserve">
                        <g>
                           <g>
                              <path fill="#C50084"
                                 d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                    c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z">
                              </path>
                              <path fill="#C50084"
                                 d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                    c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z">
                              </path>
                              <g>
                                 <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                              </g>
                           </g>
                           <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                 7.707,19.5 7.707,16 11.207,16 	"></polygon>
                        </g>
                     </svg>
                  </span>
                  <span>for treatment options that are affected, or added, as a result of your patient's comorbidities.</span>
                  <button type="button" class="btn btn-secondary showalg close-look-out" data-dismiss="modal" aria-label="Close">Got it</button>
               </p>
               
            </div>
         </div>
         <!--- row --->
      </div>


      <div class="poce_contents treatment-algorithm">

         <div class="card">
               <div class="card-block">
                  <div class="container">
                     <div class="rowHead" id="ongoing">
                        <div class="col-md-12">
                           INITIAL
                        </div>
                     </div>
                     <div class="panel accordion blue-accordion">
                        <div class="panel-heading">
                           <h3>                       
                              <span class="title-04">                                    
                                 <span class="no-icon">PE suspected: haemodynamically unstable (SBP &lt;90) AND/OR hypoxaemic</span>
                              </span>
   
                              <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" id="tab_patientGroup-0" class="view-hide-all" aria-controls="panel_patientGroup-0">
                                 <span class="hidden-sm-down">
                                    <span class="msg">VIEW ALL</span>
                                    <span class="material-icons" role="button"><span></span><span></span></span>
                                 </span>
                              </a>
                           </h3>
                        </div>
                        <!--/.panel-heading -->
                        <div class="panel-body" role="tabpanel" aria-labelledby="tab_1_0_0_initial_content" id="panel_1_0_0_initial_content" aria-expanded="true">
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title">
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                       role="tab header" id="tab_1_0_0" aria-controls="panel_1_0_0" aria-expanded="false">
                                       <span class="titles-wrap col-md-12">
                                          <span class="title-02 no-icon">
                                             <span class="title-03 col-md-1 col-sm-1">
                                                1st line
                                                <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                                <span class="material-icons"><span></span><span></span></span>
                                                <span class="txtwrap no-icon">Respiratory support</span>
                                             </span>
                                             <span class="material-icons">
                                                
                                             </span>
                                          </span>
                                       </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="tab_patientGroup-0 tab_initial_content" id="panel_initial_content panel_patientGroup-0" aria-expanded="false">
                                 <p><strong>Give high-concentration oxygen, targeting a saturation of 94% to 98% (or 88% to
                                       92% in patients at risk of hypercapnic respiratory failure).[BTS02] </strong></p>
                                 <ul>
                                    <li><strong>Assess oxygen saturation early. </strong>Hypoxaemia is a typical finding in
                                       PE; it may be present at rest if a high-risk (massive) PE is present or only on
                                       exertion with a smaller PE.[ESC]</li>
                                    <li><strong>Apply mechanical ventilation if required</strong> but use with caution as
                                       this may worsen haemodynamic instability in a high-risk (massive) PE. Mechanical
                                       ventilation induces positive thoracic pressure which may reduce venous return and
                                       worsen right ventricular (RV) failure. [ESC]</li>
                                 </ul>
                                 <p><strong>Involve senior support and/or critical care in patients who are
                                       haemodynamically unstable.</strong></p>
                                 <ul>
                                    <li>Patients with suspected or confirmed PE who present with<strong> shock or
                                          hypotension are at high risk of in-hospital death</strong>, particularly in
                                       the<strong> first few hours</strong> after presentation. [ESC]</li>
                                 </ul>
                                 <div id="tip_pitfall" class="card card-inverse mb-4">
                                    <div class="card-block">
                                       
                                       <h3 class="card-title"></h3>
                                       <p><strong>Do not allow supportive therapy to delay thrombolysis (as long as there
                                             are no contraindications) - it may quickly restore haemodynamic stability.
                                          </strong></p>
                                       <ul>
                                          <li>It is common practice to give thrombolysis as first-line treatment for any
                                             patient who is in peri-arrest/cardiac arrest based on clinical suspicion of PE
                                             without waiting for results from investigations.</li>
                                          <li>In these situations the decision to thrombolyse would be based on discussion
                                             between senior clinicians.</li>
                                       </ul>
                                    </div>
                                 </div>
   
                                 <div class="evidence-accordion">
                                    <div class="option">
                                       <input type="checkbox" id="toggle1" class="toggle" />
                                       <label class="title" for="toggle1">
                                          <span class="material-icons"><span></span></span>
                                          <span class="title">Evidence: Patients with high-risk PE are at significant risk
                                             of death</span>
                                       </label>
                                       <div class="content">
                                          <ul>
                                             <li><strong>The 30-day mortality rate of patients with haemodynamically
                                                   unstable (high-risk) PE ranges from 16% to 25% and that of patients with
                                                   cardiac arrest due to PE ranges from 52% to 65%</strong>.
                                                [TANABE][KASPER]</li>
                                             <ul>
                                                <li>Most deaths in patients presenting with shock occur within the first
                                                   hour after presentation so rapid therapeutic action is essential to save
                                                   lives. [HENRY]</li>
                                                <li>The International Cooperative Pulmonary Embolism Registry (ICOPER)
                                                   showed 90-day mortality rates of 58.3% in patients with high-risk
                                                   (massive) PE. [GOLD]</li>
                                             </ul>
                                          </ul>
                                       </div>
                                    </div>
                                 </div>
   
   
   
                                 <!-- CONDITIONAL COMO CONTENT -->
                                 <div class="COPD-como-content Asthma-como-content">
                                    <div class="poce_drug_msg">
                                       
                                       <h3 class="poce_title"></h3>
                                       <h3>Oxygen therapy (in COPD)</h3>
                                       <p><strong>Oxygen therapy may be required in patients with COPD who are hypoxic, to
                                             maintain saturations. </strong></p>
                                       <ul>
                                          <li><strong>Measure resting oxygen saturations in all acutely unwell patients.
                                                <em>(O'Driscoll BR, et al, 2017)</em></strong></li>
                                       </ul>
                                       <p><strong>Use the same initial target oxygen saturation of 94% to 98% for a patient
                                             with a critical illness (e.g., shock, sepsis, major trauma) and comorbid COPD
                                             as for patients without COPD, pending the results of arterial blood gas (ABG)
                                             results. </strong><em>(O'Driscoll BR, et al, 2017)</em></p>
                                       <ul>
                                          <li><strong>Subsequently, depending on ABG results, controlled oxygen therapy
                                                with a target oxygen saturation range of 88% to 92% may be needed.
                                             </strong></li>
                                          <li>If the patient is severely hypoxaemic and/or has hypercapnia with respiratory
                                             acidosis, consider ventilation support.</li>
                                       </ul>
                                       <p><strong>Use an initial target oxygen saturation of 88% to 92% in patients with an
                                             acute but not immediately critical medical condition who have comorbid COPD or
                                             other risk factors for hypercapnia and no history of respiratory acidosis.
                                          </strong><em>(O'Driscoll BR, et al, 2017)</em></p>
                                       <ul>
                                          <li><strong>Measure ABG</strong>, and if the <strong>pCO2</strong> is in the
                                             <strong>normal range</strong>, adjust the oxygen saturation <strong>target to
                                                94% to 98%</strong>, unless the patient has a history of hypercapnic
                                             respiratory failure requiring ventilatory support.</li>
                                          <li>Some patients with COPD who are <strong>acidotic</strong>, or who have a
                                             <strong>history of hypercapnic respiratory failure,</strong> or who are
                                             particularly <strong>sensitive to oxygen therapy</strong> may need a
                                             <strong>lower target oxygen saturation range.</strong> Check to see if they
                                             carry an &lsquo;<strong>alert card</strong>&rsquo; which may guide therapy
                                             based on previous blood gas results. <em>(O'Driscoll BR, et al, 2017)</em>
                                          </li>
                                          <li>If there is no alert card to guide therapy, use target oxygen saturations of
                                             <strong>88% to 92% and check arterial blood gases urgently.</strong></li>
                                          <li>Some patients with COPD have a usual <strong>oxygen saturation of &lt;92%
                                                when clinically stable</strong>. Target oxygen saturations in these
                                             patients should be <strong>88% to 92%.</strong></li>
                                       </ul>
                                       <p><strong>Re-check </strong>ABG after 30 to 60 minutes.</p>
                                    </div>
                                 </div>
                                 <!-- CONDITIONAL COMO CONTENT ends-->
   
                              </div>
                              <!--/.panel-body -->
                           </section>
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title">
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_1_0_0" aria-controls="panel_1_0_0" aria-expanded="false">
                                       <span class="titles-wrap col-md-12">
                                          <span class="title-02 no-icon">
                                             <span class="title-03 col-md-1 col-sm-1">
                                                Plus
                                                <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                                <span class="material-icons"><span></span><span></span></span>
                                                <span class="txtwrap no-icon">Fluid resuscitation</span>
                                             </span>
                                             <span class="material-icons">
                                                
                                             </span>
                                          </span>
                                       </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="tab_patientGroup-0 tab_initial_content" id="panel_initial_content panel_patientGroup-0" aria-expanded="false">
                                 <ul>
                                    <li>
                                       <p><strong>Give intravenous fluids if systolic BP is &lt;90 mmHg or there are any
                                             other signs of shock</strong>. [ESC]</p>
                                       <ul>
                                          <li>Give intravenous fluids with <strong>caution </strong>and <strong>start with
                                                a 500 mL</strong> fluid challenge. Determine further fluid based on
                                             clinical response.[ESC]</li>
                                          <li>Use <strong>normal saline (0.9% NaCl) or Hartmann&rsquo;s/Ringer&rsquo;s
                                                lactate</strong>.[NICEF] Guidelines differ in their recommendations on
                                             choice of fluid and clinical practice varies widely so check local protocols.
                                          </li>
                                       </ul>
                                    </li>
                                 </ul>
                                 <!-- CONDITIONAL COMO CONTENT -->
                                 <div class="HeartFailure-como-content CKD-como-content">
                                    <div class="poce_drug_msg">
                                       
                                       <h3 class="poce_title"></h3>
                                       <h3>Assess fluid status and manage fluid balance particularly closely</h3>
                                       <ul>
                                          <li>
                                             <p><strong>Be aware of the difficulties assessing hypotension, low organ
                                                   perfusion and shock in a person with heart failure and/or CKD</strong>
                                             </p>
                                             <ul>
                                                <li>Hypovolaemia may be <strong>difficult to assess</strong> in a person
                                                   with <strong>heart failure</strong> and<strong> CKD</strong>.
                                                   <em>(National Institute for Health and Care Excellence, 2017)</em> It
                                                   may occur if there isvascular permeability, insensible losses, bleeding,
                                                   or with sedatives, analgesics, or positive pressure ventilation.</li>
                                                <li>Establish the patient&rsquo;s<strong> baseline blood pressure</strong>.
                                                   A systolic blood pressure of &lt;90 mmHg may suggest hypotension, but
                                                   note that a patient on <strong>medication for chronic heart failure
                                                   </strong>can have a baseline <strong>systolic blood pressure of &lt;90
                                                      mmHg</strong>.</li>
                                                <li><strong>Fluid resuscitation</strong> is required
                                                   <strong>initially</strong> in patients with <strong>CKD who are
                                                      hypotensive</strong>, particularly if they have signs of
                                                   <strong>shock</strong>. <em>(Verbrugge FH, et al, 2014)</em></li>
                                             </ul>
                                          </li>
                                          <li><strong>Reassess patient</strong> after initial fluid challenge and get
                                             senior input if the patient does not rapidly stabilise. <strong>Consider
                                                transfer</strong> to a more <strong>intensive level of care</strong>.</li>
                                          <li>
                                             <p>Patients with <strong>heart failure </strong>may need fluid resuscitation
                                                but, due to thedifficulty in accurate assessment of volume status and the
                                                <strong>risk of volume overload</strong>, <strong>seek senior
                                                   review</strong>. <strong>Consider transferring</strong> the patient to a
                                                more intensive level of care <strong>before initiating fluid
                                                   resuscitation</strong>.</p>
                                          </li>
                                       </ul>
                                    </div>
                                 </div>
                                 <!-- CONDITIONAL COMO CONTENT ends-->
                                 <p><strong>Monitor closely for signs of right heart failure. [ESC]</strong></p>
                                 <ul>
                                    <li>The <strong>leading cause of death</strong> in patients with high-risk (massive) PE
                                       is <strong>acute right ventricular failure</strong> with resulting hypotension.
                                       [ESC]</li>
                                    <li>Patients with haemodynamically unstable PE require early intravenous fluid
                                       resuscitation but should be monitored for signs of right heart failure.</li>
                                 </ul>
                                 <p><strong>Involve senior support and/or critical care in patients who are
                                       haemodynamically unstable. </strong></p>
   
                                 <div class="evidence-accordion">
                                    <div class="option">
                                       <input type="checkbox" id="toggle2" class="toggle" />
                                       <label class="title" for="toggle2">
                                          <span class="material-icons"><span></span></span>
                                          <span class="title">Evidence: Aggressive volume expansion in patients with
                                             haemodynamically unstable PE is of no benefit and may even worsen RV
                                             function</span>
                                       </label>
                                       <div class="content">
                                          <ul>
                                             <li><strong><em>There is only very scarce and conflicting evidence on the
                                                      balance of risks vs benefits from fluid resuscitation in patients
                                                      with PE who are haemodynamically unstable. </em></strong></li>
                                          </ul>
                                          <ul>
                                             <ul>
                                                <li>One prospective study of 13 patients with high-risk haemodynamically
                                                   unstable PE suggested that fluid loading (an infusion of 500 mL of
                                                   dextran 40 over 20 mins) can improve hemodynamic status. It was shown to
                                                   increase right ventricular preload which was associated with an increase
                                                   in cardiac index without reducing the right ventricular ejection
                                                   fraction. [MERCAT]</li>
                                                <li>In contrast, earlier experimental studies in dogs indicated that
                                                   aggressive volume expansion may be of no benefit and may even worsen RV
                                                   function. They found that when pulmonary vascular resistance was normal,
                                                   volume expansion increased stroke volume (SV) and mean blood pressure
                                                   whereas when RV afterload was increased, this volume expansion resulted
                                                   in RV failure. [GIRLING][TYBERG].</li>
                                             </ul>
                                          </ul>
                                          <p><strong>The 2014 ESC guideline states that evidence to date indicates that
                                                aggressive volume expansion is of no benefit and may even worsen RV
                                                function.</strong> [ESC]</p>
                                       </div>
                                    </div>
                                 </div>
   
                                 <!-- CONDITIONAL COMO CONTENT -->
                                 <div class="HeartFailure-como-content CKD-como-content">
                                    <div class="poce_drug_msg">                                    
                                       <h3 class="poce_title"></h3>
                                       <h3>Continue to monitor fluid balance particularly closely</h3>
                                       <ul>
                                          <li>
                                             <p><strong>Accurate monitoring of volume status is crucial in a person with
                                                   heart failure and/or CKD. </strong><em>(Verbrugge FH, et al, 2014)</em>
                                             </p>
                                             <ul>
                                                <li>There is a risk of <strong>pulmonary oedema</strong> with fluid
                                                   resuscitation in patients with<strong> heart failure</strong> and/or
                                                   <strong>CKD</strong> so these patients need <strong>close
                                                      monitoring</strong> (every hour initially).</li>
                                                <li><strong>Monitoring </strong>should include:</li>
                                                <ul>
                                                   <li>Regular clinical assessment of volume status (including pulse, BP,
                                                      JVP and examination for pulmonary and peripheral oedema)</li>
                                                   <li>Fluid balance monitoring (input/output chart) and daily weight</li>
                                                   <li>Checking kidney function at least daily.</li>
                                                </ul>
                                                <li>Consider urinary catheterisation if measurement of urinary output is
                                                   difficult but be aware of increased risk of infection.</li>
                                                <li>Central venous pressure or pulmonary artery catheterisation monitoring
                                                   may be required in complex patients. <em>(Verbrugge FH, et al,
                                                      2014)</em></li>
                                                <li>It&rsquo;s important to know when to <strong>de-escalate</strong> fluid
                                                   therapy. Consider<strong> early senior input</strong> to support this
                                                   decision.</li>
                                                <li>If the patient has been volume <strong>overloaded with fluid</strong>
                                                   (signs may include an elevated pulse rate, elevated respiratory rate due
                                                   to pulmonary oedema, and a raised JVP with peripheral oedema),
                                                   <strong>stop fluid resuscitation</strong>, ask for <strong>senior help
                                                   </strong>and consider <strong>intravenous diuretics.</strong></li>
                                                <li>Diuretics and intravenous fluids should not usually be given together
                                                   as they&rsquo;re unlikely to be beneficial.</li>
                                             </ul>
                                             <br />
                                             <p><strong>Specialist input may be required from a cardiologist and/or renal
                                                   physician.</strong></p>
                                          </li>
                                       </ul>
                                    </div>
                                 </div>
                                 <!-- CONDITIONAL COMO CONTENT ends-->
   
                              </div>
                              <!--/.panel-body -->
                           </section>
                           <section style="display: none;" class="panel-group HeartFailure-como-content CKD-como-content Stroke-como-content CAD-como-content Hypertension-como-content">
                              <div class="panel-header">
                                 <p class="panel-title">
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                       role="tab header" id="tab_1_0_0" aria-controls="panel_1_0_0" aria-expanded="false">
                                       <span class="titles-wrap col-md-12">
                                          <span class="title-02 no-icon">
                                             <span class="title-03 col-md-1 col-sm-1">
                                                Plus
                                                <span class="noShow">&nbsp;–&nbsp;</span>
                                             </span>
                                             <span class="title-04">
                                                <span class="material-icons"><span></span><span></span></span>
                                                <span class="txtwrap no-icon">Withhold antihypertensives and/or diuretics if hypotensive</span>
                                             </span>
                                             <span class="material-icons">
                                                
                                             </span>
                                          </span>
                                       </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="tab_patientGroup-0 tab_initial_content" id="panel_initial_content panel_patientGroup-0" aria-expanded="false">
   
                                 <!-- CONDITIONAL COMO CONTENT -->
                                 <div
                                    class="HeartFailure-como-content CKD-como-content Stroke-como-content CAD-como-content Hypertension-como-content"
                                    style="display: none;">
                                    <div class="poce_drug_msg">
                                       
                                       <h3 class="poce_title"></h3>
                                       <h3>Continue to monitor fluid balance particularly closely</h3>
                                       <p><strong>Consider withholding antihypertensives and/or diuretics in people with a
                                             history of hypertension, coronary heart disease, heart failure, stroke, or CKD
                                             and who usually take these medications if:</strong></p>
                                       <ul>
                                          <li><strong>The patient is hypotensive with signs of low organ perfusion,
                                                particularly if there are signs of shock. </strong>Signs of low organ
                                             perfusion include: <em>(Ponikowski, 2016)</em></strong>
                                             <ul>
                                                <li>Confusion</li>
                                                <li>Shock</li>
                                                <li>Low urine output</li>
                                             </ul>
                                          </li>
                                          <li><strong>The patient&rsquo;s blood pressure is &ge;40 mmHg lower than
                                                baseline.</strong>
                                             <ul>
                                                <li>Establish the patient&rsquo;s baseline blood pressure and assess volume
                                                   status.</li>
                                                <li>Patients with treated <strong>heart failure</strong> may have<strong>
                                                      chronically low blood pressure</strong> e.g., systolic BP &le;90
                                                   mmHg. In these patients it may be appropriate to withhold these
                                                   medications with a reduction in systolic blood pressure &gt;10-15 mm/Hg,
                                                   depending on the clinical context and after seeking expert review.</li>
                                             </ul>
                                          </li>
                                       </ul>
   
                                       <p>Diuretics may be withheld <strong>temporarily</strong> but<strong> be
                                             careful</strong> in patients with<strong> heart failure</strong> and/or
                                          <strong>CKD</strong> as <strong>fluid may build up quickly</strong>.</p>
                                       <p><strong>If antihypertensives or diuretics have been withheld during the acute
                                             illness, restart them before discharge.</strong></p>
                                       <p>Most patients won&rsquo;t tolerate restarting all medications at normal doses in
                                          one go. Restart one at a time at a lower dose and <strong>ask their GP to follow
                                             up</strong> and titrate back to normal dose.</p>
                                    </div>
                                 </div>
                                 <!-- CONDITIONAL COMO CONTENT ends-->
   
   
                              </div>
                              <!--/.panel-body -->
                           </section>
                        </div>
                        <!--/.panel-body -->
                     </div>
   
                     <!-- /.panel-group -->
                  </div>
               </div>
         </div>

         <div class="card">
            <div class="card-block">
               <div class="container">
                  <div class="rowHead" id="acute">
                     <div class="col-md-12">
                        ACUTE
                     </div>
                  </div>
                  <div class="panel bg-line">
                     <div class="panel-heading">
                        <h3>                          
                           <span class="title-04">                                 
                              <span class="no-icon">Haemodynamically unstable: PE confirmed (on echocardiography or CTPA)</span>
                           </span>

                           <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" id="tab_patientGroup-0-0" class="view-hide-all" aria-controls="panel_patientGroup-0-0">
                              <span class="hidden-sm-down">
                                 <span class="msg">VIEW ALL</span>
                                 <span class="material-icons" role="button"><span></span><span></span></span>
                              </span>
                           </a>
                        </h3>
                     </div>
                     <!--/.panel-heading -->
                     <div class="panel-body" role="tabpanel" aria-labelledby="tab_1_0_0_acute_content" id="panel_1_0_0_acute_content" aria-expanded="true">

                        <section class="panel-group">
                           <div class="panel-header child-accordion">
                              <p class="panel-title">                                 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_1_0_0_acute1" aria-controls="panel_1_0_0_acute1" aria-expanded="false">
                                    <span class="title-04">
                                       <span class="material-icons"><span></span><span></span></span>
                                       <span class="title-01">
                                          <span>
                                             No contraindication to anticoagulation or thrombolysis
                                          </span>
                                       </span>
                                    </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content child-accordion col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3 tab_1_0_0_acute1 tab_patientGroup-0-0" id="nested-collapse_0_0_3 panel_1_0_0_acute1 panel_patientGroup-0-0" aria-expanded="false" style="display: none;">
                              
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="#" role="tab header" id="nested-collapse_0_0_3"
                                          aria-controls="nested-collapse_0_0_3" aria-expanded="false" class="">
                                       
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   1st line
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Start unfractionated heparin</span>
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3 tab_patientGroup-0-0" id="nested-collapse_0_0_3 panel_patientGroup-0-0" aria-expanded="false" style="display: none;">

                                    <p><strong>Involve senior support and/or critical care in patients who are
                                          haemodynamically unstable (SBP &lt;90 mmHg or SBP drop of &ge;40 mmHg for &gt;15
                                          minutes).</strong></p>
                                    <p><strong>Start unfractionated heparin (UFH) in haemodynamically unstable patients prior
                                          to thrombolysis.</strong></p>
                                    <ul>
                                       <li>UFH has a short half-life, is easy to monitor, and is readily reversed by
                                          protamine. [ESC]</li>
                                    </ul>
                                    <div id="tip_pitfall" class="card card-inverse mb-4">
                                       <div class="card-block">
                                          
                                          <h3 class="card-title">In patients who are haemodynamically unstable, evidence of RV
                                             dysfunction on echocardiography is sufficient to warrant immediate
                                             anticoagulation and thrombolysis.</h3>
                                          <ul>
                                             <li>These patients are normally too unstable to undergo CTPA.</li>
                                          </ul>
                                       </div>
                                    </div>

                                    <p><strong>Continue anticoagulation with UFH for several hours after the end of
                                          thrombolysis</strong>.[ESC] In the UK it is common practice to stop UFH within 24
                                       hours.</p>


                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle3" class="toggle" />
                                          <label class="title" for="toggle3">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: There is insufficient evidence to support use of
                                                LMWH in haemodynamically unstable (high-risk) PE</span>
                                          </label>
                                          <div class="content">
                                             <p><strong>There is some evidence that LMWH has a similar safety profile to UFH
                                                   when used prior to thrombolysis.</strong></p>
                                             <ul>
                                                <li>A prospective, observational multicentre trial showed similar bleeding
                                                   rates following thrombolysis in patients who had UFH or LMWH. However this
                                                   evidence remains limited.</li>
                                                <ul>
                                                   <p><strong>There is not enough evidence to recommend LMWH as a first-line
                                                         option for patients with PE who are haemodynamically
                                                         unstable.</strong> [UCAR]</p>
                                          </div>
                                       </div>
                                    </div>

                                    <div class="treatment-wrap non-como-content show">
                                       <h4>Primary options</h4>
                                       <div class="treatment-box">
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">heparin</a><span>: </span><span>10,000
                                                units intravenously as a loading dose initially, followed by 18
                                                units/kg/hour intravenous infusion, adjust dose according to aPTT</span>
                                          </p>
                                       </div>
                                    </div>
                                    <!-- SWITCHABLE DRUG CONTENT BOX -->
                                    <div class="treatment-box-cplus mt-4 como-content hide">
                                       <h4>Primary options</h4>
                                       <div class="drug-accordion">

                                          <div class="drug-content2" style="display: none">
                                             <div class="poce_drug_msg" class="warning">
                                                <h3 class="cplus_title">These drug options and doses relateto a patient with
                                                   <strong>no comorbidities.</strong></h3>
                                             </div>
                                             <div class="treatment-box">
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">heparin</a><span>: </span><span>10,000
                                                      units intravenously as a loading dose initially, followed by 18
                                                      units/kg/hour intravenous infusion, adjust dose according to aPTT</span>
                                                </p>
                                             </div>
                                             <p class="como_link mt-4 drug-title2"><a href="#">&#9664; Back to drug doeses
                                                   with added comorbidities</a></p>
                                          </div>

                                          <div class="drug-content1">
                                             <div class="poce_drug_msg">
                                                <h3 class="cplus_title">Drug choice, dose and interactions may be affected by
                                                   the patient's comorbidities. Check your local drug formulary.</h3>
                                             </div>
                                             <div class="treatment-box">
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">heparin:</a>
                                                </p>
                                                <p>For patients with renal impairment <a href="#" data-toggle="modal"
                                                      data-target="#renal">see dose in the Renal Drug Handbook</a></p>
                                                <div class="modal fade" id="renal" tabindex="-1" role="dialog"
                                                   aria-labelledby="renal" aria-hidden="true" style="display: none;">
                                                   <div class="modal-dialog" role="document" style="max-width: 50rem;">
                                                      <div class="modal-content">
                                                         <div class="modal-header"
                                                            style="background: #fff; margin-top: 1rem;">
                                                            <h3 class="modal-title" id="exampleModalLabel"
                                                               style="color:#c50084;margin: 0 0 1.5rem 0;text-align: center;">
                                                               The Renal Handbook<br /></h3>
                                                         </div>
                                                         <iframe width="100%" height="700" src="../pdf/renalbook.pdf"
                                                            title="Renal Book"></iframe>
                                                      </div>
                                                   </div>
                                                </div>

                                             </div>
                                             <p class="como_link mt-4 drug-title1"><a href="#">&#9658; Show drug doses for a
                                                   patient with no comorbidities</a></p>
                                          </div>
                                       </div>
                                    </div>
                                    <!-- DRUG CONTENT BOX ENDS -->

                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_0" aria-controls="panel_0_0_0" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02 no-icon">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap ">
                                                      Thrombolysis
                                                   </span>
                                                </span>
                                                <span class="material-icons">
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="tab_0_0_0 tab_patientGroup-0-0" id="panel_0_0_0 panel_patientGroup-0-0" aria-expanded="false">
                                    <p><strong>Emergency primary reperfusion is indicated for any haemodynamically unstable
                                          patient with: [ESC]</strong></p>
                                    <li><strong>PE confirmed on CTPA </strong></li>
                                    <li><strong>Suspected PE and unequivocal signs of RV dysfunction on
                                          echocardiography</strong> (if CTPA is not immediately available and/or the patient
                                       is too unwell to undergo CTPA).</li>
                                    <li><strong>Thrombolysis is the first-line intervention for most patients.
                                       </strong>Surgical embolectomy or catheter-directed therapy are alternatives. [ESC]</li>
                                    <p><strong>Administer thrombolysis (unless contraindicated) to any patient with SBP &lt;90
                                          mmHg or who has other signs of shock. </strong></p>
                                    <ul>
                                       <li>Systemic thrombolysis is associated with <strong>lower all-cause mortality</strong>
                                          in these patients when compared with UFH alone. [ESC] [CARDIO]</li>
                                    </ul>
                                    <p><strong>Give thrombolysis as soon as possible and certainly within 48 hours of symptom
                                          onset to ensure optimum benefit.</strong> [ESC]</p>
                                    <p><strong>Select an accelerated regimen administered over 2 hours.</strong></p>
                                    <p>These regimens are preferred to prolonged infusions over 12-24 hours. The European
                                       Society of Cardiology guideline recommends <strong>alteplase, streptokinase, and
                                          urokinase </strong>as approved thrombolytics for acute PE. [ESC] Alteplase and
                                       higher-dose streptokinase are administered over 2 hours; whereas, lower-dose
                                       streptokinase and urokinase are administered over 12 to 24 hours.</p>

                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle4" class="toggle" />
                                          <label class="title" for="toggle4">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: Most patients with high-risk PE respond to early
                                                thrombolysis</span>
                                          </label>
                                          <div class="content">
                                             <p><strong>Thrombolysis in the treatment of acute haemodynamically unstable PE
                                                   has been shown to restore pulmonary perfusion more rapidly than
                                                   anticoagulation with UFH alone.</strong></p>
                                             <ul>
                                                <li>An RCT of 36 patients concluded that use of alteplase, compared with
                                                   heparin, resulted in a greater and faster improvement of angiographic and
                                                   hemodynamic variables. However, the high frequency of bleeding observed
                                                   with alteplase in this trial suggests that patients should be carefully
                                                   selected before thrombolytic therapy is given. [PENGO]</li>
                                             </ul>
                                             <p><strong>Overall, &gt;90% of patients appear to respond favourably to
                                                   thrombolysis</strong>.</p>
                                             <ul>
                                                <li>This was demonstrated in a prospective single-centre registry of 488 PE
                                                   patients who underwent thrombolysis as judged by clinical and
                                                   echocardiographic improvement within 36 hours. [BLONDE]</li>
                                                <li>Among the minority of patients with high-risk PE who did not respond to
                                                   thrombolysis, rescue surgical embolectomy led to lower mortality rates and
                                                   fewer recurrent PEs when compared with repeat thrombolysis.</li>
                                             </ul>
                                             <p><strong>Thrombolysis has greatest benefit when given early after symptom
                                                   onset.</strong></p>
                                             <ul>
                                                <li>An overview of 308 PE patients from 5 clinical trials who underwent
                                                   thrombolysis for PE showed an inverse relation between duration of symptoms
                                                   and improvement on post-treatment lung scan reperfusion scores. For each
                                                   additional day of symptoms before thrombolysis, there was a decrease of
                                                   0.8% in lung tissue reperfusion. Similarly, on angiography, less clot lysis
                                                   was observed immediately after thrombolysis in the group with the longest
                                                   duration of symptoms compared with those with the shortest symptom
                                                   duration.</li>
                                                <li>However the authors concluded that thrombolysis may still have some
                                                   benefit in patients who have had symptoms for 6 to 14 days. [AM]</li>
                                             </ul>
                                          </div>
                                       </div>
                                    </div>

                                    <div id="tip_pitfall" class="card card-inverse mb-4">
                                       <div class="card-block">
                                          
                                          <h3 class="card-title">Seek haematology advice if a patient with high-risk PE who is
                                             haemodynamically unstable has any contraindications to thrombolysis.</h3>
                                          <ul>
                                             <li>In practice, almost any contraindication to thrombolysis should be considered
                                                only relative in high-risk patients who present with haemodynamic instability.
                                             </li>
                                             <li>This is because the mortality risk from high-risk PE is so high that it is
                                                likely to outweigh any bleeding risk from thrombolysis in this patient group.
                                                [ESC]</li>
                                          </ul>
                                          <p><strong>Absolute contraindications: [ESC]</strong></p>
                                          <ul>
                                             <li>haemorrhagic stroke or stroke of unknown origin at any time</li>
                                             <li>ischaemic stroke in the preceding 6 months</li>
                                             <li>central nervous system damage or neoplasms</li>
                                             <li>recent major trauma/surgery/head injury (in the preceding 3 weeks)</li>
                                             <li>gastrointestinal bleeding within the last month</li>
                                             <li>known bleeding risk.</li>
                                          </ul>
                                          <p><strong>Relative contraindications:</strong></p>
                                          <ul>
                                             <li>transient ischaemic attack in the preceding 6 months</li>
                                             <li>oral anticoagulant therapy</li>
                                             <li>pregnancy or within 1 week postnatally</li>
                                             <li>traumatic resuscitation (in relation to this episode of PE)</li>
                                             <li>refractory hypertension (SBP &gt;180 mmHg)</li>
                                             <li>advanced liver disease</li>
                                             <li>infective endocarditis</li>
                                             <li>active peptic ulcer</li>
                                          </ul>
                                       </div>
                                    </div>

                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle5" class="toggle" />
                                          <label class="title" for="toggle5">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: Thrombolysis carries a significant risk of major
                                                bleeding, including intracranial bleeding</span>
                                          </label>
                                          <div class="content">
                                             <ul>
                                                <li>Analysis of pooled data from trials using various thrombolytic agents and
                                                   regimens reported intracranial bleeding rates between 1.9% and 2.2%.
                                                   [PARKER][CALIFF]</li>
                                                <li>Increasing age and the presence of comorbidities have been associated with
                                                   a higher risk of bleeding complications.[MIKKOLA]</li>
                                                <li>The PEITHO trial showed a 2% incidence of haemorrhagic stroke after
                                                   thrombolytic treatment with tenecteplase (versus 0.2% in the placebo arm)
                                                   in patients with intermediate-high-risk PE. Major non-intracranial bleeding
                                                   events were also increased in the tenecteplase group, compared with placebo
                                                   (6.3% vs. 1.5%; <em>P &lt;</em> 0.001). [VICAUT] Note that tenecteplase is
                                                   not licensed for use in PE.</li>
                                                <li>These results underline the need to improve the safety of thrombolytic
                                                   treatment in patients at increased risk of intracranial or other
                                                   life-threatening bleeding.</li>
                                                <li>A strategy using reduced-dose alteplase appeared to be safe in the setting
                                                   of &lsquo;moderate&rsquo; PE in a study that included 121
                                                   patients,[SHARIFI] and another trial on 118 patients with haemodynamic
                                                   instability or &lsquo;massive pulmonary obstruction&rsquo; reported similar
                                                   results. [WU]</li>
                                                <li>An alternative approach may consist of local, catheter-delivered,
                                                   ultrasound-assisted thrombolysis using small doses of a thrombolytic agent.
                                                   [ESC]</li>
                                             </ul>
                                          </div>
                                       </div>
                                    </div>
                                    <p><strong>Do not give routine thrombolysis to patients who have SBP &gt;90 mmHg but have
                                          significant evidence of cardiopulmonary deterioration</strong>. [ESC] [SPRINGER]</p>
                                    <ul>
                                       <li><strong>Routine thrombolysis is not recommended in most major guidelines for this
                                             intermediate-risk group even if signs of both right ventricular dysfunction and
                                             myocardial injury (positive cardiac biomarkers) are initially present.</strong>
                                       </li>
                                       <li>In these patients, use of systemic thrombolysis is associated with a
                                          <strong>mortality benefit</strong> but it significantly <strong>increases the risk
                                             of bleeding</strong>, including intracranial haemorrhage. [CARDIO]</li>
                                       <li>Patients in this intermediate risk group should receive anticoagulation and be
                                          monitored closely over at least 48 to 72 hours. Rescue thrombolysis should be
                                          considered if there are clinical signs of haemodynamic decompensation and the
                                          benefits/risks of thrombolysis have been weighed up by a specialist after taking
                                          account of the patient&rsquo;s comorbidities. [KONST][ESC][CHEST]</li>
                                    </ul>


                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle6" class="toggle" />
                                          <label class="title" for="toggle6">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence does not support the routine use of thrombolysis in
                                                patients with intermediate-risk PE</span>
                                          </label>
                                          <div class="content">
                                             <p>Current European guidelines do not recommend giving thrombolysis routinely in
                                                patients with intermediate-risk PE. Evidence suggests it carries an
                                                unacceptably high bleeding risk in this group.</p>
                                             <p><strong>Current European guidelines do not recommend giving thrombolysis
                                                   routinely in patients with intermediate-risk PE. Evidence suggests it
                                                   carries an unacceptably high bleeding risk in this group.
                                                </strong>[ESC][CHEST] .</p>
                                             <ul>
                                                <li>The intermediate-risk group is defined by a PESI score of III-V or an
                                                   sPESI score &ge;1. (see Risk Stratification below)</li>
                                                <li>The international PEITHO (Pulmonary Embolism Thrombolysis) trial compared
                                                   a single intravenous bolus of tenecteplase plus heparin with placebo plus
                                                   heparin in 1,006 patients with confirmed PE, right ventricular dysfunction
                                                   detected by echocardiography or CT, and a positive troponin I or T test.
                                                </li>
                                                <li>In the thrombolysis group, haemodynamic decompensation/collapse or death
                                                   within 7 days occurred less frequently than in the group receiving heparin
                                                   alone.</li>
                                                <li>However, in the thrombolysis group compared with the placebo group, there
                                                   was also a higher incidence of haemorrhagic stroke (2.0% vs 0.2%) and major
                                                   non-intracranial bleeding (6.3% vs 1.5%).</li>
                                             </ul>
                                          </div>
                                       </div>
                                    </div>

                                    <div class="treatment-wrap non-como-content show">
                                       <h4>Primary options</h4>
                                       <div class="treatment-box">
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">alteplase: </a>
                                             <span>10 mg intravenous bolus over 1-2 minutes, followed by 90 mg intravenous
                                                infusion over 2 hours, maximum 1.5 mg/kg/total dose in patients &lt;65 kg body
                                                weight</span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">streptokinase: </a>
                                             <span>1,500,000 units by intravenous infusion over 1-2 hours; or 250,000 units by
                                                intravenous infusion over 30 minutes, followed by 100,000 units/hour for 24
                                                hours</span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">urokinase: </a>
                                             <span>4400 units/kg by intravenous infusion over 10-20 minutes, followed by 4400
                                                units/kg/hour for 12 hours</span>
                                          </p>
                                       </div>
                                    </div>

                                    <!-- SWITCHABLE DRUG CONTENT BOX -->
                                    <div class="treatment-box-cplus mt-4 como-content hide">
                                          <h4>Primary options</h4>

                                          <div class="drug-accordion">
         
                                             <div class="drug-content2" style="display: none">
                                                <div class="poce_drug_msg" class="warning">
                                                   <h3 class="cplus_title">These drug options and doses relateto a patient with
                                                      <strong>no comorbidities.</strong></h3>
                                                </div>
                                                <div class="treatment-box">                                             
                                                   <p>
                                                      <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                         data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                         data-original-title="" title="">alteplase: </a>
                                                      <span>10 mg intravenous bolus over 1-2 minutes, followed by 90 mg intravenous
                                                         infusion over 2 hours, maximum 1.5 mg/kg/total dose in patients &lt;65 kg body
                                                         weight</span>
                                                   </p>
                                                   <p class="small-or">OR</p>
                                                   <p>
                                                      <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                         data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                         data-original-title="" title="">streptokinase:</a>
                                                      <span>1,500,000 units by intravenous infusion over 1-2 hours; or 250,000 units by
                                                         intravenous infusion over 30 minutes, followed by 100,000 units/hour for 24
                                                         hours</span>
                                                   </p>
                                                   <p class="small-or">OR</p>
                                                   <p>
                                                      <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                         data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                         data-original-title="" title="">urokinase: </a>
                                                      <span>4400 units/kg by intravenous infusion over 10-20 minutes, followed by 4400
                                                         units/kg/hour for 12 hours</span>
                                                   </p>
                                                </div>
                                                <p class="como_link mt-4 drug-title2"><a href="#">&#9664; Back to drug doeses with added comorbidities</a></p>
                                             </div>
         
                                             <div class="drug-content1">
                                                <div class="poce_drug_msg">
                                                   <h3 class="cplus_title">Drug choice, dose and interactions may be affected by
                                                      the patient's comorbidities. Check your local drug formulary.</h3>
                                                </div>
                                                <div class="treatment-box">                                          
                                                      <p>
                                                         <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                            data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                            data-original-title="" title="">alteplase:</a>
                                                         
                                                      </p>
                                                      <p class="small-or">OR</p>
                                                      <p>
                                                         <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                            data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                            data-original-title="" title="">streptokinase:</a>
                                                      </p>
                                                      <p class="small-or">OR</p>
                                                      <p>
                                                         <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                            data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                            data-original-title="" title="">urokinase: </a>
                                                      </p>
                                                   </div>
                                                   <p>For patients with renal impairment <a href="#" data-toggle="modal" data-target="#renal">see dose in the Renal Drug Handbook</a></p>
                                                   <div class="modal fade" id="renal" tabindex="-1" role="dialog" aria-labelledby="renal" aria-hidden="true" style="display: none;">
                                                      <div class="modal-dialog" role="document">
                                                         <div class="modal-content">
                                                            <div class="modal-header">
                                                               <h3 class="modal-title" id="exampleModalLabel">
                                                                  The Renal Handbook<br /></h3>
                                                            </div>
                                                            <iframe width="100%" height="700" src="../pdf/renalbook.pdf" title="Renal Book"></iframe>
                                                         </div>
                                                      </div>
                                                   </div>
                                                   <p class="como_link mt-4 drug-title1"><a href="#">&#9658; Show drug doses for a patient with no comorbidities</a></p>
                                             </div>
                                                
                                          </div>
                                    </div>
                                       <!-- DRUG CONTENT BOX ENDS -->
                                 </div>
                              </section>
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_1" aria-controls="panel_0_0_1" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02 no-icon">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Switch to alternative anticoagulant</span>
                                                </span>
                                                <span class="material-icons">
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="tab_0_0_1 tab_patientGroup-0-0" id="panel_0_0_1 panel_patientGroup-0-0" aria-expanded="false">

                                    <p><strong>Continue anticoagulation with UFH for several hours after the end of
                                          thrombolysis before switching to a low molecular weight heparin (LMWH),
                                          fondaparinux, apixaban, or rivaroxaban</strong>.[ESC] In the UK it is common
                                       practice to stop UFH within 24 hours.</p>
                                    <ul>
                                       <li><strong>If switching to LMWH (e.g,. dalteparin, enoxaparin) or fondaparinux, the
                                             total duration of treatment with UFH and then LMWH or fondaparinux should be at
                                             least 5 days.</strong>[NICE][ESC]</li>
                                       <ul>
                                          <li>If ongoing anticoagulation will be with warfarin, ensure overlap with UFH, LMWH,
                                             or fondaparinux for at least 5 days or until the INR is &ge;2 for at least 24
                                             hours (whichever is the longer).[NICE] Seek specialist advice to decide when to
                                             start warfarin.</li>
                                       </ul>
                                    </ul>
                                    <p><strong>OR</strong></p>
                                    <ul>
                                       <ul>
                                          <li>If ongoing anticoagulation will be with edoxaban or dabigatran, at least 5 days
                                             of lead-in therapy with LMWH or fondaparinux is required first. Stop the LMWH or
                                             fondaparinux before starting dabigatran or edoxaban.[BTS]</li>
                                       </ul>
                                       <li><strong>If switching to rivaroxaban or apixaban, these drugs may be started after
                                             stopping UFH without the need for lead-in therapy with LMWH or fondaparinux
                                             first</strong>.</li>
                                       <ul>
                                          <li>Acute-phase treatment consists of an increased dose of the oral anticoagulant
                                             over the first 3 weeks (for rivaroxaban), or over the first 7 days (for
                                             apixaban).</li>
                                       </ul>
                                    </ul>
                                    <p><strong>Seek specialist advice when switching between anticoagulants</strong></p>
                                    <ul>
                                       <li>The protocol depends on which anticoagulant you are switching to and from.
                                          Haematology input is important.</li>
                                    </ul>
                                    <p><br /><strong>Be aware of special patient groups such as pregnancy, renal impairment,
                                          and active cancer</strong> as these groups will need a specific type/dose of
                                       anticoagulant. <strong>Seek haematology advice for all patients with hepatic impairment
                                          or who are at increased risk of bleeding.</strong></p>

                                    <div id="tip_pitfall" class="card card-inverse mb-4">
                                       <div class="card-block">
                                          
                                          <h3 class="card-title">Never give a DOAC simultaneously with parenteral
                                             anticoagulation</h3>
                                          <ul>
                                             <li>While warfarin is started at the same time as a parenteral anticoagulant and
                                                overlapped for at least 5 days or until the INR is &ge;2 for at least 24 hours
                                                (whichever is the longer), DOACs should never be overlapped or given at the
                                                same time as a parenteral anticoagulant.</li>
                                             <li>Apixaban and rivaroxaban may be started without the need for lead-in therapy
                                                with a parenteral anticoagulant first. Either of these DOACs can be used as a
                                                single-drug approach; this is why BTS guidelines recommend them as the
                                                preferred DOAC options in any patient who might be suitable for early
                                                discharge. [BTS]</li>
                                             <li>However, dabigatran and edoxaban require at least 5 days lead-in therapy with
                                                a parenteral anticoagulant before starting treatment. The parenteral
                                                anticoagulant should be stopped before dabigatran or edoxaban are started.
                                             </li>
                                          </ul>
                                       </div>
                                    </div>

                                    <div class="treatment-wrap non-como-content show">
                                       <h4>Primary options</h4>
                                       <div class="treatment-box">
                                          <p><strong>[No special considerations]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">apixaban</a>
                                             <span>: </span>
                                             <span>10 mg orally twice daily for 7 days, followed by 5 mg twice daily</span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p><strong>[No special considerations]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">rivaroxaban:</a>
                                             <span>: </span>
                                             <span>15 mg orally twice daily for 21 days, followed by 20 mg once daily</span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p><strong>[No special considerations]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">enoxaparin</a>
                                             <span>: </span>
                                             <span>1 mg/kg subcutaneously every 12 hours</span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">dalteparin</a>
                                             <span>: </span>
                                             <span>100 units/kg subcutaneously every 12 hours</span>
                                          </p>
                                          <p class="small-or">AND</p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">warfarin</a>
                                             <span>: </span>
                                             <span>5-10 mg orally once daily initially, adjust dose according to target
                                                INR</span>
                                          </p>
                                          <span class="reference">
                                             <a href="#referencePop-more8" data-trigger="click focus" data-toggle="popover"
                                                class="morePop" data-original-title="" title=""
                                                aria-describedby="popover621629">More</a>
                                             <span class="popTitle" aria-hidden="true"></span>
                                             <span class="popText" aria-hidden="true">
                                                <p class="w-75">
                                                   Starting dose can be calculated using an online tool that takes patient
                                                   characteristics and/or CYP2C9/VKORC1 genotype information (if available)
                                                   into account. [ONLINE RESOURCE: Warfarin dosing
                                                   http://www.warfarindosing.org/Source/Home.aspx]
                                                </p>
                                             </span>
                                          </span>
                                          <p class="small-or">OR</p>
                                          <p><strong>[No special considerations]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">enoxaparin</a>
                                             <span>: </span>
                                             <span>1 mg/kg subcutaneously every 12 hours</span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p><strong>[No special considerations]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">dalteparin</a>
                                             <span>: </span>
                                             <span>200 units/kg subcutaneously once daily for the first 30 days, followed by
                                                150 units/kg once daily for 5 months, maximum 18,000 units/dose</span>
                                          </p>
                                          <span class="reference">
                                             <a href="#referencePop-more1" data-trigger="click focus" data-toggle="popover"
                                                class="morePop" data-original-title="" title=""
                                                aria-describedby="popover621629">More</a>
                                             <span class="popTitle" aria-hidden="true"></span>
                                             <span class="popText" aria-hidden="true">
                                                <p class="w-75">Refer to local drug formulary for a table of recommended
                                                   weight-based doses. Use fixed-dose syringes for this indication.</p>
                                             </span>
                                          </span>
                                          <p class="small-or">OR</p>
                                          <p><strong>[No special considerations]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">enoxaparin</a>
                                             <span>: </span>
                                             <span>body weight &lt;50 kg: 40 mg subcutaneously twice daily; body weight 50-69
                                                kg: 60 mg subcutaneously twice daily; body weight 70-89 kg: 80 mg
                                                subcutaneously twice daily; body weight ≥90 kg: 100 mg subcutaneously twice
                                                daily </span>
                                          </p>

                                          <span class="reference">
                                             <a href="#referencePop-more2" data-trigger="click focus" data-toggle="popover"
                                                class="morePop" data-original-title="" title=""
                                                aria-describedby="popover621629">More</a>
                                             <span class="popTitle" aria-hidden="true"></span>
                                             <span class="popText" aria-hidden="true">
                                                <p class="w-75">Dose based on early pregnancy body weight.</p>
                                             </span>
                                          </span>
                                          <p class="small-or">OR</p>
                                          <p><strong>[No special considerations]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">dalteparin</a>
                                             <span>: </span>
                                             <span>body weight &lt;50 kg: 5000 units subcutaneously twice daily; body weight
                                                50-69 kg: 6000 units subcutaneously twice daily; body weight 70-89 kg: 8000
                                                units subcutaneously twice daily; body weight ≥90 kg: 10,000 units
                                                subcutaneously twice daily </span>
                                          </p>
                                          <span class="reference">
                                             <a href="#referencePop-more3" data-trigger="click focus" data-toggle="popover"
                                                class="morePop" data-original-title="" title=""
                                                aria-describedby="popover621629">More</a>
                                             <span class="popTitle" aria-hidden="true">
                                             </span>
                                             <span class="popText" aria-hidden="true">
                                                <p class="w-75">Dose based on early pregnancy body weight.</p>
                                             </span>
                                          </span>
                                          <h4>Secondary options</h4>
                                          <p><strong>[No special considerations]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">fondaparinux</a>
                                             <span>: </span>
                                             <span>body weight &lt;50 kg: 5 mg subcutaneously once daily; body weight 50-100
                                                kg: 7.5 mg subcutaneously once daily; body weight ≥100 kg: 10 mg
                                                subcutaneously once daily
                                             </span>
                                          </p>
                                          <span class="reference">
                                             <a href="#referencePop-more4" data-trigger="click focus" data-toggle="popover"
                                                class="morePop" data-original-title="" title=""
                                                aria-describedby="popover621629">More</a>
                                             <span class="popTitle" aria-hidden="true">
                                             </span>
                                             <span class="popText" aria-hidden="true">
                                                <p class="w-75">Dose based on early pregnancy body weight.</p>
                                             </span>
                                          </span>
                                          <p class="small-or">AND</p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">warfarin</a>
                                             <span>: </span>
                                             <span>5-10 mg orally once daily initially, adjust dose according to target
                                                INR</span>
                                          </p>
                                          <span class="reference">
                                             <a href="#referencePop-more5" data-trigger="click focus" data-toggle="popover"
                                                class="morePop" data-original-title="" title=""
                                                aria-describedby="popover621629">More</a>
                                             <span class="popTitle" aria-hidden="true">
                                             </span>
                                             <span class="popText" aria-hidden="true">
                                                <p class="w-75">Starting dose can be calculated using an online tool that
                                                   takes patient characteristics and/or CYP2C9/VKORC1 genotype information (if
                                                   available) into account. [ONLINE RESOURCE: Warfarin dosing
                                                   http://www.warfarindosing.org/Source/Home.aspx]
                                                </p>
                                             </span>
                                          </span>
                                          <p class="small-or">OR</p>
                                          <p><strong>[No special considerations]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">edoxaban</a>
                                             <span>: </span>
                                             <span>start following initial use of a parenteral anticoagulant for at least 5
                                                days; body weight &lt;60 kg: 30 mg orally once daily; body weight ≥60 kg: 60
                                                mg orally once daily</span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p><strong>[No special considerations]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">dabigatran</a>
                                             <span>: </span>
                                             <span>start following initial use of a parenteral anticoagulant for at least 5
                                                days; 18-74 years of age: 150 mg orally twice daily; 75-79 years of age:
                                                110-150 mg orally twice daily; ≥80 years of age: 110 mg orally twice
                                                daily</span>
                                          </p>
                                       </div>
                                    </div>
                                    
                                    <!-- SWITCHABLE DRUG CONTENT BOX -->
                                    <div class="treatment-box-cplus mt-4 como-content hide">
                                       <h4>Primary options</h4>
                                       <div class="drug-accordion">

                                          <div class="drug-content2" style="display: none">
                                             <div class="poce_drug_msg" class="warning">
                                                <h3 class="cplus_title">These drug options and doses relateto a patient with
                                                   <strong>no comorbidities.</strong></h3>
                                             </div>
                                             <div class="treatment-box">
                                                <p><strong>[No special considerations]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">apixaban: </a>
                                                   <span>10 mg orally twice daily for 7 days, followed by 5 mg twice daily</span>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p><strong>[No special considerations]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">rivaroxaban:</a>
                                                   <span>: </span>
                                                   <span>15 mg orally twice daily for 21 days, followed by 20 mg once daily</span>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p><strong>[No special considerations]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">enoxaparin: </a>
                                                   <span>1 mg/kg subcutaneously every 12 hours</span>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dalteparin: </a>
                                                   <span>100 units/kg subcutaneously every 12 hours</span>
                                                </p>
                                                <p class="small-or">AND</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">warfarin</a>
                                                   <span>: </span>
                                                   <span>5-10 mg orally once daily initially, adjust dose according to target
                                                      INR</span>
                                                </p>
                                                <span class="reference">
                                                   <a href="#referencePop-more8" data-trigger="click focus" data-toggle="popover"
                                                      class="morePop" data-original-title="" title=""
                                                      aria-describedby="popover621629">More</a>
                                                   <span class="popTitle" aria-hidden="true"></span>
                                                   <span class="popText" aria-hidden="true">
                                                      <p class="w-75">
                                                         Starting dose can be calculated using an online tool that takes patient
                                                         characteristics and/or CYP2C9/VKORC1 genotype information (if available)
                                                         into account. [ONLINE RESOURCE: Warfarin dosing
                                                         http://www.warfarindosing.org/Source/Home.aspx]
                                                      </p>
                                                   </span>
                                                </span>
                                                <p class="small-or">OR</p>
                                                <p><strong>[No special considerations]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">enoxaparin: </a>
                                                   <span>1 mg/kg subcutaneously every 12 hours</span>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p><strong>[No special considerations]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dalteparin: </a>
                                                   <span>200 units/kg subcutaneously once daily for the first 30 days, followed by
                                                      150 units/kg once daily for 5 months, maximum 18,000 units/dose</span>
                                                </p>
                                                <span class="reference">
                                                   <a href="#referencePop-more1" data-trigger="click focus" data-toggle="popover"
                                                      class="morePop" data-original-title="" title=""
                                                      aria-describedby="popover621629">More</a>
                                                   <span class="popTitle" aria-hidden="true"></span>
                                                   <span class="popText" aria-hidden="true">
                                                      <p class="w-75">Refer to local drug formulary for a table of recommended
                                                         weight-based doses. Use fixed-dose syringes for this indication.</p>
                                                   </span>
                                                </span>
                                                <p class="small-or">OR</p>
                                                <p><strong>[No special considerations]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">enoxaparin: </a>
                                                   <span>body weight &lt;50 kg: 40 mg subcutaneously twice daily; body weight 50-69
                                                      kg: 60 mg subcutaneously twice daily; body weight 70-89 kg: 80 mg
                                                      subcutaneously twice daily; body weight ≥90 kg: 100 mg subcutaneously twice
                                                      daily </span>
                                                </p>
            
                                                <span class="reference">
                                                   <a href="#referencePop-more2" data-trigger="click focus" data-toggle="popover"
                                                      class="morePop" data-original-title="" title=""
                                                      aria-describedby="popover621629">More</a>
                                                   <span class="popTitle" aria-hidden="true"></span>
                                                   <span class="popText" aria-hidden="true">
                                                      <p class="w-75">Dose based on early pregnancy body weight.</p>
                                                   </span>
                                                </span>
                                                <p class="small-or">OR</p>
                                                <p><strong>[No special considerations]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dalteparin: </a>
                                                   <span>body weight &lt;50 kg: 5000 units subcutaneously twice daily; body weight
                                                      50-69 kg: 6000 units subcutaneously twice daily; body weight 70-89 kg: 8000
                                                      units subcutaneously twice daily; body weight ≥90 kg: 10,000 units
                                                      subcutaneously twice daily </span>
                                                </p>
                                                <span class="reference">
                                                   <a href="#referencePop-more3" data-trigger="click focus" data-toggle="popover"
                                                      class="morePop" data-original-title="" title=""
                                                      aria-describedby="popover621629">More</a>
                                                   <span class="popTitle" aria-hidden="true">
                                                   </span>
                                                   <span class="popText" aria-hidden="true">
                                                      <p class="w-75">Dose based on early pregnancy body weight.</p>
                                                   </span>
                                                </span>
                                                <h4>Secondary options</h4>
                                                <p><strong>[No special considerations]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">fondaparinux: </a>
                                                   <span>body weight &lt;50 kg: 5 mg subcutaneously once daily; body weight 50-100
                                                      kg: 7.5 mg subcutaneously once daily; body weight ≥100 kg: 10 mg
                                                      subcutaneously once daily
                                                   </span>
                                                </p>
                                                <span class="reference">
                                                   <a href="#referencePop-more4" data-trigger="click focus" data-toggle="popover"
                                                      class="morePop" data-original-title="" title=""
                                                      aria-describedby="popover621629">More</a>
                                                   <span class="popTitle" aria-hidden="true">
                                                   </span>
                                                   <span class="popText" aria-hidden="true">
                                                      <p class="w-75">Dose based on early pregnancy body weight.</p>
                                                   </span>
                                                </span>
                                                <p class="small-or">AND</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">warfarin: </a>
                                                   <span>5-10 mg orally once daily initially, adjust dose according to target
                                                      INR</span>
                                                </p>
                                                <span class="reference">
                                                   <a href="#referencePop-more5" data-trigger="click focus" data-toggle="popover"
                                                      class="morePop" data-original-title="" title=""
                                                      aria-describedby="popover621629">More</a>
                                                   <span class="popTitle" aria-hidden="true">
                                                   </span>
                                                   <span class="popText" aria-hidden="true">
                                                      <p class="w-75">Starting dose can be calculated using an online tool that
                                                         takes patient characteristics and/or CYP2C9/VKORC1 genotype information (if
                                                         available) into account. [ONLINE RESOURCE: Warfarin dosing
                                                         http://www.warfarindosing.org/Source/Home.aspx]
                                                      </p>
                                                   </span>
                                                </span>
                                                <p class="small-or">OR</p>
                                                <p><strong>[No special considerations]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">edoxaban: </a>
                                                   <span>start following initial use of a parenteral anticoagulant for at least 5
                                                      days; body weight &lt;60 kg: 30 mg orally once daily; body weight ≥60 kg: 60
                                                      mg orally once daily</span>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p><strong>[No special considerations]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dabigatran: </a>
                                                   <span>start following initial use of a parenteral anticoagulant for at least 5
                                                      days; 18-74 years of age: 150 mg orally twice daily; 75-79 years of age:
                                                      110-150 mg orally twice daily; ≥80 years of age: 110 mg orally twice
                                                      daily</span>
                                                </p>
                                                
                                             </div>
                                             <p class="como_link mt-4 drug-title2"><a href="#">&#9664; Back to drug doeses with added comorbidities</a></p>
                                          </div>

                                          <div class="drug-content1">
                                             <div class="poce_drug_msg">
                                                <h3 class="cplus_title">Drug choice, dose and interactions may be affected by
                                                   the patient's comorbidities. Check your local drug formulary.</h3>
                                             </div>
                                             <div class="treatment-box">
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">apixaban: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">rivaroxaban: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">enoxaparin: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dalteparin: </a>
                                                </p>
                                                <p class="small-or">AND</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">warfarin: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">enoxaparin: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dalteparin: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">enoxaparin: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dalteparin: </a>
                                                </p>
                                                <h4>Secondary options</h4>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">fondaparinux:</a>
                                                </p>
                                                <p class="small-or">AND</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">warfarin: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">edoxaban: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dabigatran: </a>
                                                </p>
                                             </div>
                                             <p>For patients with renal impairment <a href="#" data-toggle="modal" data-target="#renal">see dose in the Renal Drug Handbook</a></p>
                                             <div class="modal fade" id="renal" tabindex="-1" role="dialog" aria-labelledby="renal" aria-hidden="true" style="display: none;">
                                                <div class="modal-dialog" role="document">
                                                   <div class="modal-content">
                                                      <div class="modal-header">
                                                         <h3 class="modal-title" id="exampleModalLabel">
                                                            The Renal Handbook<br /></h3>
                                                      </div>
                                                      <iframe width="100%" height="700" src="../pdf/renalbook.pdf" title="Renal Book"></iframe>
                                                   </div>
                                                </div>
                                             </div>
                                             <p class="como_link mt-4 drug-title1"><a href="#">&#9658; Show drug doses for a patient with no comorbidities</a></p>
                                          </div>                                       
                                       </div>
                                    </div>
                                    <!-- DRUG CONTENT BOX ENDS -->


                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_2" aria-controls="panel_0_0_2" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02 no-icon">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Consider
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">
                                                      Vasoactive drug
                                                   </span>
                                                </span>
                                                <span class="material-icons">
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="tab_0_0_2 tab_patientGroup-0-0" id="panel_0_0_2 panel_patientGroup-0-0" aria-expanded="false">
                                    <!--  Consider/PLUS DISCLAIMER -->
                                    <p><strong>Give a vasopressor such as adrenaline (epinephrine) or noradrenaline
                                          (norepinephrine), or an inotrope such as dobutamine if SBP remains &lt;90 mmHg after
                                          thrombolysis </strong>[ESC]</p>
                                    <ul>
                                       <li>In haemodynamically unstable patients, use of a vasopressor or inotrope is often
                                          needed in parallel with reperfusion. [ESC]</li>
                                    </ul>


                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle7" class="toggle" />
                                          <label class="title" for="toggle7">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: Choice of vasopressor is based on limited
                                                evidence</span>
                                          </label>
                                          <div class="content">
                                             <p><strong>Adrenaline combines the beneficial properties of noradrenaline
                                                   (vasoconstriction with increased right ventricular perfusion, positive
                                                   inotropy) and dobutamine (positive inotropy), but without the vasodilatory
                                                   effects associated with the latter.</strong> [ESC]</p>
                                             <ul>
                                                <li>A small prospective descriptive study of patients with RV failure and
                                                   shock demonstrated that during adrenaline infusion, mean arterial pressure
                                                   (MAP), cardiac index (CI) and stroke volume index (SVI) were increased and
                                                   right ventricular ejection fraction (RVEF) improved as well.</li>
                                                <li>Another small study showed that adrenaline improved cardiac output in
                                                   patients with shock without having a detrimental effect on pulmonary
                                                   vascular resistance. [BARRINGTON]</li>
                                             </ul>
                                             <p><strong>Evidence suggests that noradrenaline appears to improve RV function
                                                   through its inotropic effect, as well as improving coronary perfusion by
                                                   raising systemic pressure.</strong></p>
                                             <ul>
                                                <li>However, noradrenaline increases pulmonary vascular resistance and, in
                                                   fact, no conclusive data are available regarding its potential use in PE.
                                                   [PREWITT]</li>
                                             </ul>
                                             <p><strong>The use of dobutamine and/or dopamine may be considered for patients
                                                   with PE, low cardiac index, and normal BP based on the results of some
                                                   studies.</strong></p>
                                             <ul>
                                                <li>Dobutamine enhances contractility with an increase in stroke volume and
                                                   cardiac output. However, raising the cardiac index above physiological
                                                   values may aggravate the ventilation&ndash;perfusion mismatch by further
                                                   redistributing ﬂow from (partly) obstructed to unobstructed vessels.
                                                   [DIS][ESC]</li>
                                             </ul>
                                          </div>
                                       </div>
                                    </div>

                                    <div class="treatment-wrap non-como-content show">
                                       <h4>Primary options</h4>
                                       <div class="treatment-box">
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">adrenaline (epinephrine): </a>
                                             <span>2-10 micrograms/minute by intravenous infusion initially, adjust dose
                                                according to response</span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">noradrenaline (norepinephrine): </a>
                                             <span> 0.4 to 0.8 mg/hour by intravenous infusion initially, adjust dose
                                                according to response</span>
                                          </p>
                                          <span class="reference">
                                             <a href="#referencePop-more6" data-trigger="click focus" data-toggle="popover"
                                                class="morePop" data-original-title="" title=""
                                                aria-describedby="popover621629">More</a>
                                             <span class="popTitle" aria-hidden="true"></span>
                                             <span class="popText" aria-hidden="true">
                                                <p class="w-75">
                                                   Dose refers to noradrenaline base.
                                                </p>
                                             </span>
                                          </span>
                                          <p class="small-or">OR</p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">dobutamine: </a>
                                             <span>2.5 to 10 micrograms/kg/minute by intravenous infusion initially, adjust
                                                dose according to response, maximum 40 micrograms/kg/minute</span>
                                          </p>
                                       </div>
                                    </div>
                                    
                                    <!-- SWITCHABLE DRUG CONTENT BOX -->
                                    <div class="treatment-box-cplus mt-4 como-content hide">
                                       <h4>Primary options</h4>
                                       <div class="drug-accordion">

                                          <div class="drug-content2" style="display: none">
                                             <div class="poce_drug_msg" class="warning">
                                                <h3 class="cplus_title">These drug options and doses relateto a patient with
                                                   <strong>no comorbidities.</strong></h3>
                                             </div>
                                             <div class="treatment-box">                                             
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">adrenaline (epinephrine): </a>
                                                   <span>2-10 micrograms/minute by intravenous infusion initially, adjust dose
                                                      according to response</span>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">noradrenaline (norepinephrine): </a>
                                                   <span> 0.4 to 0.8 mg/hour by intravenous infusion initially, adjust dose
                                                      according to response</span>
                                                </p>
                                                <span class="reference">
                                                   <a href="#referencePop-more6" data-trigger="click focus" data-toggle="popover"
                                                      class="morePop" data-original-title="" title=""
                                                      aria-describedby="popover621629">More</a>
                                                   <span class="popTitle" aria-hidden="true"></span>
                                                   <span class="popText" aria-hidden="true">
                                                      <p class="w-75">
                                                         Dose refers to noradrenaline base.
                                                      </p>
                                                   </span>
                                                </span>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dobutamine: </a>
                                                   <span>2.5 to 10 micrograms/kg/minute by intravenous infusion initially, adjust
                                                      dose according to response, maximum 40 micrograms/kg/minute</span>
                                                </p>
                                             </div>
                                             <p class="como_link mt-4 drug-title2"><a href="#">&#9664; Back to drug doeses with added comorbidities</a></p>
                                          </div>

                                          <div class="drug-content1">
                                             <div class="poce_drug_msg">
                                                <h3 class="cplus_title">Drug choice, dose and interactions may be affected by
                                                   the patient's comorbidities. Check your local drug formulary.</h3>
                                             </div>
                                             <div class="treatment-box">                                               
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">adrenaline (epinephrine): </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">noradrenaline (norepinephrine): </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dobutamine: </a>
                                                </p>
                                             </div>
                                                <p>For patients with renal impairment <a href="#" data-toggle="modal" data-target="#renal">see dose in the Renal Drug Handbook</a></p>
                                                <div class="modal fade" id="renal" tabindex="-1" role="dialog" aria-labelledby="renal" aria-hidden="true" style="display: none;">
                                                   <div class="modal-dialog" role="document">
                                                      <div class="modal-content">
                                                         <div class="modal-header">
                                                            <h3 class="modal-title" id="exampleModalLabel">
                                                               The Renal Handbook<br /></h3>
                                                         </div>
                                                         <iframe width="100%" height="700" src="../pdf/renalbook.pdf" title="Renal Book"></iframe>
                                                      </div>
                                                   </div>
                                                </div>
                                                <p class="como_link mt-4 drug-title1"><a href="#">&#9658; Show drug doses for a patient with no comorbidities</a></p>
                                          </div>
                                             
                                          </div>
                                    </div>
                                       <!-- DRUG CONTENT BOX ENDS -->

                                 </div>
                                    <!--/.panel-body -->
                              </section>
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02 no-icon">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Consider
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Surgical embolectomy/percutaneous catheter-directed
                                                      treatment</span>
                                                </span>
                                                <span class="material-icons">
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="tab_0_0_3 tab_patientGroup-0-0"  id="panel_0_0_3 panel_patientGroup-0-0" aria-expanded="false">
                                    <p><strong>If thrombolysis has failed the use of these interventions will depend on local
                                          expertise and availability.</strong></p>
                                    <p><strong>According to the European Society of Cardiology guidelines [ESC] [CTS],
                                          surgical embolectomy or percutaneous catheter-directed therapy may be indicated in
                                          the following circumstances: </strong></p>
                                    <ul>
                                       <li>Patients who are unable to receive thrombolytic therapy because of bleeding risk
                                       </li>
                                       <li>Insufficient time for effective systemic thrombolysis</li>
                                       <li>Failed thrombolysis</li>
                                    </ul>
                                    <p><strong>Surgical pulmonary embolectomy</strong></p>
                                    <ul>
                                       <li>Although this is rarely performed in the UK, the ESC guideline states that is
                                          technically a relatively simple operation although in practice it is normally only
                                          undertaken in specialist cardiothoracic centres. [ESC]</li>
                                    </ul>
                                    <p><strong>Catheter-directed therapy</strong></p>
                                    <ul>
                                       <li>Catheter-directed therapy uses a lower dose of thrombolytic drug (approximately one
                                          third of full-dose systemic thrombolysis) and is believed to reduce the risks of
                                          bleeding at remote sites(e.g. Intracranial or gastrointestinal). [KEARON]</li>
                                       <li>For patients with absolute contraindications to thrombolysis, interventional
                                          options include: [ESC]</li>
                                       <ul>
                                          <li>thrombus fragmentation with pigtail or balloon catheter,</li>
                                          <li>rheolytic thrombectomy with hydrodynamic catheter devices,</li>
                                          <li>suction thrombectomy with aspiration catheters</li>
                                          <li>rotational thrombectomy.</li>
                                       </ul>
                                       <li>For patients with relative contraindications to thrombolysis, interventional
                                          options include:[ESC]</li>
                                       <ul>
                                          <li>catheter-directed thrombolysis</li>
                                          <li>pharmacomechanical thrombolysis</li>
                                       </ul>
                                    </ul>

                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle8" class="toggle" />
                                          <label class="title" for="toggle8">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: Surgical pulmonary embolectomy and
                                                catheter-directed therapy outcomes</span>
                                          </label>
                                          <div class="content">
                                             <p><strong>There is no comparative data to guide the primary management of
                                                   patients with high-risk (massive) PE and a strong contraindication to
                                                   systemic thrombolysis and therefore management will depend on local options
                                                   and expertise</strong>.</p>
                                             <ul>
                                                <li>However, some small studies have looked at outcomes from surgical
                                                   pulmonary embolectomy and catheter-directed therapy.</li>
                                                <li>Mortality rates following pulmonary embolectomy range from 4% to 27%.
                                                   [FUKUDA] In a small cohort of patients who underwent surgical pulmonary
                                                   embolectomy for acute high-risk (massive) pulmonary thromboembolism, the
                                                   10-year survival rate was 84%. [FUKUI]</li>
                                                <li>A meta-analysis of non-randomised trials of catheter-directed therapies
                                                   reported a clinical success rate of 87% with an associated risk of major
                                                   and minor complications of 2% and 8%, respectively [KUO],</li>
                                                <li>The extent of early RV recovery after low-dose catheter-directed
                                                   thrombolysis appears comparable to that after standard-dose systemic
                                                   thrombolysis whereas anticoagulation with heparin alone has little effect
                                                   on improvement of RV size and performance within the first 24&ndash;48
                                                   hours.</li>
                                                <li>In a randomized, controlled clinical trial of 59 intermediate-risk
                                                   patients, when compared with treatment by heparin alone, catheter-directed
                                                   ultrasound-accelerated thrombolysis&mdash;administering 10 mg alteplase per
                                                   treated lung over 15 hours&mdash;significantly reduced the subannular RV/LV
                                                   dimension ratio between baseline and 24-hour follow-up without an increase
                                                   in bleeding complications [TIEDE] [BOLUS][KUCHER]</li>
                                             </ul>
                                          </div>
                                       </div>
                                    </div>

                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02 no-icon">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Review diabetes medication (NEVER stop insulin in
                                                      people with type 1 diabetes)</span>
                                                </span>
                                                <span class="material-icons">
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="tab_0_0_3 tab_patientGroup-0-0" id="panel_0_0_3 panel_patientGroup-0-0" aria-expanded="false">
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="Diabetes-como-content" style="display: block;">
                                       <div class="poce_drug_msg">
                                          <h3 class="poce_title"></h3>

                                          <p><strong>Never stop insulin in people with type 1 diabetes coming into hospital -
                                                insulin deficiency can rapidly precipitate ketoacidosis, particularly during
                                                illness. </strong></p>
                                          <ul>
                                             <li><strong>Always continue basal insulins</strong> (long-acting or background
                                                insulins e.g., determir or glargine) as this will <strong>prevent
                                                   ketoacidosis</strong> if doses of rapid-acting insulin are inadvertently
                                                missed or delayed.</li>
                                             <li><strong>Dose adjustments</strong> up or down may be needed.</li>
                                             <ul>
                                                <li>For example, in the<strong> absence of significant hyperglycaemia
                                                   </strong>consider <strong>reducing the evening basal insulin by 20% on
                                                      admission</strong>, as most patients will have a <strong>smaller evening
                                                      meal in hospital</strong> compared with at home.</li>
                                             </ul>
                                          </ul>
                                          <p><strong>If a variable rate intravenous insulin infusion (VRIII) is
                                                started</strong>:</p>
                                          <ul>
                                             <li><strong>Continue the basal insulin </strong><em>(Joint British Diabetes
                                                   Societies for inpatient care [JBDS-IP], 2014)</em> as this will reduce the
                                                risk of ketosis in the advent of the VRIII being <strong>accidentally
                                                   interrupted </strong>(e.g., by cannula displacement or blockage) or
                                                <strong>switched off </strong>(e.g., during transfer to another ward or
                                                department)<strong>.</strong></li>
                                             <li>The patient&rsquo;s usual <strong>rapid-acting </strong>and <strong>mixed
                                                   insulins</strong> can be <strong>stopped while on a VRIII</strong>.
                                                <em>Joint British Diabetes Societies for inpatient care [JBDS-IP], 2014)</em>
                                             </li>
                                             <li>Use the VRIII for as <strong>short a time as possible</strong>, <em>(Joint
                                                   British Diabetes Societies for inpatient care [JBDS-IP], 2014) </em>as
                                                incorrect use and insufficient monitoring can result in<strong> severe
                                                   hypoglycaemia</strong> or<strong> ketoacidosis</strong>.</li>
                                          </ul>
                                          <p><strong>Indications for a VRIII include</strong>: <em>(Joint British Diabetes
                                                Societies for inpatient care [JBDS-IP], 2014)</em></p>
                                          <ul>
                                             <li>Patients with diabetes or hospital-related hyperglycaemia who
                                                <strong>can&rsquo;t take oral food or fluid </strong>and where it&rsquo;s
                                                <strong>not possible to adjust their insulin regimen</strong>, e.g., when:
                                             </li>
                                             <ul>
                                                <li>Vomiting</li>
                                                <li>Nil by mouth and patient will miss more than one meal</li>
                                                <li>There is severe illness with a need to achieve good glycaemic control
                                                   (such as with sepsis).</li>
                                             </ul>
                                             <li>Most patients with diabetes <strong>requiring emergency surgery</strong>.
                                                <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2016)</em>
                                             </li>
                                             <li><strong>Special circumstances</strong>, such as hyperglycaemia with
                                                <strong>acute coronary syndrome</strong>, when <strong>pregnant</strong>, or
                                                when receiving <strong>TPN or enteral feeding</strong>, or <strong>taking
                                                   corticosteroids</strong>. <em>(Joint British Diabetes Societies for
                                                   inpatient care., 2012) </em></li>
                                             <ul>
                                                <li><strong>Get specialist advice</strong> from the <strong>diabetes
                                                      team</strong> in these circumstances.</li>
                                             </ul>
                                          </ul>
                                          <p><strong>People with type 2 diabetes on basal insulin should continue to take it,
                                                unless otherwise indicated</strong>.</p>
                                          <ul>
                                             <li>In the <strong>absence of significant hyperglycaemia</strong> consider
                                                <strong>reducing the evening basal insulin</strong> by <strong>20% on
                                                   admission</strong>, as most patients will have a <strong>smaller evening
                                                   meal in hospital </strong>compared with at home.</li>
                                          </ul>
                                          <p>Give<strong> oral hypoglycaemic</strong> medication<strong> with food</strong> to
                                             reduce the<strong> risk of hypoglycaemia</strong>.</p>
                                          <ul>
                                             <li><strong>Never give oral hypoglycaemic medication at bedtime </strong>and
                                                consider <strong>reducing the evening dose of sulphonylurea</strong>.</li>
                                             <ul>
                                                <li>This is because most patients have a <strong>smaller evening meal in
                                                      hospital </strong>compared with their usual evening meal at home.</li>
                                             </ul>
                                          </ul>
                                          <p><strong>Withhold metformin in patients:</strong></p>
                                          <ul>
                                             <li>With <strong>contraindications</strong>, such as <strong>significant renal
                                                   impairment</strong> (&lt;30 mL/minute/1.73 m2)</li>
                                             <li>With <strong>metabolic acidosis </strong>(including lactic acidosis and DKA)
                                             </li>
                                             <li>At<strong> risk of lactic acidosis</strong> with metformin, such as:</li>
                                             <ul>
                                                <li>With conditions associated with <strong>acute kidney injury
                                                   </strong>or<strong> tissue hypoxia,</strong> including<strong>
                                                      dehydration</strong></li>
                                                <li>With <strong>renal impairment</strong>and who have, or are to be
                                                   <strong>fasted for a prolonged period</strong> or who are due to have
                                                   a<strong> radio-opaque contrast injection</strong> as part of an imaging
                                                   procedure. <strong>Follow local protocols </strong>for guidance on the
                                                   specific eGFR levels indicating renal impairment for this to be applied.
                                                </li>
                                             </ul>
                                          </ul>
                                          <p><strong>Be aware that withholding metformin results in hyperglycemia</strong>.
                                          </p>
                                          <ul>
                                             <li>If your patient is taking <strong>other glucose-lowering medication</strong>,
                                                these may need to be<strong> increased in dose</strong> or an
                                                <strong>alternative hypoglycaemic medication to metformin</strong> prescribed.
                                             </li>
                                             <li>Some patients may need <strong>insulin as a temporary measure</strong>,
                                                but<strong> seek diabetes inpatient specialist team advice</strong>.</li>
                                          </ul>
                                          <p><strong>Stop sodium-glucose cotransporter-2 (SGLT-2) inhibitors in all acutely
                                                ill patients, particularly if dehydrated or with infection, as they are at
                                                risk of euglycaemic ketoacidosis.</strong></p>
                                          <ul>
                                             <li>SGLT-2 inhibitors (e.g., dapagliflozin) <strong>reduce blood glucose
                                                   reabsorption</strong> in the kidneys (independently of insulin metabolism
                                                of glucose). <em>(Peters AL, et al, 2015) </em></li>
                                             <li>They can<strong> mask underlying ketoacidosis</strong> by patients having a
                                                normal (or near normal) serum glucose level <strong>(euglycaemic
                                                   ketoacidosis)</strong>.</li>
                                             <li>Check <strong>blood ketones</strong> as urinary ketone measurement may be
                                                unreliable.</li>
                                             <li><strong>Treat for DKA</strong> if <strong>blood ketone level is &ge;3
                                                   mmol/L</strong>, blood<strong> pH &lt;7.3</strong> and <strong>bicarbonate
                                                   &lt;15 mmol/L</strong>. (<em>JBDS-IP, 2013)</em></li>
                                          </ul>
                                          <p><strong>Reduce or omit the dose of gliclazide if the patient has impaired kidney
                                                function or is eating less than usual, to avoid hypoglycaemia at night.
                                             </strong></p>
                                          <p><strong>Inform the diabetic inpatient team of the admission of any patient with
                                                diabetes. They are available for advice and support.</strong></p>
                                          <p><strong>For a patient at the end of life</strong>: <em>(Rowles S, et al
                                                2011)</em></p>
                                          <ul>
                                             <li><strong>Hypoglycaemic medication</strong> should be <strong>reduced
                                                </strong>to the minimum, <strong>but</strong></li>
                                             <li>The patient should be<strong> kept free from symptomatic
                                                   hyperglycaemia</strong>, which can lead to <strong>dehydration</strong>,
                                                <strong>ketosis</strong> or <strong>hyperosmolar hyperglycaemia</strong>.</li>
                                          </ul>
                                          <p>Refer to <strong>local protocols </strong>or the Association of British Clinical
                                             Diabetologists (ABCD). <em>(Rowles S, et al 2011)</em></p>


                                       </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02 no-icon">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Monitor and manage blood glucose</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="tab_0_0_3 tab_patientGroup-0-0" id="panel_0_0_3 panel_patientGroup-0-0" aria-expanded="false">
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="Diabetes-como-content" style="display: block;">
                                       <div class="poce_drug_msg">
                                          <h3 class="poce_title"></h3>
                                          <p><strong>Monitor blood glucose levels at least 4 times a day (pre-meal and before
                                                bedtime if eating) in all acutely unwell patients with diabetes mellitus
                                                (</strong><em>American Diabetes Association, 2019)</em></p>
                                          <ul>
                                             <li>The risk of<strong> hypo- and hyperglycaemia</strong> increases when people
                                                with diabetes are admitted to hospital with acute conditions. <em>(NHS
                                                   Digital. National Diabetes Inpatient Audit (NaDIA) - 2017, 2018)</em></li>
                                             <li><strong>More frequent monitoring</strong> is needed after <strong>episodes of
                                                   hyperglycaemia</strong> or <strong>hypoglycaemia</strong>.</li>
                                             <li>More <strong>frequent monitoring</strong> is needed after a <strong>change in
                                                   hypoglycaemic medication</strong>.</li>
                                             <li>Patients on a<strong> variable rate intravenous insulin infusion
                                                   (VRIII)</strong> need <strong>capillary blood glucose measurements every
                                                   hour</strong>. <em>(Joint British Diabetes Societies for inpatient care
                                                   [JBDS-IP], 2014)</em></li>
                                             <li>Support <strong>self-management</strong> (including monitoring blood glucose)
                                                if this conforms to local protocols, it is safe to do so, and the patient is
                                                willing. <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP],
                                                   2012) </em></li>
                                          </ul>
                                          <p><strong>Prevent and manage hyperglycaemia if it occurs</strong></p>
                                          <ul>
                                             <li>There is <strong>no consensus on target blood glucose</strong> levels for
                                                people with diabetes in hospital.</li>
                                             <li><strong>The Joint British Diabetes Societies for Inpatient Care</strong>
                                                (JBDS-IP) recommend an<strong> ideal range</strong> of between<strong> 6 to 10
                                                   mmol/L</strong>, and an <strong>acceptable range</strong> of <strong>4 to
                                                   12 mmol/L</strong><em>(JBDS-IP, 2014)</em></li>
                                             <li><strong>The American Diabetes Association</strong> recommend a <strong>target
                                                   blood glucose range</strong> of <strong>7.8 to 10.0 mmol/L</strong>
                                                (140-180 mg/dL) for most critically and noncritically ill patients.
                                                (<em>American Diabetes Association. Diabetes Care in the Hospital: Standards
                                                   of Medical Care in Diabetes&mdash;2019, 2019)</em></li>
                                             <li><em>The <strong>National Institute for Health and Care Excellence</strong>
                                                   recommends a target plasma glucose level of <strong>5 to 8 mmol/L</strong>
                                                   in adults with type 1 diabetes in hospital undergoing surgery or with acute
                                                   illness. <em>(NICE, 2017)</em></em></li>
                                             <li><strong>More liberal blood glucose targets</strong> are appropriate for
                                                people at<strong> high risk of falls </strong>and who are<strong> frail
                                                </strong>or have <strong>dementia</strong>. <em>(JBDS-IP, 2014)</em></li>
                                          </ul>
                                          <div class="evidence-accordion">
                                             <div class="option">
                                                <input type="checkbox" id="toggle9" class="toggle" />
                                                <label class="title" for="toggle9">
                                                   <span class="material-icons"><span></span></span>
                                                   <span class="title">Evidence: patient outcomes associated with
                                                      hyperglycaemia</span>
                                                </label>
                                                <div class="content">
                                                   <p><strong>Hyperglycaemia in patients in hospital is associated with
                                                         adverse outcomes. (</strong><em>Moghissi, 2009)</em></p>
                                                   <p>Hyperglycaemia in patients in hospital, whether with known diabetes or
                                                      not, has been shown by various observational studies to be associated
                                                      with adverse patient outcomes, including increased mortality.
                                                      <strong>(</strong><em>Moghissi, 2009)</em></p>
                                                </div>
                                             </div>
                                          </div>
                                          <div class="evidence-accordion">
                                             <div class="option">
                                                <input type="checkbox" id="toggle10" class="toggle" />
                                                <label class="title" for="toggle10">
                                                   <span class="material-icons"><span></span></span>
                                                   <span class="title">Evidence: blood glucose targets for people with
                                                      diabetes in hospital</span>
                                                </label>
                                                <div class="content">
                                                   <p><strong>Conflicting evidence for optimal blood glucose targets has led
                                                         to variations in recommendations in different countries and settings.
                                                         Follow your local protocol.</strong></p>
                                                   <ul>
                                                      <li>Intensive care setting</li>
                                                      <ul>
                                                         <li>A randomised controlled trial (RCT) of critically ill patients in
                                                            a primarily surgical intensive care setting found lower patient
                                                            mortality with tight glucose control - 80 to 110 mg/dL (4.4 to 6.1
                                                            mmol/L) compared with &lsquo;conventional&rsquo; more liberal
                                                            glucose control. <em>(Van den Berghe G et al, 2001) </em></li>
                                                         <li>However, a subsequent multicentre RCT in critically ill medical
                                                            and surgical patients in other intensive care settings found
                                                            increased mortality with tighter glucose control, possibly due to
                                                            increased episodes of hypoglycaemia. <em>(Finfer et al, 2009)</em>
                                                         </li>
                                                      </ul>
                                                   </ul>
                                                   <p>A 2010 systematic review of 6 RCTs and a meta-analysis investigating
                                                      tight glucose control (80 to 110 mg/dL [4.4 to 6.1 mmol/L]) vs less
                                                      strict glucose control in critically ill patients in the ICU setting
                                                      found no significant improvement in mortality with tight glucose
                                                      control, but it was associated with significantly more hypoglycaemic
                                                      episodes compared with less strict glucose control. (<em>Marik,
                                                         2010)</em></p>
                                                </div>
                                             </div>
                                          </div>

                                          <p><strong>Follow your local hospital protocol on steps to take if your
                                                patient&rsquo;s capillary blood glucose is &ge;15 mmol/L. Exclude diabetic
                                                ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS), both of which
                                                require specific urgent management.</strong></p>
                                          <ul>
                                             <li><strong>Treat hyperglycaemia</strong> to avoid <strong>DKA
                                                </strong>and<strong> HHS</strong>.</li>
                                             <li><strong>DKA</strong> and <strong>HHS</strong> are <strong>medical
                                                   emergencies</strong>. Follow JBDS or local hospital guidelines for patients
                                                with DKA (<em>JBDS-IP, 2013) </em>or HHS (<em>JBDS-IP, 2012). </em></li>
                                             <li>The <strong>diabetes inpatient specialist team</strong> should be involved in
                                                the management of any patient with <strong>DKA</strong>. (<em>JBDS-IP,
                                                   2013)</em></li>
                                             <li><strong>Early senior review</strong> by a clinician who is familiar with the
                                                management of<strong> HHS</strong> is imperative. (<em>JBDS-IP, 2012)
                                                </em>Patients with <strong>other comorbidities</strong> may need to be on a
                                                <strong>high dependency unit. </strong>(<em>JBDS-IP, 2012)</em></li>
                                          </ul>
                                          <p><strong>Be aware that the following medication may be associated with
                                                hyperglycaemia and may need to be reviewed: </strong><em>(Abdur R, et al,
                                                2011)</em></p>
                                          <ul>
                                             <li>Corticosteroids</li>
                                             <li>Some beta-blockers (e.g., propranolol, atenolol)</li>
                                             <li>Thiazide diuretics (e.g., hydrochlorozide)</li>
                                             <li>Some second-generation antipsychotics (e.g., olanzapine and clozaine)</li>
                                             <li>Certain fluoroquinolone antibiotics (e.g., gatifloxin)</li>
                                             <li>Calcineurin inhibitors (e.g., cyclosporine, tacrolimus)</li>
                                             <li>Protease inhibitors (e.g., as a component in antiretroviral therapy, such as
                                                ritonavir)</li>
                                          </ul>

                                          <div id="tip_pitfall" class="card card-inverse mb-4">
                                             <div class="card-block">
                                                
                                                <h3 class="card-title"></h3>
                                                <p>Ask for expert advice from the diabetes team in complex patients, or where
                                                   hyperglycaemia is difficult to control.</p>

                                             </div>
                                          </div>

                                          <p><strong>Prevent and manage hypoglycaemia if it occurs</strong></p>
                                          <ul>
                                             <li><strong>Monitor blood glucose</strong> in people with diabetes in hospital
                                                and <strong>adjust medication </strong>in response to illness and hospital
                                                meal times, in order to <strong>reduce risk</strong> of <strong>hypoglycaemic
                                                   episodes</strong>.</li>
                                             <li>1 in 5 inpatients with diabetes in England and Wales have a<strong>
                                                   hypoglycaemic episode </strong>during their hospital stay. <em>(NHS
                                                   Digital. National Diabetes Inpatient Audit (NaDIA) - 2017, 2018)</em></li>
                                             <li>Causes include:<em> (JBDS-IP, 2018)</em></li>
                                             <ul>
                                                <li>Recovery from an acute illness</li>
                                                <li>Insulin or oral hypoglycaemic medication error</li>
                                                <li>Wrong timing of insulin in relation to meals</li>
                                                <li>Patients eating less but taking the same amount of diabetes medication
                                                </li>
                                                <li>No bedtime snacks</li>
                                                <li>Reduced appetite or vomiting.</li>
                                             </ul>
                                          </ul>

                                          <div id="tip_pitfall" class="card card-inverse mb-4">
                                             <div class="card-block">
                                                
                                                <h3 class="card-title"></h3>
                                                <p><strong>Bedtime snacks </strong>can reduce the risk of <strong>early
                                                      morning hypoglycaemia</strong>. <em>(NHS Digital. National Diabetes
                                                      Inpatient Audit (NaDIA) - 2017, 2018)</em></p>
                                             </div>
                                          </div>

                                          <p><strong>Treat hypoglycaemia actively if the blood glucose falls below 4.0 mmol/L.
                                             </strong><em>(JBDS-IP, 2018)</em></p>
                                          <ul>
                                             <li>Follow hospital protocol. The JBDS-IP has guidelines on hospital management
                                                of hypoglycaemia in adults with diabetes. <em>(JBDS-IP, 2018)</em></li>
                                          </ul>

                                       </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group CKD-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02 no-icon">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Check baseline kidney function</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="tab_0_0_3"
                                    id="panel_0_0_3" aria-expanded="false">
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="CKD-como-content" style="display: block;">
                                       <div class="poce_drug_msg">
                                          <h3 class="poce_title"></h3>

                                          <p><strong>Check baseline serum kidney function on admission in all patients with a
                                                previous history of chronic kidney disease (CKD). </strong><em>[National
                                                Institute for Health and Care Excellence. 2013)</em></p>
                                          <ul>
                                             <li><strong>CKD</strong> is a significant<strong> risk factor</strong> for the
                                                development of <strong>acute kidney injury</strong>. <em>(Hsu CY, et al,
                                                   2008)</em></li>
                                             <li>Acute illness increases the risk of deterioration in renal function.</li>
                                          </ul>

                                       </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Stroke-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02 no-icon">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Baseline neurological assessment</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="tab_0_0_3 tab_patientGroup-0-0" id="panel_0_0_3 panel_patientGroup-0-0" aria-expanded="false">
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="Stroke-como-content" style="display: block;">
                                       <div class="poce_drug_msg">
                                          <h3 class="poce_title"></h3>

                                          <p><strong>Do a baseline neurological assessment on admission for all patients with
                                                a history of stroke.</strong></p>
                                          <ul>
                                             <li>Patients with <strong>acute illness</strong> (including infections and causes
                                                of hypotension) are at <strong>increased risk of stroke</strong> (both
                                                ischaemic and haemorrhagic). <em>(Grau AJ, et al, 2010) (Eigenbrodt ML, et al,
                                                   2000)</em></li>
                                             <li>If there is a suspicion of a change in neurological status during admission,
                                                repeat the<strong>neurological assessment</strong> in case of a
                                                <strong>possible new stroke</strong>.</li>
                                          </ul>
                                          <p>Following assessment, consider appropriate level of <strong>patient
                                                supervision</strong> e.g., relating to possible <strong>confusion</strong> at
                                             night, <strong>falls</strong> related to <strong>frailty</strong>.</p>

                                       </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Dementia-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02 no-icon">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Baseline cognitive assessment and collateral
                                                      history</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="tab_0_0_3 tab_patientGroup-0-0" id="panel_0_0_3 panel_patientGroup-0-0" aria-expanded="false">
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="Dementia-como-content" style="display: block;">
                                       <div class="poce_drug_msg">
                                          <h3 class="poce_title"></h3>

                                          <p><strong>Do a baseline cognitive assessment in all older patients, particularly
                                                those with a history of dementia. </strong><em>(Pendlebury ST, et al,
                                                2015)</em></p>
                                          <ul>
                                             <li>Use a<strong> validated scoring system</strong> that is also feasible in the
                                                acute setting, such as:<em>(Pendlebury ST, et al, 2015)</em></li>
                                             <ul>
                                                <li>The <strong>abbreviated mental test score</strong> (AMTS/10)
                                                   <em>(</em><em>Hodkinson,1972)</em></li>
                                                <li><strong>Montreal Cognitive Assessment</strong> (MoCA) <em>(Nasreddine,
                                                      2005).</em></li>
                                             </ul>
                                          </ul>
                                          <p><strong>Dementia increases the risk of delirium. </strong></p>
                                          <ul>
                                             <li>This can acutely reduce patients' cognitive assessment scores. <em>(George J,
                                                   2013)</em></li>
                                          </ul>
                                          <p><strong>Take a collateral history from family, friend or carer, to establish the
                                                patient&rsquo;s level of function and baseline cognition before this
                                                illness.</strong></p>
                                          <ul>
                                             <li>It&rsquo;s important to know if the <strong>decline</strong> in function and
                                                cognition has been <strong>gradual </strong>or <strong>acute</strong>.</li>
                                          </ul>
                                          <p>Use this information for <strong>monitoring clinical improvement</strong>, and
                                             for establishing <strong>needs on discharge</strong>.</p>

                                       </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Dementia-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02 no-icon">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Assess for and manage delirium</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="tab_0_0_3 tab_patientGroup-0-0" id="panel_0_0_3 panel_patientGroup-0-0" aria-expanded="false">
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="Dementia-como-content" style="display: block;">
                                       <div class="poce_drug_msg">
                                          <h3 class="poce_title"></h3>


                                          <p><strong>Assess the patient with de mentia for delirium. </strong><em>(National
                                                Institute for Health and Clinical Excellence. 2010)</em></p>
                                          <ul>
                                             <li>People living with dementia are at increased risk of delirium when they are
                                                admitted to hospital. (<em>National Institute for Health and Clinical
                                                   Excellence, 2018)</em></li>
                                             <li>Use a<strong> screening tool</strong>, such as:</li>
                                             <ul>
                                                <li>The <strong>4-AT</strong><em>(</em><em>Bellelli, 2014)</em></li>
                                                <li>The <strong>short confusion assessment method (S-CAM), </strong>as
                                                   recommended by the National Institute of Health and Care Excellence (NICE).
                                                   <em>(National Institute for Health and Clinical Excellence. 2010)</em></li>
                                                <li>Document the results clearly.</li>
                                             </ul>
                                          </ul>
                                          <p>&nbsp;</p>
                                          <p><strong>Assess the patient for any reversible causes of delirium</strong>.
                                             <em>(National Institute for Health and Clinical Excellence. 2010)</em>These
                                             include:</p>
                                          <ul>
                                             <li>Infection</li>
                                             <li>Pain</li>
                                             <li>Dehydration</li>
                                             <li>Constipation</li>
                                             <li>Hypoxia</li>
                                             <li>Immobility</li>
                                             <li>Medications</li>
                                             <li>Poor sleep</li>
                                             <li>Sensory impairment (e.g., ear wax or loss of glasses)</li>
                                          </ul>
                                          <p>&nbsp;</p>
                                          <p><strong>Investigations</strong> to help diagnose underlying causes include:</p>
                                          <ul>
                                             <li>Full blood count, electrolytes, renal function, liver function tests,
                                                calcium, glucose, CRP, folate and vitamin B12.</li>
                                             <li>Blood cultures (if bacteraemia is suspected)</li>
                                             <li>Urine microscopy and culture</li>
                                             <li>Chest x-ray</li>
                                          </ul>
                                          <p>&nbsp;</p>
                                          <p><strong>Manage according to the cause</strong>.</p>
                                          <p>&nbsp;</p>
                                          <p><strong>Manage patients with delirium initially with non-pharmacological
                                                treatment. </strong><em>(National Institute for Health and Clinical
                                                Excellence. 2010)</em></p>
                                          <p>&nbsp;</p>
                                          <ul>
                                             <li>Reduce <strong>disorientation</strong> by providing a <strong>well-lit
                                                   room,</strong> with a <strong>clock</strong> and <strong>calendar
                                                </strong>visible (e.g., on the wall).</li>
                                             <li>Encourage and facilitate <strong>family, friends and carers</strong> visiting
                                                the patient.</li>
                                             <li>Use verbal and non-verbal techniques to<strong> de-escalate</strong> conflict
                                                and distress.</li>
                                          </ul>
                                          <p>&nbsp;</p>
                                          <p><strong>Where non-pharmacological treatments are ineffective, and the patient is
                                                distressed or considered a risk to themselves or others, short-term
                                                antipsychotic or sedative drugs may be used.</strong></p>
                                          <p>&nbsp;</p>
                                          <p><strong>Only use antipsychotics as a last resort and not in patients with
                                                Parkinson&rsquo;s disease or dementia with Lewy bodies.</strong><em>(National
                                                Institute for Health and Clinical Excellence. 2010)</em></p>
                                          <ul>
                                             <li><strong>Risperidone</strong> has the least anticholinergic effects.
                                                <em>(Tracy JI, et al, 1998)</em></li>
                                             <li><strong>Haloperidol</strong> is also licenced for this indication, but has
                                                the highest risk associated with its use. The UK National Institute for Health
                                                and Care Excellence recommends short-term use of haloperidol (usually for less
                                                than one week), starting at the <strong>lowest dose</strong> and
                                                <strong>titrating carefully</strong> according to the symptoms. <em>(National
                                                   Institute for Health and Clinical Excellence. 2010)</em></li>
                                             <li>Consider sedation in significantly agitated patients who pose a risk to
                                                themselves or others.<strong> Lorazepam </strong>is a suitable choice, but it
                                                should only be given orally or intramuscularly (i.e., not intravenously).</li>
                                             <li>Lorazepam should only be used in the<strong> smallest possible dose</strong>
                                                for the <strong>shortest possible duration</strong>.</li>
                                          </ul>
                                          <p>&nbsp;</p>
                                          <p><strong>Avoid typical antipsychotics, particularly haloperidol in patients with
                                                Parkinson&rsquo;s disease or dementia with Lewy bodies. </strong><em>(National
                                                Institute for Health and Clinical Excellence. 2010)</em></p>
                                          <ul>
                                             <li>The dopamine receptor antagonistic effect of typical antipsychotics can
                                                <strong>dramatically worsen physical and cognitive symptoms</strong> in people
                                                with Parkinson&rsquo;s disease or with dementia with Lewy bodies.</li>
                                             <li>Consider a <strong>low-dose short-acting oral benzodiazepine,</strong> such
                                                as lorazepam, or l<strong>ow-dose quetiapine </strong>in patients with
                                                Parkinson&rsquo;s disease or dementia with Lewy bodies who require sedation to
                                                enable safe care because of delirium.</li>
                                             <li>Consult your local drug formulary for advice.</li>
                                          </ul>
                                          <p><strong><br /><strong>Document</strong> any episodes of current or resolved
                                                delirium in the<strong> discharge summary for the GP</strong>. <em>(National
                                                   Institute for Health and Clinical Excellence. 2010)</em></strong></p>


                                          <div class="evidence-accordion">
                                             <div class="option">
                                                <input type="checkbox" id="toggle11" class="toggle" />
                                                <label class="title" for="toggle11">
                                                   <span class="material-icons"><span></span></span>
                                                   <span class="title">Evidence: risks and safe withdrawal of antipsychotics
                                                      in the elderly</span>
                                                </label>
                                                <div class="content">
                                                   <p><strong>Short-term antipsychotics may be needed in people with dementia
                                                         to enable safe care. However, antipsychotics have various adverse
                                                         effects in the elderly and are associated with an increased risk of
                                                         death in people with dementia.</strong></p>
                                                   <ul>
                                                      <li>A meta-analysis found that people with dementia who take atypical
                                                         antipsychotics have an <strong>increased mortality risk
                                                         </strong>compared with people taking placebo. <em>(</em><em>Ma H, et
                                                            al, 2014)</em></li>

                                                      <li><em>A large cohort study of elderly people found that <strong>higher
                                                               doses</strong> of antipsychotics are generally associated with
                                                            <strong>greater risk</strong>. <em>(Huybrechts K, 2012)</em></em>
                                                      </li>

                                                      <li>It also found that of all the antipsychotics studied,
                                                         <strong>haloperidol </strong>has the highest risk associated with its
                                                         use. <em>(Huybrechts K, 2012)</em></li>

                                                      <li>Contrary to popular belief, long-term antipsychotic prescriptions in
                                                         people with dementia whose behaviour is now settled, can be
                                                         <strong>withdrawn safely </strong>in the majority of cases. (<em>Van
                                                            Leeuwen, 2018)</em></li>
                                                   </ul>
                                                </div>
                                             </div>
                                          </div>

                                          <div class="evidence-accordion">
                                             <div class="option">
                                                <input type="checkbox" id="toggle12" class="toggle" />
                                                <label class="title" for="toggle12">
                                                   <span class="material-icons"><span></span></span>
                                                   <span class="title">Evidence: primary prevention of delirium: this may be
                                                      the most effective treatment strategy</span>
                                                </label>
                                                <div class="content">
                                                   <p><strong>A non-randomised trial studying how to reduce risk factors for
                                                         delirium compared a multicomponent strategy with usual care in 852
                                                         elderly patients (over 70 years) in hospital. </strong><em>(Inouye,
                                                         1999)</em></p>
                                                   <ul>
                                                      <li>The multicomponent strategy targeted the following 6 risk factors:
                                                      </li>
                                                      <ul>
                                                         <li>cognitive impairment</li>
                                                         <li>sleep deprivation</li>
                                                         <li>immobility</li>
                                                         <li>visual impairment</li>
                                                         <li>hearing impairment</li>
                                                         <li>dehydration.</li>
                                                      </ul>
                                                   </ul>
                                                   <p>It found: <em>(Inouye, 1999)</em></p>
                                                   <ul>
                                                      <li>There were <strong>significantly fewer first episodes of
                                                            delirium</strong> with the <strong>multicomponent strategy
                                                         </strong>vs usual care (44 [9.9%] vs 64 [15%] respectively)</li>
                                                      <li>Matched group analysis found an odds ratio (OR) of 0.60 (95%CI:
                                                         0.39-0.92; p=0.02)</li>
                                                      <li><strong>Total number of days with delirium</strong> was
                                                         <strong>significantly lower </strong>with the <strong>multicomponent
                                                            strategy</strong> vs usual care (105 vs. 161 days respectively,
                                                         p=0.02)</li>
                                                   </ul>
                                                   <p><strong>Delirium severity and recurrence rates</strong> were <strong>not
                                                         significantly different </strong>in the 2 groups.</p>
                                                </div>
                                             </div>
                                          </div>

                                       </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02 no-icon">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Set an escalation plan</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="tab_0_0_3 tab_patientGroup-0-0" id="panel_0_0_3 panel_patientGroup-0-0" aria-expanded="false">
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="Diabetes-como-content" style="display: block;">
                                       <div class="poce_drug_msg">
                                          <h3 class="poce_title"></h3>

                                          <p><strong>Set an escalation plan for all patients with dementia as early as
                                                possible.</strong></p>
                                          <ul>
                                             <li>This should include: <em>(Fritz Z, et al, 2017):</em></li>
                                             <ul>
                                                <li><strong>Resuscitation status</strong> (i.e., do not attempt
                                                   cardiopulmonary resuscitation [DNACPR] decision)</li>
                                                <li><strong>Ceiling of care</strong> (e.g., is the patient suitable for
                                                   intubation or intensive care admission)</li>
                                             </ul>
                                             <li>Escalation plans should take account of<strong> advanced care
                                                   planning</strong>, including legally-binding advanced directives.
                                                <em>(Fritz Z, et al, 2017)</em></li>
                                          </ul>
                                          <p><strong>Communicate</strong> all decisions regarding the escalation plan
                                             <strong>with the patient</strong>.<em>(Fritz Z, et al, 2017)</em></p>
                                          <ul>
                                             <li><strong>Assess mental capacity</strong> (the ability to make decisions at a
                                                specific time a decision needs to be made) and document. <em>(NICE, 2018)</em>
                                                Follow the appropriate legislation in your region.</li>
                                             <li>In England and Wales, health professionals must comply with the <strong>2005
                                                   Mental Capacity Act</strong>. <em>(Department of Health, 2005)
                                                </em>Assessments should follow the principles in the Act. <em>(Department of
                                                   Health, 2005) </em></li>
                                             <li>If a patient is assessed to lack mental capacity, ensure decisions are made
                                                in the <strong>best interests of the patient</strong>. <em>(Department of
                                                   Health, 2005) (NICE, 2018)</em></li>
                                          </ul>
                                          <p><strong>If the patient is assessed to lack mental capacity, consult with the
                                                patient&rsquo;s next of kin in order to make &lsquo;best interests&rsquo;
                                                decisions. </strong><em>(Department of Health, 2005) </em></p>
                                          <p>According to the 2005 Mental Capacity Act in England and Wales, if a patient is
                                             unbefriended and a decision is not time critical, an independent mental capacity
                                             advocate (IMCA) should be sought to perform this role instead. (<em>Social Care
                                                Institute for Excellence, 2011)</em></p>
                                       </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Asthma-como-content COPD-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02 no-icon">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Remember to prescribe usual inhalers</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="tab_0_0_3 tab_patientGroup-0-0" id="panel_0_0_3 panel_patientGroup-0-0" aria-expanded="false">
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="Asthma-como-content COPD-como-content" style="display: block;">
                                       <div class="poce_drug_msg">
                                          <h3 class="poce_title"></h3>
                                          <p><strong>Patients may not think to tell you about their usual inhalers when asked
                                                about their medication, so remember to check and prescribe these if
                                                appropriate</strong></p>
                                          <ul>
                                             <li>Patients with asthma should continue any inhaled corticosteroid medication
                                                they usually take. These should not be stopped without a clear medical reason.
                                             </li>
                                             <li>Many inhalers are combined medications, so check there is no dual prescribing
                                             </li>
                                          </ul>
                                          <p><strong>Temporarily stop inhaled long-acting muscarinic receptor antagonists if
                                                your patient with COPD or asthma usually takes this and develops acute kidney
                                                injury with an eGFR &lt;30.</strong></p>
                                       </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Asthma-como-content COPD-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02 no-icon">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Consider
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Nicotene replacement therapy in current
                                                      smokers</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="tab_0_0_3 tab_patientGroup-0-0" id="panel_0_0_3 panel_patientGroup-0-0" aria-expanded="false">
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="Asthma-como-content COPD-como-content" style="display: block;">
                                       <div class="poce_drug_msg">
                                          <h3 class="poce_title"></h3>
                                          <p><strong>All current smokers are nicotine dependent</strong></p>
                                          <ul>
                                             <li>Nicotine replacement therapy should be prescribed to prevent withdrawal
                                                regardless of a patient&rsquo;s intention regarding smoking cessation</li>
                                             <li>Please consult your local hospital guidance.</li>
                                          </ul>
                                          <p><br /><strong>Make every contact count:</strong></p>
                                          <ul>
                                             <li>Being in hospital with an acute illness is the ideal time to support someone
                                                to give up smoking</li>
                                             <li>Provide brief advice.</li>
                                          </ul>
                                       </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Asthma-como-content COPD-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02 no-icon">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Monitor for and manage any acute exacerbation of
                                                      asthma or COPD</span>
                                                </span>
                                                <span class="material-icons">
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="tab_0_0_3 tab_patientGroup-0-0" id="panel_0_0_3 panel_patientGroup-0-0" aria-expanded="false">
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="Asthma-como-content COPD-como-content" style="display: block;">
                                       <div class="poce_drug_msg">
                                          <h3 class="poce_title"></h3>
                                          <p><strong>Monitor patient for symptoms and signs of an acute exacerbation of their
                                                COPD or asthma.</strong></p>
                                          <ul>
                                             <li>A patient with airways disease may have an acute exacerbation while in
                                                hospital with a separate another medical or surgical condition.</li>
                                          </ul>
                                          <p><strong>Patients with comorbid COPD may be having an acute exacerbation if there
                                                is an acute worsening of respiratory symptoms that results in the need for
                                                additional therapy.</strong><em>(Global Initiative for Chronic Obstructive
                                                Lung Disease, 2019)</em></p>
                                          <ul>
                                             <li><strong>Differentiate</strong> from other conditions which may present very
                                                similarly, such as <strong>acute coronary syndrome</strong>, <strong>acute
                                                   heart failure</strong> and <strong>pneumonia</strong>.</li>
                                             <li>Follow guideline recommendations on <strong>investigations</strong>,
                                                including:</li>
                                             <ul>
                                                <li><strong>ABG</strong> measurement</li>
                                                <li><strong>Chest x-ray.</strong> Generally, do a chest x-ray if a patient
                                                   with COPD is admitted with breathlessness or cough, or has worse symptoms
                                                   than usual.</li>
                                             </ul>
                                             <li>Follow <strong>COPD guideline </strong>recommendations on <strong>initial
                                                   management</strong>, including:</li>
                                             <ul>
                                                <li><strong>Assessing severity</strong></li>
                                                <li>Increasing dose and/or frequency of <strong>bronchodilator
                                                      therapy</strong>, using nebulisers (driven with air) or spacers</li>
                                                <li>Considering <strong>oral corticosteroids</strong>,
                                                   <strong>antibiotics</strong> and need for <strong>noninvasive
                                                      ventilation</strong>.</li>
                                                <li>See BMJ Best Practice topic on Acute exacerbation in COPD</li>
                                             </ul>
                                          </ul>
                                          <p><strong>Follow guideline recommendations for assessment of severity and
                                                management of an acute exacerbation of asthma in adults.
                                             </strong><em>(</em><em>British Thoracic Society; Scottish Intercollegiate
                                                Guidelines Network, 2016) </em></p>
                                          <ul>
                                             <li>Initial treatment of acute severe asthma includes:</li>
                                             <ul>
                                                <li><strong>Supplementary oxygen</strong> if hypoxaemic. Titrate to maintain
                                                   an oxygen saturation level of <strong>94% to 98%</strong></li>
                                                <li><strong>High-dose inhaled beta2 agonists</strong> as early as possible,
                                                   usually via nebuliser (oxygen-driven)</li>
                                                <li><strong>Ipratropium bromide</strong> via nebuliser (oxygen-driven) if
                                                   needed</li>
                                                <li><strong>Corticosteroids</strong> in adequate doses (40 to 50 mg daily for
                                                   at least 5 days)</li>
                                                <li>Other therapies may be required, <strong>follow guideline
                                                      recommendations</strong></li>
                                                <li>See BMJ Best Practice topic on Acute exacerbation of asthma in adults.
                                                </li>
                                             </ul>
                                          </ul>
                                          <p><strong>Stop long-acting muscarinic receptor antagonists (LAMAs) e.g., tiotropium
                                                temporarily if short-acting muscarinic antagonists (SAMAs) e.g., ipratropium
                                                bromide are prescribed via nebuliser.</strong></p>
                                          <ul>
                                             <li>This is based on expert opinion due to concern over possible anticholinergic
                                                adverse effects.</li>
                                          </ul>
                                          <p><strong>Regular nebulisers should only be prescribed for 24 to 48 hours and then
                                                switched back to the patient&rsquo;s usual inhalers.</strong></p>

                                          <div class="evidence-accordion">
                                             <div class="option">
                                                <input type="checkbox" id="toggle13" class="toggle" />
                                                <label class="title" for="toggle13">
                                                   <span class="material-icons"><span></span></span>
                                                   <span class="title">Evidence: cardiovascular harm with beta2-
                                                      agonists.</span>
                                                </label>
                                                <div class="content">
                                                   <p><strong>Beta2-agonists increase the risk of myocardial infarction and
                                                         other adverse cardiovascular events</strong></p>
                                                   <p>Beta2-agonists increase heart rate and reduce potassium levels.
                                                      <em>(Salpeter SR, et al, 2004) </em>They are absorbed into the systemic
                                                      circulation and there is evidence they are associated with an increased
                                                      risk of myocardial infarction, unable angina, congestive heart failure
                                                      and arrhythmias. <em>(Au DH, et al, 2002) (Salpeter SR, et al, 2004)
                                                         (Baker JG, 2017)</em></p>
                                                </div>
                                             </div>
                                          </div>

                                          <div class="evidence-accordion">
                                             <div class="option">
                                                <input type="checkbox" id="toggle14" class="toggle" />
                                                <label class="title" for="toggle14">
                                                   <span class="material-icons"><span></span></span>
                                                   <span class="title">Evidence: short duration vs longer duration of
                                                      corticosteroids for acute exacerbation of COPD</span>
                                                </label>
                                                <div class="content">
                                                   <p><strong>A systematic review found no difference in outcomes (treatment
                                                         failure, time to next exacerbation, time in hospital, lung function,
                                                         adverse effects, mortality) between short courses (7 days or less) vs
                                                         more conventional longer courses (longer than 7 days) of
                                                         corticosteroids in people with acute exacerbation of COPD
                                                      </strong><em>(Walters JAE, et al, 2018)</em></p>
                                                   <ul>
                                                      <li>The randomised controlled trials included in this Cochrane review
                                                         were all in hospital settings and only included people with severe to
                                                         very severe COPD<em> (Walters JAE, et al, 2018)</em></li>
                                                      <li>The review authors concluded that due to the addition of a new
                                                         trial, they have increased confidence that a corticosteroid course of
                                                         around 5 days is likely to be sufficient for the treatment of an
                                                         acute exacerbation of COPD. <em>(Walters JAE, et al, 2018)</em></li>
                                                   </ul>
                                                </div>
                                             </div>
                                          </div>
                                       </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02 no-icon">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Check patient's feet</span>
                                                </span>
                                                <span class="material-icons">
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="tab_0_0_3 tab_patientGroup-0-0" id="panel_0_0_3 panel_patientGroup-0-0" aria-expanded="false">
                                    <!-- CONDITIONAL COMO CONTENT -->
                                    <div class="Diabetes-como-content" style="display: block;">
                                       <div class="poce_drug_msg">
                                          <h3 class="poce_title"></h3>
                                          <p><strong>Check the feet of all adults with diabetes on admission to hospital and
                                                whenever there has been a change in their status. </strong><em>(NICE,
                                                2016)</em></p>
                                          <ul>
                                             <li><strong>Why? </strong></li>
                                             <ul>
                                                <li>To detect <strong>new ulceration </strong>or<strong> infection,
                                                   </strong>which may be<strong> unnoticed</strong> by the patient andmay even
                                                   be the <strong>underlying cause </strong>of their illness (e.g., patient
                                                   presenting with sepsis, spinal abscess or endocarditis where the original
                                                   focus of infection is the foot lesion).</li>
                                                <li>To determine if patient is at<strong> high risk of pressure ulceration
                                                   </strong>and <strong>requires pressure relief</strong>.</li>
                                             </ul>
                                             <li><strong>Take action </strong></li>
                                             <ul>
                                                <li>You must <strong>remove any foot dressings</strong> to see if any
                                                   wound/ulcer is<strong> infected. </strong><em>(NICE NG19, 2016)</em></li>
                                                <li><strong>Inspect</strong> the foot for lesions and examine for loss of
                                                   protective <strong>sensation</strong>. Follow your local guidelines, but a
                                                   quick simple test is the <strong>Ipswich Touch Test&copy;️</strong>.
                                                   (Rayman G, et al, 2011)</li>
                                                <li>If your patient has <strong>reduced sensation</strong>, they are at
                                                   <strong>high risk of pressure ulceration</strong>. Inform the nursing staff
                                                   and <strong>provide pressure relieving devices</strong>.</li>
                                             </ul>
                                          </ul>
                                          <p>A <strong>daily heel check</strong> for <strong>signs of pressure trauma</strong>
                                             should be undertaken by nursing or health care assistant staff.</p>
                                       </div>
                                    </div>
                                    <!-- CONDITIONAL COMO CONTENT ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>

                           </div>
                           <!--/.panel-body -->
                        </section>

                        <section class="panel-group">
                           <div class="panel-header child-accordion">
                              <p class="panel-title">
                                 <a href="#" role="tab header" id="tab_1_0_0_acute2" aria-controls="panel_1_0_0_acute2" aria-expanded="false">
                                    <span class="title-04">
                                       <span class="material-icons"><span></span><span></span></span>                                       
                                       <span class="title-01">
                                          <span>
                                             Contraindication to thrombolysis; and no contraindication to anticoagulation
                                          </span>
                                       </span>
                                    </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content child-accordion col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_3 tab_1_0_0_acute2" id="panel_1_0_0_acute2 panel_patientGroup-0-0" aria-expanded="false" style="display: none;">                              
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="#" role="tab header" id="nested-collapse_0_0_3"
                                          aria-controls="nested-collapse_0_0_3" aria-expanded="false" class="">                                    
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   1st line
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Start unfractionated heparin</span>
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <p><strong>Involve senior support and/or critical care in patients who are
                                          haemodynamically unstable (SBP &lt;90 mmHg or SBP drop of &ge;40 mmHg for &gt;15
                                          minutes).</strong></p>
                                    <p><strong>Start UFH in haemodynamically unstable patients prior to primary
                                          reperfusion.</strong></p>
                                    <ul>
                                       <li>UFH has a short half-life, is easy to monitor, and is readily reversed by
                                          protamine. [ESC]</li>
                                    </ul>
                                    <p><br /><strong>Check local guidelines and seek specialist advice when deciding how long
                                          to continue UFH for</strong>.[ESC] In the UK it is common practice to stop UFH
                                       within 24 hours but this will depend on the stability of the patient.</p>
      
                                    <div id="tip_pitfall" class="card card-inverse mb-4">
                                       <div class="card-block">
                                          
                                          <h3 class="card-title">In patients who are haemodynamically unstable, evidence of RV
                                             dysfunction on echocardiography is sufficient to warrant immediate
                                             anticoagulation.</h3>
                                          <p><strong></strong></p>
                                          <ul>
                                             <li><strong>These patients are normally too unstable to undergo CTPA.</strong>
                                             </li>
                                          </ul>
                                       </div>
                                    </div>
      
      
      
                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle15" class="toggle" />
                                          <label class="title" for="toggle15">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: There is insufficient evidence to support use of
                                                LMWH in haemodynamically unstable (high-risk) PE</span>
                                          </label>
                                          <div class="content">
                                             <p><strong>There is some evidence that LMWH has a similar safety profile to UFH
                                                   when used prior to thrombolysis.</strong></p>
                                             <ul>
                                                <li>A prospective, observational multicentre trial showed similar bleeding
                                                   rates following thrombolysis in patients who had UFH or LMWH. However this
                                                   evidence remains limited.</li>
                                             </ul>
                                             <p><strong>There is not enough evidence to recommend LMWH as a first-line option
                                                   for patients with PE who are haemodynamically unstable. </strong>[UCAR]</p>
                                          </div>
                                       </div>
                                    </div>
      
                                    <div id="tip_pitfall" class="card card-inverse mb-4">
                                       <div class="card-block">
                                          
                                          <h3 class="card-title">Seek haematology advice if a patient with high-risk PE who is
                                             haemodynamically unstable has any contraindications to thrombolysis.</h3>
                                          <ul>
                                             <li>In practice, almost any contraindication to thrombolysis should be considered
                                                only relative in high-risk patients who present with haemodynamic instability.
                                             </li>
                                             <li>This is because the mortality risk from high-risk PE is so high that it is
                                                likely to outweigh any bleeding risk from thrombolysis in this patient group.
                                                [ESC]</li>
                                          </ul>
                                          <p><strong>Absolute contraindications: [ESC]</strong></p>
                                          <ul>
                                             <li>haemorrhagic stroke or stroke of unknown origin at any time</li>
                                             <li>ischaemic stroke in the preceding 6 months</li>
                                             <li>central nervous system damage or neoplasms</li>
                                             <li>recent major trauma/surgery/head injury (in the preceding 3 weeks)</li>
                                             <li>gastrointestinal bleeding within the last month</li>
                                             <li>known bleeding risk.</li>
                                          </ul>
                                          <p><strong>Relative contraindications:</strong></p>
                                          <ul>
                                             <li>transient ischaemic attack in the preceding 6 months</li>
                                             <li>oral anticoagulant therapy</li>
                                             <li>pregnancy or within 1 week postnatally</li>
                                             <li>traumatic resuscitation (in relation to this episode of PE)</li>
                                             <li>refractory hypertension (SBP &gt;180 mmHg)</li>
                                             <li>advanced liver disease</li>
                                             <li>infective endocarditis</li>
                                             <li>active peptic ulcer</li>
                                          </ul>
                                       </div>
                                    </div>
      
      
                                    <div class="treatment-wrap non-como-content show">
                                       <h4>Primary options</h4>
                                       <div class="treatment-box">
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">heparin</a><span>: </span><span>10,000 units
                                                intravenously as a loading dose initially, followed by 18 units/kg/hour
                                                intravenous infusion, adjust dose according to aPTT</span>
                                          </p>
                                       </div>
                                    </div>
                                    
                                    <!-- SWITCHABLE DRUG CONTENT BOX -->
                                    <div class="treatment-box-cplus mt-4 como-content hide">
                                       <h4>Primary options</h4>
                                       <div class="drug-accordion">
      
                                          <div class="drug-content2" style="display: none">
                                             <div class="poce_drug_msg" class="warning">
                                                <h3 class="cplus_title">These drug options and doses relate to a patient with
                                                   <strong>no comorbidities.</strong></h3>
                                             </div>
                                             <div class="treatment-box">                                             
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">heparin: </a>
                                                      <span>10,000 units intravenously as a loading dose initially, followed by 18 units/kg/hour intravenous infusion, adjust dose according to aPTT</span>
                                                </p>
                                             </div>
                                             <p class="como_link mt-4 drug-title2"><a href="#">&#9664; Back to drug doeses with added comorbidities</a></p>
                                          </div>
      
                                          <div class="drug-content1">
                                             <div class="poce_drug_msg">
                                                <h3 class="cplus_title">Drug choice, dose and interactions may be affected by
                                                   the patient's comorbidities. Check your local drug formulary.</h3>
                                             </div>
                                             <div class="treatment-box">                                          
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">heparin: </a>
                                                </p>
                                             </div>
                                             <p>For patients with renal impairment <a href="#" data-toggle="modal" data-target="#renal">see dose in the Renal Drug Handbook</a></p>
                                             <div class="modal fade" id="renal" tabindex="-1" role="dialog" aria-labelledby="renal" aria-hidden="true" style="display: none;">
                                                <div class="modal-dialog" role="document">
                                                   <div class="modal-content">
                                                      <div class="modal-header">
                                                         <h3 class="modal-title" id="exampleModalLabel">
                                                            The Renal Handbook<br /></h3>
                                                      </div>
                                                      <iframe width="100%" height="700" src="../pdf/renalbook.pdf" title="Renal Book"></iframe>
                                                   </div>
                                                </div>
                                             </div>
                                             <p class="como_link mt-4 drug-title1"><a href="#">&#9658; Show drug doses for a patient with no comorbidities</a></p>
                                          </div>
                                             
                                          </div>
                                    </div>
                                    <!-- DRUG CONTENT BOX ENDS -->
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="#" role="tab header" id="nested-collapse_0_0_3"
                                          aria-controls="nested-collapse_0_0_3" aria-expanded="false" class="">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Switch to alternative anticoagulant</span>
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <p><strong>Continue anticoagulation with UFH before switching to LMWH, fondaparinux,
                                          apixaban, or rivaroxaban</strong>.[ESC] <strong>Check local guidelines and seek
                                          specialist advice when deciding how long to continue UFH for</strong>. [ESC] In the
                                       UK it is common practice to stop UFH within 24 hours but this will depend on the
                                       stability of the patient.</p>
                                    <ul>
                                       <li><strong>If switching to LMWH (e.g,. dalteparin, enoxaparin) or fondaparinux, the
                                             total duration of treatment with UFH and then LMWH or fondaparinux should be at
                                             least 5 days.</strong>[NICE][ESC]</li>
                                       <ul>
                                          <li>If ongoing anticoagulation will be with warfarin, ensure overlap with UFH, LMWH,
                                             or fondaparinux for at least 5 days or until the INR is &ge;2 for at least 24
                                             hours (whichever is the longer).[NICE] Seek specialist advice to decide when to
                                             start warfarin.</li>
                                       </ul>
                                    </ul>
                                    <p><strong>OR</strong></p>
                                    <ul>
                                       <ul>
                                          <li>If ongoing anticoagulation will be with edoxaban or dabigatran, at least 5 days
                                             of lead-in therapy with LMWH or fondaparinux is required first. Stop the LMWH or
                                             fondaparinux before starting dabigatran or edoxaban.[BTS]</li>
                                       </ul>
                                       <li><strong>If switching to rivaroxaban or apixaban, these drugs may be started after
                                             stopping UFH without the need for lead-in therapywith LMWH or fondaparinux
                                             first</strong>.</li>
                                       <ul>
                                          <li>Acute-phase treatment consists of an increased dose of the oral anticoagulant
                                             over the first 3 weeks (for rivaroxaban), or over the first 7 days (for
                                             apixaban).</li>
                                       </ul>
                                    </ul>
                                    <p><strong>Seek specialist advice when switching between anticoagulants</strong></p>
                                    <ul>
                                       <li>The protocol depends on which anticoagulant you are switching to and from.
                                          Haematology input is important.</li>
                                    </ul>
                                    <p><br /><strong>Be aware of special patient groups such as pregnancy, renal impairment,
                                          and active cancer</strong> as these groups will need a specific type/dose of
                                       anticoagulant. <strong>Seek haematology advice for all patients with hepatic impairment
                                          or who are at increased risk of bleeding.</strong></p>
      
                                    <div id="tip_pitfall" class="card card-inverse mb-4">
                                       <div class="card-block">
                                          
                                          <h3 class="card-title">Never give a DOAC simultaneously with parenteral
                                             anticoagulation</h3>
                                          <ul>
                                             <li>While warfarin is started at the same time as a parenteral anticoagulant and
                                                overlapped for at least 5 days or until the INR is &ge;2 for at least 24 hours
                                                (whichever is the longer), DOACs should never be overlapped or given at the
                                                same time as a parenteral anticoagulant.</li>
                                             <li>Apixaban and rivaroxaban may be started without the need for lead-in therapy
                                                with a parenteral anticoagulant first. Either of these DOACs can be used as a
                                                single-drug approach; this is why BTS guidelines recommend them as the
                                                preferred DOAC options in any patient who might be suitable for early
                                                discharge. [BTS]</li>
                                             <li>However, dabigatran and edoxaban require at least 5 days lead-in therapy with
                                                a parenteral anticoagulant before starting treatment. The parenteral
                                                anticoagulant should be stopped before dabigatran or edoxaban are started.
                                             </li>
                                          </ul>
      
                                       </div>
                                    </div>
      
                                    <div class="treatment-wrap non-como-content show">
                                       <h4>Primary options</h4>
                                       <div class="treatment-box">
                                          <p><strong>[No special considerations]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">apixaban</a><span>: </span><span>10 mg orally
                                                twice daily for 7 days, followed by 5 mg twice daily</span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p><strong>[No special considerations]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">rivaroxaban</a>
                                             <span>: </span>
                                             <span>15 mg orally twice daily for 21 days, followed by 20 mg once daily</span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p><strong>[No special considerations]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">enoxaparin:</a>
                                             <span>: </span>
                                             <span>1 mg/kg subcutaneously every 12 hours</span>
                                          </p>
                                          <p class="small-or">-or-</p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">dalteparin</a>
                                             <span>: </span>
                                             <span>100 units/kg subcutaneously every 12 hours</span>
                                          </p>
                                          <p class="small-or">-AND-</p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">warfarin</a>
                                             <span>: </span>
                                             <span>5-10 mg orally once daily initially, adjust dose according to target
                                                INR</span>
      
                                             <span class="reference">
                                                <a href="#referencePop-more4" data-trigger="click focus" data-toggle="popover"
                                                   class="morePop" data-original-title="" title=""
                                                   aria-describedby="popover621629">More</a>
                                                <span class="popTitle" aria-hidden="true">
                                                </span>
                                                <span class="popText" aria-hidden="true">
                                                   <p class="w-75">Starting dose can be calculated using an online tool that
                                                      takes patient characteristics and/or CYP2C9/VKORC1 genotype information
                                                      (if available) into account.
                                                      [http://www.warfarindosing.org/Source/Home.aspx ONLINE RESOURCE:
                                                      Warfarin dosing]</p>
                                                </span>
                                             </span>
      
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p><strong>[Active cancer]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">enoxaparin:</a>
                                             <span>: </span>
                                             <span>1 mg/kg subcutaneously every 12 hours</span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p><strong>[Active cancer]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">dalteparin:</a>
                                             <span>: </span>
                                             <span>200 units/kg subcutaneously once daily for the first 30 days, followed by
                                                150 units/kg once daily for 5 months, maximum 18,000 units/dose
                                                |
      
                                                <span class="reference">
                                                   <a href="#referencePop-more4" data-trigger="click focus"
                                                      data-toggle="popover" class="morePop" data-original-title="" title=""
                                                      aria-describedby="popover621629">More</a>
                                                   <span class="popTitle" aria-hidden="true">
                                                   </span>
                                                   <span class="popText" aria-hidden="true">
                                                      <p class="w-75">Refer to local drug formulary for a table of recommended
                                                         weight-based doses. Use fixed-dose syringes for this indication. </p>
                                                   </span>
                                                </span>
      
                                             </span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p><strong>[Pregnant women]</strong></p>
      
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">enoxaparin</a>
                                             <span>: </span>
                                             <span> body weight &lt;50 kg: 40 mg subcutaneously twice daily; body weight 50-69
                                                kg: 60 mg subcutaneously twice daily; body weight 70-89 kg: 80 mg
                                                subcutaneously twice daily; body weight ≥90 kg: 100 mg subcutaneously twice
                                                daily </span>
                                          </p>
                                          <span class="reference">
                                             <a href="#referencePop-more8" data-trigger="click focus" data-toggle="popover"
                                                class="morePop" data-original-title="" title=""
                                                aria-describedby="popover621629">More</a>
                                             <span class="popTitle" aria-hidden="true"></span>
                                             <span class="popText" aria-hidden="true">
                                                <p class="w-75">
                                                   Dose based on early pregnancy body weight.
                                                </p>
                                             </span>
                                          </span>
      
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p><strong>[Pregnant women]</strong></p>
      
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">dalteparin</a>
                                             <span>: </span>
                                             <span>body weight &lt;50 kg: 5000 units subcutaneously twice daily; body weight
                                                50-69 kg: 6000 units subcutaneously twice daily; body weight 70-89 kg: 8000
                                                units subcutaneously twice daily; body weight ≥90 kg: 10,000 units
                                                subcutaneously twice daily</span>
                                          </p>
                                          <span class="reference">
                                             <a href="#referencePop-more8" data-trigger="click focus" data-toggle="popover"
                                                class="morePop" data-original-title="" title=""
                                                aria-describedby="popover621629">More</a>
                                             <span class="popTitle" aria-hidden="true"></span>
                                             <span class="popText" aria-hidden="true">
                                                <p class="w-75">
                                                   Dose based on early pregnancy body weight.
                                                </p>
                                             </span>
                                          </span>
      
      
                                          </p>
                                          <h4>Secondary options</h4>
                                          <p><strong>[No special considerations]</strong></p>
      
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">fondaparinux</a>
                                             <span>: </span>
                                             <span>body weight &lt;50 kg: 5 mg subcutaneously once daily; body weight 50-100
                                                kg: 7.5 mg subcutaneously once daily; body weight ≥100 kg: 10 mg
                                                subcutaneously once daily</span>
                                          </p>
      
                                          </p>
                                          <p class="small-or">AND</p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">warfarin</a>
                                             <span>: </span>
                                             <span>5-10 mg orally once daily initially, adjust dose according to target
                                                INR</span>
                                          </p>
                                          <span class="reference">
                                             <a href="#referencePop-more8" data-trigger="click focus" data-toggle="popover"
                                                class="morePop" data-original-title="" title=""
                                                aria-describedby="popover621629">More</a>
                                             <span class="popTitle" aria-hidden="true"></span>
                                             <span class="popText" aria-hidden="true">
                                                <p class="w-75">
                                                   Starting dose can be calculated using an online tool that takes patient
                                                   characteristics and/or CYP2C9/VKORC1 genotype information (if available)
                                                   into account. [ONLINE RESOURCE: Warfarin dosing
                                                   http://www.warfarindosing.org/Source/Home.aspx]
                                                </p>
                                             </span>
                                          </span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p><strong>[No special considerations]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">edoxaban</a>
                                             <span>: </span>
                                             <span>start following initial use of a parenteral anticoagulant for at least 5
                                                days; body weight &lt;60 kg: 30 mg orally once daily; body weight ≥60 kg: 60
                                                mg orally once daily</span>
                                          </p>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p><strong>[No special considerations]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">dabigatran</a>
                                             <span>: </span>
                                             <span>start following initial use of a parenteral anticoagulant for at least 5
                                                days; 18-74 years of age: 150 mg orally twice daily; 75-79 years of age:
                                                110-150 mg orally twice daily; ≥80 years of age: 110 mg orally twice
                                                daily</span>
                                          </p>
                                       </div>
                                    </div>
      
                                    <!-- SWITCHABLE DRUG CONTENT BOX -->
                                    <div class="treatment-box-cplus mt-4 como-content hide">
                                       <h4>Primary options</h4>
                                       <div class="drug-accordion">
      
                                          <div class="drug-content2" style="display: none">
                                             <div class="poce_drug_msg" class="warning">
                                                <h3 class="cplus_title">These drug options and doses relate to a patient with
                                                   <strong>no comorbidities.</strong></h3>
                                             </div>
                                             <div class="treatment-box">                                             
                                                
                                                <p><strong>[No special considerations]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">apixaban: </a>
                                                      <span>10 mg orally
                                                      twice daily for 7 days, followed by 5 mg twice daily</span>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p><strong>[No special considerations]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">rivaroxaban: </a>
                                                   <span>15 mg orally twice daily for 21 days, followed by 20 mg once daily</span>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p><strong>[No special considerations]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">enoxaparin: </a>
                                                   <span>1 mg/kg subcutaneously every 12 hours</span>
                                                </p>
                                                <p class="small-or">-or-</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dalteparin: </a>
                                                   <span>100 units/kg subcutaneously every 12 hours</span>
                                                </p>
                                                <p class="small-or">-AND-</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">warfarin: </a>
                                                   <span>5-10 mg orally once daily initially, adjust dose according to target
                                                      INR</span>
            
                                                   <span class="reference">
                                                      <a href="#referencePop-more4" data-trigger="click focus" data-toggle="popover"
                                                         class="morePop" data-original-title="" title=""
                                                         aria-describedby="popover621629">More</a>
                                                      <span class="popTitle" aria-hidden="true">
                                                      </span>
                                                      <span class="popText" aria-hidden="true">
                                                         <p class="w-75">Starting dose can be calculated using an online tool that
                                                            takes patient characteristics and/or CYP2C9/VKORC1 genotype information
                                                            (if available) into account.
                                                            [http://www.warfarindosing.org/Source/Home.aspx ONLINE RESOURCE:
                                                            Warfarin dosing]</p>
                                                      </span>
                                                   </span>
            
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p><strong>[Active cancer]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">enoxaparin: </a>
                                                   <span>1 mg/kg subcutaneously every 12 hours</span>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p><strong>[Active cancer]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dalteparin: </a>
                                                   <span>200 units/kg subcutaneously once daily for the first 30 days, followed by
                                                      150 units/kg once daily for 5 months, maximum 18,000 units/dose
                                                      |
            
                                                      <span class="reference">
                                                         <a href="#referencePop-more4" data-trigger="click focus"
                                                            data-toggle="popover" class="morePop" data-original-title="" title=""
                                                            aria-describedby="popover621629">More</a>
                                                         <span class="popTitle" aria-hidden="true">
                                                         </span>
                                                         <span class="popText" aria-hidden="true">
                                                            <p class="w-75">Refer to local drug formulary for a table of recommended
                                                               weight-based doses. Use fixed-dose syringes for this indication. </p>
                                                         </span>
                                                      </span>
            
                                                   </span>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p><strong>[Pregnant women]</strong></p>
            
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">enoxaparin: </a>
                                                   <span> body weight &lt;50 kg: 40 mg subcutaneously twice daily; body weight 50-69
                                                      kg: 60 mg subcutaneously twice daily; body weight 70-89 kg: 80 mg
                                                      subcutaneously twice daily; body weight ≥90 kg: 100 mg subcutaneously twice
                                                      daily </span>
                                                </p>
                                                <span class="reference">
                                                   <a href="#referencePop-more8" data-trigger="click focus" data-toggle="popover"
                                                      class="morePop" data-original-title="" title=""
                                                      aria-describedby="popover621629">More</a>
                                                   <span class="popTitle" aria-hidden="true"></span>
                                                   <span class="popText" aria-hidden="true">
                                                      <p class="w-75">
                                                         Dose based on early pregnancy body weight.
                                                      </p>
                                                   </span>
                                                </span>
            
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p><strong>[Pregnant women]</strong></p>
            
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dalteparin: </a>
                                                   <span>body weight &lt;50 kg: 5000 units subcutaneously twice daily; body weight
                                                      50-69 kg: 6000 units subcutaneously twice daily; body weight 70-89 kg: 8000
                                                      units subcutaneously twice daily; body weight ≥90 kg: 10,000 units
                                                      subcutaneously twice daily</span>
                                                </p>
                                                <span class="reference">
                                                   <a href="#referencePop-more8" data-trigger="click focus" data-toggle="popover"
                                                      class="morePop" data-original-title="" title=""
                                                      aria-describedby="popover621629">More</a>
                                                   <span class="popTitle" aria-hidden="true"></span>
                                                   <span class="popText" aria-hidden="true">
                                                      <p class="w-75">
                                                         Dose based on early pregnancy body weight.
                                                      </p>
                                                   </span>
                                                </span>
            
            
                                                </p>
                                                <h4>Secondary options</h4>
                                                <p><strong>[No special considerations]</strong></p>
            
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">fondaparinux: </a>
                                                   <span>body weight &lt;50 kg: 5 mg subcutaneously once daily; body weight 50-100
                                                      kg: 7.5 mg subcutaneously once daily; body weight ≥100 kg: 10 mg
                                                      subcutaneously once daily</span>
                                                </p>
            
                                                </p>
                                                <p class="small-or">AND</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">warfarin: </a>
                                                   <span>5-10 mg orally once daily initially, adjust dose according to target
                                                      INR</span>
                                                </p>
                                                <span class="reference">
                                                   <a href="#referencePop-more8" data-trigger="click focus" data-toggle="popover"
                                                      class="morePop" data-original-title="" title=""
                                                      aria-describedby="popover621629">More</a>
                                                   <span class="popTitle" aria-hidden="true"></span>
                                                   <span class="popText" aria-hidden="true">
                                                      <p class="w-75">
                                                         Starting dose can be calculated using an online tool that takes patient
                                                         characteristics and/or CYP2C9/VKORC1 genotype information (if available)
                                                         into account. [ONLINE RESOURCE: Warfarin dosing
                                                         http://www.warfarindosing.org/Source/Home.aspx]
                                                      </p>
                                                   </span>
                                                </span>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p><strong>[No special considerations]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">edoxaban: </a>
                                                   <span>start following initial use of a parenteral anticoagulant for at least 5
                                                      days; body weight &lt;60 kg: 30 mg orally once daily; body weight ≥60 kg: 60
                                                      mg orally once daily</span>
                                                </p>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p><strong>[No special considerations]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dabigatran: </a>
                                                   <span>start following initial use of a parenteral anticoagulant for at least 5
                                                      days; 18-74 years of age: 150 mg orally twice daily; 75-79 years of age:
                                                      110-150 mg orally twice daily; ≥80 years of age: 110 mg orally twice
                                                      daily</span>
                                                </p>
                                             </div>
                                             <p class="como_link mt-4 drug-title2"><a href="#">&#9664; Back to drug doeses with added comorbidities</a></p>
                                          </div>
      
                                          <div class="drug-content1">
                                             <div class="poce_drug_msg">
                                                <h3 class="cplus_title">Drug choice, dose and interactions may be affected by
                                                   the patient's comorbidities. Check your local drug formulary.</h3>
                                             </div>
                                             <div class="treatment-box">                                
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">apixaban: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">rivaroxaban: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">enoxaparin: </a>
                                                </p>
                                                <p class="small-or">-or-</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dalteparin: </a>
                                                </p>
                                                <p class="small-or">-AND-</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">warfarin: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">enoxaparin: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dalteparin: </a>
                                                </p>
                                                <p class="small-or">OR</p>
      
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">enoxaparin: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dalteparin: </a>
                                                </p>
                                                <h4>Secondary options</h4>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">fondaparinux: </a>
                                                </p>
                                                </p>
                                                <p class="small-or">AND</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">warfarin: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">edoxaban: </a>
                                                </p>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dabigatran: </a>
                                                </p>
                                                </div>
                                                <p>For patients with renal impairment <a href="#" data-toggle="modal" data-target="#renal">see dose in the Renal Drug Handbook</a></p>
                                                <div class="modal fade" id="renal" tabindex="-1" role="dialog" aria-labelledby="renal" aria-hidden="true" style="display: none;">
                                                   <div class="modal-dialog" role="document">
                                                      <div class="modal-content">
                                                         <div class="modal-header">
                                                            <h3 class="modal-title" id="exampleModalLabel">
                                                               The Renal Handbook<br /></h3>
                                                         </div>
                                                         <iframe width="100%" height="700" src="../pdf/renalbook.pdf" title="Renal Book"></iframe>
                                                      </div>
                                                   </div>
                                                </div>
                                                <p class="como_link mt-4 drug-title1"><a href="#">&#9658; Show drug doses for a patient with no comorbidities</a></p>
                                             </div>
                                             
                                          </div>
                                    </div>
                                    <!-- DRUG CONTENT BOX ENDS -->
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="#" role="tab header" id="nested-collapse_0_0_3"
                                          aria-controls="nested-collapse_0_0_3" aria-expanded="false" class="">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Consider
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Vasoactive drug</span>
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <p><strong>Give a vasopressor such as adrenaline (epinephrine) or noradrenaline
                                          (norepinephrine), or an inotrope such as dobutamine if SBP remains &lt;90 mmHg
                                          despite giving adequate intravenous fluids.</strong>[ESC]</p>
      
      
                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle16" class="toggle" />
                                          <label class="title" for="toggle16">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: Choice of vasopressor is based on limited
                                                evidence</span>
                                          </label>
                                          <div class="content">
                                             <p><strong>Adrenaline combines the beneficial properties of noradrenaline
                                                   (vasoconstriction with increased right ventricular perfusion, positive
                                                   inotropy) and dobutamine (positive inotropy), but without the vasodilatory
                                                   effects associated with the latter.</strong> [ESC]</p>
                                             <ul>
                                                <li>A small prospective descriptive study of patients with RV failure and
                                                   shock demonstrated that during adrenaline infusion, mean arterial pressure
                                                   (MAP), cardiac index (CI) and stroke volume index (SVI) were increased and
                                                   right ventricular ejection fraction (RVEF) improved as well.</li>
                                                <li>Another small study showed that adrenaline improved cardiac output in
                                                   patients with shock without having a detrimental effect on pulmonary
                                                   vascular resistance. [BARRINGTON]</li>
                                             </ul>
                                             <p><strong>Evidence suggests that noradrenaline appears to improve RV function
                                                   through its inotropic effect, as well as improving coronary perfusion by
                                                   raising systemic pressure.</strong></p>
                                             <ul>
                                                <li>However, noradrenaline increases pulmonary vascular resistance and, in
                                                   fact, no conclusive data are available regarding its potential use in PE.
                                                   [PREWITT]</li>
                                             </ul>
                                             <p><strong>The use of dobutamine and/or dopamine may be considered for patients
                                                   with PE, low cardiac index, and normal BP based on the results of some
                                                   studies.</strong></p>
                                             <ul>
                                                <li>Dobutamine enhances contractility with an increase in stroke volume and
                                                   cardiac output. However, raising the cardiac index above physiological
                                                   values may aggravate the ventilation&ndash;perfusion mismatch by further
                                                   redistributing ﬂow from (partly) obstructed to unobstructed vessels.
                                                   [DIS][ESC]</li>
                                             </ul>
                                          </div>
                                       </div>
                                    </div>
      
                                    <div class="treatment-wrap non-como-content show">
                                       <h4>Primary options</h4>
                                       <div class="treatment-box">
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">adrenaline (epinephrine)</a><span>:
                                             </span><span>2-10 micrograms/minute by intravenous infusion initially, adjust
                                                dose according to response</span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">noradrenaline (norepinephrine)</a>
                                             <span>: </span>
                                             <span> 0.4 to 0.8 mg/hour by intravenous infusion initially, adjust dose
                                                according to response</span>
                                          </p>
      
                                          <span class="reference">
                                             <a href="#referencePop-more8" data-trigger="click focus" data-toggle="popover"
                                                class="morePop" data-original-title="" title=""
                                                aria-describedby="popover621629">More</a>
                                             <span class="popTitle" aria-hidden="true"></span>
                                             <span class="popText" aria-hidden="true">
                                                <p class="w-75">
                                                   Dose refers to noradrenaline base.
                                                </p>
                                             </span>
                                          </span>
                                          <p class="small-or">OR</p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">dobutamine:</a>
                                             <span>: </span>
                                             <span>2.5 to 10 micrograms/kg/minute by intravenous infusion initially, adjust
                                                dose according to response, maximum 40 micrograms/kg/minute</span>
                                          </p>
                                       </div>
                                    </div>
      
                                    <!-- SWITCHABLE DRUG CONTENT BOX -->
                                    <div class="treatment-box-cplus mt-4 como-content hide">
                                       <h4>Primary options</h4>
                                       <div class="drug-accordion">
      
                                          <div class="drug-content2" style="display: none">
                                             <div class="poce_drug_msg" class="warning">
                                                <h3 class="cplus_title">These drug options and doses relate to a patient with
                                                   <strong>no comorbidities.</strong></h3>
                                             </div>
                                             <div class="treatment-box">                                             
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">adrenaline (epinephrine): </a>
                                                      <span>2-10 micrograms/minute by intravenous infusion initially, adjust
                                                      dose according to response</span>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">noradrenaline (norepinephrine): </a>
                                                   <span> 0.4 to 0.8 mg/hour by intravenous infusion initially, adjust dose
                                                      according to response</span>
                                                </p>
            
                                                <span class="reference">
                                                   <a href="#referencePop-more8" data-trigger="click focus" data-toggle="popover"
                                                      class="morePop" data-original-title="" title=""
                                                      aria-describedby="popover621629">More</a>
                                                   <span class="popTitle" aria-hidden="true"></span>
                                                   <span class="popText" aria-hidden="true">
                                                      <p class="w-75">
                                                         Dose refers to noradrenaline base.
                                                      </p>
                                                   </span>
                                                </span>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dobutamine: </a>
                                                   <span>2.5 to 10 micrograms/kg/minute by intravenous infusion initially, adjust
                                                      dose according to response, maximum 40 micrograms/kg/minute</span>
                                                </p>
                                             </div>
                                             <p class="como_link mt-4 drug-title2"><a href="#">&#9664; Back to drug doeses with added comorbidities</a></p>
                                          </div>
      
                                          <div class="drug-content1">
                                             <div class="poce_drug_msg">
                                                <h3 class="cplus_title">Drug choice, dose and interactions may be affected by
                                                   the patient's comorbidities. Check your local drug formulary.</h3>
                                             </div>
                                             <div class="treatment-box">                                          
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">adrenaline (epinephrine): </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">noradrenaline (norepinephrine): </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dobutamine: </a>
                                                </p>
                                                </div>
                                                <p>For patients with renal impairment <a href="#" data-toggle="modal" data-target="#renal">see dose in the Renal Drug Handbook</a></p>
                                                <div class="modal fade" id="renal" tabindex="-1" role="dialog" aria-labelledby="renal" aria-hidden="true" style="display: none;">
                                                   <div class="modal-dialog" role="document">
                                                      <div class="modal-content">
                                                         <div class="modal-header">
                                                            <h3 class="modal-title" id="exampleModalLabel">
                                                               The Renal Handbook<br /></h3>
                                                         </div>
                                                         <iframe width="100%" height="700" src="../pdf/renalbook.pdf" title="Renal Book"></iframe>
                                                      </div>
                                                   </div>
                                                </div>
                                                <p class="como_link mt-4 drug-title1"><a href="#">&#9658; Show drug doses for a patient with no comorbidities</a></p>
                                             </div>
                                             
                                          </div>
                                    </div>
                                    <!-- DRUG CONTENT BOX ENDS -->
      
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="#" role="tab header" id="nested-collapse_0_0_3"
                                          aria-controls="nested-collapse_0_0_3" aria-expanded="false" class="">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Consider
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Surgical embolectomy/percutaneous catheter-directed
                                                      treatment</span>
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <p><strong>According to the European Society of Cardiology (ESC) guidelines [ESC] [CTS],
                                          surgical embolectomy or percutaneous catheter-directed therapy may be indicated in
                                          the following circumstances: </strong></p>
                                    <ul>
                                       <li>Patients who are unable to receive thrombolytic therapy because of bleeding risk
                                       </li>
                                       <li>Insufficient time for effective systemic thrombolysis</li>
                                       <li>Failed thrombolysis</li>
                                    </ul>
                                    <p><strong>The use of these interventions will depend on local expertise and
                                          availability.</strong></p>
                                    <p><strong>Surgical pulmonary embolectomy</strong></p>
                                    <ul>
                                       <li>Although this is rarely performed in the UK, the ESC guideline states that is
                                          technically a relatively simple operation although in practice it is normally only
                                          undertaken in specialist cardiothoracic centres. [ESC]</li>
                                    </ul>
                                    <p><strong>Catheter-directed therapy</strong></p>
                                    <ul>
                                       <li>Catheter-directed therapy uses a lower dose of thrombolytic drug (approximately one
                                          third of full-dose systemic thrombolysis) and is believed to reduce the risks of
                                          bleeding at remote sites(e.g. Intracranial or gastrointestinal). [KEARON]</li>
                                       <li>For patients with absolute contraindications to thrombolysis, interventional
                                          options include: [ESC]</li>
                                       <ul>
                                          <li>thrombus fragmentation with pigtail or balloon catheter,</li>
                                          <li>rheolytic thrombectomy with hydrodynamic catheter devices,</li>
                                          <li>suction thrombectomy with aspiration catheters</li>
                                          <li>rotational thrombectomy.</li>
                                       </ul>
                                       <li>For patients with relative contraindications to thrombolysis, interventional
                                          options include:[ESC]</li>
                                       <ul>
                                          <li>catheter-directed thrombolysis</li>
                                          <li>pharmacomechanical thrombolysis</li>
                                       </ul>
                                    </ul>
      
      
                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle17" class="toggle" />
                                          <label class="title" for="toggle17">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: Surgical pulmonary embolectomy and
                                                catheter-directed therapy outcomes</span>
                                          </label>
                                          <div class="content">
                                             <p><strong>There is no comparative data to guide the primary management of
                                                   patients with high-risk (massive) PE and a strong contraindication to
                                                   systemic thrombolysis and therefore management will depend on local options
                                                   and expertise</strong>.</p>
                                             <ul>
                                                <li>However, some small studies have looked at outcomes from surgical
                                                   pulmonary embolectomy and catheter-directed therapy.</li>
                                                <li>Mortality rates following pulmonary embolectomy range from 4% to 27%.
                                                   [FUKUDA] In a small cohort of patients who underwent surgical pulmonary
                                                   embolectomy for acute high-risk (massive) pulmonary thromboembolism, the
                                                   10-year survival rate was 84%. [FUKUI]</li>
                                                <li>A meta-analysis of non-randomised trials of catheter-directed therapies
                                                   reported a clinical success rate of 87% with an associated risk of major
                                                   and minor complications of 2% and 8%, respectively. [KUO]</li>
                                                <li>The extent of early RV recovery after low-dose catheter-directed
                                                   thrombolysis appears comparable to that after standard-dose systemic
                                                   thrombolysis whereas anticoagulation with heparin alone has little effect
                                                   on improvement of RV size and performance within the first 24&ndash;48
                                                   hours.
                                                </li>
                                                <li>In a randomized, controlled clinical trial of 59 intermediate-risk
                                                   patients, when compared with treatment by heparin alone, catheter-directed
                                                   ultrasound-accelerated thrombolysis&mdash;administering 10 mg alteplase per
                                                   treated lung over 15 hours&mdash;significantly reduced the subannular RV/LV
                                                   dimension ratio between baseline and 24-hour follow-up without an increase
                                                   in bleeding complications [TIEDE] [BOLUS][KUCHER]</li>
                                             </ul>
                                          </div>
                                       </div>
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Review diabetes medication (NEVER stop insulin in
                                                      people with type 1 diabetes)</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                       </span>
                                       <h3 class="poce_title"></h3>
      
                                       <p><strong>Never stop insulin in people with type 1 diabetes coming into hospital -
                                             insulin deficiency can rapidly precipitate ketoacidosis, particularly during
                                             illness. </strong></p>
                                       <ul>
                                          <li><strong>Always continue basal insulins</strong> (long-acting or background
                                             insulins e.g., determir or glargine) as this will <strong>prevent
                                                ketoacidosis</strong> if doses of rapid-acting insulin are inadvertently
                                             missed or delayed.</li>
                                          <li><strong>Dose adjustments</strong> up or down may be needed.</li>
                                          <ul>
                                             <li>For example, in the<strong> absence of significant hyperglycaemia
                                                </strong>consider <strong>reducing the evening basal insulin by 20% on
                                                   admission</strong>, as most patients will have a <strong>smaller evening
                                                   meal in hospital</strong> compared with at home.</li>
                                          </ul>
                                       </ul>
                                       <p><strong>If a variable rate intravenous insulin infusion (VRIII) is started</strong>:
                                       </p>
                                       <ul>
                                          <li><strong>Continue the basal insulin </strong><em>(Joint British Diabetes
                                                Societies for inpatient care [JBDS-IP], 2014)</em> as this will reduce the
                                             risk of ketosis in the advent of the VRIII being <strong>accidentally interrupted
                                             </strong>(e.g., by cannula displacement or blockage) or <strong>switched off
                                             </strong>(e.g., during transfer to another ward or department)<strong>.</strong>
                                          </li>
                                          <li>The patient&rsquo;s usual <strong>rapid-acting </strong>and <strong>mixed
                                                insulins</strong> can be <strong>stopped while on a VRIII</strong>. <em>Joint
                                                British Diabetes Societies for inpatient care [JBDS-IP], 2014)</em></li>
                                          <li>Use the VRIII for as <strong>short a time as possible</strong>, <em>(Joint
                                                British Diabetes Societies for inpatient care [JBDS-IP], 2014) </em>as
                                             incorrect use and insufficient monitoring can result in<strong> severe
                                                hypoglycaemia</strong> or<strong> ketoacidosis</strong>.</li>
                                       </ul>
                                       <p><strong>Indications for a VRIII include</strong>: <em>(Joint British Diabetes
                                             Societies for inpatient care [JBDS-IP], 2014)</em></p>
                                       <ul>
                                          <li>Patients with diabetes or hospital-related hyperglycaemia who
                                             <strong>can&rsquo;t take oral food or fluid </strong>and where it&rsquo;s
                                             <strong>not possible to adjust their insulin regimen</strong>, e.g., when:</li>
                                          <ul>
                                             <li>Vomiting</li>
                                             <li>Nil by mouth and patient will miss more than one meal</li>
                                             <li>There is severe illness with a need to achieve good glycaemic control (such
                                                as with sepsis).</li>
                                          </ul>
                                          <li>Most patients with diabetes <strong>requiring emergency surgery</strong>.
                                             <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2016)</em>
                                          </li>
                                          <li><strong>Special circumstances</strong>, such as hyperglycaemia with
                                             <strong>acute coronary syndrome</strong>, when <strong>pregnant</strong>, or when
                                             receiving <strong>TPN or enteral feeding</strong>, or <strong>taking
                                                corticosteroids</strong>. <em>(Joint British Diabetes Societies for inpatient
                                                care., 2012) </em></li>
                                          <ul>
                                             <li><strong>Get specialist advice</strong> from the <strong>diabetes
                                                   team</strong> in these circumstances.</li>
                                          </ul>
                                       </ul>
                                       <p><strong>People with type 2 diabetes on basal insulin should continue to take it,
                                             unless otherwise indicated</strong>.</p>
                                       <ul>
                                          <li>In the <strong>absence of significant hyperglycaemia</strong> consider
                                             <strong>reducing the evening basal insulin</strong> by <strong>20% on
                                                admission</strong>, as most patients will have a <strong>smaller evening
                                                mealin hospital </strong>compared with at home.</li>
                                       </ul>
                                       <p>Give<strong> oral hypoglycaemic</strong> medication<strong> with food</strong> to
                                          reduce the<strong> risk of hypoglycaemia</strong>.</p>
                                       <ul>
                                          <li><strong>Never give oral hypoglycaemic medication at bedtime </strong>and
                                             consider <strong>reducing the evening dose of sulphonylurea</strong>.</li>
                                          <ul>
                                             <li>This is because most patients have a <strong>smaller evening meal in hospital
                                                </strong>compared with their usual evening meal at home.</li>
                                          </ul>
                                       </ul>
                                       <p><strong>Withhold metformin in patients:</strong></p>
                                       <ul>
                                          <li>With <strong>contraindications</strong>, such as <strong>significant renal
                                                impairment</strong> (&lt;30 mL/minute/1.73 m2)</li>
                                          <li>With <strong>metabolic acidosis </strong>(including lactic acidosis and DKA)
                                          </li>
                                          <li>At<strong> risk of lactic acidosis</strong> with metformin, such as:</li>
                                          <ul>
                                             <li>With conditions associated with <strong>acute kidney injury
                                                </strong>or<strong> tissue hypoxia,</strong> including<strong>
                                                   dehydration</strong></li>
                                             <li>With <strong>renal impairment</strong>and who have, or are to be
                                                <strong>fasted for a prolonged period</strong> or who are due to have
                                                a<strong> radio-opaque contrast injection</strong> as part of an imaging
                                                procedure. <strong>Follow local protocols </strong>for guidance on the
                                                specific eGFR levels indicating renal impairment for this to be applied.</li>
                                          </ul>
                                       </ul>
                                       <p><strong>Be aware that withholding metformin results in hyperglycemia</strong>.</p>
                                       <ul>
                                          <li>If your patient is taking <strong>other glucose-lowering medication</strong>,
                                             these may need to be<strong> increased in dose</strong> or an <strong>alternative
                                                hypoglycaemic medication to metformin</strong> prescribed.</li>
                                          <li>Some patients may need <strong>insulin as a temporary measure</strong>,
                                             but<strong> seek diabetes inpatient specialist team advice</strong>.</li>
                                       </ul>
                                       <p><strong>Stop sodium-glucose cotransporter-2 (SGLT-2) inhibitors in all acutely ill
                                             patients, particularly if dehydrated or with infection, as they are at risk of
                                             euglycaemic ketoacidosis.</strong></p>
                                       <ul>
                                          <li>SGLT-2 inhibitors (e.g., dapagliflozin) <strong>reduce blood glucose
                                                reabsorption</strong> in the kidneys (independently of insulin metabolism of
                                             glucose). <em>(Peters AL, et al, 2015) </em></li>
                                          <li>They can<strong> mask underlying ketoacidosis</strong> by patients having a
                                             normal (or near normal) serum glucose level <strong>(euglycaemic
                                                ketoacidosis)</strong>.</li>
                                          <li>Check <strong>blood ketones</strong> as urinary ketone measurement may be
                                             unreliable.</li>
                                          <li><strong>Treat for DKA</strong> if <strong>blood ketone level is &ge;3
                                                mmol/L</strong>, blood<strong> pH &lt;7.3</strong> and <strong>bicarbonate
                                                &lt;15 mmol/L</strong>. (<em>JBDS-IP, 2013)</em></li>
                                       </ul>
                                       <p><strong>Reduce or omit the dose of gliclazide if the patient has impaired kidney
                                             function or is eating less than usual, to avoid hypoglycaemia at night. </strong>
                                       </p>
                                       <p><strong>Inform the diabetic inpatient team of the admission of any patient with
                                             diabetes. They are available for advice and support.</strong></p>
                                       <p><strong>For a patient at theend of life</strong>: <em>(Rowles S, et al 2011)</em>
                                       </p>
                                       <ul>
                                          <li><strong>Hypoglycaemic medication</strong> should be <strong>reduced </strong>to
                                             the minimum, <strong>but</strong></li>
                                          <li>The patient should be<strong> kept free from symptomatic
                                                hyperglycaemia</strong>, which can lead to <strong>dehydration</strong>,
                                             <strong>ketosis</strong> or <strong>hyperosmolar hyperglycaemia</strong>.</li>
                                       </ul>
                                       <p>Refer to <strong>local protocols </strong>or the Association of British Clinical
                                          Diabetologists (ABCD). <em>(Rowles S, et al 2011)</em></p>
                                    </div>
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Monitor and manage blood glucose</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
      
                                       <p><strong>Monitor blood glucose levels at least 4 times a day (pre-meal and before
                                             bedtime if eating) in all acutely unwell patients with diabetes mellitus
                                             (</strong><em>American Diabetes Association, 2019)</em></p>
                                       <ul>
                                          <li>The risk of<strong> hypo- and hyperglycaemia</strong> increases when people with
                                             diabetes are admitted to hospital with acute conditions. <em>(NHS Digital.
                                                National Diabetes Inpatient Audit (NaDIA) - 2017, 2018)</em></li>
                                          <li><strong>More frequent monitoring</strong> is needed after <strong>episodes of
                                                hyperglycaemia</strong> or <strong>hypoglycaemia</strong>.</li>
                                          <li>More <strong>frequent monitoring</strong> is needed after a <strong>change in
                                                hypoglycaemic medication</strong>.</li>
                                          <li>Patients on a<strong> variable rate intravenous insulin infusion
                                                (VRIII)</strong> need <strong>capillary blood glucose measurements every
                                                hour</strong>. <em>(Joint British Diabetes Societies for inpatient care
                                                [JBDS-IP], 2014)</em></li>
                                          <li>Support <strong>self-management</strong> (including monitoring blood glucose) if
                                             this conforms to local protocols, it is safe to do so, and the patient is
                                             willing. <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP],
                                                2012) </em></li>
                                       </ul>
                                       <p><strong>Prevent and manage hyperglycaemia if it occurs</strong></p>
                                       <ul>
                                          <li>There is <strong>no consensus ontarget blood glucose</strong> levels for people
                                             with diabetes in hospital.</li>
      
                                          <li><strong>The Joint British Diabetes Societies for Inpatient Care</strong>
                                             (JBDS-IP) recommend an<strong> ideal range</strong> of between<strong> 6 to 10
                                                mmol/L</strong>, and an <strong>acceptable range</strong> of <strong>4 to 12
                                                mmol/L</strong><em>(JBDS-IP, 2014)</em></li>
                                          <li><strong>TheAmerican Diabetes Association</strong> recommend a <strong>target
                                                blood glucose range</strong> of <strong>7.8 to 10.0 mmol/L</strong> (140-180
                                             mg/dL) for most critically and noncritically ill patients. (<em>American Diabetes
                                                Association. Diabetes Care in the Hospital: Standards of Medical Care in
                                                Diabetes&mdash;2019, 2019)</em></li>
      
                                          <li><em>The <strong>National Institute for Health and Care Excellence</strong>
                                                recommends a target plasma glucose level of <strong>5 to 8 mmol/L</strong> in
                                                adults with type 1 diabetes in hospital undergoing surgery or with acute
                                                illness. <em>(NICE, 2017)</em></em></li>
                                       </ul>
                                       <p><strong>More liberal blood glucose targets</strong> are appropriate for people
                                          at<strong> high risk of falls </strong>and who are<strong> frail </strong>or have
                                          <strong>dementia</strong>. <em>(JBDS-IP, 2014)</em></p>
                                    </div>
      
                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle18" class="toggle" />
                                          <label class="title" for="toggle18">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: patient outcomes associated with
                                                hyperglycaemia</span>
                                          </label>
                                          <div class="content">
                                             <p><strong>Hyperglycaemia in patients in hospital is associated with adverse
                                                   outcomes. (</strong><em>Moghissi, 2009)</em></p>
                                             <p>Hyperglycaemia in patients in hospital, whether with known diabetes or not,
                                                has been shown by various observational studies to be associated with adverse
                                                patient outcomes, including increased mortality.
                                                <strong>(</strong><em>Moghissi, 2009)</em></p>
                                          </div>
                                       </div>
                                    </div>
      
      
                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle19" class="toggle" />
                                          <label class="title" for="toggle19">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: blood glucose targets for people with diabetes in
                                                hospital</span>
                                          </label>
                                          <div class="content">
                                             <p><strong>Conflicting evidence for optimal blood glucose targets has led to
                                                   variations in recommendations in different countries and settings. Follow
                                                   your local protocol.</strong></p>
                                             <ul>
                                                <li>Intensive care setting</li>
                                                <ul>
                                                   <li>A randomised controlled trial (RCT) of critically ill patients in a
                                                      primarily surgical intensive care setting found lower patient mortality
                                                      with tight glucose control - 80 to 110 mg/dL (4.4 to 6.1 mmol/L)
                                                      compared with &lsquo;conventional&rsquo; more liberal glucose control.
                                                      <em>(Van den Berghe G et al, 2001) </em></li>
                                                   <li>However, a subsequent multicentre RCT in critically ill medical and
                                                      surgical patients in other intensive care settings found increased
                                                      mortality with tighter glucose control, possibly due to increased
                                                      episodes of hypoglycaemia. <em>(Finfer et al, 2009)</em></li>
                                                </ul>
                                             </ul>
                                             <p>A 2010 systematic review of 6 RCTs and a meta-analysis investigating tight
                                                glucose control (80 to 110 mg/dL [4.4 to 6.1 mmol/L]) vs less strict glucose
                                                control in critically ill patients in the ICU setting found no significant
                                                improvement in mortality with tight glucose control, but it was associated
                                                with significantly more hypoglycaemic episodes compared with less strict
                                                glucose control. (<em>Marik, 2010)</em></p>
                                          </div>
                                       </div>
                                    </div>
      
      
      
                                    <div id="tip_pitfall" class="card card-inverse mb-4">
                                       <div class="card-block">
                                          
                                          <h3 class="card-title"></h3>
                                          <p><strong>Ask for expert advice from the diabetes team in complex patients, or
                                                where hyperglycaemia is difficult to control.</strong></p>
                                       </div>
                                    </div>
      
                                    <p><strong>Prevent and manage hypoglycaemia if it occurs</strong></p>
                                    <ul>
                                       <li><strong>Monitor blood glucose</strong> in people with diabetes in hospital and
                                          <strong>adjust medication </strong>in response to illness and hospital meal times,
                                          in order to <strong>reduce risk</strong> of <strong>hypoglycaemic episodes</strong>.
                                       </li>
                                       <li>1 in 5 inpatients with diabetes in England and Wales have a<strong> hypoglycaemic
                                             episode </strong>during their hospital stay. <em>(NHS Digital. National Diabetes
                                             Inpatient Audit (NaDIA) - 2017, 2018)</em></li>
                                       <li>Causes include:<em> (JBDS-IP, 2018)</em></li>
                                       <ul>
                                          <li>Recovery from an acute illness</li>
                                          <li>Insulin or oral hypoglycaemic medication error</li>
                                          <li>Wrong timing of insulin in relation to meals</li>
                                          <li>Patients eating less but taking the same amount of diabetes medication</li>
                                          <li>No bedtime snacks</li>
                                          <li>Reduced appetite or vomiting.</li>
                                       </ul>
                                    </ul>
                                    <div id="tip_pitfall" class="card card-inverse mb-4">
                                       <div class="card-block">
                                          
                                          <h3 class="card-title"></h3>
                                          <p><strong>Bedtime snacks </strong>can reduce the risk of <strong>early morning
                                                hypoglycaemia</strong>. <em>(NHS Digital. National Diabetes Inpatient Audit
                                                (NaDIA) - 2017, 2018)</em></p>
                                       </div>
                                    </div>
      
                                    <p><strong>Treat hypoglycaemia actively if the blood glucose falls below 4.0 mmol/L.
                                       </strong><em>(JBDS-IP, 2018)</em></p>
                                    <ul>
                                       <li>Follow hospital protocol. The JBDS-IP has guidelines on hospital management of
                                          hypoglycaemia in adults with diabetes. <em>(JBDS-IP, 2018)</em></li>
                                    </ul>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group CKD-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Check baseline kidney function</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Check baseline serum kidney function on admission in all patients with a
                                             previous history of chronic kidney disease (CKD). </strong><em>[National
                                             Institute for Health and Care Excellence. 2013)</em></p>
                                       <ul>
                                          <li><strong>CKD</strong> is a significant<strong> risk factor</strong> for the
                                             development of <strong>acute kidney injury</strong>. <em>(Hsu CY, et al,
                                                2008)</em></li>
                                          <li>Acute illness increases the risk of deterioration in renal function.</li>
                                       </ul>
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Stroke-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Baseline neurological assessment</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Do a baseline neurological assessment on admission for all patients with a
                                             history of stroke.</strong></p>
                                       <ul>
                                          <li>Patients with <strong>acute illness</strong> (including infections and causes of
                                             hypotension) are at <strong>increased risk of stroke</strong> (both ischaemic and
                                             haemorrhagic). <em>(Grau AJ, et al, 2010) (Eigenbrodt ML, et al, 2000)</em></li>
                                          <li>If there is a suspicion of a change in neurological status during admission,
                                             repeat the<strong>neurological assessment</strong> in case of a <strong>possible
                                                new stroke</strong>.</li>
                                          <li>Following assessment, consider appropriate level of <strong>patient
                                                supervision</strong> e.g., relating to possible <strong>confusion</strong> at
                                             night, <strong>falls</strong> related to <strong>frailty</strong>.</li>
                                       </ul>
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Dementia-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Baseline cognitive assessment and collateral
                                                      history</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Do a baseline cognitive assessment in all older patients, particularly those
                                             with a history of dementia. </strong><em>(Pendlebury ST, et al, 2015)</em></p>
                                       <ul>
                                          <li>Use a<strong> validated scoring system</strong> that is also feasible in the
                                             acute setting, such as:<em>(Pendlebury ST, et al, 2015)</em>
                                             <ul>
                                                <li>The <strong>abbreviated mental test score</strong> (AMTS/10)
                                                   <em>(</em><em>Hodkinson,1972)</em></li>
                                                <li><strong>Montreal Cognitive Assessment</strong> (MoCA) <em>(Nasreddine,
                                                      2005).</em></li>
                                             </ul>
                                          </li>
                                       </ul>
                                       <p><strong>Dementia increases the risk of delirium. </strong></p>
                                       <ul>
                                          <li>This can acutely reduce patients' cognitive assessment scores. <em>(George J,
                                                2013)</em></li>
                                       </ul>
                                       <p><strong>Take a collateral history from family, friend or carer, to establish the
                                             patient&rsquo;s level of function and baseline cognition before this
                                             illness.</strong></p>
                                       <ul>
                                          <li>It&rsquo;s important to know if the <strong>decline</strong> in function and
                                             cognition has been <strong>gradual </strong>or <strong>acute</strong>.</li>
                                       </ul>
                                       <p>Use this information for <strong>monitoring clinical improvement</strong>, and for
                                          establishing <strong>needs on discharge</strong>.</p>
                                       <p>Read <a href="https://html-online.com/articles/" rel="nofollow noopener">HTML code
                                             related articles</a> on our blog to get the best tips on web content composing.
                                       </p>
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Dementia-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Assess for and manage delirium</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Assess the patient with dementia for delirium. </strong><em>(National
                                             Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                          <li>People living with dementia are at increased risk of delirium when they are
                                             admitted to hospital. (<em>National Institute for Health and Clinical Excellence,
                                                2018)</em></li>
                                          <li>Use a<strong> screening tool</strong>, such as:
                                             <ul>
                                                <li>The <strong>4-AT</strong><em>(</em><em>Bellelli, 2014)</em></li>
                                                <li>The <strong>short confusion assessment method (S-CAM), </strong>as
                                                   recommended by the National Institute of Health and Care Excellence (NICE).
                                                   <em>(National Institute for Health and Clinical Excellence. 2010)</em></li>
                                                <li>Document the results clearly.</li>
                                             </ul>
                                          </li>
                                       </ul>
                                       <p><strong>Assess the patient for any reversible causes of delirium</strong>.
                                          <em>(National Institute for Health and Clinical Excellence. 2010)</em>These include:
                                       </p>
                                       <ul>
                                          <li>Infection</li>
                                          <li>Pain</li>
                                          <li>Dehydration</li>
                                          <li>Constipation</li>
                                          <li>Hypoxia</li>
                                          <li>Immobility</li>
                                          <li>Medications</li>
                                          <li>Poor sleep</li>
                                          <li>Sensory impairment (e.g., ear wax or loss of glasses)</li>
                                       </ul>
                                       <p><strong>Investigations</strong> to help diagnose underlying causes include:</p>
                                       <ul>
                                          <li>Full blood count, electrolytes, renal function, liver function tests, calcium,
                                             glucose, CRP, folate and vitamin B12.</li>
                                          <li>Blood cultures (if bacteraemia is suspected)</li>
                                          <li>Urine microscopy and culture</li>
                                          <li>Chest x-ray</li>
                                       </ul>
                                       <p><strong>Manage according to the cause</strong>.</p>
                                       <p><strong>Manage patients with delirium initially with non-pharmacological treatment.
                                          </strong><em>(National Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                          <li>Reduce <strong>disorientation</strong> by providing a <strong>well-lit
                                                room,</strong> with a <strong>clock</strong> and <strong>calendar
                                             </strong>visible (e.g., on the wall).</li>
                                          <li>Encourage and facilitate <strong>family, friends and carers</strong> visiting
                                             the patient.</li>
                                          <li>Use verbal and non-verbal techniques to<strong> de-escalate</strong> conflict
                                             and distress.</li>
                                       </ul>
                                       <p><strong>Where non-pharmacological treatments are ineffective, and the patient is
                                             distressed or considered a risk to themselves or others, short-term antipsychotic
                                             or sedative drugs may be used.</strong></p>
                                       <p><strong>Only use antipsychotics as a last resort and not in patients with
                                             Parkinson&rsquo;s disease or dementia with Lewy bodies.</strong><em>(National
                                             Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                          <li><strong>Risperidone</strong> has the least anticholinergic effects. <em>(Tracy
                                                JI, et al, 1998)</em></li>
                                          <li><strong>Haloperidol</strong> is also licenced for this indication, but has the
                                             highest risk associated with its use. The UK National Institute for Health and
                                             Care Excellence recommends short-term use of haloperidol (usually for less than
                                             one week), starting at the <strong>lowest dose</strong> and <strong>titrating
                                                carefully</strong> according to the symptoms. <em>(National Institute for
                                                Health and Clinical Excellence. 2010)</em></li>
                                          <li>Consider sedation in significantly agitated patients who pose a risk to
                                             themselves or others.<strong> Lorazepam </strong>is a suitable choice, but it
                                             should only be given orally or intramuscularly (i.e., not intravenously).</li>
                                          <li>Lorazepam should only be used in the<strong> smallest possible dose</strong> for
                                             the <strong>shortest possible duration</strong>.</li>
                                       </ul>
                                       <p><strong>Avoid typical antipsychotics, particularly haloperidol in patients with
                                             Parkinson&rsquo;s disease or dementia with Lewy bodies. </strong><em>(National
                                             Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                          <li>The dopamine receptor antagonistic effect of typical antipsychotics can
                                             <strong>dramatically worsen physical and cognitive symptoms</strong> in people
                                             with Parkinson&rsquo;s disease or with dementia with Lewy bodies.</li>
                                          <li>Consider a <strong>low-dose short-acting oral benzodiazepine,</strong> such as
                                             lorazepam, or l<strong>ow-dose quetiapine </strong>in patients with
                                             Parkinson&rsquo;s disease or dementia with Lewy bodies who require sedation to
                                             enable safe care because of delirium.</li>
                                          <li>Consult your local drug formulary for advice.</li>
                                       </ul>
                                       <p><br /><strong>Document</strong> any episodes of current or resolved delirium in
                                          the<strong> discharge summary for the GP</strong>. <em>(National Institute for
                                             Health and Clinical Excellence. 2010)</em></p>
      
      
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle20" class="toggle" />
                                             <label class="title" for="toggle20">
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: risks and safe withdrawal of antipsychotics in
                                                   the elderly</span>
                                             </label>
                                             <div class="content">
                                                <p><strong>Short-term antipsychotics may be needed in people with dementia to
                                                      enable safe care. However, antipsychotics have various adverse effects
                                                      in the elderly and are associated with an increased risk of death in
                                                      people with dementia.</strong></p>
                                                <ul>
                                                   <ul>
                                                      <li>A meta-analysis found that people with dementia who take atypical
                                                         antipsychotics have an <strong>increased mortality risk
                                                         </strong>compared with people taking placebo. <em>(</em><em>Ma H, et
                                                            al, 2014)</em></li>
                                                   </ul>
                                                </ul>
                                                <ul>
                                                   <li><em>A large cohort study of elderly people found that <strong>higher
                                                            doses</strong> of antipsychotics are generally associated with
                                                         <strong>greater risk</strong>. <em>(Huybrechts K, 2012)</em></em>
                                                   </li>
                                                </ul>
                                                <ul>
                                                   <li>It also found that of all the antipsychotics studied,
                                                      <strong>haloperidol </strong>has the highest risk associated with its
                                                      use. <em>(Huybrechts K, 2012)</em></li>
                                                </ul>
                                                <ul>
                                                   <li>Contrary to popular belief, long-term antipsychotic prescriptions in
                                                      people with dementia whose behaviour is now settled, can be
                                                      <strong>withdrawn safely </strong>in the majority of cases. (<em>Van
                                                         Leeuwen, 2018)</em></li>
                                                </ul>
                                             </div>
                                          </div>
                                       </div>
      
      
      
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle21" class="toggle" />
                                             <label class="title" for="toggle21">
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: primary prevention of delirium: this may be the
                                                   most effective treatment strategy</span>
                                             </label>
                                             <div class="content">
                                                <p><strong>A non-randomised trial studying how to reduce risk factors for
                                                      delirium compared a multicomponent strategy with usual care in 852
                                                      elderly patients (over 70 years) in hospital. </strong><em>(Inouye,
                                                      1999)</em></p>
                                                <ul>
                                                   <li>The multicomponent strategy targeted the following 6 risk factors:</li>
                                                   <ul>
                                                      <li>cognitive impairment</li>
                                                      <li>sleep deprivation</li>
                                                      <li>immobility</li>
                                                      <li>visual impairment</li>
                                                      <li>hearing impairment</li>
                                                      <li>dehydration.</li>
                                                   </ul>
                                                </ul>
                                                <p>It found: <em>(Inouye, 1999)</em></p>
                                                <ul>
                                                   <li>There were <strong>significantly fewer first episodes of
                                                         delirium</strong> with the <strong>multicomponent strategy
                                                      </strong>vs usual care (44 [9.9%] vs 64 [15%] respectively)</li>
                                                   <li>Matched group analysis found an odds ratio (OR) of 0.60 (95%CI:
                                                      0.39-0.92; p=0.02)</li>
                                                   <li><strong>Total number of days with delirium</strong> was
                                                      <strong>significantly lower </strong>with the <strong>multicomponent
                                                         strategy</strong> vs usual care (105 vs. 161 days respectively,
                                                      p=0.02)</li>
                                                </ul>
                                                <p><strong>Delirium severity and recurrence rates</strong> were <strong>not
                                                      significantly different </strong>in the 2 groups.</p>
                                             </div>
                                          </div>
                                       </div>
      
      
                                    </div>
      
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Dementia-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Set an escalation plan</span>
                                                </span>
                                                <span class="material-icons">
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Set an escalation plan for all patients with dementia as early as
                                             possible.</strong></p>
                                       <ul>
                                          <li>This should include: <em>(Fritz Z, et al, 2017):</em>
                                             <ul>
                                                <li><strong>Resuscitation status</strong> (i.e., do not attempt
                                                   cardiopulmonary resuscitation [DNACPR] decision)</li>
                                                <li><strong>Ceiling of care</strong> (e.g., is the patient suitable for
                                                   intubation or intensive care admission)</li>
                                             </ul>
                                          </li>
      
                                          <li>Escalation plans should take account of<strong> advanced care planning</strong>,
                                             including legally-binding advanced directives. <em>(Fritz Z, et al, 2017)</em>
                                          </li>
                                       </ul>
                                       <p><strong>Communicate</strong> all decisions regarding the escalation plan
                                          <strong>with the patient</strong>.<em>(Fritz Z, et al, 2017)</em></p>
                                       <ul>
                                          <li><strong>Assess mental capacity</strong> (the ability to make decisions at a
                                             specific time a decision needs to be made) and document. <em>(NICE, 2018)</em>
                                             Follow the appropriate legislation in your region.</li>
                                          <li>In England and Wales, health professionals must comply with the <strong>2005
                                                Mental Capacity Act</strong>. <em>(Department of Health, 2005)
                                             </em>Assessments should follow the principles in the Act. <em>(Department of
                                                Health, 2005) </em></li>
                                          <li>If a patient is assessed to lack mental capacity, ensure decisions are made in
                                             the <strong>best interests of the patient</strong>. <em>(Department of Health,
                                                2005) (NICE, 2018)</em></li>
                                       </ul>
                                       <p><strong>If the patient is assessed to lack mental capacity, consult with the
                                             patient&rsquo;s next of kin in order to make &lsquo;best interests&rsquo;
                                             decisions. </strong><em>(Department of Health, 2005) </em></p>
                                       <p>According to the 2005 Mental Capacity Act in England and Wales, if a patient is
                                          unbefriended and a decision is not time critical, an independent mental capacity
                                          advocate (IMCA) should be sought to perform this role instead. (<em>Social Care
                                             Institute for Excellence, 2011)</em></p>
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group COPD-como-content Asthma-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Monitor for and manage any acute exacerbation of
                                                      asthma or COPD</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Monitor patient for symptoms and signs of an acute exacerbation of their
                                             COPD or asthma.</strong></p>
                                       <ul>
                                          <li>A patient with airways disease may have an acute exacerbation while in hospital
                                             with a separate another medical or surgical condition.</li>
                                       </ul>
                                       <p><strong>Patients with comorbid COPD may be having an acute exacerbation if there is
                                             an acute worsening of respiratory symptoms that results in the need for
                                             additional therapy.</strong><em>(Global Initiative for Chronic Obstructive Lung
                                             Disease, 2019)</em></p>
                                       <ul>
                                          <li><strong>Differentiate</strong> from other conditions which may present very
                                             similarly, such as <strong>acute coronary syndrome</strong>, <strong>acute heart
                                                failure</strong> and <strong>pneumonia</strong>.</li>
                                          <li>Follow guideline recommendations on <strong>investigations</strong>, including:
                                          </li>
                                          <ul>
                                             <li><strong>ABG</strong> measurement</li>
                                             <li><strong>Chest x-ray.</strong> Generally, do a chest x-ray if a patient with
                                                COPD is admitted with breathlessness or cough, or has worse symptoms than
                                                usual.</li>
                                          </ul>
                                          <li>Follow <strong>COPD guideline </strong>recommendations on <strong>initial
                                                management</strong>, including:</li>
                                          <ul>
                                             <li><strong>Assessingseverity</strong></li>
                                             <li>Increasing dose and/or frequency of <strong>bronchodilator therapy</strong>,
                                                using nebulisers (driven with air) or spacers</li>
                                             <li>Considering <strong>oral corticosteroids</strong>,
                                                <strong>antibiotics</strong> and need for <strong>noninvasive
                                                   ventilation</strong>.</li>
                                             <li>See BMJ Best Practice topic on Acute exacerbation in COPD</li>
                                          </ul>
                                       </ul>
                                       <p><strong>Follow guideline recommendations for assessment of severity and management
                                             of an acute exacerbation of asthma in adults. </strong><em>(</em><em>British
                                             Thoracic Society; Scottish Intercollegiate Guidelines Network, 2016) </em></p>
                                       <ul>
                                          <li>Initial treatment of acute severe asthma includes:</li>
                                          <ul>
                                             <li><strong>Supplementary oxygen</strong> if hypoxaemic. Titrate to maintain an
                                                oxygen saturation level of <strong>94% to 98%</strong></li>
                                             <li><strong>High-dose inhaled beta2 agonists</strong> as early as possible,
                                                usually via nebuliser (oxygen-driven)</li>
                                             <li><strong>Ipratropium bromide</strong> via nebuliser (oxygen-driven) if needed
                                             </li>
                                             <li><strong>Corticosteroids</strong> in adequate doses (40 to 50 mg daily for at
                                                least 5 days)</li>
                                             <li>Other therapies may be required, <strong>follow guideline
                                                   recommendations</strong></li>
                                             <li>See BMJ Best Practice topic on Acute exacerbation of asthma in adults.</li>
                                          </ul>
                                       </ul>
                                       <p><strong>Stop long-acting muscarinic receptor antagonists (LAMAs) e.g., tiotropium
                                             temporarily if short-acting muscarinic antagonists (SAMAs) e.g., ipratropium
                                             bromide are prescribed via nebuliser.</strong></p>
                                       <ul>
                                          <li>This is based on expert opinion due to concern over possible anticholinergic
                                             adverse effects.</li>
                                       </ul>
                                       <p><strong>Regular nebulisers should only be prescribed for 24 to 48 hours and then
                                             switched back to the patient&rsquo;s usual inhalers.</strong></p>
      
      
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle22" class="toggle" />
                                             <label class="title" for="toggle22">
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: cardiovascular harm with beta2- agonists.</span>
                                             </label>
                                             <div class="content">
                                                <p><strong>Beta2-agonists increase the risk of myocardial infarction and other
                                                      adverse cardiovascular events</strong></p>
                                                <ul>
                                                   <li>Beta2-agonists increase heart rate and reduce potassium levels.
                                                      <em>(Salpeter SR, et al, 2004) </em>They are absorbed into the systemic
                                                      circulation and there is evidence they are associated with an increased
                                                      risk of myocardial infarction, unable angina, congestive heart failure
                                                      and arrhythmias. <em>(Au DH, et al, 2002) (Salpeter SR, et al, 2004)
                                                         (Baker JG, 2017)</em></li>
                                                </ul>
                                             </div>
                                          </div>
                                       </div>
      
      
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle23" class="toggle" />
                                             <label class="title" for="toggle23">
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: short duration vs longer duration of
                                                   corticosteroids for acute exacerbation of COPD</span>
                                             </label>
                                             <div class="content">
                                                <p><strong>A systematic review found no difference in outcomes (treatment
                                                      failure, time to next exacerbation, time in hospital, lung function,
                                                      adverse effects, mortality) between short courses (7 days or less) vs
                                                      more conventional longer courses (longer than 7 days) of corticosteroids
                                                      in people with acute exacerbation of COPD </strong><em>(Walters JAE, et
                                                      al, 2018)</em></p>
                                                <ul>
                                                   <li>The randomised controlled trials included in this Cochrane review were
                                                      all in hospital settings and only included people with severe to very
                                                      severe COPD<em> (Walters JAE, et al, 2018)</em></li>
                                                   <li>The review authors concluded that due to the addition of a new trial,
                                                      they have increased confidence that a corticosteroid course of around 5
                                                      days is likely to be sufficient for the treatment of an acute
                                                      exacerbation of COPD. <em>(Walters JAE, et al, 2018)</em></li>
                                                </ul>
                                             </div>
                                          </div>
                                       </div>
      
      
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group COPD-como-content Asthma-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Remember to prescribe usual inhalers</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Patients may not think to tell you about their usual inhalers when asked
                                             about their medication, so remember to check and prescribe these if
                                             appropriate</strong></p>
                                       <ul>
                                          <li>Patients with asthma should continue any inhaled corticosteroid medication they
                                             usually take. These should not be stopped without a clear medical reason.</li>
                                          <li>Many inhalers are combined medications, so check there is no dual prescribing
                                          </li>
                                       </ul>
                                       <p><strong>Temporarily stop inhaled long-acting muscarinic receptor antagonists if your
                                             patient with COPD or asthma usually takes this and develops acute kidney injury
                                             with an eGFR &lt;30.</strong></p>
      
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group COPD-como-content Asthma-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Consider
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Nicotene replacement therapy in current
                                                      smokers</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>All current smokers are nicotine dependent</strong></p>
                                       <ul>
                                          <li>Nicotine replacement therapy should be prescribed to prevent withdrawal
                                             regardless of a patient&rsquo;s intention regarding smoking cessation</li>
                                          <li>Please consult your local hospital guidance.</li>
                                       </ul>
                                       <p><br /><strong>Make every contact count:</strong></p>
                                       <ul>
                                          <li>Being in hospital with an acute illness is the ideal time to support someone to
                                             give up smoking</li>
                                          <li>Provide brief advice.</li>
                                       </ul>
      
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Check patient’s feet</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Check the feet of all adults with diabetes on admission to hospital and
                                             whenever there has been a change in their status. </strong><em>(NICE, 2016)</em>
                                       </p>
                                       <ul>
                                          <li><strong>Why? </strong>
                                             <ul>
                                                <li>To detect <strong>new ulceration </strong>or<strong> infection,
                                                   </strong>which may be<strong> unnoticed</strong> by the patient andmay even
                                                   be the <strong>underlying cause </strong>of their illness (e.g., patient
                                                   presenting with sepsis, spinal abscess or endocarditis where the original
                                                   focus of infection is the foot lesion).</li>
                                                <li>To determine if patient is at<strong> high risk of pressure ulceration
                                                   </strong>and <strong>requires pressure relief</strong>.</li>
                                             </ul>
                                          <li><strong>Take action </strong></li>
                                          <ul>
      
                                             </li>
                                             <li>You must <strong>remove any foot dressings</strong> to see if any wound/ulcer
                                                is<strong> infected. </strong><em>(NICE NG19, 2016)</em></li>
                                             <li><strong>Inspect</strong> the foot for lesions and examine for loss of
                                                protective <strong>sensation</strong>. Follow your local guidelines, but a
                                                quick simple test is the <strong>Ipswich Touch Test&copy;️</strong>. (Rayman
                                                G, et al, 2011)</li>
                                             <li>If your patient has <strong>reduced sensation</strong>, they are at
                                                <strong>high risk of pressure ulceration</strong>. Inform the nursing staff
                                                and <strong>provide pressure relieving devices</strong>.</li>
                                             <li>A <strong>daily heel check</strong> for <strong>signs of pressure
                                                   trauma</strong> should be undertaken by nursing or health care assistant
                                                staff.</li>
                                          </ul>
      
      
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                           </div>
                        </section>

                        <section class="panel-group">
                           <div class="panel-header child-accordion">
                              <p class="panel-title">
                                 <a href="#" role="tab header" id="tab_1_0_0_acute3" aria-controls="panel_1_0_0_acute3" aria-expanded="false">
                                       <span class="title-04">
                                             <span class="material-icons"><span></span><span></span></span>
                                             <span class="title-01">
                                                <span>
                                                      Absolute contraindication to both anticoagulation and thrombolysis
                                                </span>
                                             </span>
                                          </span>
                                 </a>
                              </p>
                           </div>                           
                           <div class="panel-content child-accordion col-md-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3 tab_1_0_0_acute3 tab_patientGroup-0-0" id="panel_1_0_0_acute3 panel_patientGroup-0-0" aria-expanded="false" style="display: none;">

                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="#" role="tab header" id="nested-collapse_0_0_3"
                                          aria-controls="nested-collapse_0_0_3" aria-expanded="false" class="">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   1st line
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Vasoactive drug</span>
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3 tab_patientGroup-0-0" id="nested-collapse_0_0_3 panel_patientGroup-0-0" aria-expanded="false" style="display: none;">
      
                                    <p><strong>Give a vasopressor such as adrenaline (epinephrine) or noradrenaline
                                          (norepinephrine), or an inotrope such as dobutamine if SBP remains &lt;90 mmHg
                                          despite giving adequate intravenous fluids. </strong>[ESC]</p>
                                    <p><strong>Consult a haematologist if a patient has a contraindication to
                                          anticoagulation.</strong></p>
                                    <ul>
                                       <li>Many patients with relative contraindications will still be able to have a
                                          different choice or altered dose of anticoagulation but a specialist opinion is
                                          needed to weigh up the benefit-risk balance.</li>
                                       <li><strong>Absolute contraindications are rare but include:</strong>[HOR]
      
                                          <ul>
                                             <li>active bleeding</li>
                                             <li>recent intracranial hemorrhage</li>
                                             <li>recent, planned, or emergent surgery or procedure with high bleeding risk
                                             </li>
                                             <li>platelet count &lt;50,000/uL</li>
                                             <li>severe bleeding diathesis.</li>
                                          </ul>
                                       </li>
                                       <li><strong>Relative contraindications are: </strong>[HOR]
                                          <ul>
                                             <li>recurrent but inactive gastrointestinal bleeding</li>
                                             <li>intracranial or spinal tumor</li>
                                             <li>recent, planned, or emergent surgery or procedure with intermediate bleeding
                                                risk</li>
                                             <li>major trauma including cardiopulmonary resuscitation</li>
                                             <li>aortic dissection</li>
                                             <li>platelet count &lt;150,000/uL</li>
                                          </ul>
                                       </li>
                                       <li><strong>Remember too that each anticoagulant may have its own specific relative and
                                             absolute contraindications</strong> (e.g., heparin is contraindicated in patients
                                          with a history of heparin-induced thrombocytopenia), and these should be checked
                                          before starting treatment.</li>
                                    </ul>
      
                                    <div id="tip_pitfall" class="card card-inverse mb-4">
                                       <div class="card-block">
                                          
                                          <h3 class="card-title"></h3>
                                          <ul>
                                             <li>Peptic ulcer disease with no history of bleeding or faecal occult blood is
                                                not a contraindication to anticoagulation.[HOR]</li>
                                             <li>Anticoagulation is safe in most trauma and neurosurgical patients after the
                                                first or second postoperative week and in most stroke patients without
                                                haemorrhage. [HOR]</li>
                                             <li>Patients with spinal cord injury without haematomyelia may still be
                                                considered for anticoagulation [HOR]</li>
                                          </ul>
                                       </div>
                                    </div>
      
                                    <p><strong>Seek haematology advice if a patient with high-risk PE who is haemodynamically
                                          unstable has any contraindications to thrombolysis. </strong></p>
                                    <ul>
                                       <li><strong>Absolute contraindications: [ESC]</strong>
                                          <ul>
                                             <li>haemorrhagic stroke or stroke of unknown origin at any time</li>
                                             <li>ischaemic stroke in the preceding 6 months</li>
                                             <li>central nervous system damage or neoplasms</li>
                                             <li>recent major trauma/surgery/head injury (in the preceding 3 weeks)</li>
                                             <li>gastrointestinal bleeding within the last month</li>
                                             <li>known bleeding risk.</li>
                                          </ul>
                                       </li>
                                       <li><strong>Relative contraindications:</strong>
                                          <ul>
                                             <li>transient ischaemic attack in the preceding 6 months</li>
                                             <li>oral anticoagulant therapy</li>
                                             <li>pregnancy or within 1 week postnatally</li>
                                             <li>traumatic resuscitation (in relation to this episode of PE)</li>
                                             <li>refractory hypertension (SBP &gt;180 mmHg)</li>
                                             <li>advanced liver disease</li>
                                             <li>infective endocarditis</li>
                                             <li>active peptic ulcer</li>
                                          </ul>
                                       </li>
                                    </ul>
      
                                    <div id="tip_pitfall" class="card card-inverse mb-4">
                                       <div class="card-block">
                                          
                                          <h3 class="card-title">In practice, almost any contraindication to thrombolysis
                                             should be considered only relative in a patient who present with haemodynamic
                                             instability.</h3>
                                          <ul>
                                             <li>This is because the mortality risk from high-risk PE is so high that it is
                                                likely to outweigh any bleeding risk from thrombolysis in this patient group.
                                                However, specialist haematology advice is needed to weigh up the balance of
                                                benefits vs risks.. [ESC]</li>
                                          </ul>
                                       </div>
                                    </div>
      
                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle24" class="toggle" />
                                          <label class="title" for="toggle24">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: Choice of vasopressor is based on limited
                                                evidence</span>
                                          </label>
                                          <div class="content">
                                             <p><strong>Adrenaline combines the beneficial properties of noradrenaline
                                                   (vasoconstriction with increased right ventricular perfusion, positive
                                                   inotropy) and dobutamine (positive inotropy), but without the vasodilatory
                                                   effects associated with the latter. </strong>[ESC]</p>
                                             <ul>
                                                <li>A small prospective descriptive study of patients with RV failure and
                                                   shock demonstrated that during adrenaline infusion, mean arterial pressure
                                                   (MAP), cardiac index (CI) and stroke volume index (SVI) were increased and
                                                   right ventricular ejection fraction (RVEF) improved as well.</li>
                                                <li>Another small study showed that adrenaline improved cardiac output in
                                                   patients with shock without having a detrimental effect on pulmonary
                                                   vascular resistance. [BARRINGTON]</li>
                                             </ul>
                                             <p><strong>Evidence suggests that noradrenaline appears to improve RV function
                                                   through its inotropic effect, as well as improving coronary perfusion by
                                                   raising systemic pressure</strong>.</p>
                                             <ul>
                                                <li>However, noradrenaline increases pulmonary vascular resistance and, in
                                                   fact, no conclusive data are available regarding its potential use in PE.
                                                   [PREWITT]</li>
                                             </ul>
                                             <p><strong>The use of dobutamine and/or dopamine may be considered for patients
                                                   with PE, low cardiac index, and normal BP based on the results of some
                                                   studies</strong>.</p>
                                             <ul>
                                                <li>Dobutamine enhances contractility with an increase in stroke volume and
                                                   cardiac output. However, raising the cardiac index above physiological
                                                   values may aggravate the ventilation&ndash;perfusion mismatch by further
                                                   redistributing ﬂow from (partly) obstructed to unobstructed vessels.
                                                   [DIS][ESC]</li>
                                             </ul>
                                          </div>
                                       </div>
                                    </div>
      
                                    <div class="treatment-wrap non-como-content show">
                                       <h4>Primary options</h4>
                                       <div class="treatment-box">
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">adrenaline (epinephrine)</a>
                                             <span>: </span>
                                             <span>2-10 micrograms/minute by intravenous infusion initially, adjust dose
                                                according to response</span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">noradrenaline (norepinephrine):</a>
                                             <span>: </span>
                                             <span>0.4 to 0.8 mg/hour by intravenous infusion initially, adjust dose according
                                                to response</span>
      
                                             <span class="reference">
                                                <a href="#referencePop-more88" data-trigger="click focus"
                                                   data-toggle="popover" class="morePop" data-original-title="" title=""
                                                   aria-describedby="popover621629">More</a>
                                                <span class="popTitle" aria-hidden="true">Dose refers to noradrenaline
                                                   base.</span>
                                                <span class="popText" aria-hidden="true">
                                                   <p class="w-75">
      
                                                   </p>
                                                </span>
                                             </span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">dobutamine</a>
                                             <span>: </span>
                                             <span>2.5 to 10 micrograms/kg/minute by intravenous infusion initially, adjust
                                                dose according to response, maximum 40 micrograms/kg/minute</span>
                                          </p>
                                       </div>
                                    </div>
                                    
                                    <!-- SWITCHABLE DRUG CONTENT BOX -->
                                    <div class="treatment-box-cplus mt-4 como-content hide">
                                       <h4>Primary options</h4>
                                       <div class="drug-accordion">
      
                                          <div class="drug-content2" style="display: none">
                                             <div class="poce_drug_msg" class="warning">
                                                <h3 class="cplus_title">These drug options and doses relate to a patient with
                                                   <strong>no comorbidities.</strong></h3>
                                             </div>
                                             <div class="treatment-box">                                             
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">adrenaline (epinephrine): </a>
                                                   <span>2-10 micrograms/minute by intravenous infusion initially, adjust dose
                                                      according to response</span>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">noradrenaline (norepinephrine): </a>
                                                   <span>0.4 to 0.8 mg/hour by intravenous infusion initially, adjust dose according
                                                      to response</span>
            
                                                   <span class="reference">
                                                      <a href="#referencePop-more88" data-trigger="click focus"
                                                         data-toggle="popover" class="morePop" data-original-title="" title=""
                                                         aria-describedby="popover621629">More</a>
                                                      <span class="popTitle" aria-hidden="true">Dose refers to noradrenaline
                                                         base.</span>
                                                      <span class="popText" aria-hidden="true">
                                                         <p class="w-75">
            
                                                         </p>
                                                      </span>
                                                   </span>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dobutamine: </a>
                                                   <span>2.5 to 10 micrograms/kg/minute by intravenous infusion initially, adjust
                                                      dose according to response, maximum 40 micrograms/kg/minute</span>
                                                </p>
                                             </div>
                                             <p class="como_link mt-4 drug-title2"><a href="#">&#9664; Back to drug doeses with added comorbidities</a></p>
                                          </div>
      
                                          <div class="drug-content1">
                                             <div class="poce_drug_msg">
                                                <h3 class="cplus_title">Drug choice, dose and interactions may be affected by
                                                   the patient's comorbidities. Check your local drug formulary.</h3>
                                             </div>
                                             <div class="treatment-box">                                          
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">adrenaline (epinephrine): </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">noradrenaline (norepinephrine): </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dobutamine: </a>
                                                </p>
                                                </div>
                                                <p>For patients with renal impairment <a href="#" data-toggle="modal" data-target="#renal">see dose in the Renal Drug Handbook</a></p>
                                                <div class="modal fade" id="renal" tabindex="-1" role="dialog" aria-labelledby="renal" aria-hidden="true" style="display: none;">
                                                   <div class="modal-dialog" role="document">
                                                      <div class="modal-content">
                                                         <div class="modal-header">
                                                            <h3 class="modal-title" id="exampleModalLabel">
                                                               The Renal Handbook<br /></h3>
                                                         </div>
                                                         <iframe width="100%" height="700" src="../pdf/renalbook.pdf" title="Renal Book"></iframe>
                                                      </div>
                                                   </div>
                                                </div>
                                                <p class="como_link mt-4 drug-title1"><a href="#">&#9658; Show drug doses for a patient with no comorbidities</a></p>
                                             </div>
                                             
                                          </div>
                                    </div>
                                    <!-- DRUG CONTENT BOX ENDS -->
      
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Seek multidisciplinary team discussion to consider surgical embolectomy or catheter-directed therapy</span>
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3 tab_patientGroup-0-0" id="nested-collapse_0_0_3 panel_patientGroup-0-0" aria-expanded="false" style="display: none;">
      
                                    <p><strong>In practice, patients who are unsuitable for both anticoagulation and
                                          thrombolysis are extremely rare as the benefits generally outweigh the risks even
                                          with significant contraindications.</strong></p>
                                    <ul>
                                       <li>I<strong>t is important to discuss any such patient with a multidisciplinary team
                                             (MDT),</strong> which may include cardiac surgeons, a haematologist and an
                                          interventional radiologist.</li>
                                    </ul>
                                    <p><strong>According to the European Society of Cardiology (ESC) guidelines [ESC] [CTS],
                                          surgical embolectomy or percutaneous catheter-directed therapy may be indicated in
                                          the following circumstances: </strong></p>
                                    <ul>
                                       <li>Patients who are unable to receive thrombolytic therapy because of bleeding risk
                                       </li>
                                       <li>Insufficient time for effective systemic thrombolysis</li>
                                       <li>Failed thrombolysis</li>
                                    </ul>
                                    <p><strong>The use of these interventions will depend on local expertise and
                                          availability.</strong></p>
                                    <p><strong>Surgical pulmonary embolectomy</strong></p>
                                    <ul>
                                       <li>Although this is rarely performed in the UK, the ESC guideline states that is
                                          technically a relatively simple operation although in practice it is normally only
                                          undertaken in specialist cardiothoracic centres. [ESC]</li>
                                    </ul>
                                    <p><strong>Catheter-directed therapy</strong></p>
                                    <ul>
                                       <li>Catheter-directed therapy uses a lower dose of thrombolytic drug (approximately one
                                          third of full-dose systemic thrombolysis) and is believed to reduce the risks of
                                          bleeding at remote sites (e.g., intracranial or gastrointestinal). [KEARON]</li>
                                       <li>For patients with absolute contraindications to thrombolysis, interventional
                                          options include: [ESC]<ul>
                                             <li>thrombus fragmentation with pigtail or balloon catheter,</li>
                                             <li>rheolytic thrombectomy with hydrodynamic catheter devices,</li>
                                             <li>suction thrombectomy with aspiration catheters</li>
                                             <li>rotational thrombectomy.</li>
                                          </ul>
                                       </li>
                                       <li>For patients with relative contraindications to thrombolysis, interventional
                                          options include:[ESC]
                                          <ul>
                                             <li>catheter-directed thrombolysis</li>
                                             <li>pharmacomechanical thrombolysis</li>
                                          </ul>
                                       </li>
                                    </ul>
      
      
                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle25" class="toggle">
                                          <label class="title" for="toggle25">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: Surgical pulmonary embolectomy and
                                                catheter-directed therapy outcomes</span>
                                          </label>
                                          <div class="content">
                                             <p><strong>There is no comparative data to guide the primary management of
                                                   patients with high-risk (massive) PE and a strong contraindication to
                                                   systemic thrombolysis and therefore management will depend on local options
                                                   and expertise</strong>.</p>
                                             <ul>
                                                <li>However, some small studies have looked at outcomes from surgical
                                                   pulmonary embolectomy and catheter-directed therapy.</li>
                                                <li>Mortality rates following pulmonary embolectomy range from 4% to 27%.
                                                   [FUKUDA] In a small cohort of patients who underwent surgical pulmonary
                                                   embolectomy for acute high-risk (massive) pulmonary thromboembolism, the
                                                   10-year survival rate was 84%. [FUKUI]</li>
                                                <li>
                                                   <h4>A meta-analysis of non-randomised trials of catheter-directed therapies
                                                      reported a clinical success rate of 87% with an associated risk of major
                                                      and minor complications of 2% and 8%, respectively [KUO],</h4>
                                                </li>
                                                <li>
                                                   <h4>The extent of early RV recovery after low-dose catheter-directed
                                                      thrombolysis appears comparable to that after standard-dose systemic
                                                      thrombolysis whereas anticoagulation with heparin alone has little
                                                      effect on improvement of RV size and performance within the first
                                                      24&ndash;48 hours.</h4>
                                                </li>
                                                <li>
                                                   <h4>In a randomized, controlled clinical trial of 59 intermediate-risk
                                                      patients, when compared with treatment by heparin alone,
                                                      catheter-directed ultrasound-accelerated
                                                      thrombolysis&mdash;administering 10 mg alteplase per treated lung over
                                                      15 hours&mdash;significantly reduced the subannular RV/LV dimension
                                                      ratio between baseline and 24-hour follow-up without an increase in
                                                      bleeding complications [TIEDE] [BOLUS][KUCHER]</h4>
                                                </li>
                                             </ul>
                                          </div>
                                       </div>
                                    </div>
      
      
                                 </div>
                              </section>
                              <section class="panel-group Diabetes-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Review diabetes medication (NEVER stop insulin in
                                                      people with type 1 diabetes)</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3 tab_patientGroup-0-0" id="nested-collapse_0_0_3 panel_patientGroup-0-0" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Never stop insulin in people with type 1 diabetes coming into hospital -
                                             insulin deficiency can rapidly precipitate ketoacidosis, particularly during
                                             illness. </strong></p>
                                       <ul>
                                          <li><strong>Always continue basal insulins</strong> (long-acting or background
                                             insulins e.g., determir or glargine) as this will <strong>prevent
                                                ketoacidosis</strong> if doses of rapid-acting insulin are inadvertently
                                             missed or delayed.</li>
                                          <li><strong>Dose adjustments</strong> up or down may be needed.<ul>
                                                <li>For example, in the<strong> absence of significant hyperglycaemia
                                                   </strong>consider <strong>reducing the evening basal insulin by 20% on
                                                      admission</strong>, as most patients will have a <strong>smaller evening
                                                      meal in hospital</strong> compared with at home.</li>
                                             </ul>
                                          </li>
                                       </ul>
      
                                       <p><strong>If a variable rate intravenous insulin infusion (VRIII) is started</strong>:
                                       </p>
                                       <ul>
                                          <li><strong>Continue the basal insulin </strong><em>(Joint British Diabetes
                                                Societies for inpatient care [JBDS-IP], 2014)</em> as this will reduce the
                                             risk of ketosis in the advent of the VRIII being <strong>accidentally interrupted
                                             </strong>(e.g., by cannula displacement or blockage) or <strong>switched off
                                             </strong>(e.g., during transfer to another ward or department)<strong>.</strong>
                                          </li>
                                          <li>The patient&rsquo;s usual <strong>rapid-acting </strong>and <strong>mixed
                                                insulins</strong> can be <strong>stopped while on a VRIII</strong>. <em>Joint
                                                British Diabetes Societies for inpatient care [JBDS-IP], 2014)</em></li>
                                          <li>Use the VRIII for as <strong>short a time as possible</strong>, <em>(Joint
                                                British Diabetes Societies for inpatient care [JBDS-IP], 2014) </em>as
                                             incorrect use and insufficient monitoring can result in<strong> severe
                                                hypoglycaemia</strong> or<strong> ketoacidosis</strong>.</li>
                                       </ul>
      
                                       <p><strong>Indications for a VRIII include</strong>: <em>(Joint British Diabetes
                                             Societies for inpatient care [JBDS-IP], 2014)</em></p>
                                       <ul>
                                          <li>Patients with diabetes or hospital-related hyperglycaemia who
                                             <strong>can&rsquo;t take oral food or fluid </strong>and where it&rsquo;s
                                             <strong>not possible to adjust their insulin regimen</strong>, e.g., when:
                                             <ul>
                                                <li>Vomiting</li>
                                                <li>Nil by mouth and patient will miss more than one meal</li>
                                                <li>There is severe illness with a need to achieve good glycaemic control
                                                   (such as with sepsis).</li>
                                             </ul>
                                          </li>
                                          <li>Most patients with diabetes <strong>requiring emergency surgery</strong>.
                                             <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2016)</em>
                                          </li>
                                          <li><strong>Special circumstances</strong>, such as hyperglycaemia with
                                             <strong>acute coronary syndrome</strong>, when <strong>pregnant</strong>, or when
                                             receiving <strong>TPN or enteral feeding</strong>, or <strong>taking
                                                corticosteroids</strong>. <em>(Joint British Diabetes Societies for inpatient
                                                care., 2012) </em>
                                             <ul>
                                                <li><strong>Get specialist advice</strong> from the <strong>diabetes
                                                      team</strong> in these circumstances.</li>
                                             </ul>
                                          </li>
                                       </ul>
                                       <p><strong>People with type 2 diabetes on basal insulin should continue to take it,
                                             unless otherwise indicated</strong>.</p>
                                       <ul>
                                          <li>In the <strong>absence of significant hyperglycaemia</strong> consider
                                             <strong>reducing the evening basal insulin</strong> by <strong>20% on
                                                admission</strong>, as most patients will have a <strong>smaller evening meal
                                                in hospital </strong>compared with at home.</li>
                                       </ul>
                                       <p>Give<strong> oral hypoglycaemic</strong> medication<strong> with food</strong> to
                                          reduce the<strong> risk of hypoglycaemia</strong>.</p>
                                       <ul>
                                          <li><strong>Never give oral hypoglycaemic medication at bedtime </strong>and
                                             consider <strong>reducing the evening dose of sulphonylurea</strong>.<ul>
                                                <li>This is because most patients have a <strong>smaller evening meal in
                                                      hospital </strong>compared with their usual evening meal at home.</li>
                                             </ul>
                                          </li>
      
                                       </ul>
                                       <p><strong>Withhold metformin in patients:</strong></p>
                                       <ul>
                                          <li>With <strong>contraindications</strong>, such as <strong>significant renal
                                                impairment</strong> (&lt;30 mL/minute/1.73 m2)</li>
                                          <li>With <strong>metabolic acidosis </strong>(including lactic acidosis and DKA)
                                          </li>
                                          <li>At<strong> risk of lactic acidosis</strong> with metformin, such as:
                                             <ul>
                                                <li>With conditions associated with <strong>acute kidney injury
                                                   </strong>or<strong> tissue hypoxia,</strong> including<strong>
                                                      dehydration</strong></li>
                                                <li>With <strong>renal impairment</strong>and who have, or are to be
                                                   <strong>fasted for a prolonged period</strong> or who are due to have
                                                   a<strong> radio-opaque contrast injection</strong> as part of an imaging
                                                   procedure. <strong>Follow local protocols </strong>for guidance on the
                                                   specific eGFR levels indicating renal impairment for this to be applied.
                                                </li>
                                             </ul>
                                          </li>
                                       </ul>
                                       <p><strong>Be aware that withholding metformin results in hyperglycemia</strong>.</p>
                                       <ul>
                                          <li>If your patient is taking <strong>other glucose-lowering medication</strong>,
                                             these may need to be<strong> increased in dose</strong> or an <strong>alternative
                                                hypoglycaemic medication to metformin</strong> prescribed.</li>
                                          <li>Some patients may need <strong>insulin as a temporary measure</strong>,
                                             but<strong> seek diabetes inpatient specialist team advice</strong>.</li>
                                       </ul>
                                       <p><strong>Stop sodium-glucose cotransporter-2 (SGLT-2) inhibitors in all acutely ill
                                             patients, particularly if dehydrated or with infection, as they are at risk of
                                             euglycaemic ketoacidosis.</strong></p>
                                       <ul>
                                          <li>SGLT-2 inhibitors (e.g., dapagliflozin) <strong>reduce blood glucose
                                                reabsorption</strong> in the kidneys (independently of insulin metabolism of
                                             glucose). <em>(Peters AL, et al, 2015) </em></li>
                                          <li>They can<strong> mask underlying ketoacidosis</strong> by patients having a
                                             normal (or near normal) serum glucose level <strong>(euglycaemic
                                                ketoacidosis)</strong>.</li>
                                          <li>Check <strong>blood ketones</strong> as urinary ketone measurement may be
                                             unreliable.</li>
                                          <li><strong>Treat for DKA</strong> if <strong>blood ketone level is &ge;3
                                                mmol/L</strong>, blood<strong> pH &lt;7.3</strong> and <strong>bicarbonate
                                                &lt;15 mmol/L</strong>. (<em>JBDS-IP, 2013)</em></li>
                                       </ul>
                                       <p><strong>Reduce or omit the dose of gliclazide if the patient has impaired kidney
                                             function or is eating less than usual, to avoid hypoglycaemia at night. </strong>
                                       </p>
                                       <p><strong>Inform the diabetic inpatient team of the admission of any patient with
                                             diabetes. They are available for advice and support.</strong></p>
                                       <p><strong>For a patient at the end of life</strong>: <em>(Rowles S, et al 2011)</em>
                                       </p>
                                       <ul>
                                          <li><strong>Hypoglycaemic medication</strong> should be <strong>reduced </strong>to
                                             the minimum, <strong>but</strong></li>
                                          <li>The patient should be<strong> kept free from symptomatic
                                                hyperglycaemia</strong>, which can lead to <strong>dehydration</strong>,
                                             <strong>ketosis</strong> or <strong>hyperosmolar hyperglycaemia</strong>.</li>
                                       </ul>
                                       <p>Refer to <strong>local protocols </strong>or the Association of British Clinical
                                          Diabetologists (ABCD). <em>(Rowles S, et al 2011)</em></p>
      
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Monitor and manage blood glucose</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3 tab_patientGroup-0-0" id="nested-collapse_0_0_3 panel_patientGroup-0-0" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                       </span>
                                       <h3 class="poce_title"></h3>
      
                                       <p><strong>Monitor blood glucose levels at least 4 times a day (pre-meal and before
                                             bedtime if eating) in all acutely unwell patients with diabetes mellitus
                                             (</strong><em>American Diabetes Association, 2019)</em></p>
                                       <ul>
                                          <li>The risk of<strong> hypo- and hyperglycaemia</strong> increases when people with
                                             diabetes are admitted to hospital with acute conditions. <em>(NHS Digital.
                                                National Diabetes Inpatient Audit (NaDIA) - 2017, 2018)</em></li>
                                          <li><strong>More frequent monitoring</strong> is needed after <strong>episodes of
                                                hyperglycaemia</strong> or <strong>hypoglycaemia</strong>.</li>
                                          <li>More <strong>frequent monitoring</strong> is needed after a <strong>change in
                                                hypoglycaemic medication</strong>.</li>
                                          <li>Patients on a<strong> variable rate intravenous insulin infusion
                                                (VRIII)</strong> need <strong>capillary blood glucose measurements every
                                                hour</strong>. <em>(Joint British Diabetes Societies for inpatient care
                                                [JBDS-IP], 2014)</em></li>
                                          <li>Support <strong>self-management</strong> (including monitoring blood glucose) if
                                             this conforms to local protocols, it is safe to do so, and the patient is
                                             willing. <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP],
                                                2012) </em></li>
                                       </ul>
                                       <p><strong>Prevent and manage hyperglycaemia if it occurs</strong></p>
                                       <ul>
                                          <li>There is <strong>no consensus on target blood glucose</strong> levels for people
                                             with diabetes in hospital.
                                             <ul>
                                                <li><strong>The Joint British Diabetes Societies for Inpatient Care</strong>
                                                   (JBDS-IP) recommend an<strong> ideal range</strong> of between<strong> 6 to
                                                      10 mmol/L</strong>, and an <strong>acceptable range</strong> of
                                                   <strong>4 to 12 mmol/L</strong><em>(JBDS-IP, 2014)</em></li>
                                                <li><strong>The American Diabetes Association</strong> recommend a
                                                   <strong>target blood glucose range</strong> of <strong>7.8 to 10.0
                                                      mmol/L</strong> (140-180 mg/dL) for most critically and noncritically
                                                   ill patients. (<em>American Diabetes Association. Diabetes Care in the
                                                      Hospital: Standards of Medical Care in Diabetes&mdash;2019, 2019)</em>
                                                </li>
                                             </ul>
                                          </li>
                                          <li><em>The <strong>National Institute for Health and Care Excellence</strong>
                                                recommends a target plasma glucose level of <strong>5 to 8 mmol/L</strong> in
                                                adults with type 1 diabetes in hospital undergoing surgery or with acute
                                                illness. <em>(NICE, 2017)</em></em></li>
                                       </ul>
                                       <p><strong>More liberal blood glucose targets</strong> are appropriate for people
                                          at<strong> high risk of falls </strong>and who are<strong> frail </strong>or have
                                          <strong>dementia</strong>. <em>(JBDS-IP, 2014)</em></p>
      
      
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle43" class="toggle" />
                                             <label class="title" for="toggle43">
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: patient outcomes associated with
                                                   hyperglycaemia</span>
                                             </label>
                                             <div class="content">
                                                <p><strong>Hyperglycaemia in patients in hospital is associated with adverse
                                                      outcomes. (</strong><em>Moghissi, 2009)</em></p>
                                                <ul>
                                                   <li>Hyperglycaemia in patients in hospital, whether with known diabetes or
                                                      not, has been shown by various observational studies to be associated
                                                      with adverse patient outcomes, including increased mortality.
                                                      <strong>(</strong><em>Moghissi, 2009)</em></li>
                                                </ul>
                                             </div>
                                          </div>
                                       </div>
      
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle44" class="toggle" />
                                             <label class="title" for="toggle44">
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: blood glucose targets for people with diabetes
                                                   in hospital</span>
                                             </label>
                                             <div class="content">
                                                <p><strong>Conflicting evidence for optimal blood glucose targets has led to
                                                      variations in recommendations in different countries and settings.
                                                      Follow your local protocol.</strong></p>
                                                <ul>
                                                   <li>Intensive care setting
                                                      <ul>
                                                         <li>A randomised controlled trial (RCT) of critically ill patients in
                                                            a primarily surgical intensive care setting found lower patient
                                                            mortality with tight glucose control - 80 to 110 mg/dL (4.4 to 6.1
                                                            mmol/L) compared with &lsquo;conventional&rsquo; more liberal
                                                            glucose control. <em>(Van den Berghe G et al, 2001) </em></li>
                                                         <li>However, a subsequent multicentre RCT in critically ill medical
                                                            and surgical patients in other intensive care settings found
                                                            increased mortality with tighter glucose control, possibly due to
                                                            increased episodes of hypoglycaemia. <em>(Finfer et al, 2009)</em>
                                                         </li>
                                                      </ul>
                                                   </li>
                                                </ul>
                                                <p>A 2010 systematic review of 6 RCTs and a meta-analysis investigating tight
                                                   glucose control (80 to 110 mg/dL [4.4 to 6.1 mmol/L]) vs less strict
                                                   glucose control in critically ill patients in the ICU setting found no
                                                   significant improvement in mortality with tight glucose control, but it was
                                                   associated with significantly more hypoglycaemic episodes compared with
                                                   less strict glucose control. (<em>Marik, 2010)</em></p>
                                             </div>
                                          </div>
                                       </div>
      
                                       <p><strong>Follow your local hospital protocol on steps to take if your patient&rsquo;s
                                             capillary blood glucose is &ge;15 mmol/L. Exclude diabetic ketoacidosis (DKA) or
                                             hyperosmolar hyperglycemic state (HHS), both of which require specific urgent
                                             management.</strong></p>
                                       <ul>
                                          <li><strong>Treat hyperglycaemia</strong> to avoid <strong>DKA </strong>and<strong>
                                                HHS</strong>.</li>
                                          <li><strong>DKA</strong> and <strong>HHS</strong> are <strong>medical
                                                emergencies</strong>. Follow JBDS or local hospital guidelines for patients
                                             with DKA (<em>JBDS-IP, 2013) </em>or HHS (<em>JBDS-IP, 2012). </em></li>
                                          <li>The <strong>diabetes inpatient specialist team</strong> should be involved in
                                             the management of any patient with <strong>DKA</strong>. (<em>JBDS-IP, 2013)</em>
                                          </li>
                                          <li><strong>Early senior review</strong> by a clinician who is familiar with the
                                             management of<strong> HHS</strong> is imperative. (<em>JBDS-IP, 2012)
                                             </em>Patients with <strong>other comorbidities</strong> may need to be on a
                                             <strong>high dependency unit. </strong>(<em>JBDS-IP, 2012)</em></li>
                                       </ul>
                                       <p><strong>Be aware that the following medication may be associated with hyperglycaemia
                                             and may need to be reviewed: </strong><em>(Abdur R, et al, 2011)</em></p>
                                       <ul>
                                          <li>Corticosteroids</li>
                                          <li>Some beta-blockers (e.g., propranolol, atenolol)</li>
                                          <li>Thiazide diuretics (e.g., hydrochlorozide)</li>
                                          <li>Some second-generation antipsychotics (e.g., olanzapine and clozaine)</li>
                                          <li>Certain fluoroquinolone antibiotics (e.g., gatifloxin)</li>
                                          <li>Calcineurin inhibitors (e.g., cyclosporine, tacrolimus)</li>
                                          <li>Protease inhibitors (e.g., as a component in antiretroviral therapy, such as
                                             ritonavir)</li>
                                       </ul>
      
      
                                       <div id="tip_pitfall" class="card card-inverse mb-4">
                                          <div class="card-block">
                                             
                                             <h3 class="card-title"></h3>
                                             <p><strong>Ask for expert advice from the diabetes team in complex patients, or
                                                   where hyperglycaemia is difficult to control.</strong></p>
                                          </div>
                                       </div>
      
                                       <p><strong>Prevent and manage hypoglycaemia if it occurs</strong></p>
                                       <ul>
                                          <li><strong>Monitor blood glucose</strong> in people with diabetes in hospital and
                                             <strong>adjust medication </strong>in response to illness and hospital meal
                                             times, in order to <strong>reduce risk</strong> of <strong>hypoglycaemic
                                                episodes</strong>.</li>
                                          <li>1 in 5 inpatients with diabetes in England and Wales have a<strong>
                                                hypoglycaemic episode </strong>during their hospital stay. <em>(NHS Digital.
                                                National Diabetes Inpatient Audit (NaDIA) - 2017, 2018)</em></li>
                                          <li>Causes include:<em> (JBDS-IP, 2018)</em>
                                             <ul>
                                                <li>Recovery from an acute illness</li>
                                                <li>Insulin or oral hypoglycaemic medication error</li>
                                                <li>Wrong timing of insulin in relation to meals</li>
                                                <li>Patients eating less but taking the same amount of diabetes medication
                                                </li>
                                                <li>No bedtime snacks</li>
                                                <li>Reduced appetite or vomiting.</li>
                                             </ul>
                                          </li>
                                       </ul>
      
      
                                       <div id="tip_pitfall" class="card card-inverse mb-4">
                                          <div class="card-block">
                                             
                                             <h3 class="card-title"></h3>
                                             <p><strong>Bedtime snacks can reduce the risk of early morning hypoglycaemia.
                                                   (NHS Digital. National Diabetes Inpatient Audit (NaDIA) - 2017,
                                                   2018)</strong></p>
                                          </div>
                                       </div>
      
                                       <p><strong>Treat hypoglycaemia actively if the blood glucose falls below 4.0 mmol/L.
                                          </strong><em>(JBDS-IP, 2018)</em></p>
                                       <ul>
                                          <li>Follow hospital protocol. The JBDS-IP has guidelines on hospital management of
                                             hypoglycaemia in adults with diabetes. <em>(JBDS-IP, 2018)</em></li>
                                       </ul>
      
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group CKD-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Check baseline kidney function</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3 tab_patientGroup-0-0" id="nested-collapse_0_0_3 panel_patientGroup-0-0" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                       </span>
                                       <h3 class="poce_title"></h3>
      
                                       <p><strong>Check baseline serum kidney function on admission in all patients with a
                                             previous history of chronic kidney disease (CKD). </strong><em>[National
                                             Institute for Health and Care Excellence. 2013)</em></p>
                                       <ul>
                                          <li><strong>CKD</strong> is a significant<strong> risk factor</strong> for the
                                             development of <strong>acute kidney injury</strong>. <em>(Hsu CY, et al,
                                                2008)</em></li>
                                          <li>Acute illness increases the risk of deterioration in renal function.</li>
                                       </ul>
      
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Stroke-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Baseline neurological assessment</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3 tab_patientGroup-0-0" id="nested-collapse_0_0_3 panel_patientGroup-0-0" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                       </span>
                                       <h3 class="poce_title"></h3>
      
                                       <p><strong>Do a baseline neurological assessment on admission for all patients with a
                                             history of stroke.</strong></p>
                                       <ul>
                                          <li>Patients with <strong>acute illness</strong> (including infections and causes of
                                             hypotension) are at <strong>increased risk of stroke</strong> (both ischaemic and
                                             haemorrhagic). <em>(Grau AJ, et al, 2010) (Eigenbrodt ML, et al, 2000)</em></li>
                                          <li>If there is a suspicion of a change in neurological status during admission,
                                             repeat the<strong>neurological assessment</strong> in case of a <strong>possible
                                                new stroke</strong>.</li>
                                          <li>Following assessment, consider appropriate level of <strong>patient
                                                supervision</strong> e.g., relating to possible <strong>confusion</strong> at
                                             night, <strong>falls</strong> related to <strong>frailty</strong>.</li>
                                       </ul>
      
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Dementia-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Baseline cognitive assessment and collateral
                                                      history</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3 tab_patientGroup-0-0" id="nested-collapse_0_0_3 panel_patientGroup-0-0" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                       </span>
                                       <h3 class="poce_title"></h3>
      
                                       <p><strong>Do a baseline cognitive assessment in all older patients, particularly those
                                             with a history of dementia. </strong><em>(Pendlebury ST, et al, 2015)</em></p>
                                       <ul>
                                          <li>Use a<strong> validated scoring system</strong> that is also feasible in the
                                             acute setting, such as:<em>(Pendlebury ST, et al, 2015)</em>
                                             <ul>
                                                <li>The <strong>abbreviated mental test score</strong> (AMTS/10)
                                                   <em>(</em><em>Hodkinson,1972)</em></li>
                                                <li><strong>Montreal Cognitive Assessment</strong> (MoCA) <em>(Nasreddine,
                                                      2005).</em></li>
                                             </ul>
                                          </li>
                                       </ul>
                                       <p><strong>Dementia increases the risk of delirium. </strong></p>
                                       <ul>
                                          <li>This can acutely reduce patients' cognitive assessment scores. <em>(George J,
                                                2013)</em></li>
                                       </ul>
                                       <p><strong>Take a collateral history from family, friend or carer, to establish the
                                             patient&rsquo;s level of function and baseline cognition before this
                                             illness.</strong></p>
                                       <ul>
                                          <li>It&rsquo;s important to know if the <strong>decline</strong> in function and
                                             cognition has been <strong>gradual </strong>or <strong>acute</strong>.</li>
                                       </ul>
                                       <p>Use this information for <strong>monitoring clinical improvement</strong>, and for
                                          establishing <strong>needs on discharge</strong>.</p>
      
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Dementia-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Assess for and manage delirium</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3 tab_patientGroup-0-0" id="nested-collapse_0_0_3 panel_patientGroup-0-0" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                       </span>
                                       <h3 class="poce_title"></h3>
      
                                       <p><strong>Assess the patient with de mentia for delirium. </strong><em>(National
                                             Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                          <li>People living with dementia are at increased risk of delirium when they are
                                             admitted to hospital. (<em>National Institute for Health and Clinical Excellence,
                                                2018)</em></li>
                                          <li>Use a<strong> screening tool</strong>, such as:
      
                                             <ul>
                                                <li>The <strong>4-AT</strong><em>(</em><em>Bellelli, 2014)</em></li>
                                                <li>The <strong>short confusion assessment method (S-CAM), </strong>as
                                                   recommended by the National Institute of Health and Care Excellence (NICE).
                                                   <em>(National Institute for Health and Clinical Excellence. 2010)</em></li>
                                                <li>Document the results clearly.</li>
                                             </ul>
                                          </li>
                                       </ul>
                                       <p><strong>Assess the patient for any reversible causes of delirium</strong>.
                                          <em>(National Institute for Health and Clinical Excellence. 2010)</em>These include:
                                       </p>
                                       <ul>
                                          <li>Infection</li>
                                          <li>Pain</li>
                                          <li>Dehydration</li>
                                          <li>Constipation</li>
                                          <li>Hypoxia</li>
                                          <li>Immobility</li>
                                          <li>Medications</li>
                                          <li>Poor sleep</li>
                                          <li>Sensory impairment (e.g., ear wax or loss of glasses)</li>
                                       </ul>
                                       <p><strong>Investigations</strong> to help diagnose underlying causes include:</p>
                                       <ul>
                                          <li>Full blood count, electrolytes, renal function, liver function tests, calcium,
                                             glucose, CRP, folate and vitamin B12.</li>
                                          <li>Blood cultures (if bacteraemia is suspected)</li>
                                          <li>Urine microscopy and culture</li>
                                          <li>Chest x-ray</li>
                                       </ul>
                                       <p><strong>Manage according to the cause</strong>.</p>
                                       <p><strong>Manage patients with delirium initially with non-pharmacological treatment.
                                          </strong><em>(National Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                          <li>Reduce <strong>disorientation</strong> by providing a <strong>well-lit
                                                room,</strong> with a <strong>clock</strong> and <strong>calendar
                                             </strong>visible (e.g., on the wall).</li>
                                          <li>Encourage and facilitate <strong>family, friends and carers</strong> visiting
                                             the patient.</li>
                                          <li>Use verbal and non-verbal techniques to<strong> de-escalate</strong> conflict
                                             and distress.</li>
                                       </ul>
                                       <p><strong>Where non-pharmacological treatments are ineffective, and the patient is
                                             distressed or considered a risk to themselves or others, short-term antipsychotic
                                             or sedative drugs may be used.</strong></p>
                                       <p><strong>Only use antipsychotics as a last resort and not in patients with
                                             Parkinson&rsquo;s disease or dementia with Lewy bodies.</strong><em>(National
                                             Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                          <li><strong>Risperidone</strong> has the least anticholinergic effects. <em>(Tracy
                                                JI, et al, 1998)</em></li>
                                          <li><strong>Haloperidol</strong> is also licenced for this indication, but has the
                                             highest risk associated with its use. The UK National Institute for Health and
                                             Care Excellence recommends short-term use of haloperidol (usually for less than
                                             one week), starting at the <strong>lowest dose</strong> and <strong>titrating
                                                carefully</strong> according to the symptoms. <em>(National Institute for
                                                Health and Clinical Excellence. 2010)</em></li>
                                          <li>Consider sedation in significantly agitated patients who pose a risk to
                                             themselves or others.<strong> Lorazepam </strong>is a suitable choice, but it
                                             should only be given orally or intramuscularly (i.e., not intravenously).</li>
                                          <li>Lorazepam should only be used in the<strong> smallest possible dose</strong> for
                                             the <strong>shortest possible duration</strong>.</li>
                                       </ul>
                                       <p><strong>Avoid typical antipsychotics, particularly haloperidol in patients with
                                             Parkinson&rsquo;s disease or dementia with Lewy bodies. </strong><em>(National
                                             Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                          <li>The dopamine receptor antagonistic effect of typical antipsychotics can
                                             <strong>dramatically worsen physical and cognitive symptoms</strong> in people
                                             with Parkinson&rsquo;s disease or with dementia with Lewy bodies.</li>
                                          <li>Consider a <strong>low-dose short-acting oral benzodiazepine,</strong> such as
                                             lorazepam, or l<strong>ow-dose quetiapine </strong>in patients with
                                             Parkinson&rsquo;s disease or dementia with Lewy bodies who require sedation to
                                             enable safe care because of delirium.</li>
                                          <li>Consult your local drug formulary for advice.</li>
                                       </ul>
                                       <p><br /><strong>Document</strong> any episodes of current or resolved delirium in
                                          the<strong> discharge summary for the GP</strong>. <em>(National Institute for
                                             Health and Clinical Excellence. 2010)</em></p>
      
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle45" class="toggle" />
                                             <label class="title" for="toggle45">
                                                <span class="material-icons"><span></span></span>
                                                <h3>Evidence: risks and safe withdrawal of antipsychotics in the elderly</h3>
                                             </label>
                                             <div class="content">
                                                <p><strong>Short-term antipsychotics may be needed in people with dementia to
                                                      enable safe care. However, antipsychotics have various adverse effects
                                                      in the elderly and are associated with an increased risk of death in
                                                      people with dementia.</strong></p>
                                                <ul>
                                                   <ul>
                                                      <li>A meta-analysis found that people with dementia who take atypical
                                                         antipsychotics have an <strong>increased mortality risk
                                                         </strong>compared with people taking placebo. <em>(</em><em>Ma H, et
                                                            al, 2014)</em></li>
                                                   </ul>
                                                </ul>
                                                <ul>
                                                   <li><em>A large cohort study of elderly people found that <strong>higher
                                                            doses</strong> of antipsychotics are generally associated with
                                                         <strong>greater risk</strong>. <em>(Huybrechts K, 2012)</em></em>
                                                   </li>
                                                </ul>
                                                <ul>
                                                   <li>It also found that of all the antipsychotics studied,
                                                      <strong>haloperidol </strong>has the highest risk associated with its
                                                      use. <em>(Huybrechts K, 2012)</em></li>
                                                </ul>
                                                <ul>
                                                   <li>Contrary to popular belief, long-term antipsychotic prescriptions in
                                                      people with dementia whose behaviour is now settled, can be
                                                      <strong>withdrawn safely </strong>in the majority of cases. (<em>Van
                                                         Leeuwen, 2018)</em></li>
                                                </ul>
                                             </div>
                                          </div>
                                       </div>
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle46" class="toggle" />
                                             <label class="title" for="toggle46">
                                                <span class="material-icons"><span></span></span>
                                                <h3>Evidence: primary prevention of delirium: this may be the most effective
                                                   treatment strategy</h3>
                                             </label>
                                             <div class="content">
                                                <p><strong>A non-randomised trial studying how to reduce risk factors for
                                                      delirium compared a multicomponent strategy with usual care in 852
                                                      elderly patients (over 70 years) in hospital. </strong><em>(Inouye,
                                                      1999)</em></p>
                                                <ul>
                                                   <li>The multicomponent strategy targeted the following 6 risk factors:<ul>
                                                         <li>cognitive impairment</li>
                                                         <li>sleep deprivation</li>
                                                         <li>immobility</li>
                                                         <li>visual impairment</li>
                                                         <li>hearing impairment</li>
                                                         <li>dehydration.</li>
                                                      </ul>
                                                   </li>
      
                                                </ul>
                                                <p>It found: <em>(Inouye, 1999)</em></p>
                                                <ul>
                                                   <li>There were <strong>significantly fewer first episodes of
                                                         delirium</strong> with the <strong>multicomponent strategy
                                                      </strong>vs usual care (44 [9.9%] vs 64 [15%] respectively)</li>
                                                   <li>Matched group analysis found an odds ratio (OR) of 0.60 (95%CI:
                                                      0.39-0.92; p=0.02)</li>
                                                   <li><strong>Total number of days with delirium</strong> was
                                                      <strong>significantly lower </strong>with the <strong>multicomponent
                                                         strategy</strong> vs usual care (105 vs. 161 days respectively,
                                                      p=0.02)</li>
                                                </ul>
                                                <p><strong>Delirium severity and recurrence rates</strong> were <strong>not
                                                      significantly different </strong>in the 2 groups.</p>
                                             </div>
                                          </div>
                                       </div>
      
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Dementia-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Set an escalation plan</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3 tab_patientGroup-0-0" id="nested-collapse_0_0_3 panel_patientGroup-0-0" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                       </span>
                                       <h3 class="poce_title"></h3>
      
                                       <p><strong>Set an escalation plan for all patients with dementia as early as
                                             possible.</strong></p>
                                       <ul>
                                          <li>This should include: <em>(Fritz Z, et al, 2017):</em>
                                             <ul>
                                                <li><strong>Resuscitation status</strong> (i.e., do not attempt
                                                   cardiopulmonary resuscitation [DNACPR] decision)</li>
                                                <li><strong>Ceiling of care</strong> (e.g., is the patient suitable for
                                                   intubation or intensive care admission)</li>
                                             </ul>
                                          </li>
      
                                          <li>Escalation plans should take account of<strong> advanced care planning</strong>,
                                             including legally-binding advanced directives. <em>(Fritz Z, et al, 2017)</em>
                                          </li>
                                       </ul>
                                       <p><strong>Communicate</strong> all decisions regarding the escalation plan
                                          <strong>with the patient</strong>.<em>(Fritz Z, et al, 2017)</em></p>
                                       <ul>
                                          <li><strong>Assess mental capacity</strong> (the ability to make decisions at a
                                             specific time a decision needs to be made) and document. <em>(NICE, 2018)</em>
                                             Follow the appropriate legislation in your region.</li>
                                          <li>In England and Wales, health professionals must comply with the <strong>2005
                                                Mental Capacity Act</strong>. <em>(Department of Health, 2005)
                                             </em>Assessments should follow the principles in the Act. <em>(Department of
                                                Health, 2005) </em></li>
                                          <li>If a patient is assessed to lack mental capacity, ensure decisions are made in
                                             the <strong>best interests of the patient</strong>. <em>(Department of Health,
                                                2005) (NICE, 2018)</em></li>
                                       </ul>
                                       <p><strong>If the patient is assessed to lack mental capacity, consult with the
                                             patient&rsquo;s next of kin in order to make &lsquo;best interests&rsquo;
                                             decisions. </strong><em>(Department of Health, 2005) </em></p>
                                       <p>According to the 2005 Mental Capacity Act in England and Wales, if a patient is
                                          unbefriended and a decision is not time critical, an independent mental capacity
                                          advocate (IMCA) should be sought to perform this role instead. (<em>Social Care
                                             Institute for Excellence, 2011)</em></p>
      
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Asthma-como-content COPD-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Remember to prescribe usual inhalers</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3 tab_patientGroup-0-0" id="nested-collapse_0_0_3 panel_patientGroup-0-0" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                       </span>
                                       <h3 class="poce_title"></h3>
      
                                       <p><strong>Patients may not think to tell you about their usual inhalers when asked
                                             about their medication, so remember to check and prescribe these if
                                             appropriate</strong></p>
                                       <ul>
                                          <li>Patients with asthma should continue any inhaled corticosteroid medication they
                                             usually take. These should not be stopped without a clear medical reason.</li>
                                          <li>Many inhalers are combined medications, so check there is no dual prescribing
                                          </li>
                                       </ul>
                                       <p><strong>Temporarily stop inhaled long-acting muscarinic receptor antagonists if your
                                             patient with COPD or asthma usually takes this and develops acute kidney injury
                                             with an eGFR &lt;30.</strong></p>
      
      
      
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Asthma-como-content COPD-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Consider
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Nicotene replacement therapy in current
                                                      smokers</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3 tab_patientGroup-0-0" id="nested-collapse_0_0_3 panel_patientGroup-0-0" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                       </span>
                                       <h3 class="poce_title"></h3>
      
                                       <p><strong>All current smokers are nicotine dependent</strong></p>
                                       <ul>
                                          <li>Nicotine replacement therapy should be prescribed to prevent withdrawal
                                             regardless of a patient&rsquo;s intention regarding smoking cessation</li>
                                          <li>Please consult your local hospital guidance.</li>
                                       </ul>
                                       <p><br /><strong>Make every contact count:</strong></p>
                                       <ul>
                                          <li>Being in hospital with an acute illness is the ideal time to support someone to
                                             give up smoking</li>
                                          <li>Provide brief advice.</li>
                                       </ul>
      
      
      
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Asthma-como-content COPD-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Monitor for and manage any acute exacerbation of
                                                      asthma or COPD</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3 tab_patientGroup-0-0" id="nested-collapse_0_0_3 panel_patientGroup-0-0" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                       </span>
                                       <h3 class="poce_title"></h3>
      
                                       <p><strong>Monitor patient for symptoms and signs of an acute exacerbation of their
                                             COPD or asthma.</strong></p>
                                       <ul>
                                          <li>A patient with airways disease may have an acute exacerbation while in hospital
                                             with a separate another medical or surgical condition.</li>
                                       </ul>
                                       <p><strong>Patients with comorbid COPD may be having an acute exacerbation if there is
                                             an acute worsening of respiratory symptoms that results in the need for
                                             additional therapy.</strong><em>(Global Initiative for Chronic Obstructive Lung
                                             Disease, 2019)</em></p>
                                       <ul>
                                          <li><strong>Differentiate</strong> from other conditions which may present very
                                             similarly, such as <strong>acute coronary syndrome</strong>, <strong>acute heart
                                                failure</strong> and <strong>pneumonia</strong>.</li>
                                          <li>Follow guideline recommendations on <strong>investigations</strong>, including:
                                             <ul>
                                                <li><strong>ABG</strong> measurement</li>
                                                <li><strong>Chest x-ray.</strong> Generally, do a chest x-ray if a patient
                                                   with COPD is admitted with breathlessness or cough, or has worse symptoms
                                                   than usual.</li>
                                             </ul>
                                          </li>
      
                                          <li>Follow <strong>COPD guideline </strong>recommendations on <strong>initial
                                                management</strong>, including:<ul>
                                                <li><strong>Assessing severity</strong></li>
                                                <li>Increasing dose and/or frequency of <strong>bronchodilator
                                                      therapy</strong>, using nebulisers (driven with air) or spacers</li>
                                                <li>Considering <strong>oral corticosteroids</strong>,
                                                   <strong>antibiotics</strong> and need for <strong>noninvasive
                                                      ventilation</strong>.</li>
                                                <li>See BMJ Best Practice topic on Acute exacerbation in COPD</li>
                                             </ul>
                                          </li>
      
                                       </ul>
                                       <p><strong>Follow guideline recommendations for assessment of severity and management
                                             of an acute exacerbation of asthma in adults. </strong><em>(</em><em>British
                                             Thoracic Society; Scottish Intercollegiate Guidelines Network, 2016) </em></p>
                                       <ul>
                                          <li>Initial treatment of acute severe asthma includes:<ul>
                                                <li><strong>Supplementary oxygen</strong> if hypoxaemic. Titrate to maintain
                                                   an oxygen saturation level of <strong>94% to 98%</strong></li>
                                                <li><strong>High-dose inhaled beta2 agonists</strong> as early as possible,
                                                   usually via nebuliser (oxygen-driven)</li>
                                                <li><strong>Ipratropium bromide</strong> via nebuliser (oxygen-driven) if
                                                   needed</li>
                                                <li><strong>Corticosteroids</strong> in adequate doses (40 to 50 mg daily for
                                                   at least 5 days)</li>
                                                <li>Other therapies may be required, <strong>follow guideline
                                                      recommendations</strong></li>
                                                <li>See BMJ Best Practice topic on Acute exacerbation of asthma in adults.
                                                </li>
                                             </ul>
                                          </li>
      
                                       </ul>
                                       <p><strong>Stop long-acting muscarinic receptor antagonists (LAMAs) e.g., tiotropium
                                             temporarily if short-acting muscarinic antagonists (SAMAs) e.g., ipratropium
                                             bromide are prescribed via nebuliser.</strong></p>
                                       <ul>
                                          <li>This is based on expert opinion due to concern over possible anticholinergic
                                             adverse effects.</li>
                                       </ul>
                                       <p><strong>Regular nebulisers should only be prescribed for 24 to 48 hours and then
                                             switched back to the patient&rsquo;s usual inhalers.</strong></p>
      
      
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle1" class="toggle" />
                                             <label class="title" for="toggle1">
                                                <span class="material-icons"><span></span></span>
                                                <h3>Evidence: cardiovascular harm with beta2- agonists.</h3>
                                             </label>
                                             <div class="content">
                                                <p><strong>Beta2-agonists increase the risk of myocardial infarction and other
                                                      adverse cardiovascular events</strong></p>
                                                <p>Beta2-agonists increase heart rate and reduce potassium levels.
                                                   <em>(Salpeter SR, et al, 2004) </em>They are absorbed into the systemic
                                                   circulation and there is evidence they are associated with an increased
                                                   risk of myocardial infarction, unable angina, congestive heart failure and
                                                   arrhythmias. <em>(Au DH, et al, 2002) (Salpeter SR, et al, 2004) (Baker JG,
                                                      2017)</em></p>
                                             </div>
                                          </div>
                                       </div>
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle1" class="toggle" />
                                             <label class="title" for="toggle1">
                                                <span class="material-icons"><span></span></span>
                                                <h3>Evidence: short duration vs longer duration of corticosteroids for acute
                                                   exacerbation of COPD</h3>
                                             </label>
                                             <div class="content">
                                                <p><strong>A systematic review found no difference in outcomes (treatment
                                                      failure, time to next exacerbation, time in hospital, lung function,
                                                      adverse effects, mortality) between short courses (7 days or less) vs
                                                      more conventional longer courses (longer than 7 days) of corticosteroids
                                                      in people with acute exacerbation of COPD </strong><em>(Walters JAE, et
                                                      al, 2018)</em></p>
                                                <ul>
                                                   <li>The randomised controlled trials included in this Cochrane review were
                                                      all in hospital settings and only included people with severe to very
                                                      severe COPD<em> (Walters JAE, et al, 2018)</em></li>
                                                   <li>The review authors concluded that due to the addition of a new trial,
                                                      they have increased confidence that a corticosteroid course of around 5
                                                      days is likely to be sufficient for the treatment of an acute
                                                      exacerbation of COPD. <em>(Walters JAE, et al, 2018)</em></li>
                                                </ul>
                                             </div>
                                          </div>
                                       </div>
      
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Check patient’s feet</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3 tab_patientGroup-0-0" id="nested-collapse_0_0_3 panel_patientGroup-0-0" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                       </span>
                                       <h3 class="poce_title"></h3>
      
                                       <p><strong>Check the feet of all adults with diabetes on admission to hospital and
                                             whenever there has been a change in their status. </strong><em>(NICE, 2016)</em>
                                       </p>
                                       <ul>
                                          <li><strong>Why? </strong>
                                             <ul>
                                                <li>To detect <strong>new ulceration </strong>or<strong> infection,
                                                   </strong>which may be<strong> unnoticed</strong> by the patient andmay even
                                                   be the <strong>underlying cause </strong>of their illness (e.g., patient
                                                   presenting with sepsis, spinal abscess or endocarditis where the original
                                                   focus of infection is the foot lesion).</li>
                                                <li>To determine if patient is at<strong> high risk of pressure ulceration
                                                   </strong>and <strong>requires pressure relief</strong>.</li>
                                             </ul>
                                          </li>
      
                                          <li><strong>Take action </strong>
                                             <ul>
                                                <li>You must <strong>remove any foot dressings</strong> to see if any
                                                   wound/ulcer is<strong> infected. </strong><em>(NICE NG19, 2016)</em></li>
                                                <li><strong>Inspect</strong> the foot for lesions and examine for loss of
                                                   protective <strong>sensation</strong>. Follow your local guidelines, but a
                                                   quick simple test is the <strong>Ipswich Touch Test&copy;️</strong>.
                                                   (Rayman G, et al, 2011)</li>
                                                <li>If your patient has <strong>reduced sensation</strong>, they are at
                                                   <strong>high risk of pressure ulceration</strong>. Inform the nursing staff
                                                   and <strong>provide pressure relieving devices</strong>.</li>
                                                <li>A <strong>daily heel check</strong> for <strong>signs of pressure
                                                      trauma</strong> should be undertaken by nursing or health care assistant
                                                   staff.</li>
                                             </ul>
                                          </li>
                                       </ul>
      
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>

                           </div>
                        </section>
                     </div>

                     </div>
                  </div>

                  <div class="panel bg-line">
                     <div class="panel-heading">
                        <h3>
                           <span class="title-04">                                 
                              <span class="no-icon">Haemodynamically stable: PE confirmed (on CTPA) or highly suspected (Wells>4 or positive D-dimer)</span>
                           </span>

                           <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" id="tab_haemodynamically_stable" class="view-hide-all" aria-controls="panel_haemodynamically_stable">
                              <span class="hidden-sm-down">
                                 <span class="msg">VIEW ALL</span>
                                 <span class="material-icons" role="button"><span></span><span></span></span>
                              </span>
                           </a>

                        </h3>
                     </div>
                     <div class="panel-body" role="tabpanel" aria-labelledby="tab_1_0_0_acute2_content" id="panel_1_0_0_acute2_content" aria-expanded="true">

                        <section class="panel-group">
                           <div class="panel-header child-accordion">
                              <p class="panel-title">
                                 <a href="#" role="tab header" id="tab_1_0_0_acute4 " aria-controls="panel_1_0_0_acute4" aria-expanded="false" class="">                                    
                                    <span class="title-04">
                                       <span class="material-icons"><span></span><span></span></span>
                                       <span class="title-01">
                                          <span>No contraindication to anticoagulation</span>
                                          <span class="noShow">&nbsp;–&nbsp;</span>
                                       </span>
                                    </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content child-accordion col-md-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3 tab_1_0_0_acute4 tab_haemodynamically_stable" id="panel_1_0_0_acute4 panel_haemodynamically_stable" aria-expanded="false" style="display: none;">
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="#" role="tab header" id="nested-collapse_0_0_3"
                                          aria-controls="nested-collapse_0_0_3" aria-expanded="false" class="">                                    
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   1st line
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Anticoagulation</span>
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <p><strong>Base your choice of anticoagulant on the patient&rsquo;s comorbidities and
                                          contraindications as well as taking account of local guidelines.</strong> [NICE]</p>
                                    <p><strong>Start initial anticoagulation as soon as possible with any one of the
                                          following: LMWH, fondaparinux, apixaban, or rivaroxaban.</strong></p>
                                    <ul>
                                       <li><strong>If using LMWH or fondaparinux, continue treatment for at least 5
                                             days.</strong>[NICE][ESC]
                                          <ul>
                                             <li>If ongoing anticoagulation will be with warfarin, start warfarin within 24
                                                hours of diagnosis and ensure overlap with LMWH or fondaparinux for at least 5
                                                days or until the INR is &ge;2 for at least 24 hours (whichever is the
                                                longer).[NICE] <p><strong>OR</strong></p>
                                             </li>
                                             <li>If ongoing anticoagulation will be with edoxaban or dabigatran, at least 5
                                                days of lead-in therapy with LMWH or fondaparinux is required first. Stop the
                                                LMWH or fondaparinux before starting dabigatran or edoxaban.[BTS]</li>
                                          </ul>
                                       </li>
                                       <li><strong>If using rivaroxaban or apixaban, these drugs may be started without the
                                             need for lead-in therapy with a parenteral anticoagulant first</strong>.
                                          <ul>
                                             <li>Acute-phase treatment consists of an increased dose of the oral anticoagulant
                                                over the first 3 weeks (for rivaroxaban), or over the first 7 days (for
                                                apixaban).</li>
                                             <li>The 2018 British Thoracic Society (BTS) guideline recommends using a single
                                                direct-acting oral anticoagulant (DOAC) in patients being considered for
                                                outpatient management to minimise potential confusion over dosing and
                                                administration. [BTS]</li>
                                          </ul>
                                       </li>
                                    </ul>
      
                                    <div id="tip_pitfall" class="card card-inverse mb-4">
                                       <div class="card-block">
                                          
                                          <h3 class="card-title">Dabigatran and edoxaban are not recommended as the initial
                                             anticoagulant because they require lead-in therapy with a parenteral
                                             anticoagulant first.</h3>
                                       </div>
                                    </div>
      
                                    <div id="tip_pitfall" class="card card-inverse mb-4">
                                       <div class="card-block">
                                          
                                          <h3 class="card-title">Never give a DOAC simultaneously with parenteral
                                             anticoagulation</h3>
                                          <ul>
                                             <li>While warfarin is started at the same time as a parenteral anticoagulant and
                                                overlapped for at least 5 days or until the INR is &ge;2 for at least 24 hours
                                                (whichever is the longer), DOACs should never be overlapped or given at the
                                                same time as a parenteral anticoagulant.</li>
                                             <li>Apixaban and rivaroxaban may be started without the need for lead-in therapy
                                                with a parenteral anticoagulant first. Either of these DOACs can be used as a
                                                single-drug approach; this is why BTS guidelines recommend them as the
                                                preferred DOAC options in any patient who might be suitable for early
                                                discharge. [BTS]</li>
                                             <li>However, dabigatran and edoxaban require at least 5 days lead-in therapy with
                                                a parenteral anticoagulant before starting treatment. The parenteral
                                                anticoagulant should be stopped before dabigatran or edoxaban are started.
                                             </li>
                                          </ul>
                                       </div>
                                    </div>
                                    <p><strong>DOACs have non-inferior efficacy and are possibly safer</strong>,
                                       <strong>particularly in terms of major bleeding, than the standard regimen of LMWH plus
                                          warfarin.</strong>[ESC] [BTS] [ADD CCA link]</p>
                                    <ul>
                                       <li>Select a DOAC after discussion with the patient about which regimen would be most
                                          suited to them as well as taking into account the risks and benefits of each DOAC.
                                       </li>
                                    </ul>
      
      
                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle49" class="toggle" />
                                          <label class="title" for="toggle49">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: DOACs have emerged as an equally effective and
                                                likely safer option than heparin/warfarin</span>
                                          </label>
                                          <div class="content">
                                             <p><strong>There is now strong evidence that DOACs are non-inferior and have a
                                                   favourable safety profile for management of PE when compared to either
                                                   LMWH/warfarin or fondaparinux. [BTS]</strong></p>
                                             <ul>
                                                <li>Results of the major trials using DOACs in the treatment of VTE indicate
                                                   that these agents are non-inferior (in terms of efficacy) and possibly
                                                   safer (particularly in terms of major bleeding) than the standard
                                                   heparin/warfarin regimen. [WELLS][ESC][GALLUS] [BRENNER] [COCHRANE] [LIB]
                                                </li>
                                                <li>A Cochrane review concluded there was [CCA LINK AS ABOVE]</li>
                                                <ul>
                                                   <li>no difference between dabigatran and the standard regimen in preventing
                                                      recurrent VTE (OR 1.02, 95% CI 0.50 to 2.04), recurrent VTE (OR 0.93,
                                                      95% CI 0.52 to 1.66) and DVT (OR 0.79, 95% CI 0.29 to 2.13) or in
                                                      causing major bleeding (OR 0.50, 95% CI 0.15 to 1.68)</li>
                                                   <li>no difference between the factor Xa inhibitors (apixaban, rivaroxaban,
                                                      edoxaban) compared to the standard regimen, in preventing recurrent VTE
                                                      (OR 0.85, 95% CI 0.15 to 1.68), DVT (OR 0.72, 95% CI 0.39 to 1.32) and
                                                      all-cause mortality (OR 1.16, 95% CI 0.59 to 1.62) or in causing major
                                                      bleeding (OR 0.97, 95% CI 0.59 to 1.62).</li>
                                                </ul>
                                                <li>High time in therapeutic range (TTR) values were achieved under warfarin
                                                   treatment in all trials. On the other hand, the study populations included
                                                   relatively young patients, very few of whom had cancer.</li>
                                             </ul>
                                             <p><strong>Experience with DOACs remains limited but they can be viewed as an
                                                   alternative to standard treatment.</strong></p>
                                          </div>
                                       </div>
                                    </div>
                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle50" class="toggle" />
                                          <label class="title" for="toggle50">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: There is lack of evidence comparing different DOACs
                                                in PE</span>
                                          </label>
                                          <div class="content">
                                             <p><strong>There are no trials that have directly compared different DOACs with
                                                   each other, so it is difficult to determine which drug should be
                                                   recommended as a first choice for most patients. </strong></p>
      
                                             <ul>
                                                <li>However, a systematic review, network meta-analysis, and cost
                                                   effectiveness analysis has indirectly compared DOACs with each other for
                                                   prevention of stroke in patients with atrial fibrillation.<ul>
                                                      <li><strong>The authors concluded that apixaban 5 mg twice daily has the
                                                            highest expected incremental net benefit</strong>, followed by
                                                         rivaroxaban 20 mg once daily, edoxaban 60 mg once daily, and
                                                         dabigatran 150 mg twice daily. It should be emphasised that this
                                                         analysis was looking at evidence relating to patients with atrial
                                                         fibrillation on longer term anticoagulation for stroke prevention.
                                                         However the different risks/benefits of each anticoagulant can be
                                                         taken into account when deciding which DOAC to use for a patient with
                                                         PE. [META]</li>
                                                   </ul>
                                                </li>
                                                <li><strong>Reversal agents exist for dabigatran, apixaban, and rivaroxaban if
                                                      patients develop serious bleeding or require surgery. There is no
                                                      licensed reversal agent yet for edoxaban. </strong>
                                                   <ul>
                                                      <li><strong>Idarucizumab is licensed to reverse the effect of
                                                            dabigatran.</strong>
                                                         <ul>
                                                            <li>Results from an ongoing, uncontrolled, phase III, cohort study
                                                               (RE‑VERSE AD) of 90 adults taking dabigatran who had either
                                                               serious bleeding or required urgent surgery, showed that
                                                               treatment with idarucizumab reversed the anticoagulant effect
                                                               of dabigatran (median maximum reversal 100%) and normalised
                                                               dilute thrombin time and ecarin clotting time in 88% to 98% of
                                                               people.[NEJM]</li>
                                                         </ul>
                                                      </li>
                                                      <li><strong>Andexanet alfa (recombinant coagulation factor Xa) is
                                                            licensed to reverse the effect of apixaban and
                                                            rivaroxaban.</strong>
                                                         <ul>
                                                            <li>Andexanet alfa quickly reverses the anticlotting effects of
                                                               factor Xa inhibitors, according to an industry-supported study
                                                               published in the <em>New England Journal of Medicine. </em>
                                                            </li>
                                                            <li>Researchers enrolled 350 adults who presented with acute major
                                                               bleeding (e.g., intracranial, gastrointestinal) within 18 hours
                                                               of receiving apixaban or rivaroxaban. Andexanet alfa rapidly
                                                               reduced anti-factor Xa activity. For example, among patients
                                                               who'd been receiving apixaban or rivaroxaban, the initial
                                                               andexanet alfa bolus reduced anti-factor Xa activity by 92%. In
                                                               addition, at 12 hours after the infusion, 82% of patients were
                                                               deemed to have good or excellent haemostatic efficacy. [ANDEX]
                                                            </li>
                                                         </ul>
                                                      </li>
                                                   </ul>
                                                </li>
                                             </ul>
                                          </div>
                                       </div>
                                    </div>
      
                                    <h3><strong>Special patient groups</strong></h3>
                                    <p><strong>Pregnancy</strong></p>
                                    <p><strong>Use a weight-adjusted dose of LMWH in women who are (or may be) pregnant.
                                       </strong>[ESC]</p>
                                    <ul>
                                       <li>It does not cross the placenta, and routine monitoring is not generally required.
                                       </li>
                                    </ul>
                                    <p><strong>Avoid DOACs and warfarin during pregnancy as they may cross the placenta.
                                          [ESC]</strong></p>
                                    <ul>
                                       <li>Warfarin is associated with a well-defined embryopathy during the first trimester.
                                          Administration of warfarin in the third trimester can result in foetal and neonatal
                                          haemorrhage, as well as placental abruption. Warfarin may be associated with central
                                          nervous system anomalies throughout pregnancy. [ESC]</li>
                                       <li>DOACs are not recommended because there is a lack of evidence of their safety in
                                          pregnancy as pregnant women were not included in trials.</li>
                                    </ul>
                                    <p><strong>However, warfarin, LMWH, and UFH are compatible with breastfeeding</strong>
                                       because they do not accumulate in breast milk and do not lead to anticoagulation in the
                                       infant. [ACOG]</p>
      
      
                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle51" class="toggle" />
                                          <label class="title" for="toggle51">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: LMWH is safe and well tolerated in pregnancy</span>
                                          </label>
                                          <div class="content">
                                             <p><strong>Several studies show that heparin is safe to use in
                                                   pregnancy.</strong></p>
                                             <ul>
                                                <li>A systematic review and a meta-analysis of the literature was carried out
                                                   to provide an estimate of the risk of bleeding complications and VTE
                                                   recurrence in patients with acute VTE during pregnancy treated with either
                                                   LMWH or UFH. Eighteen studies, giving a total of 981 pregnant patients with
                                                   acute VTE, were included. It concluded that LMWH and UFH appears to be safe
                                                   and effective for the treatment of pregnancy-related VTE, but the optimal
                                                   dosing regimens remain uncertain. [RANCAN]</li>
                                                <li>A case series of 33 women showed that the initial dose of enoxaparin
                                                   provided satisfactory peak anti-Xa activity. No woman developed
                                                   thrombocytopaenia, haemorrhagic complication or further thromboembolic
                                                   episode. Fifteen women had regional anaesthesia for delivery, with a
                                                   reduced dose of enoxaparin, all without complication. [RODIE]</li>
                                                <li>In a retrospective observational study enoxaparin was administered for
                                                   treatment of an acute episode in 49 cases and for thromboprophylaxis in 574
                                                   cases. Serious maternal haemorrhage occurred in 11 cases during pregnancy
                                                   (1.8%), one being reasonably related to enoxaparin, and in nine cases at
                                                   delivery (1.4%), all unrelated to enoxaparin. Maternal thrombocytopenia was
                                                   reported in 10 cases (1.6%), two being serious but unrelated to enoxaparin.
                                                   Eight pregnancies ended in stillbirth (1.1%). Among the 693 live births, 17
                                                   major congenital abnormalities (2.5%) and 10 serious neonatal haemorrhages
                                                   (1.4%) were reported. None of the fetal or neonatal adverse events was
                                                   related to enoxaparin. Eight venous thromboembolic events (1.3%) were
                                                   reported.The incidence of adverse events reported could be explained by the
                                                   high risk profile of the study population. Overall, this retrospective
                                                   study suggests enoxaparin is well tolerated during pregnancy.[BJOG]</li>
                                             </ul>
                                          </div>
                                       </div>
                                    </div>
      
                                    <p><strong>Active cancer</strong></p>
                                    <p><strong>Use LMWH in patients with active cancer [NICE] [ACP]</strong></p>
                                    <ul>
                                       <li><strong>LMWH is more effective than warfarin in patients with cancer [LINK TO CCA]
                                          </strong>
                                          <ul>
                                             <li>It is also therapeutically reliable in patients for whom oral therapy may be
                                                inappropriate (e.g., vomiting), and is easier to adjust/withhold if
                                                thrombocytopenia develops or an invasive intervention is needed.[ACP]</li>
                                             <li>Patients with cancer treated with warfarin may be difficult to maintain
                                                within the therapeutic range, and experience substantial rates of recurrence.
                                                [ACP]</li>
                                          </ul>
                                       </li>
                                       <li><strong>Start the LMWH in the acute phase and continue it for 3-6 months.
                                             [NICE]</strong></li>
                                    </ul>
      
      
                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle52" class="toggle" />
                                          <label class="title" for="toggle52">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: LMWH vs UFH/warfarin in patients with cancer</span>
                                          </label>
                                          <div class="content">
                                             <p><strong> LMWH administered in the acute phase and continued over the first
                                                   3&ndash;6 months is the accepted first-line therapy in patients with cancer
                                                   (except for high-risk PE). .</strong></p>
                                             <ul>
                                                <li>A Cochrane review that analysed seven RCTs comparing LMWH with warfarin
                                                   (after acute-phase heparin) in patients with cancer found a significant
                                                   reduction in the rate of recurrence of VTE (HR 0.47, 95% CI 0.32 to 0.71)
                                                   without increased bleeding risk. However, there was no statistically
                                                   significant reduction in overall mortality (HR 0.96, 95% CI 0.81 to 1.14).
                                                   [AKL]</li>
                                                <li>An earlier Cochrane review showed a significant reduction in mortality at
                                                   three months of follow up with LMWH compared with UFH although it showed no
                                                   statistically significant reduction in VTE recurrence. [MUTI]</li>
                                             </ul>
                                             <p><strong>There is some emerging evidence indicating DOACs may be as effective
                                                   as LMWH.</strong></p>
                                             <ul>
                                                <li>A multicentre RCT compared rivaroxaban with dalteparin in 203 patients
                                                   with active cancer who had symptomatic PE. It found rivaroxaban was
                                                   associated with relatively low VTE recurrence but higher clinically
                                                   relevant non-major bleeding compared with dalteparin. This is a rapidly
                                                   evolving area with continuing developments in the evidence. [ASCO]</li>
                                             </ul>
                                             <p><strong>Evidence regarding treatment of cancer-related PE with fondaparinux is
                                                   limited.</strong></p>
                                          </div>
                                       </div>
                                    </div>
      
                                    <h3><strong>Severe renal impairment or established renal failure [NICE]</strong></h3>
                                    <p><strong>Seek advice from a haematologist for these patients. Among the options
                                          suggested by NICE for this patient group are:</strong></p>
                                    <ul>
                                       <li><strong>LMWH </strong>with dose adjustments based on an anti-Xa assay. This should
                                          be overlapped with warfarin..</li>
                                    </ul>
                                    <p><strong>OR</strong></p>
                                    <p><strong>Rivaroxaban, edoxaban, and apixaban</strong> can be used with caution and at a
                                       reduced dose in patients with renal impairment.[NICETA287] [TA354][TA341]</p>
      
      
                                    <div id="tip_pitfall" class="card card-inverse mb-4">
                                       <div class="card-block">
                                          
                                          <h3 class="card-title">Warfarin is safe to use in patients with renal impairment
                                             with no dose adjustments necessary. However, monitor the INR more carefully in
                                             these patients.</h3>
                                       </div>
                                    </div>
      
                                    <p><strong>Seek haematology advice for all patients with hepatic impairment or who are at
                                          increased risk of bleeding.</strong></p>
                                    <p><strong>Subsegmental PE</strong></p>
                                    <p><strong>The management of subsegmental PE remains controversial </strong></p>
                                    <p>Practice varies but <strong>surveillance rather than anticoagulation </strong>is
                                       considered the best option for most patients. [ESC]</p>
      
                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle53" class="toggle" />
                                          <label class="title" for="toggle53">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: Evidence suggests subsegmental PE may be of little
                                                clinical significance in most cases</span>
                                          </label>
                                          <div class="content">
                                             <p><strong>The decision over whether to anticoagulate subsegmental PE (SSPE)
                                                   remains controversial and practice varies widely. Seek specialist
                                                   advice.</strong></p>
                                             <ul>
                                                <li>Increasing use of CTPA has increased the number of patients diagnosed with
                                                   SSPE without any change in mortality rates, suggesting these PEs may not be
                                                   clinically relevant. [BOONE][BRODER][SOJ]</li>
                                                <li>There may also be overdiagnosis of SSPE. Evidence shows low clinical
                                                   agreement between radiologists when diagnosing patients with small distal
                                                   clots as they are subtle and hard to distinguish from artefact. [FRIER]
                                                </li>
                                             </ul>
                                             <p><strong>European guidelines suggest weighing up clinical probability against
                                                   the bleeding risk but recommend surveillance rather than anticoagulation
                                                   for patients who have no proximal DVT and have a low risk of recurrent VTE.
                                                   [CHEST][ESC] </strong></p>
                                             <ul>
                                                <li>Evidence on outcomes in patients who are diagnosed with SSPE is scarce and
                                                   is based on small numbers of patients, making it difficult to formulate
                                                   evidence-based guidance.</li>
                                                <li>Some studies have shown that anticoagulation may be of no clinical
                                                   benefit. One meta-analysis examined 750 patients with SSPE, of whom 81%
                                                   were treated with anticoagulation. Over 90 days there was no difference in
                                                   mortality or recurrence of PE between those who did and did not receive
                                                   anticoagulation but 8% of treated patients had an episode of bleeding.
                                                   [JEFF] In an observational study, 15% (82 patients) of PEs found on CTPA
                                                   were SSPEs. Around half of these patients were anticoagulated, and 2
                                                   developed life-threatening bleeding. No patient had an identified recurrent
                                                   PE, whether or not they were anticoagulated. [GOY] The risk of recurrence
                                                   of VTE in patients with SSPE without a concurrent DVT has been found to be
                                                   insignificant in retrospective studies. [SOJ] [HULL]</li>
                                                <li>On the other hand, a retrospective study of over 3000 patients showed that
                                                   the rate of recurrence of PE during anticoagulant therapy was the same in
                                                   patients with SSPE and those with larger PE (ie. segmental or lobar). It
                                                   also showed that VTE recurrence was higher with SSPE than in those in whom
                                                   PE was excluded. [KLOK]</li>
                                             </ul>
                                          </div>
                                       </div>
                                    </div>
      
      
                                    <div class="treatment-wrap non-como-content show">
                                       <h4>Primary options</h4>
                                       <div class="treatment-box">
                                          <p><strong>[No special considerations]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">apixaban</a>
                                             <span>: </span>
                                             <span>10 mg orally twice daily for 7 days, followed by 5 mg twice daily</span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p><strong>[No special considerations]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">rivaroxaban:</a>
                                             <span>: </span>
                                             <span>15 mg orally twice daily for 21 days, followed by 20 mg once daily</span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p><strong>[No special considerations]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">enoxaparin</a>
                                             <span>: </span>
                                             <span>uncomplicated patients with low risk of recurrence: 1.5 mg/kg
                                                subcutaneously every 24 hours; patients with risk factors: 1 mg/kg
                                                subcutaneously every 12 hours</span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">dalteparin</a>
                                             <span>: </span>
                                             <span>patients with increased risk of bleeding: 100 units/kg subcutaneously every
                                                12 hours; patients with no increased risk of bleeding: 200 units/kg
                                                subcutaneously every 24 hours, maximum 18,000 units/dose</span>
                                          </p>
                                          <p class="small-or">- AND -</p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">warfarin:</a>
                                             <span>: </span>
                                             <span>5-10 mg orally once daily initially, adjust dose according to target INR;
                                                start warfarin within 24 hours of diagnosis and overlap with the parenteral
                                                anticoagulant for at least 5 days or until INR is ≥2 for at least 24 hours
                                                (whichever is longer)</span>
      
                                             <span class="reference">
                                                <a href="#referencePop-more88" data-trigger="click focus"
                                                   data-toggle="popover" class="morePop" data-original-title="" title=""
                                                   aria-describedby="popover621629">More</a>
                                                <span class="popTitle" aria-hidden="true">Starting dose can be calculated
                                                   using an online tool that takes patient characteristics and/or
                                                   CYP2C9/VKORC1 genotype information (if available) into account. [ONLINE
                                                   RESOURCE: Warfarin dosing
                                                   http://www.warfarindosing.org/Source/Home.aspx]</span>
                                                <span class="popText" aria-hidden="true">
      
                                                </span>
                                             </span></p>
                                          <p><strong>[Active cancer]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">enoxaparin:</a>
                                             <span>: </span>
                                             <span>1 mg/kg subcutaneously every 12 hours</span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p><strong>[Active cancer]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">dalteparin:</a>
                                             <span>: </span>
                                             <span>200 units/kg subcutaneously once daily for the first 30 days, followed by
                                                150 units/kg once daily for 5 months, maximum 18,000 units/dose</span>
      
                                             <span class="reference">
                                                <a href="#referencePop-more88" data-trigger="click focus"
                                                   data-toggle="popover" class="morePop" data-original-title="" title=""
                                                   aria-describedby="popover621629">More</a>
                                                <span class="popTitle" aria-hidden="true"> Refer to local drug formulary for a
                                                   table of recommended weight-based doses. Use fixed-dose syringes for this
                                                   indication</span>
                                                <span class="popText" aria-hidden="true">
                                                   <p class="w-75">
      
                                                   </p>
                                                </span>
                                             </span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p><strong>[Pregnant women]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">enoxaparin:</a>
                                             <span>: </span>
                                             <span> body weight &lt;50 kg: 40 mg subcutaneously twice daily; body weight 50-69
                                                kg: 60 mg subcutaneously twice daily; body weight 70-89 kg: 80 mg
                                                subcutaneously twice daily; body weight ≥90 kg: 100 mg subcutaneously twice
                                                daily </span>
                                             <span class="reference">
                                                <a href="#referencePop-more89" data-trigger="click focus"
                                                   data-toggle="popover" class="morePop" data-original-title="" title=""
                                                   aria-describedby="popover621629">More</a>
                                                <span class="popTitle" aria-hidden="true">Dose based on early pregnancy body
                                                   weight.</span>
                                                <span class="popText" aria-hidden="true">
      
                                                </span>
                                             </span>
                                          </p>
                                          <p class="small-or">OR</p>
                                          <p><strong>[Pregnant women]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">dalteparin:</a>
                                             <span>: </span>
                                             <span>body weight &lt;50 kg: 5000 units subcutaneously twice daily; body weight
                                                50-69 kg: 6000 units subcutaneously twice daily; body weight 70-89 kg: 8000
                                                units subcutaneously twice daily; body weight ≥90 kg: 10,000 units
                                                subcutaneously twice daily</span>
                                             <span class="reference">
                                                <a href="#referencePop-more89" data-trigger="click focus"
                                                   data-toggle="popover" class="morePop" data-original-title="" title=""
                                                   aria-describedby="popover621629">More</a>
                                                <span class="popTitle" aria-hidden="true">Dose based on early pregnancy body
                                                   weight.</span>
                                                <span class="popText" aria-hidden="true">
      
                                                </span>
                                             </span>
                                          </p>
                                          <h4>Secondary options</h4>
                                          <p><strong>[No special considerations]</strong></p>
                                          <p>
                                             <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                data-original-title="" title="">fondaparinux</a>
                                             <span>: </span>
                                             <span>body weight &lt;50 kg: 5 mg subcutaneously once daily; body weight 50-100
                                                kg: 7.5 mg subcutaneously once daily; body weight ≥100 kg: 10 mg
                                                subcutaneously once daily</span>
                                             <p class="small-or">-AND-</p>
      
                                             <p>
                                                <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                   data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                   data-original-title="" title="">warfarin:</a>
                                                <span>: </span>
                                                <span>5-10 mg orally once daily initially, adjust dose according to target
                                                   INR; start warfarin within 24 hours of diagnosis and overlap with the
                                                   parenteral anticoagulant for at least 5 days or until INR is ≥2 for at
                                                   least 24 hours (whichever is longer)</span>
                                                <span class="reference">
                                                   <a href="#referencePop-more89" data-trigger="click focus"
                                                      data-toggle="popover" class="morePop" data-original-title="" title=""
                                                      aria-describedby="popover621629">More</a>
                                                   <span class="popTitle" aria-hidden="true">Starting dose can be calculated
                                                      using an online tool that takes patient characteristics and/or
                                                      CYP2C9/VKORC1 genotype information (if available) into account. [ONLINE
                                                      RESOURCE: Warfarin dosing
                                                      http://www.warfarindosing.org/Source/Home.aspx]</span>
                                                   <span class="popText" aria-hidden="true">
      
                                                   </span>
                                                </span>
                                             </p>
                                             <p class="small-or">OR</p>
                                             <p><strong>[No special considerations]</strong></p>
                                             <p>
                                                <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                   data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                   data-original-title="" title="">edoxaban:</a>
                                                <span>: </span>
                                                <span>start following initial use of a parenteral anticoagulant for at least 5
                                                   days; body weight &lt;60 kg: 30 mg orally once daily; body weight ≥60 kg:
                                                   60 mg orally once daily</span>
                                             </p>
                                             <p class="small-or">OR</p>
                                             <p><strong>[No special considerations]</strong></p>
                                             <p>
                                                <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                   data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                   data-original-title="" title="">dabigatran:</a>
                                                <span>: </span>
                                                <span>start following initial use of a parenteral anticoagulant for at least 5
                                                   days; 18-74 years of age: 150 mg orally twice daily; 75-79 years of age:
                                                   110-150 mg orally twice daily; ≥80 years of age: 110 mg orally twice
                                                   daily</span>
                                             </p>
                                       </div>
                                    </div>
                                    
                                    <!-- SWITCHABLE DRUG CONTENT BOX -->
                                    <div class="treatment-box-cplus mt-4 como-content hide">
                                       <h4>Primary options</h4>
                                       <div class="drug-accordion">
      
                                          <div class="drug-content2" style="display: none">
                                             <div class="poce_drug_msg" class="warning">
                                                <h3 class="cplus_title">These drug options and doses relate to a patient with
                                                   <strong>no comorbidities.</strong></h3>
                                             </div>
                                             <div class="treatment-box">                                             
                                                <p><strong>[No special considerations]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">apixaban: </a>
                                                   <span>10 mg orally twice daily for 7 days, followed by 5 mg twice daily</span>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p><strong>[No special considerations]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">rivaroxaban: </a>
                                                   <span>15 mg orally twice daily for 21 days, followed by 20 mg once daily</span>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p><strong>[No special considerations]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">enoxaparin: </a>
                                                   <span>uncomplicated patients with low risk of recurrence: 1.5 mg/kg
                                                      subcutaneously every 24 hours; patients with risk factors: 1 mg/kg
                                                      subcutaneously every 12 hours</span>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dalteparin: </a>
                                                   <span>patients with increased risk of bleeding: 100 units/kg subcutaneously every
                                                      12 hours; patients with no increased risk of bleeding: 200 units/kg
                                                      subcutaneously every 24 hours, maximum 18,000 units/dose</span>
                                                </p>
                                                <p class="small-or">- AND -</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">warfarin: </a>
                                                   <span>5-10 mg orally once daily initially, adjust dose according to target INR;
                                                      start warfarin within 24 hours of diagnosis and overlap with the parenteral
                                                      anticoagulant for at least 5 days or until INR is ≥2 for at least 24 hours
                                                      (whichever is longer)</span>
      
                                                   <span class="reference">
                                                      <a href="#referencePop-more88" data-trigger="click focus"
                                                         data-toggle="popover" class="morePop" data-original-title="" title=""
                                                         aria-describedby="popover621629">More</a>
                                                      <span class="popTitle" aria-hidden="true">Starting dose can be calculated
                                                         using an online tool that takes patient characteristics and/or
                                                         CYP2C9/VKORC1 genotype information (if available) into account. [ONLINE
                                                         RESOURCE: Warfarin dosing
                                                         http://www.warfarindosing.org/Source/Home.aspx]</span>
                                                      <span class="popText" aria-hidden="true">
      
                                                      </span>
                                                   </span>
                                                </p>
                                                <p><strong>[Active cancer]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">enoxaparin: </a>
                                                   <span>1 mg/kg subcutaneously every 12 hours</span>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p><strong>[Active cancer]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dalteparin: </a>
                                                   <span>200 units/kg subcutaneously once daily for the first 30 days, followed by
                                                      150 units/kg once daily for 5 months, maximum 18,000 units/dose</span>
      
                                                   <span class="reference">
                                                      <a href="#referencePop-more88" data-trigger="click focus"
                                                         data-toggle="popover" class="morePop" data-original-title="" title=""
                                                         aria-describedby="popover621629">More</a>
                                                      <span class="popTitle" aria-hidden="true"> Refer to local drug formulary for a
                                                         table of recommended weight-based doses. Use fixed-dose syringes for this
                                                         indication</span>
                                                      <span class="popText" aria-hidden="true">
                                                         <p class="w-75">
                                                         </p>
                                                      </span>
                                                   </span>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p><strong>[Pregnant women]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">enoxaparin: </a>
                                                   <span> body weight &lt;50 kg: 40 mg subcutaneously twice daily; body weight 50-69
                                                      kg: 60 mg subcutaneously twice daily; body weight 70-89 kg: 80 mg
                                                      subcutaneously twice daily; body weight ≥90 kg: 100 mg subcutaneously twice
                                                      daily </span>
                                                   <span class="reference">
                                                      <a href="#referencePop-more89" data-trigger="click focus"
                                                         data-toggle="popover" class="morePop" data-original-title="" title=""
                                                         aria-describedby="popover621629">More</a>
                                                      <span class="popTitle" aria-hidden="true">Dose based on early pregnancy body
                                                         weight.</span>
                                                      <span class="popText" aria-hidden="true">
      
                                                      </span>
                                                   </span>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p><strong>[Pregnant women]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dalteparin: </a>
                                                   <span>body weight &lt;50 kg: 5000 units subcutaneously twice daily; body weight
                                                      50-69 kg: 6000 units subcutaneously twice daily; body weight 70-89 kg: 8000
                                                      units subcutaneously twice daily; body weight ≥90 kg: 10,000 units
                                                      subcutaneously twice daily</span>
                                                   <span class="reference">
                                                      <a href="#referencePop-more89" data-trigger="click focus"
                                                         data-toggle="popover" class="morePop" data-original-title="" title=""
                                                         aria-describedby="popover621629">More</a>
                                                      <span class="popTitle" aria-hidden="true">Dose based on early pregnancy body
                                                         weight.</span>
                                                      <span class="popText" aria-hidden="true">
      
                                                      </span>
                                                   </span>
                                                </p>
                                                <h4>Secondary options</h4>
                                                <p><strong>[No special considerations]</strong></p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">fondaparinux: </a>
                                                   <span>body weight &lt;50 kg: 5 mg subcutaneously once daily; body weight 50-100
                                                      kg: 7.5 mg subcutaneously once daily; body weight ≥100 kg: 10 mg
                                                      subcutaneously once daily</span>
                                                </p>
                                                   <p class="small-or">-AND-</p>
                                                   <p>
                                                      <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                         data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                         data-original-title="" title="">warfarin: </a>
                                                      <span>5-10 mg orally once daily initially, adjust dose according to target
                                                         INR; start warfarin within 24 hours of diagnosis and overlap with the
                                                         parenteral anticoagulant for at least 5 days or until INR is ≥2 for at
                                                         least 24 hours (whichever is longer)</span>
                                                      <span class="reference">
                                                         <a href="#referencePop-more89" data-trigger="click focus"
                                                            data-toggle="popover" class="morePop" data-original-title="" title=""
                                                            aria-describedby="popover621629">More</a>
                                                         <span class="popTitle" aria-hidden="true">Starting dose can be calculated
                                                            using an online tool that takes patient characteristics and/or
                                                            CYP2C9/VKORC1 genotype information (if available) into account. [ONLINE
                                                            RESOURCE: Warfarin dosing
                                                            http://www.warfarindosing.org/Source/Home.aspx]</span>
                                                         <span class="popText" aria-hidden="true">
                                                         </span>
                                                      </span>
                                                   </p>
                                                   <p class="small-or">OR</p>
                                                   <p><strong>[No special considerations]</strong></p>
                                                   <p>
                                                      <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                         data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                         data-original-title="" title="">edoxaban: </a>
                                                      <span>start following initial use of a parenteral anticoagulant for at least 5
                                                         days; body weight &lt;60 kg: 30 mg orally once daily; body weight ≥60 kg:
                                                         60 mg orally once daily</span>
                                                   </p>
                                                   <p class="small-or">OR</p>
                                                   <p><strong>[No special considerations]</strong></p>
                                                   <p>
                                                      <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                         data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                         data-original-title="" title="">dabigatran: </a>
                                                      <span>start following initial use of a parenteral anticoagulant for at least 5
                                                         days; 18-74 years of age: 150 mg orally twice daily; 75-79 years of age:
                                                         110-150 mg orally twice daily; ≥80 years of age: 110 mg orally twice
                                                         daily</span>
                                                   </p>
                                             </div>
                                             <p class="como_link mt-4 drug-title2"><a href="#">&#9664; Back to drug doeses with added comorbidities</a></p>
                                          </div>
      
                                          <div class="drug-content1">
                                             <div class="poce_drug_msg">
                                                <h3 class="cplus_title">Drug choice, dose and interactions may be affected by
                                                   the patient's comorbidities. Check your local drug formulary.</h3>
                                             </div>
                                             <div class="treatment-box">                                          
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">apixaban: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">rivaroxaban: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">enoxaparin: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dalteparin: </a>
                                                </p>
                                                <p class="small-or">- AND -</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">warfarin: </a>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">enoxaparin: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dalteparin: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">enoxaparin: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dalteparin: </a>
                                                </p>
                                                <h4>Secondary options</h4>
                                                <p>
                                                   <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">fondaparinux: </a>
                                                </p>
                                                <p class="small-or">-AND-</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">warfarin: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">edoxaban: </a>
                                                </p>
                                                <p class="small-or">OR</p>
                                                <p>
                                                   <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb"
                                                      data-trigger="click focus" class="drugDbPop" data-toggle="popover"
                                                      data-original-title="" title="">dabigatran: </a>
                                                </p>
                                             </div>
                                             <p>For patients with renal impairment <a href="#" data-toggle="modal" data-target="#renal">see dose in the Renal Drug Handbook</a></p>
                                             <div class="modal fade" id="renal" tabindex="-1" role="dialog" aria-labelledby="renal" aria-hidden="true" style="display: none;">
                                                <div class="modal-dialog" role="document">
                                                   <div class="modal-content">
                                                      <div class="modal-header">
                                                         <h3 class="modal-title" id="exampleModalLabel">
                                                            The Renal Handbook<br /></h3>
                                                      </div>
                                                      <iframe width="100%" height="700" src="../pdf/renalbook.pdf" title="Renal Book"></iframe>
                                                   </div>
                                                </div>
                                             </div>
                                             <p class="como_link mt-4 drug-title1"><a href="#">&#9658; Show drug doses for a patient with no comorbidities</a></p>
                                          </div>
                                             
                                          </div>
                                    </div>
                                    <!-- DRUG CONTENT BOX ENDS -->
      
                                    
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="#" role="tab header" id="nested-collapse_0_0_3"
                                          aria-controls="nested-collapse_0_0_3" aria-expanded="false" class="">
      
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Risk assessment</span>
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
                                    <p><strong>Risk stratify stable patients using the Pulmonary Embolism Severity Index
                                          (PESI) score or the simplified Pulmonary Embolism Severity Index (sPESI)
                                          score</strong>. <strong>[LINK TO PESI scoring calculator AND sPESI scoring
                                          calculator EBM calc] </strong></p>
                                    <ul>
                                       <li>The PESI/sPESI risk score can be used to risk stratify haemodynamically stable
                                          patients to: [ESC] [BTS]</li>
                                       <ul>
                                          <li><strong>identify an intermediate-risk group</strong> who need close monitoring
                                             (PESI III-IV or sPESI &ge;1)</li>
                                          <li><strong>select low-risk patients who can be considered for outpatient
                                                management</strong> or early discharge (PESI I-II or sPESI 0)</li>
                                       </ul>
                                       <li>The <strong>sPESI is non-inferior to the PESI </strong>in predicting 30-day
                                          mortality. [BTS]</li>
                                    </ul>
                                    <p><strong>Do not use PESI/sPESI scoring in:</strong></p>
                                    <ul>
                                       <li><strong><strong>Patients with hypotension or shock. </strong>All such patients are
                                             high-risk and must be managed accordingly with emergency primary reperfusion and
                                             anticoagulation<strong>.</strong></strong></li>
                                    </ul>
                                    <ul>
                                       <li><strong>Pregnant women</strong></li>
                                    </ul>
                                    <p><strong>Monitor intermediate-risk patients (PESI score &ge; III or sPESI &ge;I)
                                          patients closely over at least 48-72 hours as they are at risk of deterioration and
                                          may need rescue thrombolysis. </strong>&nbsp;[KONST][ESC][CHEST]</p>
                                    <ul>
                                       <li><strong>Rescue thrombolysis may be indicated in </strong>intermediate-risk
                                          patients, and in patients with other clinical features of cardiopulmonary impairment
                                          (e.g., elevated heart rate, respiratory rate, jugular venous pressure) who have
                                          started anticoagulant therapy, and:</li>
                                    </ul>
                                    <ul>
                                       <li>are clinically deteriorating, but have not yet developed hypotension</li>
                                       <li>are exhibiting signs of haemodynamic decompensation (e.g., SBP &lt;90 mmHg for at
                                          least 15 minutes, or drop of SBP by at least 40 mmHg for at least 15 minutes with
                                          signs of end organ hypoperfusion). [ESC]</li>
                                    </ul>
                                    <ul>
                                       <li><strong>Routine thrombolysis is not recommended in most major guidelines for this
                                             intermediate-risk group </strong>even if signs of both right ventricular
                                          dysfunction and myocardial injury (positive cardiac biomarkers) are initially
                                          present.</li>
                                    </ul>
                                    <p>In these patients, use of systemic thrombolysis is associated with a <strong>mortality
                                          benefit</strong> but it significantly <strong>increases the risk of
                                          bleeding</strong>, including intracranial haemorrhage. [CARDIO]</p>
      
      
                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle54" class="toggle" />
                                          <label class="title" for="toggle54">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: Evidence does not support the routine use of
                                                thrombolysis in patients with intermediate-risk PE</span>
                                          </label>
                                          <div class="content">
                                             <p><strong>Current European guidelines do not recommend giving thrombolysis
                                                   routinely in patients with intermediate-risk PE. Evidence suggests it
                                                   carries an unacceptably high bleeding risk in this group.
                                                </strong>[ESC][CHEST] .</p>
                                             <ul>
                                                <li>The intermediate-risk group is defined by a PESI score of III-V or an
                                                   sPESI score &ge;1.</li>
                                                <li>The international PEITHO (Pulmonary Embolism Thrombolysis) trial compared
                                                   a single intravenous bolus of tenecteplase plus heparin with placebo plus
                                                   heparin in 1,006 patients with confirmed PE, right ventricular dysfunction
                                                   detected by echocardiography or CT, and a positive troponin I or T test.
                                                </li>
                                                <li>In the thrombolysis group, haemodynamic decompensation/collapse or death
                                                   within 7 days occurred less frequently than in the group receiving heparin
                                                   alone.</li>
                                                <li>However, in the thrombolysis group compared with the placebo group, there
                                                   was also a higher incidence of haemorrhagic stroke (2.0% vs 0.2%) and major
                                                   non-intracranial bleeding (6.3% vs 1.5%).</li>
                                             </ul>
                                          </div>
                                       </div>
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="#" role="tab header" id="nested-collapse_0_0_3"
                                          aria-controls="nested-collapse_0_0_3" aria-expanded="false" class="">
      
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Consider
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Outpatient management if low risk (PESI I-II or sPESI
                                                      0)</span>
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
                                    <p><strong>Consider outpatient management for any patient classified as low risk.</strong>
                                    </p>
                                    <ul>
                                       <li><strong>PE does not need to be confirmed on CTPA prior to discharge but it should
                                             be performed within 24 hours (if available). [BTS]</strong></li>
                                    </ul>
                                    <p><strong>Assessment of RV size/function on CTPA or echocardiography is not essential to
                                          confirm a patient as low-risk and suitable for outpatient management</strong> [BTS]
                                    </p>
                                    <ul>
                                       <li>The 2018 British Thoracic Society (BTS) guideline states that<strong>
                                             echocardiography does not increase the predictive power of validated risk
                                             scores</strong> such as PESI/sPESI or HESTIA.</li>
                                       <li>It recommends considering measurement of cardiac biomarkers (high sensitivity
                                          troponin, BNP or NT-proBNP) only in patients who had evidence of RV strain on
                                          CTPA/echo if performed during diagnostic work-up.</li>
                                       <ul>
                                          <li>If these are normal the patient can be considered for discharge. If they are
                                             elevated they should be admitted for observation. [BTS]</li>
                                       </ul>
                                    </ul>
                                    <p><strong>Do not discharge any patient with a low-risk sPESI score who meets one or more
                                          of these exclusion criteria:</strong> [BTS]</p>
                                    <ul>
                                       <li><strong>Haemodynamic instability (HR&gt;110 bpm; systolic blood pressure
                                             (SBP)&lt;100 mmHg</strong></li>
                                    </ul>
                                    <ul>
                                       <li>requirement for inotropes and critical care</li>
                                       <li>requirement for thrombolysis or embolectomy</li>
                                       <li>Oxygen saturations &lt;90% on air</li>
                                       <li>Active bleeding or risk of major bleeding (e.g., recent gastrointestinal bleed or
                                          surgery, previous intracranial bleeding, uncontrolled hypertension).</li>
                                       <li>On full-dose anticoagulation at the time of the PE</li>
                                       <li>Severe pain (e.g., requiring opioid analgesics)</li>
                                       <li>Other medical comorbidities requiring hospital admission</li>
                                       <li>Chronic kidney disease (CKD) stages 4 or 5 (estimated glomerular filtration rate
                                          (eGFR)&lt;30 mL/min) or severe liver disease</li>
                                       <li>Heparin-induced thrombocytopenia (HIT) within the last year and where there is no
                                          alternative to repeating heparin treatment</li>
                                       <li>Social reasons which may include inability to return home, inadequate care at home,
                                          lack of telephone communication, concerns over compliance, etc. [BTS]</li>
                                    </ul>
                                    <p><strong>Request a consultant review prior to discharge of any patient with confirmed or
                                          suspected PE.</strong></p>
                                    <ul>
                                       <li>If no consultant is available, then patients may be reviewed by a senior trainee
                                          (ST3 or above; ST4 in the case of Emergency Medicine) by a staff grade or similar
                                          substantive career grade doctor, advanced nurse practitioner or clinical nurse
                                          specialist designated to undertake this role within the department with consultant
                                          advice available.</li>
                                    </ul>
                                    <p><strong>Provide verbal and written information on the signs and symptoms of recurrence,
                                          major bleeding and additional complications. </strong></p>
                                    <ul>
                                       <li>There should also be an appropriate point of contact in the event of complications
                                          or concerns, both in and out of hours.</li>
                                    </ul>
                                    <p><strong>Organise a formal review (telephone/face to face) at least once during the
                                          first week after discharge to ensure therapeutic compliance and to check for any
                                          complications. </strong></p>
                                    <p><strong>There should be local protocols and pathways in place for follow-up of all
                                          patients with PE, whether treated as an inpatient or outpatient.</strong></p>
                                    <ul>
                                       <li>This should include assessment of ongoing symptoms (with further directed
                                          investigation as appropriate) and consideration of optimal duration/type of
                                          anticoagulation. [BTS]</li>
                                    </ul>
      
                                    <div id="tip_pitfall" class="card card-inverse mb-4">
                                       <div class="card-block">
                                          
                                          <h3 class="card-title"></h3>
                                          <p><strong>HESTIA is an alternative validated risk score that is less commonly used
                                                than sPESI to select patients suitable for outpatient management of PE.
                                             </strong></p>
                                          <ul>
                                             <li>Check local guidelines to decide whether to use PESI/sPESI or HESTIA</li>
                                          </ul>
      
                                          <p><strong>If any one or more of the HESTIA exclusion criteria are present, the
                                                HESTIA score is considered positive and patients are deemed unsuitable for
                                                discharge [BTS]</strong></p>
                                          <p><strong>The HESTIA exclusion criteria are very similar to the BTS exclusion
                                                criteria for patients with a low-risk sPESI score:</strong></p>
                                          <ul>
                                             <li><strong>Haemodynamic instability</strong>
                                                <ul>
                                                   <li>Systolic BP &lt;100 mmHg with heart rate &gt;100 bpm.</li>
                                                   <li>Condition requiring admission to an intensive care unit</li>
                                                </ul>
                                             </li>
                                             <li><strong>Thrombolysis or embolectomy indicated</strong></li>
                                             <li><strong>Active bleeding or high risk of bleeding</strong>
                                                <ul>
                                                   <li>Gastrointestinal bleeding in the preceding 14 days</li>
                                                   <li>Recent stroke (&lt;4 weeks ago).</li>
                                                   <li>Recent operation (&lt;2 weeks ago).</li>
                                                   <li>Bleeding disorder</li>
                                                   <li>Thrombocytopaenia (platelet count &lt;75 x 109/L)</li>
                                                   <li>Uncontrolled hypertension (SBP &gt;180 mmHg or DBP &gt;110 mmHg)</li>
                                                </ul>
                                             </li>
                                             <li><strong>Oxygen required for &gt;24 hours to maintain oxygen saturations
                                                   &gt;90%</strong></li>
                                             <li><strong>PE diagnosed during anticoagulant treatment</strong></li>
                                             <li><strong>Severe pain requiring intravenous pain medication for &gt;24
                                                   hours.</strong></li>
                                             <li><strong>Medical or social reason for treatment in the hospital for &gt;24
                                                   hours</strong></li>
                                             <li><strong>Creatinine clearance &lt; 30 mL/min</strong></li>
                                             <li><strong>Severe liver impairment (at discretion of clinician)</strong></li>
                                             <li><strong>Pregnancy</strong></li>
                                             <li><strong>Documented history of heparin-induced thrombocytopaenia.</strong>
                                             </li>
                                          </ul>
                                       </div>
                                    </div>
      
                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle55" class="toggle" />
                                          <label class="title" for="toggle55">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: sPESI and HESTIA risk scores perform similarly in
                                                identifying patients at risk of poor outcomes</span>
                                          </label>
                                          <div class="content">
                                             <ul>
                                                <li>One study compared the Hestia criteria with sPESI for identifying patients
                                                   at risk of 30-day mortality. Of 468 patients, 53% were identified as
                                                   suitable for outpatient management using the Hestia exclusion criteria,
                                                   with 59% deemed low risk according to sPESI. [ZONDAG]</li>
                                                <li>Although both tools selected slightly different patients as low risk, they
                                                   had similar overall outcomes, with 30-day adverse events (major bleeding,
                                                   recurrent VTE or death) of 2.4% in the Hestia group and 2.2% in the sPESI
                                                   low-risk group. sPESI performed slightly better than Hestia in testing.
                                                </li>
                                             </ul>
                                          </div>
                                       </div>
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Review diabetes medication (NEVER stop insulin in
                                                      people with type 1 diabetes)</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Never stop insulin in people with type 1 diabetes coming into hospital -
                                             insulin deficiency can rapidly precipitate ketoacidosis, particularly during
                                             illness. </strong></p>
                                       <ul>
                                          <li><strong>Always continue basal insulins</strong> (long-acting or background
                                             insulins e.g., determir or glargine) as this will <strong>prevent
                                                ketoacidosis</strong> if doses of rapid-acting insulin are inadvertently
                                             missed or delayed.</li>
                                          <li><strong>Dose adjustments</strong> up or down may be needed.</li>
                                          <ul>
                                             <li>For example, in the<strong> absence of significant hyperglycaemia
                                                </strong>consider <strong>reducing the evening basal insulin by 20% on
                                                   admission</strong>, as most patients will have a <strong>smaller evening
                                                   meal in hospital</strong> compared with at home.</li>
                                          </ul>
                                       </ul>
                                       <p><strong>If a variable rate intravenous insulin infusion (VRIII) is started</strong>:
                                       </p>
                                       <ul>
                                          <li><strong>Continue the basal insulin </strong><em>(Joint British Diabetes
                                                Societies for inpatient care [JBDS-IP], 2014)</em> as this will reduce the
                                             risk of ketosis in the advent of the VRIII being <strong>accidentally interrupted
                                             </strong>(e.g., by cannula displacement or blockage) or <strong>switched off
                                             </strong>(e.g., during transfer to another ward or department).</li>
                                          <li>The patient&rsquo;s usual <strong>rapid-acting </strong>and <strong>mixed
                                                insulins</strong> can be <strong>stopped while on a VRIII</strong>. <em>Joint
                                                British Diabetes Societies for inpatient care [JBDS-IP], 2014)</em></li>
                                          <li>Use the VRIII for as <strong>short a time as possible</strong>, <em>(Joint
                                                British Diabetes Societies for inpatient care [JBDS-IP], 2014) </em>as
                                             incorrect use and insufficient monitoring can result in<strong> severe
                                                hypoglycaemia</strong> or<strong> ketoacidosis</strong>.</li>
                                       </ul>
                                       <p><strong>Indications for a VRIII include</strong>: <em>(Joint British Diabetes
                                             Societies for inpatient care [JBDS-IP], 2014)</em></p>
                                       <ul>
                                          <li>Patients with diabetes or hospital-related hyperglycaemia who
                                             <strong>can&rsquo;t take oral food or fluid </strong>and where it&rsquo;s
                                             <strong>not possible to adjust their insulin regimen</strong>, e.g., when:<ul>
                                                <li>Vomiting</li>
                                                <li>Nil by mouth and patient will miss more than one meal</li>
                                                <li>There is severe illness with a need to achieve good glycaemic control
                                                   (such as with sepsis).</li>
                                             </ul>
                                          </li>
      
                                          <li>Most patients with diabetes <strong>requiring emergency surgery</strong>.
                                             <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2016)</em>
                                          </li>
                                          <li><strong>Special circumstances</strong>, such as hyperglycaemia with
                                             <strong>acute coronary syndrome</strong>, when <strong>pregnant</strong>, or when
                                             receiving <strong>TPN or enteral feeding</strong>, or <strong>taking
                                                corticosteroids</strong>. <em>(Joint British Diabetes Societies for inpatient
                                                care., 2012) </em>
                                             <ul>
                                                <li><strong>Get specialist advice</strong> from the <strong>diabetes
                                                      team</strong> in these circumstances.</li>
                                             </ul>
                                          </li>
                                       </ul>
                                       <p><strong>People with type 2 diabetes on basal insulin should continue to take it,
                                             unless otherwise indicated</strong>.</p>
                                       <ul>
                                          <li>In the <strong>absence of significant hyperglycaemia</strong> consider
                                             <strong>reducing the evening basal insulin</strong> by <strong>20% on
                                                admission</strong>, as most patients will have a <strong>smaller evening meal
                                                in hospital </strong>compared with at home.</li>
                                       </ul>
                                       <p>Give<strong> oral hypoglycaemic</strong> medication<strong> with food</strong> to
                                          reduce the<strong> risk of hypoglycaemia</strong>.</p>
                                       <ul>
                                          <li><strong>Never give oral hypoglycaemic medication at bedtime </strong>and
                                             consider <strong>reducing the evening dose of sulphonylurea</strong>.<ul>
                                                <li>This is because most patients have a <strong>smaller evening meal in
                                                      hospital </strong>compared with their usual evening meal at home.</li>
                                             </ul>
                                          </li>
      
                                       </ul>
                                       <p><strong>Withhold metformin in patients:</strong></p>
                                       <ul>
                                          <li>With <strong>contraindications</strong>, such as <strong>significant renal
                                                impairment</strong> (&lt;30 mL/minute/1.73 m2)</li>
                                          <li>With <strong>metabolic acidosis </strong>(including lactic acidosis and DKA)
                                          </li>
                                          <li>At<strong> risk of lactic acidosis</strong> with metformin, such as:<ul>
                                                <li>With conditions associated with <strong>acute kidney injury
                                                   </strong>or<strong> tissue hypoxia,</strong> including<strong>
                                                      dehydration</strong></li>
                                                <li>With <strong>renal impairment</strong>and who have, or are to be
                                                   <strong>fasted for a prolonged period</strong> or who are due to have
                                                   a<strong> radio-opaque contrast injection</strong> as part of an imaging
                                                   procedure. <strong>Follow local protocols </strong>for guidance on the
                                                   specific eGFR levels indicating renal impairment for this to be applied.
                                                </li>
                                             </ul>
                                          </li>
      
                                       </ul>
                                       <p><strong>Be aware that withholding metformin results in hyperglycemia</strong>.</p>
                                       <ul>
                                          <li>If your patient is taking <strong>other glucose-lowering medication</strong>,
                                             these may need to be<strong> increased in dose</strong> or an <strong>alternative
                                                hypoglycaemic medication to metformin</strong> prescribed.</li>
                                          <li>Some patients may need <strong>insulin as a temporary measure</strong>,
                                             but<strong> seek diabetes inpatient specialist team advice</strong>.</li>
                                       </ul>
                                       <p><strong>Stop sodium-glucose cotransporter-2 (SGLT-2) inhibitors in all acutely ill
                                             patients, particularly if dehydrated or with infection, as they are at risk of
                                             euglycaemic ketoacidosis.</strong></p>
                                       <ul>
                                          <li>SGLT-2 inhibitors (e.g., dapagliflozin) <strong>reduce blood glucose
                                                reabsorption</strong> in the kidneys (independently of insulin metabolism of
                                             glucose). <em>(Peters AL, et al, 2015) </em></li>
                                          <li>They can<strong> mask underlying ketoacidosis</strong> by patients having a
                                             normal (or near normal) serum glucose level <strong>(euglycaemic
                                                ketoacidosis)</strong>.</li>
                                          <li>Check <strong>blood ketones</strong> as urinary ketone measurement may be
                                             unreliable.</li>
                                          <li><strong>Treat for DKA</strong> if <strong>blood ketone level is &ge;3
                                                mmol/L</strong>, blood<strong> pH &lt;7.3</strong> and <strong>bicarbonate
                                                &lt;15 mmol/L</strong>. (<em>JBDS-IP, 2013)</em></li>
                                       </ul>
                                       <p><strong>Reduce or omit the dose of gliclazide if the patient has impaired kidney
                                             function or is eating less than usual, to avoid hypoglycaemia at night. </strong>
                                       </p>
                                       <p><strong>Inform the diabetic inpatient team of the admission of any patient with
                                             diabetes. They are available for advice and support.</strong></p>
                                       <p><strong>For a patient at the end of life</strong>: <em>(Rowles S, et al 2011)</em>
                                       </p>
                                       <ul>
                                          <li><strong>Hypoglycaemic medication</strong> should be <strong>reduced </strong>to
                                             the minimum, <strong>but</strong></li>
                                          <li>The patient should be<strong> kept free from symptomatic
                                                hyperglycaemia</strong>, which can lead to <strong>dehydration</strong>,
                                             <strong>ketosis</strong> or <strong>hyperosmolar hyperglycaemia</strong>.</li>
                                       </ul>
                                       <p>Refer to <strong>local protocols </strong>or the Association of British Clinical
                                          Diabetologists (ABCD). <em>(Rowles S, et al 2011)</em></p>
      
                                    </div>

                                 </div>
                                    <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Monitor and manage blood glucose</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Monitor blood glucose levels at least 4 times a day (pre-meal and before
                                             bedtime if eating) in all acutely unwell patients with diabetes mellitus
                                             (</strong><em>American Diabetes Association, 2019)</em></p>
                                       <ul>
                                          <li>The risk of<strong> hypo- and hyperglycaemia</strong> increases when people with
                                             diabetes are admitted to hospital with acute conditions. <em>(NHS Digital.
                                                National Diabetes Inpatient Audit (NaDIA) - 2017, 2018)</em></li>
                                          <li><strong>More frequent monitoring</strong> is needed after <strong>episodes of
                                                hyperglycaemia</strong> or <strong>hypoglycaemia</strong>.</li>
                                          <li>More <strong>frequent monitoring</strong> is needed after a <strong>change in
                                                hypoglycaemic medication</strong>.</li>
                                          <li>Patients on a<strong> variable rate intravenous insulin infusion
                                                (VRIII)</strong> need <strong>capillary blood glucose measurements every
                                                hour</strong>. <em>(Joint British Diabetes Societies for inpatient care
                                                [JBDS-IP], 2014)</em></li>
                                          <li>Support <strong>self-management</strong> (including monitoring blood glucose) if
                                             this conforms to local protocols, it is safe to do so, and the patient is
                                             willing. <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP],
                                                2012) </em></li>
                                       </ul>
                                       <p><strong>Prevent and manage hyperglycaemia if it occurs</strong></p>
      
                                       <ul>
                                          <li>There is <strong>no consensus on target blood glucose</strong> levels for people
                                             with diabetes in hospital.
                                             <ul>
                                                <li><strong>The Joint British Diabetes Societies for Inpatient Care</strong>
                                                   (JBDS-IP) recommend an<strong> ideal range</strong> of between<strong> 6 to
                                                      10 mmol/L</strong>, and an <strong>acceptable range</strong> of
                                                   <strong>4 to 12 mmol/L</strong><em>(JBDS-IP, 2014)</em></li>
                                                <li><strong>The American Diabetes Association</strong> recommend a
                                                   <strong>target blood glucose range</strong> of <strong>7.8 to 10.0
                                                      mmol/L</strong> (140-180 mg/dL) for most critically and noncritically
                                                   ill patients. (<em>American Diabetes Association. Diabetes Care in the
                                                      Hospital: Standards of Medical Care in Diabetes&mdash;2019, 2019)</em>
                                                </li>
                                                <li><em>The <strong>National Institute for Health and Care Excellence</strong>
                                                      recommends a target plasma glucose level of <strong>5 to 8
                                                         mmol/L</strong> in adults with type 1 diabetes in hospital undergoing
                                                      surgery or with acute illness. <em>(NICE, 2017)</em></em></li>
                                             </ul>
                                          </li>
                                          <li><strong>More liberal blood glucose targets</strong> are appropriate for people
                                             at<strong> high risk of falls </strong>and who are<strong> frail </strong>or have
                                             <strong>dementia</strong>. <em>(JBDS-IP, 2014)</em></li>
                                       </ul>
      
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle56" class="toggle" />
                                             <label class="title" for="toggle56">
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: patient outcomes associated with
                                                   hyperglycaemia</span>
                                             </label>
                                             <div class="content">
                                                <p><strong>Hyperglycaemia in patients in hospital is associated with adverse
                                                      outcomes. (</strong><em>Moghissi, 2009)</em></p>
                                                <ul>
                                                   <li>Hyperglycaemia in patients in hospital, whether with known diabetes or
                                                      not, has been shown by various observational studies to be associated
                                                      with adverse patient outcomes, including increased mortality.
                                                      <strong>(</strong><em>Moghissi, 2009)</em></li>
                                                </ul>
                                             </div>
                                          </div>
                                       </div>
      
      
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle57" class="toggle" />
                                             <label class="title" for="toggle57">
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: blood glucose targets for people with diabetes
                                                   in hospital</span>
                                             </label>
                                             <div class="content">
                                                <p><strong>Conflicting evidence for optimal blood glucose targets has led to
                                                      variations in recommendations in different countries and settings.
                                                      Follow your local protocol.</strong></p>
                                                <ul>
                                                   <li>Intensive care setting</li>
                                                   <ul>
                                                      <li>A randomised controlled trial (RCT) of critically ill patients in a
                                                         primarily surgical intensive care setting found lower patient
                                                         mortality with tight glucose control - 80 to 110 mg/dL (4.4 to 6.1
                                                         mmol/L) compared with &lsquo;conventional&rsquo; more liberal glucose
                                                         control. <em>(Van den Berghe G et al, 2001) </em></li>
                                                      <li>However, a subsequent multicentre RCT in critically ill medical and
                                                         surgical patients in other intensive care settings found increased
                                                         mortality with tighter glucose control, possibly due to increased
                                                         episodes of hypoglycaemia. <em>(Finfer et al, 2009)</em></li>
                                                   </ul>
                                                </ul>
                                                <p>A 2010 systematic review of 6 RCTs and a meta-analysis investigating tight
                                                   glucose control (80 to 110 mg/dL [4.4 to 6.1 mmol/L]) vs less strict
                                                   glucose control in critically ill patients in the ICU setting found no
                                                   significant improvement in mortality with tight glucose control, but it was
                                                   associated with significantly more hypoglycaemic episodes compared with
                                                   less strict glucose control. (<em>Marik, 2010)</em></p>
                                             </div>
                                          </div>
                                       </div>
      
                                       <p><strong>Follow your local hospital protocol on steps to take if your patient&rsquo;s
                                             capillary blood glucose is &ge;15 mmol/L. Exclude diabetic ketoacidosis (DKA) or
                                             hyperosmolar hyperglycemic state (HHS), both of which require specific urgent
                                             management.</strong></p>
                                       <ul>
                                          <li><strong>Treat hyperglycaemia</strong> to avoid <strong>DKA </strong>and<strong>
                                                HHS</strong>.</li>
                                          <li><strong>DKA</strong> and <strong>HHS</strong> are <strong>medical
                                                emergencies</strong>. Follow JBDS or local hospital guidelines for patients
                                             with DKA (<em>JBDS-IP, 2013) </em>or HHS (<em>JBDS-IP, 2012). </em></li>
                                          <li>The <strong>diabetes inpatient specialist team</strong> should be involved in
                                             the management of any patient with <strong>DKA</strong>. (<em>JBDS-IP, 2013)</em>
                                          </li>
                                          <li><strong>Early senior review</strong> by a clinician who is familiar with the
                                             management of<strong> HHS</strong> is imperative. (<em>JBDS-IP, 2012)
                                             </em>Patients with <strong>other comorbidities</strong> may need to be on a
                                             <strong>high dependency unit. </strong>(<em>JBDS-IP, 2012)</em></li>
                                       </ul>
                                       <p><strong>Be aware that the following medication may be associated with hyperglycaemia
                                             and may need to be reviewed: </strong><em>(Abdur R, et al, 2011)</em></p>
                                       <ul>
                                          <li>Corticosteroids</li>
                                          <li>Some beta-blockers (e.g., propranolol, atenolol)</li>
                                          <li>Thiazide diuretics (e.g., hydrochlorozide)</li>
                                          <li>Some second-generation antipsychotics (e.g., olanzapine and clozaine)</li>
                                          <li>Certain fluoroquinolone antibiotics (e.g., gatifloxin)</li>
                                          <li>Calcineurin inhibitors (e.g., cyclosporine, tacrolimus)</li>
                                          <li>Protease inhibitors (e.g., as a component in antiretroviral therapy, such as
                                             ritonavir)</li>
                                       </ul>
      
      
                                       <div id="tip_pitfall" class="card card-inverse mb-4">
                                          <div class="card-block">
                                             
                                             <h3 class="card-title"></h3>
                                             <p><strong>Ask for expert advice from the diabetes team in complex patients, or
                                                   where hyperglycaemia is difficult to control.</strong></p>
      
                                          </div>
                                       </div>
      
                                       <p><strong>Prevent and manage hypoglycaemia if it occurs</strong></p>
                                       <ul>
                                          <li><strong>Monitor blood glucose</strong> in people with diabetes in hospital and
                                             <strong>adjust medication </strong>in response to illness and hospital meal
                                             times, in order to <strong>reduce risk</strong> of <strong>hypoglycaemic
                                                episodes</strong>.</li>
                                          <li>1 in 5 inpatients with diabetes in England and Wales have a<strong>
                                                hypoglycaemic episode </strong>during their hospital stay. <em>(NHS Digital.
                                                National Diabetes Inpatient Audit (NaDIA) - 2017, 2018)</em></li>
                                          <li>Causes include:<em> (JBDS-IP, 2018)</em>
                                             <ul>
                                                <li>Recovery from an acute illness</li>
                                                <li>Insulin or oral hypoglycaemic medication error</li>
                                                <li>Wrong timing of insulin in relation to meals</li>
                                                <li>Patients eating less but taking the same amount of diabetes medication
                                                </li>
                                                <li>No bedtime snacks</li>
                                                <li>Reduced appetite or vomiting.</li>
                                             </ul>
                                          </li>
                                       </ul>
      
      
      
                                       <div id="tip_pitfall" class="card card-inverse mb-4">
                                          <div class="card-block">
                                             
                                             <h3 class="card-title">
                                                <p><strong>Bedtime snacks </strong>can reduce the risk of <strong>early
                                                      morning hypoglycaemia</strong>. <em>(NHS Digital. National Diabetes
                                                      Inpatient Audit (NaDIA) - 2017, 2018)</em></p>
                                             </h3>
      
                                          </div>
                                       </div>
                                       <p><strong>Treat hypoglycaemia actively if the blood glucose falls below 4.0 mmol/L.
                                          </strong><em>(JBDS-IP, 2018)</em></p>
                                       <ul>
                                          <li>Follow hospital protocol. The JBDS-IP has guidelines on hospital management of
                                             hypoglycaemia in adults with diabetes. <em>(JBDS-IP, 2018)</em></li>
                                       </ul>
      
                                    </div>
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group CKD-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Check baseline kidney function</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Check baseline serum kidney function on admission in all patients with a
                                             previous history of chronic kidney disease (CKD). </strong><em>[National
                                             Institute for Health and Care Excellence. 2013)</em></p>
                                       <ul>
                                          <li><strong>CKD</strong> is a significant<strong> risk factor</strong> for the
                                             development of <strong>acute kidney injury</strong>. <em>(Hsu CY, et al,
                                                2008)</em></li>
                                          <li>Acute illness increases the risk of deterioration in renal function.</li>
                                       </ul>
      
                                    </div>
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Stroke-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Baseline neurological assessment</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Do a baseline neurological assessment on admission for all patients with a
                                             history of stroke.</strong></p>
                                       <ul>
                                          <li>Patients with <strong>acute illness</strong> (including infections and causes of
                                             hypotension) are at <strong>increased risk of stroke</strong> (both ischaemic and
                                             haemorrhagic). <em>(Grau AJ, et al, 2010) (Eigenbrodt ML, et al, 2000)</em></li>
                                          <li>If there is a suspicion of a change in neurological status during admission,
                                             repeat the<strong>neurological assessment</strong> in case of a <strong>possible
                                                new stroke</strong>.</li>
                                          <li>Following assessment, consider appropriate level of <strong>patient
                                                supervision</strong> e.g., relating to possible <strong>confusion</strong> at
                                             night, <strong>falls</strong> related to <strong>frailty</strong>.</li>
                                       </ul>
      
                                    </div>
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Dementia-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Baseline cognitive assessment and collateral
                                                      history</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Do</strong><strong> a baseline cognitive assessment in all older patients,
                                             particularly those with a history of dementia. </strong><em>(Pendlebury ST, et
                                             al, 2015)</em></p>
                                       <ul>
                                          <li>Use a<strong> validated scoring system</strong> that is also feasible in the
                                             acute setting, such as:<em>(Pendlebury ST, et al, 2015)</em>
                                             <ul>
                                                <li>The <strong>abbreviated mental test score</strong> (AMTS/10)
                                                   <em>(</em><em>Hodkinson,1972)</em></li>
                                                <li><strong>Montreal Cognitive Assessment</strong> (MoCA) <em>(Nasreddine,
                                                      2005).</em></li>
                                             </ul>
                                          </li>
      
                                       </ul>
                                       <p><strong>Dementia increases the risk of delirium. </strong></p>
                                       <ul>
                                          <li>This can acutely reduce patients' cognitive assessment scores. <em>(George J,
                                                2013)</em></li>
                                       </ul>
                                       <p><strong>Take a collateral history from family, friend or carer, to establish the
                                             patient&rsquo;s level of function and baseline cognition before this
                                             illness.</strong></p>
                                       <ul>
                                          <li>It&rsquo;s important to know if the <strong>decline</strong> in function and
                                             cognition has been <strong>gradual </strong>or <strong>acute</strong>.</li>
                                       </ul>
                                       <p>Use this information for <strong>monitoring clinical improvement</strong>, and for
                                          establishing <strong>needs on discharge</strong>.</p>
      
      
                                    </div>
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Dementia-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Assess for and manage delirium</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Assess the patient with dementia for delirium. </strong><em>(National
                                             Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                          <li>People living with dementia are at increased risk of delirium when they are
                                             admitted to hospital. (<em>National Institute for Health and Clinical Excellence,
                                                2018)</em></li>
                                          <li>Use a<strong> screening tool</strong>, such as:<ul>
                                                <li>The <strong>4-AT</strong><em>(Bellelli, 2014)</em></li>
                                                <li>The <strong>short confusion assessment method (S-CAM), </strong>as
                                                   recommended by the National Institute of Health and Care Excellence (NICE).
                                                   <em>(National Institute for Health and Clinical Excellence. 2010)</em></li>
                                                <li>Document the results clearly.</li>
                                             </ul>
                                          </li>
      
                                       </ul>
                                       <p><strong>Assess the patient for any reversible causes of delirium</strong>.
                                          <em>(National Institute for Health and Clinical Excellence. 2010)</em>These include:
                                       </p>
                                       <ul>
                                          <li>Infection</li>
                                          <li>Pain</li>
                                          <li>Dehydration</li>
                                          <li>Constipation</li>
                                          <li>Hypoxia</li>
                                          <li>Immobility</li>
                                          <li>Medications</li>
                                          <li>Poor sleep</li>
                                          <li>Sensory impairment (e.g., ear wax or loss of glasses)</li>
                                       </ul>
                                       <p><strong>Investigations</strong> to help diagnose underlying causes include:</p>
                                       <ul>
                                          <li>Full blood count, electrolytes, renal function, liver function tests, calcium,
                                             glucose, CRP, folate and vitamin B12.</li>
                                          <li>Blood cultures (if bacteraemia is suspected)</li>
                                          <li>Urine microscopy and culture</li>
                                          <li>Chest x-ray</li>
                                       </ul>
                                       <p><strong>Manage according to the cause</strong>.</p>
                                       <p><strong>Manage patients with delirium initially with non-pharmacological treatment.
                                          </strong><em>(National Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                          <li>Reduce <strong>disorientation</strong> by providing a <strong>well-lit
                                                room,</strong> with a <strong>clock</strong> and <strong>calendar
                                             </strong>visible (e.g., on the wall).</li>
                                          <li>Encourage and facilitate <strong>family, friends and carers</strong> visiting
                                             the patient.</li>
                                          <li>Use verbal and non-verbal techniques to<strong> de-escalate</strong> conflict
                                             and distress.</li>
                                       </ul>
                                       <p><strong>Where non-pharmacological treatments are ineffective, and the patient is
                                             distressed or considered a risk to themselves or others, short-term antipsychotic
                                             or sedative drugs may be used.</strong></p>
                                       <p><strong>Only use antipsychotics as a last resort and not in patients with
                                             Parkinson&rsquo;s disease or dementia with Lewy bodies.</strong><em>(National
                                             Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                          <li><strong>Risperidone</strong> has the least anticholinergic effects. <em>(Tracy
                                                JI, et al, 1998)</em></li>
                                          <li><strong>Haloperidol</strong> is also licenced for this indication, but has the
                                             highest risk associated with its use. The UK National Institute for Health and
                                             Care Excellence recommends short-term use of haloperidol (usually for less than
                                             one week), starting at the <strong>lowest dose</strong> and <strong>titrating
                                                carefully</strong> according to the symptoms. <em>(National Institute for
                                                Health and Clinical Excellence. 2010)</em></li>
                                          <li>Consider sedation in significantly agitated patients who pose a risk to
                                             themselves or others.<strong> Lorazepam </strong>is a suitable choice, but it
                                             should only be given orally or intramuscularly (i.e., not intravenously).</li>
                                          <li>Lorazepam should only be used in the<strong> smallest possible dose</strong> for
                                             the <strong>shortest possible duration</strong>.</li>
                                       </ul>
                                       <p><strong>Avoid typical antipsychotics, particularly haloperidol in patients with
                                             Parkinson&rsquo;s disease or dementia with Lewy bodies. </strong><em>(National
                                             Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                          <li>The dopamine receptor antagonistic effect of typical antipsychotics can
                                             <strong>dramatically worsen physical and cognitive symptoms</strong> in people
                                             with Parkinson&rsquo;s disease or with dementia with Lewy bodies.</li>
                                          <li>Consider a <strong>low-dose short-acting oral benzodiazepine,</strong> such as
                                             lorazepam, or l<strong>ow-dose quetiapine </strong>in patients with
                                             Parkinson&rsquo;s disease or dementia with Lewy bodies who require sedation to
                                             enable safe care because of delirium.</li>
                                          <li>Consult your local drug formulary for advice.</li>
                                       </ul>
                                       <p><br /><strong>Document</strong> any episodes of current or resolved delirium in
                                          the<strong> discharge summary for the GP</strong>. <em>(National Institute for
                                             Health and Clinical Excellence. 2010)</em></p>
      
      
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle59" class="toggle" />
                                             <label class="title" for="toggle59">
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: sPESI and HESTIA risk scores perform similarly
                                                   in identifying patients at risk of poor outcomes</span>
                                             </label>
                                             <div class="content">
                                                <p><strong>Short-term antipsychotics may be needed in people with dementia to
                                                      enable safe care. However, antipsychotics have various adverse effects
                                                      in the elderly and are associated with an increased risk of death in
                                                      people with dementia.</strong></p>
                                                <ul>
                                                   <li>A meta-analysis found that people with dementia who take atypical
                                                      antipsychotics have an <strong>increased mortality risk
                                                      </strong>compared with people taking placebo. <em>(Ma H, et al,
                                                         2014)</em></li>
      
                                                   <li>A large cohort study of elderly people found that <strong>higher
                                                         doses</strong> of antipsychotics are generally associated with
                                                      <strong>greater risk</strong>. <em>(Huybrechts K, 2012)</em></li>
      
                                                   <li>It also found that of all the antipsychotics studied,
                                                      <strong>haloperidol </strong>has the highest risk associated with its
                                                      use. <em>(Huybrechts K, 2012)</em></li>
                                                </ul>
                                                <p>Contrary to popular belief, long-term antipsychotic prescriptions in people
                                                   with dementia whose behaviour is now settled, can be <strong>withdrawn
                                                      safely </strong>in the majority of cases. (<em>Van Leeuwen, 2018)</em>
                                                </p>
                                             </div>
                                          </div>
                                       </div>
      
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle58" class="toggle" />
                                             <label class="title" for="toggle58">
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: primary prevention of delirium: this may be the
                                                   most effective treatment strategy</span>
                                             </label>
                                             <div class="content">
                                                <p><strong>A non-randomised trial studying how to reduce risk factors for
                                                      delirium compared a multicomponent strategy with usual care in 852
                                                      elderly patients (over 70 years) in hospital. </strong><em>(Inouye,
                                                      1999)</em></p>
                                                <ul>
                                                   <li>The multicomponent strategy targeted the following 6 risk factors:<ul>
                                                         <li>cognitive impairment</li>
                                                         <li>sleep deprivation</li>
                                                         <li>immobility</li>
                                                         <li>visual impairment</li>
                                                         <li>hearing impairment</li>
                                                         <li>dehydration.</li>
                                                      </ul>
                                                   </li>
      
                                                </ul>
                                                <p>It found: <em>(Inouye, 1999)</em></p>
                                                <ul>
                                                   <li>There were <strong>significantly fewer first episodes of
                                                         delirium</strong> with the <strong>multicomponent strategy
                                                      </strong>vs usual care (44 [9.9%] vs 64 [15%] respectively)</li>
                                                   <li>Matched group analysis found an odds ratio (OR) of 0.60 (95%CI:
                                                      0.39-0.92; p=0.02)</li>
                                                   <li><strong>Total number of days with delirium</strong> was
                                                      <strong>significantly lower </strong>with the <strong>multicomponent
                                                         strategy</strong> vs usual care (105 vs. 161 days respectively,
                                                      p=0.02)</li>
                                                </ul>
                                                <p><strong>Delirium severity and recurrence rates</strong> were <strong>not
                                                      significantly different </strong>in the 2 groups.</p>
                                             </div>
                                          </div>
                                       </div>
      
                                    </div>
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Dementia-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Set an escalation plan</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Set an escalation plan for all patients with dementia as early as
                                             possible.</strong></p>
                                       <ul>
                                          <li>This should include: <em>(Fritz Z, et al, 2017):</em>
                                             <ul>
                                                <li><strong>Resuscitation status</strong> (i.e., do not attempt
                                                   cardiopulmonary resuscitation [DNACPR] decision)</li>
                                                <li><strong>Ceiling of care</strong> (e.g., is the patient suitable for
                                                   intubation or intensive care admission)</li>
                                             </ul>
                                          </li>
                                          <li>Escalation plans should take account of<strong> advanced care planning</strong>,
                                             including legally-binding advanced directives. <em>(Fritz Z, et al, 2017)</em>
                                          </li>
                                       </ul>
                                       <p><strong>Communicate</strong> all decisions regarding the escalation plan
                                          <strong>with the patient</strong>.<em>(Fritz Z, et al, 2017)</em></p>
                                       <ul>
                                          <li><strong>Assess mental capacity</strong> (the ability to make decisions at a
                                             specific time a decision needs to be made) and document. <em>(NICE, 2018)</em>
                                             Follow the appropriate legislation in your region.</li>
                                          <li>In England and Wales, health professionals must comply with the <strong>2005
                                                Mental Capacity Act</strong>. <em>(Department of Health, 2005)
                                             </em>Assessments should follow the principles in the Act. <em>(Department of
                                                Health, 2005) </em></li>
                                          <li>If a patient is assessed to lack mental capacity, ensure decisions are made in
                                             the <strong>best interests of the patient</strong>. <em>(Department of Health,
                                                2005) (NICE, 2018)</em></li>
                                       </ul>
                                       <p><strong>If the patient is assessed to lack mental capacity, consult with the
                                             patient&rsquo;s next of kin in order to make &lsquo;best interests&rsquo;
                                             decisions. </strong><em>(Department of Health, 2005) </em></p>
                                       <p>According to the 2005 Mental Capacity Act in England and Wales, if a patient is
                                          unbefriended and a decision is not time critical, an independent mental capacity
                                          advocate (IMCA) should be sought to perform this role instead. (<em>Social Care
                                             Institute for Excellence, 2011)</em></p>
      
                                    </div>
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Asthma-como-content COPD-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Remember to prescribe usual inhalers</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Patients may not think to tell you about their usual inhalers when asked
                                             about their medication, so remember to check and prescribe these if
                                             appropriate</strong></p>
                                       <ul>
                                          <li>Patients with asthma should continue any inhaled corticosteroid medication they
                                             usually take. These should not be stopped without a clear medical reason.</li>
                                          <li>Many inhalers are combined medications, so check there is no dual prescribing
                                          </li>
                                       </ul>
                                       <p><strong>Temporarily stop inhaled long-acting muscarinic receptor antagonists if your
                                             patient with COPD or asthma usually takes this and develops acute kidney injury
                                             with an eGFR &lt;30.</strong></p>
      
                                    </div>
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Asthma-como-content COPD-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Consider
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Nicotene replacement therapy in current
                                                      smokers</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>All current smokers are nicotine dependent</strong></p>
                                       <ul>
                                          <li>Nicotine replacement therapy should be prescribed to prevent withdrawal
                                             regardless of a patient&rsquo;s intention regarding smoking cessation</li>
                                          <li>Please consult your local hospital guidance.</li>
                                       </ul>
                                       <p><br /><strong>Make every contact count:</strong></p>
                                       <ul>
                                          <li>Being in hospital with an acute illness is the ideal time to support someone to
                                             give up smoking</li>
                                          <li>Provide brief advice.</li>
                                       </ul>
      
                                    </div>
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Asthma-como-content COPD-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Monitor for and manage any acute exacerbation of
                                                      asthma or COPD</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
      
                                       <p><strong>Monitor patient for symptoms and signs of an acute exacerbation of their
                                             COPD or asthma.</strong></p>
                                       <ul>
                                          <li>A patient with airways disease may have an acute exacerbation while in hospital
                                             with a separate another medical or surgical condition.</li>
                                       </ul>
                                       <p><strong>Patients with comorbid COPD may be having an acute exacerbation if there is
                                             an acute worsening of respiratory symptoms that results in the need for
                                             additional therapy.</strong><em>(Global Initiative for Chronic Obstructive Lung
                                             Disease, 2019)</em></p>
                                       <ul>
                                          <li><strong>Differentiate</strong> from other conditions which may present very
                                             similarly, such as <strong>acute coronary syndrome</strong>, <strong>acute heart
                                                failure</strong> and <strong>pneumonia</strong>.</li>
                                          <li>Follow guideline recommendations on <strong>investigations</strong>, including:
                                             <ul>
                                                <li><strong>ABG</strong> measurement</li>
                                                <li><strong>Chest x-ray.</strong> Generally, do a chest x-ray if a patient
                                                   with COPD is admitted with breathlessness or cough, or has worse symptoms
                                                   than usual.</li>
                                             </ul>
                                          </li>
      
                                          <li>Follow <strong>COPD guideline </strong>recommendations on <strong>initial
                                                management</strong>, including:<ul>
                                                <li><strong>Assessing</strong><strong>severity</strong></li>
                                                <li>Increasing dose and/or frequency of <strong>bronchodilator
                                                      therapy</strong>, using nebulisers (driven with air) or spacers</li>
                                                <li>Considering <strong>oral corticosteroids</strong>,
                                                   <strong>antibiotics</strong> and need for <strong>noninvasive
                                                      ventilation</strong>.</li>
                                                <li>See BMJ Best Practice topic on Acute exacerbation in COPD</li>
                                             </ul>
                                          </li>
      
                                       </ul>
                                       <p><strong>Follow guideline recommendations for assessment of severity and management
                                             of an acute exacerbation of asthma in adults. </strong><em>(</em><em>British
                                             Thoracic Society; Scottish Intercollegiate Guidelines Network, 2016) </em></p>
                                       <ul>
                                          <li>Initial treatment of acute severe asthma includes:<ul>
                                                <li><strong>Supplementary oxygen</strong> if hypoxaemic. Titrate to maintain
                                                   an oxygen saturation level of <strong>94% to 98%</strong></li>
                                                <li><strong>High-dose inhaled beta2 agonists</strong> as early as possible,
                                                   usually via nebuliser (oxygen-driven)</li>
                                                <li><strong>Ipratropium bromide</strong> via nebuliser (oxygen-driven) if
                                                   needed</li>
                                                <li><strong>Corticosteroids</strong> in adequate doses (40 to 50 mg daily for
                                                   at least 5 days)</li>
                                                <li>Other therapies may be required, <strong>follow guideline
                                                      recommendations</strong></li>
                                                <li>See BMJ Best Practice topic on Acute exacerbation of asthma in adults.
                                                </li>
                                             </ul>
                                          </li>
      
                                       </ul>
                                       <p><strong>Stop long-acting muscarinic receptor antagonists (LAMAs) e.g.,
                                          </strong><strong>tiotropium </strong><strong>temporarily if short-acting muscarinic
                                             antagonists (SAMAs) e.g., ipratropium bromide are prescribed via
                                             nebuliser.</strong></p>
                                       <ul>
                                          <li>This is based on expert opinion due to concern over possible anticholinergic
                                             adverse effects.</li>
                                       </ul>
                                       <p><strong>Regular nebulisers should only be prescribed for 24 to 48 hours and then
                                             switched back to the patient&rsquo;s usual inhalers.</strong></p>
      
      
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle60" class="toggle" />
                                             <label class="title" for="toggle60">
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: cardiovascular harm with beta2- agonists.</span>
                                             </label>
                                             <div class="content">
                                                <p><strong>Beta2-agonists increase the risk of myocardial infarction and other
                                                      adverse cardiovascular events</strong></p>
                                                <p>Beta2-agonists increase heart rate and reduce potassium levels.
                                                   <em>(Salpeter SR, et al, 2004) </em>They are absorbed into the systemic
                                                   circulation and there is evidence they are associated with an increased
                                                   risk of myocardial infarction, unable angina, congestive heart failure and
                                                   arrhythmias. <em>(Au DH, et al, 2002) (Salpeter SR, et al, 2004) (Baker JG,
                                                      2017)</em></p>
                                             </div>
                                          </div>
                                       </div>
      
      
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle61" class="toggle" />
                                             <label class="title" for="toggle61">
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: short duration vs longer duration of
                                                   corticosteroids for acute exacerbation of COPD</span>
                                             </label>
                                             <div class="content">
                                                <p><strong>A systematic review found no difference in outcomes (treatment
                                                      failure, time to next exacerbation, time in hospital, lung function,
                                                      adverse effects, mortality) between short courses (7 days or less) vs
                                                      more conventional longer courses (longer than 7 days) of corticosteroids
                                                      in people with acute exacerbation of COPD </strong><em>(Walters JAE, et
                                                      al, 2018)</em></p>
                                                <ul>
                                                   <li>The randomised controlled trials included in this Cochrane review were
                                                      all in hospital settings and only included people with severe to very
                                                      severe COPD<em> (Walters JAE, et al, 2018)</em></li>
                                                   <li>The review authors concluded that due to the addition of a new trial,
                                                      they have increased confidence that a corticosteroid course of around 5
                                                      days is likely to be sufficient for the treatment of an acute
                                                      exacerbation of COPD. <em>(Walters JAE, et al, 2018)</em></li>
                                                </ul>
                                             </div>
                                          </div>
                                       </div>
      
                                    </div>
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Check patient’s feet</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
      
                                       <p><strong>Check</strong><strong> the feet of all adults with diabetes on admission to
                                             hospital and whenever there has been a change in their status.
                                          </strong><em>(NICE, 2016)</em></p>
                                       <ul>
                                          <li><strong>Why? </strong></li>
                                          <ul>
                                             <li>To detect <strong>new ulceration </strong>or<strong> infection,
                                                </strong>which may be<strong> unnoticed</strong> by the patient andmay even be
                                                the <strong>underlying cause </strong>of their illness (e.g., patient
                                                presenting with sepsis, spinal abscess or endocarditis where the original
                                                focus of infection is the foot lesion).</li>
                                             <li>To determine if patient is at<strong> high risk of pressure ulceration
                                                </strong>and <strong>requires pressure relief</strong>.</li>
                                          </ul>
                                          <li><strong>Take action </strong></li>
                                          <ul>
                                             <li>You must <strong>remove any foot dressings</strong> to see if any wound/ulcer
                                                is<strong> infected. </strong><em>(NICE NG19, 2016)</em></li>
                                             <li><strong>Inspect</strong> the foot for lesions and examine for loss of
                                                protective <strong>sensation</strong>. Follow your local guidelines, but a
                                                quick simple test is the <strong>Ipswich Touch Test&copy;️</strong>. (Rayman
                                                G, et al, 2011)</li>
                                             <li>If your patient has <strong>reduced sensation</strong>, they are at
                                                <strong>high risk of pressure ulceration</strong>. Inform the nursing staff
                                                and <strong>provide pressure relieving devices</strong>.</li>
                                             <li>A <strong>daily heel check</strong> for <strong>signs of pressure
                                                   trauma</strong> should be undertaken by nursing or health care assistant
                                                staff.</li>
                                          </ul>
                                       </ul>
      
                                    </div>
                                 </div>
                                 <!--/.panel-body -->
                              </section>                              
                           </div>
                           <!--/.panel-body -->
                        </section>

                        <section class="panel-group">
                           <div class="panel-header child-accordion">
                              <p class="panel-title">
                                 <a href="#" role="tab header" id="tab_1_0_0_acute5" aria-controls="panel_1_0_0_acute4" aria-expanded="false" class="">
                                    <span class="title-04">
                                       <span class="material-icons"><span></span><span></span></span>
                                       <span class="title-01">
                                          <span>Contraindication to anticoagulation</span>
                                          <span class="noShow">&nbsp;–&nbsp;</span>
                                       </span>
                                    </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10 col-sm-12 child-accordion" role="tabpanel" aria-labelledby="nested-collapse_0_0_3 tab_1_0_0_acute5 " id="panel_1_0_0_acute4" aria-expanded="false" style="display: none;">
                              <section class="panel-group">
                                    <div class="panel-header">
                                       <p class="panel-title">
                                          <a href="#" role="tab header" id="nested-collapse_0_0_3" aria-controls="nested-collapse_0_0_3" aria-expanded="false" class=""> 
                                             <span class="titles-wrap col-md-12">
                                                <span class="title-02">
                                                   <span class="title-03 col-md-1 col-sm-1">
                                                      1st line
                                                      <span class="noShow">&nbsp;–&nbsp;</span>
                                                   </span>
                                                   <span class="title-04">
                                                      <span class="material-icons"><span></span><span></span></span>
                                                      <span class="txtwrap">Consider anticoagulation OR venous filter (wait for
                                                         confirmation of diagnosis on CTPA)</span>
                                                   </span>
                                                </span>
                                             </span>
                                          </a>
                                       </p>
                                    </div>
                                    <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                       id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
         
                                       <p><strong>Consult a haematologist if a patient has a contraindication to
                                             anticoagulation.</strong></p>
                                       <ul>
                                          <li>Many patients with relative contraindications will still be able to have a
                                             different choice or altered dose of anticoagulation but a specialist opinion is
                                             needed to weigh up the benefit-risk balance.</li>
                                          <li><strong>Absolute contraindications are rare but include: [HOR]</strong>
                                             <ul>
                                                <li>active bleeding</li>
                                                <li>recent intracranial hemorrhage</li>
                                                <li>recent, planned, or emergent surgery or procedure with high bleeding risk
                                                </li>
                                                <li>platelet count &lt;50,000/uL</li>
                                                <li>severe bleeding diathesis.</li>
                                             </ul>
                                          </li>
                                          <li><strong>Relative contraindications include: [HOR]</strong>
                                             <ul>
                                                <li>recurrent but inactive gastrointestinal bleeding</li>
                                                <li>intracranial or spinal tumor</li>
                                                <li>recent, planned, or emergent surgery or procedure with intermediate bleeding
                                                   risk</li>
                                                <li>major trauma including cardiopulmonary resuscitation</li>
                                                <li>aortic dissection</li>
                                                <li>platelet count &lt;150,000/uL</li>
                                             </ul>
                                          </li>
                                          <li><strong>Remember too that each anticoagulant may have its own specific relative and
                                                absolute contraindications</strong> (e.g., heparin is contraindicated in patients
                                             with a history of heparin-induced thrombocytopenia), and these should be checked
                                             before starting treatment.</li>
                                       </ul>
         
                                       <div id="tip_pitfall" class="card card-inverse mb-4">
                                          <div class="card-block">
                                             
                                             <h3 class="card-title"></h3>
                                             <p><strong></strong></p>
                                             <ul>
                                                <li>Peptic ulcer disease with no history of bleeding or faecal occult blood is
                                                   not a contraindication to anticoagulation.[HOR]</li>
                                                <li>Anticoagulation is safe in most trauma and neurosurgical patients after the
                                                   first or second postoperative week and in most stroke patients without
                                                   haemorrhage. [HOR]</li>
                                                <li>Patients with spinal cord injury without haematomyelia may still be
                                                   considered for anticoagulation [HOR]</li>
                                             </ul>
                                          </div>
                                       </div>
         
                                       <p><strong>Venous filters</strong></p>
                                       <p><strong>Consider a venous filter for any patient with confirmed PE who is deemed
                                             unsuitable for anticoagulation after discussion with a haematologist - in practice,
                                             they are rarely used outside the US. [BARCO] </strong></p>
                                       <ul>
                                          <li><strong>A retrievable venous filter should be used where possible</strong> and
                                             should be removed as soon as the reason for the absolute contraindication to
                                             anticoagulation has been resolved. [ESC][ACP][ACIR]</li>
                                          <li>The filter is normally placed in the infrarenal portion of the inferior vena cava
                                             (IVC). [BARCO]</li>
                                       </ul>
         
                                       <p><strong>The role of venous filters in PE remains controversial.</strong></p>
                                       <ul>
                                          <li>The European Society of Cardiology recommends venous filters in: [ESC]
                                             <ul>
                                                <li>patients with confirmed acute PE who have an absolute contraindication to
                                                   anticoagulation.</li>
                                                <li>patients with confirmed recurrent PE despite adequate anticoagulation
                                                   treatment.</li>
                                             </ul>
                                          </li>
                                          <li>Their use is increasing rapidly in the US and the The American Society for
                                             Interventional Radiology has recommended a significantly longer list of indications
                                             for venous filter then the European Society of Cardiology. [ACRSIR]</li>
                                       </ul>
         
                                       <p><strong>Complications associated with permanent IVC filters are common and include:
                                             [HANN] [FAILLA]</strong></p>
                                       <ul>
                                          <li>Early<ul>
                                                <li>insertion site thrombosis (10%)</li>
                                                <li>pericardial tamponade (when placing filter in the superior vena cava.)</li>
                                             </ul>
                                          </li>
         
                                          <li>Late (more common)
                                             <ul>
                                                <li>recurrent DVT (20%)</li>
                                                <li>post-thrombotic syndrome (40%)</li>
                                                <li>Occlusion of the IVC (regardless of use and duration of anticoagulation)
                                                   <ul>
                                                      <li>22% at 5 years</li>
                                                      <li>33% at 9 years</li>
                                                   </ul>
                                                </li>
                                                <ul>
         
                                          </li>
                                       </ul>
         
         
         
                                       <div id="tip_pitfall" class="card card-inverse mb-4">
                                          <div class="card-block">
                                             
                                             <h3 class="card-title">In clinical practice venous filters are not commonly used in
                                                the UK or Europe. </h3>
                                             <ul>
                                                <li>It is common practice to seek advice from a haematologist in patients with
                                                   contraindications to anticoagulation.</li>
                                                <li>Many of these patients - even those with apparent absolute contraindications
                                                   - may still be able to have a different or altered dose of anticoagulation
                                                   with an acceptable risk-benefit balance and this is usually preferred to a
                                                   venous filter.</li>
                                             </ul>
                                          </div>
                                       </div>
         
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle26" class="toggle" />
                                             <label class="title" for="toggle26">
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: The evidence shows varied outcomes from use of
                                                   venous filters in PE</span>
                                             </label>
                                             <div class="content">
                                                <ul>
                                                   <li>
                                                      <p><strong>The use of venous filters is controversial and there is limited
                                                            evidence to support recommendations about their use in clinical
                                                            practice</strong>. <strong>For use in acute PE the evidence shows
                                                            varied outcomes. </strong></p>
                                                      <ul>
                                                         <li>There have only been two RCTs performed in Europe.</li>
                                                         <li>The first, PREPIC (Pr&eacute;vention du Risque d'Embolie Pulmonaire
                                                            par Interruption Cave Study Group), randomized 400 patients who
                                                            suffered acute VTE to anticoagulation alone or anticoagulation and a
                                                            permanent inferior vena cava filter (IVCF). Follow up at 8 years
                                                            showed that while IVC filters reduced the risk of recurrent PE, they
                                                            did not prevent death, and more DVTs occurred in patients who
                                                            received these devices.</li>
                                                         <li>The second study, PREPIC 2, randomised 399 patients with PE
                                                            associated with DVT to anticoagulation alone or anticoagulation plus
                                                            a retrievable IVCF. All the patients had at least one "high-risk"
                                                            feature (age &gt;75 years old, active cancer, chronic cardiac or
                                                            respiratory insufficiency, ischemic stroke with leg paralysis within
                                                            6 months, either iliocaval or bilateral DVT, or a sign of right
                                                            ventricular strain or myocardial injury). Again, use of venous filter
                                                            did not show any mortality benefit nor did they result in fewer
                                                            symptomatic PEs during the first 3 months of follow-up.</li>
                                                      </ul>
                                                      On the other hand observational studies from the US, analyzing almost
                                                      298,000 filter implantations, &nbsp;suggest that insertion of a venous
                                                      filter might reduce PE-related mortality rates in the acute phase, with
                                                      benefit possibly coming at the cost of an increased risk of recurrence of
                                                      VTE. [MURIEL]
                                                   </li>
                                                </ul>
                                             </div>
                                          </div>
                                       </div>
         
         
         
                                    </div>
                              </section>
                              <section class="panel-group">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Risk assessment</span>
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <p><strong>Risk stratify stable patients using the Pulmonary Embolism Severity Index
                                          (PESI) score or the simplified Pulmonary Embolism Severity Index (sPESI)
                                          score</strong>.</p>
                                    <p><strong>[LINK TO PESI scoring calculator AND sPESI scoring calculator EBM calc]
                                       </strong></p>
                                    <ul>
                                       <li>The PESI/sPESI risk score can be used to risk stratify haemodynamically stable
                                          patients to <strong>identify an intermediate-risk group</strong> who need close
                                          monitoring (PESI III-IV or sPESI &ge;1)[ESC] [BTS]</li>
                                       <li>The <strong>sPESI is non-inferior to the PESI </strong>in predicting 30-day
                                          mortality. [BTS]</li>
                                    </ul>
      
                                    <p><strong>Do not use PESI/sPESI scoring in:</strong></p>
                                    <ul>
                                       <li><strong>Patients with hypotension or shock. </strong>All such patients are
                                          high-risk and must be managed accordingly.</strong></li>
                                       <li><strong>Pregnant women</strong></li>
                                    </ul>
                                    <p><strong>Monescue thrombolysis. </strong>&nbsp;[KONST][ESC][CHEST]</p>
                                    <ul>
                                       <li><strong>Rescue thrombolysis may be indicated in </strong>intermediate-risk
                                          patients, and in patients with other clinical features of cardiopulmonary impairment
                                          (e.g., elevated heart rate, respiratory rate, jugular venous pressure) who have
                                          started anticoagulant therapy, and:</li>
                                    </ul>
      
                                    <p>are clinically d<strong>itor intermediate-risk patients (PESI score &ge; III or sPESI
                                          &ge;I) patients closely over at least 48-72 hours as they are at risk of
                                          deterioration and may need r</strong>eteriorating, but have not yet developed
                                       hypotension</p>
                                    <ul>
                                       <li>are exhibiting signs of haemodynamic decompensation (e.g. systolic BP &lt;90 mmHg
                                          for at least 15 minutes, or drop of systolic BP by at least 40 mmHg for at least 15
                                          minutes with signs of end organ hypoperfusion). [ESC]</li>
                                       <li><strong>Routine thrombolysis is not recommended in most major guidelines for this
                                             intermediate-risk group </strong>even if signs of both right ventricular
                                          dysfunction and myocardial injury (positive cardiac biomarkers) are initially
                                          present.</li>
                                    </ul>
      
                                    <p>In these patients, use of systemic thrombolysis is associated with a <strong>mortality
                                          benefit</strong> but it significantly <strong>increases the risk of
                                          bleeding</strong>, including intracranial haemorrhage. [CARDIO]</p>
      
      
                                    <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle27" class="toggle" />
                                          <label class="title" for="toggle27">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: Evidence does not support the routine use of
                                                thrombolysis in patients with intermediate-risk PE</span>
                                          </label>
                                          <div class="content">
                                             <ul>
                                                <li>The intermediate-risk group is defined by a PESI score of III-V or an
                                                   sPESI score &ge;1.</li>
                                                <li>The international PEITHO (Pulmonary Embolism Thrombolysis) trial compared
                                                   a single intravenous bolus of tenecteplase plus heparin with placebo plus
                                                   heparin in 1,006 patients with confirmed PE, right ventricular dysfunction
                                                   detected by echocardiography or CT, and a positive troponin I or T test.
                                                </li>
                                                <li>In the thrombolysis group, haemodynamic decompensation/collapse or death
                                                   within 7 days occurred less frequently than in the group receiving heparin
                                                   alone.</li>
                                                <li>However, in the thrombolysis group compared with the placebo group, there
                                                   was also a higher incidence of haemorrhagic stroke (2.0% vs 0.2%) and major
                                                   non-intracranial bleeding (6.3% vs 1.5%).</li>
                                             </ul>
                                          </div>
                                       </div>
                                    </div>
      
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Review diabetes medication (NEVER stop insulin in
                                                      people with type 1 diabetes)</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Never stop insulin in people with type 1 diabetes coming into hospital -
                                             insulin deficiency can rapidly precipitate ketoacidosis, particularly during
                                             illness. </strong></p>
                                       <ul>
                                          <li><strong>Always continue basal insulins</strong> (long-acting or background
                                             insulins e.g., determir or glargine) as this will <strong>prevent
                                                ketoacidosis</strong> if doses of rapid-acting insulin are inadvertently
                                             missed or delayed.</li>
                                          <li><strong>Dose adjustments</strong> up or down may be needed.
                                             <ul>
                                                <li>For example, in the<strong> absence of significant hyperglycaemia
                                                   </strong>consider <strong>reducing the evening basal insulin by 20% on
                                                      admission</strong>, as most patients will have a <strong>smaller evening
                                                      meal in hospital</strong> compared with at home.</li>
                                             </ul>
                                          </li>
                                       </ul>
      
                                       <p><strong>If a variable rate intravenous insulin infusion (VRIII) is started</strong>:
                                       </p>
                                       <ul>
                                          <li><strong>Continue the basal insulin </strong><em>(Joint British Diabetes
                                                Societies for inpatient care [JBDS-IP], 2014)</em> as this will reduce the
                                             risk of ketosis in the advent of the VRIII being <strong>accidentally interrupted
                                             </strong>(e.g., by cannula displacement or blockage) or <strong>switched off
                                             </strong>(e.g., during transfer to another ward or department)<strong>.</strong>
                                          </li>
                                          <li>The patient&rsquo;s usual <strong>rapid-acting </strong>and <strong>mixed
                                                insulins</strong> can be <strong>stopped while on a VRIII</strong>. <em>Joint
                                                British Diabetes Societies for inpatient care [JBDS-IP], 2014)</em></li>
                                          <li>Use the VRIII for as <strong>short a time as possible</strong>, <em>(Joint
                                                British Diabetes Societies for inpatient care [JBDS-IP], 2014) </em>as
                                             incorrect use and insufficient monitoring can result in<strong> severe
                                                hypoglycaemia</strong> or<strong> ketoacidosis</strong>.</li>
                                       </ul>
                                       <p><strong>Indications for a VRIII include</strong>: <em>(Joint British Diabetes
                                             Societies for inpatient care [JBDS-IP], 2014)</em></p>
                                       <ul>
                                          <li>Patients with diabetes or hospital-related hyperglycaemia who
                                             <strong>can&rsquo;t take oral food or fluid </strong>and where it&rsquo;s
                                             <strong>not possible to adjust their insulin regimen</strong>, e.g., when:</li>
                                          <ul>
                                             <li>Vomiting</li>
                                             <li>Nil by mouth and patient will miss more than one meal</li>
                                             <li>There is severe illness with a need to achieve good glycaemic control (such
                                                as with sepsis).</li>
                                          </ul>
                                          <li>Most patients with diabetes <strong>requiring emergency surgery</strong>.
                                             <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP], 2016)</em>
                                          </li>
                                          <li><strong>Special circumstances</strong>, such as hyperglycaemia with
                                             <strong>acute coronary syndrome</strong>, when <strong>pregnant</strong>, or when
                                             receiving <strong>TPN or enteral feeding</strong>, or <strong>taking
                                                corticosteroids</strong>. <em>(Joint British Diabetes Societies for inpatient
                                                care., 2012) </em></li>
                                          <ul>
                                             <li><strong>Get specialist advice</strong> from the <strong>diabetes
                                                   team</strong> in these circumstances.</li>
                                          </ul>
                                       </ul>
                                       <p><strong>People with type 2 diabetes on basal insulin should continue to take it,
                                             unless otherwise indicated</strong>.</p>
                                       <ul>
                                          <li>In the <strong>absence of significant hyperglycaemia</strong> consider
                                             <strong>reducing the evening basal insulin</strong> by <strong>20% on
                                                admission</strong>, as most patients will have a <strong>smaller evening
                                                mealin hospital </strong>compared with at home.</li>
                                       </ul>
                                       <p>Give<strong> oral hypoglycaemic</strong> medication<strong> with food</strong> to
                                          reduce the<strong> risk of hypoglycaemia</strong>.</p>
                                       <ul>
                                          <li><strong>Never give oral hypoglycaemic medication at bedtime </strong>and
                                             consider <strong>reducing the evening dose of sulphonylurea</strong>.
                                             <ul>
                                                <li>This is because most patients have a <strong>smaller evening meal in
                                                      hospital </strong>compared with their usual evening meal at home.</li>
                                             </ul>
                                          </li>
                                       </ul>
                                       <p><strong>Withhold metformin in patients:</strong></p>
                                       <ul>
                                          <li>With <strong>contraindications</strong>, such as <strong>significant renal
                                                impairment</strong> (&lt;30 mL/minute/1.73 m2)</li>
                                          <li>With <strong>metabolic acidosis </strong>(including lactic acidosis and DKA)
                                          </li>
                                          <li>At<strong> risk of lactic acidosis</strong> with metformin, such as:</li>
                                          <ul>
                                             <li>With conditions associated with <strong>acute kidney injury
                                                </strong>or<strong> tissue hypoxia,</strong> including<strong>
                                                   dehydration</strong></li>
                                             <li>With <strong>renal impairment</strong>and who have, or are to be
                                                <strong>fasted for a prolonged period</strong> or who are due to have
                                                a<strong> radio-opaque contrast injection</strong> as part of an imaging
                                                procedure. <strong>Follow local protocols </strong>for guidance on the
                                                specific eGFR levels indicating renal impairment for this to be applied.</li>
                                          </ul>
                                          <p><strong>Be aware that withholding metformin results in hyperglycemia</strong>.
                                          </p>
                                          <ul>
                                             <li>If your patient is taking <strong>other glucose-lowering medication</strong>,
                                                these may need to be<strong> increased in dose</strong> or an
                                                <strong>alternative hypoglycaemic medication to metformin</strong> prescribed.
                                             </li>
                                             <li>Some patients may need <strong>insulin as a temporary measure</strong>,
                                                but<strong> seek diabetes inpatient specialist team advice</strong>.</li>
                                          </ul>
                                          <p><strong>Stop sodium-glucose cotransporter-2 (SGLT-2) inhibitors in all acutely
                                                ill patients, particularly if dehydrated or with infection, as they are at
                                                risk of euglycaemic ketoacidosis.</strong></p>
                                          <ul>
                                             <li>SGLT-2 inhibitors (e.g., dapagliflozin) <strong>reduce blood glucose
                                                   reabsorption</strong> in the kidneys (independently of insulin metabolism
                                                of glucose). <em>(Peters AL, et al, 2015) </em></li>
                                             <li>They can<strong> mask underlying ketoacidosis</strong> by patients having a
                                                normal (or near normal) serum glucose level <strong>(euglycaemic
                                                   ketoacidosis)</strong>.</li>
                                             <li>Check <strong>blood ketones</strong> as urinary ketone measurement may be
                                                unreliable.</li>
                                             <li><strong>Treat for DKA</strong> if <strong>blood ketone level is &ge;3
                                                   mmol/L</strong>, blood<strong> pH &lt;7.3</strong> and <strong>bicarbonate
                                                   &lt;15 mmol/L</strong>. (<em>JBDS-IP, 2013)</em></li>
                                          </ul>
                                          <p><strong>Reduce or omit the dose of gliclazide if the patient has impaired kidney
                                                function or is eating less than usual, to avoid hypoglycaemia at night.
                                             </strong></p>
                                          <p><strong>Inform the diabetic inpatient team of the admission of any patient with
                                                diabetes. They are available for advice and support.</strong></p>
                                          <p><strong>For a patient at theend of life</strong>: <em>(Rowles S, et al 2011)</em>
                                          </p>
                                          <ul>
                                             <li><strong>Hypoglycaemic medication</strong> should be <strong>reduced
                                                </strong>to the minimum, <strong>but</strong></li>
                                             <li>The patient should be<strong> kept free from symptomatic
                                                   hyperglycaemia</strong>, which can lead to <strong>dehydration</strong>,
                                                <strong>ketosis</strong> or <strong>hyperosmolar hyperglycaemia</strong>.</li>
                                          </ul>
                                          <p>Refer to <strong>local protocols </strong>or the Association of British Clinical
                                             Diabetologists (ABCD). <em>(Rowles S, et al 2011)</em></p>
      
      
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Monitor and manage blood glucose</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Monitor blood glucose levels at least 4 times a day (pre-meal and before
                                             bedtime if eating) in all acutely unwell patients with diabetes mellitus
                                             (</strong><em>American Diabetes Association, 2019)</em></p>
                                       <ul>
                                          <li>The risk of<strong> hypo- and hyperglycaemia</strong> increases when people with
                                             diabetes are admitted to hospital with acute conditions. <em>(NHS Digital.
                                                National Diabetes Inpatient Audit (NaDIA) - 2017, 2018)</em></li>
                                          <li><strong>More frequent monitoring</strong> is needed after <strong>episodes of
                                                hyperglycaemia</strong> or <strong>hypoglycaemia</strong>.</li>
                                          <li>More <strong>frequent monitoring</strong> is needed after a <strong>change in
                                                hypoglycaemic medication</strong>.</li>
                                          <li>Patients on a<strong> variable rate intravenous insulin infusion
                                                (VRIII)</strong> need <strong>capillary blood glucose measurements every
                                                hour</strong>. <em>(Joint British Diabetes Societies for inpatient care
                                                [JBDS-IP], 2014)</em></li>
                                          <li>Support <strong>self-management</strong> (including monitoring blood glucose) if
                                             this conforms to local protocols, it is safe to do so, and the patient is
                                             willing. <em>(Joint British Diabetes Societies for inpatient care [JBDS-IP],
                                                2012) </em></li>
                                       </ul>
      
                                       <p><strong>Prevent and manage hyperglycaemia if it occurs</strong></p>
                                       <ul>
                                          <li>There is <strong>no consensus ontarget blood glucose</strong> levels for people
                                             with diabetes in hospital.
                                             <ul>
                                                <li><strong>The Joint British Diabetes Societies for Inpatient Care</strong>
                                                   (JBDS-IP) recommend an<strong> ideal range</strong> of between<strong> 6 to
                                                      10 mmol/L</strong>, and an <strong>acceptable range</strong> of
                                                   <strong>4 to 12 mmol/L</strong><em>(JBDS-IP, 2014)</em></li>
                                                <li><strong>The American Diabetes Association</strong> recommend a
                                                   <strong>target blood glucose range</strong> of <strong>7.8 to 10.0
                                                      mmol/L</strong> (140-180 mg/dL) for most critically and noncritically
                                                   ill patients. (<em>American Diabetes Association. Diabetes Care in the
                                                      Hospital: Standards of Medical Care in Diabetes&mdash;2019, 2019)</em>
                                                </li>
                                                <li><em>The <strong>National Institute for Health and Care Excellence</strong>
                                                      recommends a target plasma glucose level of <strong>5 to 8
                                                         mmol/L</strong> in adults with type 1 diabetes in hospital undergoing
                                                      surgery or with acute illness. <em>(NICE, 2017)</em></em></li>
                                             </ul>
                                          </li>
                                          <li><strong>More liberal blood glucose targets</strong> are appropriate for people
                                             at<strong> high risk of falls </strong>and who are<strong> frail </strong>or have
                                             <strong>dementia</strong>. <em>(JBDS-IP, 2014)</em></li>
      
      
      
                                          <div class="evidence-accordion">
                                             <div class="option">
                                                <input type="checkbox" id="toggle28" class="toggle" />
                                                <label class="title" for="toggle28">
                                                   <span class="material-icons"><span></span></span>
                                                   <span class="title">Evidence: patient outcomes associated with
                                                      hyperglycaemia</span>
                                                </label>
                                                <div class="content">
                                                   <p><strong>Hyperglycaemia in patients in hospital is associated with
                                                         adverse outcomes. (</strong><em>Moghissi, 2009)</em></p>
                                                   <ul>
                                                      <li>Hyperglycaemia in patients in hospital, whether with known diabetes
                                                         or not, has been shown by various observational studies to be
                                                         associated with adverse patient outcomes, including increased
                                                         mortality. <strong>(</strong><em>Moghissi, 2009)</em></li>
                                                   </ul>
                                                </div>
                                             </div>
                                          </div>
      
      
      
                                          <div class="evidence-accordion">
                                             <div class="option">
                                                <input type="checkbox" id="toggle29" class="toggle" />
                                                <label class="title" for="toggle29">
                                                   <span class="material-icons"><span></span></span>
                                                   <span class="title">Evidence: blood glucose targets for people with
                                                      diabetes in hospital</span>
                                                </label>
                                                <div class="content">
                                                   <p><strong>Conflicting evidence for optimal blood glucose targets has led
                                                         to variations in recommendations in different countries and settings.
                                                         Follow your local protocol.</strong></p>
                                                   <ul>
                                                      <li>Intensive care setting
                                                         <ul>
                                                            <li>A randomised controlled trial (RCT) of critically ill patients
                                                               in a primarily surgical intensive care setting found lower
                                                               patient mortality with tight glucose control - 80 to 110 mg/dL
                                                               (4.4 to 6.1 mmol/L) compared with &lsquo;conventional&rsquo;
                                                               more liberal glucose control. <em>(Van den Berghe G et al,
                                                                  2001) </em></li>
                                                            <li>However, a subsequent multicentre RCT in critically ill
                                                               medical and surgical patients in other intensive care settings
                                                               found increased mortality with tighter glucose control,
                                                               possibly due to increased episodes of hypoglycaemia.
                                                               <em>(Finfer et al, 2009)</em></li>
                                                            <li>A 2010 systematic review of 6 RCTs and a meta-analysis
                                                               investigating tight glucose control (80 to 110 mg/dL [4.4 to
                                                               6.1 mmol/L]) vs less strict glucose control in critically ill
                                                               patients in the ICU setting found no significant improvement in
                                                               mortality with tight glucose control, but it was associated
                                                               with significantly more hypoglycaemic episodes compared with
                                                               less strict glucose control. (<em>Marik, 2010)</em></li>
                                                         </ul>
                                                      </li>
                                                   </ul>
                                                </div>
                                             </div>
                                          </div>
      
                                          <p><strong>Follow your local hospital protocol on steps to take if your
                                                patient&rsquo;s capillary blood glucose is &ge;15 mmol/L. Exclude diabetic
                                                ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS), both of which
                                                require specific urgent management.</strong></p>
                                          <ul>
                                             <li><strong>Treat hyperglycaemia</strong> to avoid <strong>DKA
                                                </strong>and<strong> HHS</strong>.</li>
                                             <li><strong>DKA</strong> and <strong>HHS</strong> are <strong>medical
                                                   emergencies</strong>. Follow JBDS or local hospital guidelines for patients
                                                with DKA (<em>JBDS-IP, 2013) </em>or HHS (<em>JBDS-IP, 2012). </em></li>
                                             <li>The <strong>diabetes inpatient specialist team</strong> should be involved in
                                                the management of any patient with <strong>DKA</strong>. (<em>JBDS-IP,
                                                   2013)</em></li>
                                             <li><strong>Early senior review</strong> by a clinician who is familiar with the
                                                management of<strong> HHS</strong> is imperative. (<em>JBDS-IP, 2012)
                                                </em>Patients with <strong>other comorbidities</strong> may need to be on a
                                                <strong>high dependency unit. </strong>(<em>JBDS-IP, 2012)</em></li>
                                          </ul>
                                          <p><strong>Be aware that the following medication may be associated with
                                                hyperglycaemia and may need to be reviewed: </strong><em>(Abdur R, et al,
                                                2011)</em></p>
                                          <ul>
                                             <li>Corticosteroids</li>
                                             <li>Some beta-blockers (e.g., propranolol, atenolol)</li>
                                             <li>Thiazide diuretics (e.g., hydrochlorozide)</li>
                                             <li>Some second-generation antipsychotics (e.g., olanzapine and clozaine)</li>
                                             <li>Certain fluoroquinolone antibiotics (e.g., gatifloxin)</li>
                                             <li>Calcineurin inhibitors (e.g., cyclosporine, tacrolimus)</li>
                                             <li>Protease inhibitors (e.g., as a component in antiretroviral therapy, such as
                                                ritonavir)</li>
                                          </ul>
      
                                          <div id="tip_pitfall" class="card card-inverse mb-4">
                                             <div class="card-block">
                                                
                                                <h3 class="card-title">Ask for expert advice from the diabetes team in complex
                                                   patients, or where hyperglycaemia is difficult to control.</h3>
                                             </div>
                                          </div>
                                          <p><strong>Prevent and manage hypoglycaemia if it occurs</strong></p>
                                          <ul>
                                             <li><strong>Monitor blood glucose</strong> in people with diabetes in hospital
                                                and <strong>adjust medication </strong>in response to illness and hospital
                                                meal times, in order to <strong>reduce risk</strong> of <strong>hypoglycaemic
                                                   episodes</strong>.</li>
                                             <li>1 in 5 inpatients with diabetes in England and Wales have a<strong>
                                                   hypoglycaemic episode </strong>during their hospital stay. <em>(NHS
                                                   Digital. National Diabetes Inpatient Audit (NaDIA) - 2017, 2018)</em></li>
                                             <li>Causes include:<em> (JBDS-IP, 2018)</em>
                                                <ul>
                                                   <li>Recovery from an acute illness</li>
                                                   <li>Insulin or oral hypoglycaemic medication error</li>
                                                   <li>Wrong timing of insulin in relation to meals</li>
                                                   <li>Patients eating less but taking the same amount of diabetes medication
                                                   </li>
                                                   <li>No bedtime snacks</li>
                                                   <li>Reduced appetite or vomiting.</li>
                                                </ul>
                                             </li>
                                          </ul>
      
                                          <div id="tip_pitfall" class="card card-inverse mb-4">
                                             <div class="card-block">
                                                
                                                <h3 class="card-title">
                                                   <p><strong>Bedtime snacks </strong>can reduce the risk of <strong>early
                                                         morning hypoglycaemia</strong>. <em>(NHS Digital. National Diabetes
                                                         Inpatient Audit (NaDIA) - 2017, 2018)</em></p>
                                                </h3>
                                             </div>
                                          </div>
      
                                          <p><strong>Treat hypoglycaemia actively if the blood glucose falls below 4.0 mmol/L.
                                             </strong><em>(JBDS-IP, 2018)</em></p>
                                          <ul>
                                             <li>Follow hospital protocol. The JBDS-IP has guidelines on hospital management
                                                of hypoglycaemia in adults with diabetes. <em>(JBDS-IP, 2018)</em></li>
                                          </ul>
      
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group CKD-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Check baseline kidney function</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Check baseline serum kidney function on admission in all patients with a
                                             previous history of chronic kidney disease (CKD). </strong><em>[National
                                             Institute for Health and Care Excellence. 2013)</em></p>
                                       <ul>
                                          <li><strong>CKD</strong> is a significant<strong> risk factor</strong> for the
                                             development of <strong>acute kidney injury</strong>. <em>(Hsu CY, et al,
                                                2008)</em></li>
                                          <li>Acute illness increases the risk of deterioration in renal function.</li>
                                       </ul>
      
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Stroke-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Baseline neurological assessment</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Do a baseline neurological assessment on admission for all patients with a
                                             history of stroke.</strong></p>
                                       <ul>
                                          <li>Patients with <strong>acute illness</strong> (including infections and causes of
                                             hypotension) are at <strong>increased risk of stroke</strong> (both ischaemic and
                                             haemorrhagic). <em>(Grau AJ, et al, 2010) (Eigenbrodt ML, et al, 2000)</em></li>
                                          <li>If there is a suspicion of a change in neurological status during admission,
                                             repeat the<strong>neurological assessment</strong> in case of a <strong>possible
                                                new stroke</strong>.</li>
                                       </ul>
                                       <p>Following assessment, consider appropriate level of <strong>patient
                                             supervision</strong> e.g., relating to possible <strong>confusion</strong> at
                                          night, <strong>falls</strong> related to <strong>frailty</strong>.</p>
      
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Dementia-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Baseline cognitive assessment and collateral
                                                      history</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Do a baseline cognitive assessment in all older patients, particularly those
                                             with a history of dementia. </strong><em>(Pendlebury ST, et al, 2015)</em></p>
                                       <ul>
                                          <li>Use a<strong> validated scoring system</strong> that is also feasible in the
                                             acute setting, such as:<em>(Pendlebury ST, et al, 2015)</em>
                                             <ul>
                                                <li>The <strong>abbreviated mental test score</strong> (AMTS/10)
                                                   <em>(Hodkinson,1972)</em></li>
                                                <li><strong>Montreal Cognitive Assessment</strong> (MoCA) <em>(Nasreddine,
                                                      2005).</em></li>
                                             </ul>
                                          </li>
                                       </ul>
                                       <p><strong>Dementia increases the risk of delirium. </strong></p>
                                       <ul>
                                          <li>This can acutely reduce patients' cognitive assessment scores. <em>(George J,
                                                2013)</em></li>
                                       </ul>
                                       <p><strong>Take a collateral history from family, friend or carer, to establish the
                                             patient&rsquo;s level of function and baseline cognition before this
                                             illness.</strong></p>
                                       <ul>
                                          <li>It&rsquo;s important to know if the <strong>decline</strong> in function and
                                             cognition has been <strong>gradual </strong>or <strong>acute</strong>.</li>
                                       </ul>
                                       <p>Use this information for <strong>monitoring clinical improvement</strong>, and for
                                          establishing <strong>needs on discharge</strong>.</p>
      
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Dementia-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Assess for and manage delirium</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Assess the patient with dementia for delirium. </strong><em>(National
                                             Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                          <li>People living with dementia are at increased risk of delirium when they are
                                             admitted to hospital. (<em>National Institute for Health and Clinical Excellence,
                                                2018)</em></li>
                                          <li>Use a<strong> screening tool</strong>, such as:
                                             <ul>
                                                <li>The <strong>4-AT</strong><em>(</em><em>Bellelli, 2014)</em></li>
                                                <li>The <strong>short confusion assessment method (S-CAM), </strong>as
                                                   recommended by the National Institute of Health and Care Excellence (NICE).
                                                   <em>(National Institute for Health and Clinical Excellence. 2010)</em></li>
                                                <li>Document the results clearly.</li>
                                             </ul>
                                          </li>
                                       </ul>
                                       <p><strong>Assess the patient for any reversible causes of delirium</strong>.
                                          <em>(National Institute for Health and Clinical Excellence. 2010)</em>These include:
                                       </p>
                                       <ul>
                                          <li>Infection</li>
                                          <li>Pain</li>
                                          <li>Dehydration</li>
                                          <li>Constipation</li>
                                          <li>Hypoxia</li>
                                          <li>Immobility</li>
                                          <li>Medications</li>
                                          <li>Poor sleep</li>
                                          <li>Sensory impairment (e.g., ear wax or loss of glasses)</li>
                                       </ul>
                                       <p><strong>Investigations</strong> to help diagnose underlying causes include:</p>
                                       <ul>
                                          <li>Full blood count, electrolytes, renal function, liver function tests, calcium,
                                             glucose, CRP, folate and vitamin B12.</li>
                                          <li>Blood cultures (if bacteraemia is suspected)</li>
                                          <li>Urine microscopy and culture</li>
                                          <li>Chest x-ray</li>
                                       </ul>
                                       <p><strong>Manage according to the cause</strong>.</p>
                                       <p><strong>Manage patients with delirium initially with non-pharmacological treatment.
                                          </strong><em>(National Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                          <li>Reduce <strong>disorientation</strong> by providing a <strong>well-lit
                                                room,</strong> with a <strong>clock</strong> and <strong>calendar
                                             </strong>visible (e.g., on the wall).</li>
                                          <li>Encourage and facilitate <strong>family, friends and carers</strong> visiting
                                             the patient.</li>
                                          <li>Use verbal and non-verbal techniques to<strong> de-escalate</strong> conflict
                                             and distress.</li>
                                       </ul>
                                       <p><strong>Where non-pharmacological treatments are ineffective, and the patient is
                                             distressed or considered a risk to themselves or others, short-term antipsychotic
                                             or sedative drugs may be used.</strong></p>
                                       <p><strong>Only use antipsychotics as a last resort and not in patients with
                                             Parkinson&rsquo;s disease or dementia with Lewy bodies.</strong><em>(National
                                             Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                          <li><strong>Risperidone</strong> has the least anticholinergic effects. <em>(Tracy
                                                JI, et al, 1998)</em></li>
                                          <li><strong>Haloperidol</strong> is also licenced for this indication, but has the
                                             highest risk associated with its use. The UK National Institute for Health and
                                             Care Excellence recommends short-term use of haloperidol (usually for less than
                                             one week), starting at the <strong>lowest dose</strong> and <strong>titrating
                                                carefully</strong> according to the symptoms. <em>(National Institute for
                                                Health and Clinical Excellence. 2010)</em></li>
                                          <li>Consider sedation in significantly agitated patients who pose a risk to
                                             themselves or others.<strong> Lorazepam </strong>is a suitable choice, but it
                                             should only be given orally or intramuscularly (i.e., not intravenously).</li>
                                          <li>Lorazepam should only be used in the<strong> smallest possible dose</strong> for
                                             the <strong>shortest possible duration</strong>.</li>
                                       </ul>
                                       <p><strong>Avoid typical antipsychotics, particularly haloperidol in patients with
                                             Parkinson&rsquo;s disease or dementia with Lewy bodies. </strong><em>(National
                                             Institute for Health and Clinical Excellence. 2010)</em></p>
                                       <ul>
                                          <li>The dopamine receptor antagonistic effect of typical antipsychotics can
                                             <strong>dramatically worsen physical and cognitive symptoms</strong> in people
                                             with Parkinson&rsquo;s disease or with dementia with Lewy bodies.</li>
                                          <li>Consider a <strong>low-dose short-acting oral benzodiazepine,</strong> such as
                                             lorazepam, or l<strong>ow-dose quetiapine </strong>in patients with
                                             Parkinson&rsquo;s disease or dementia with Lewy bodies who require sedation to
                                             enable safe care because of delirium.</li>
                                          <li>Consult your local drug formulary for advice.</li>
                                       </ul>
                                       <p><br /><strong>Document</strong> any episodes of current or resolved delirium in
                                          the<strong> discharge summary for the GP</strong>. <em>(National Institute for
                                             Health and Clinical Excellence. 2010)</em></p>
      
      
      
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle30" class="toggle" />
                                             <label class="title" for="toggle30">
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: risks and safe withdrawal of antipsychotics in
                                                   the elderly</span>
                                             </label>
                                             <div class="content">
                                                <p><strong>Short-term antipsychotics may be needed in people with dementia to
                                                      enable safe care. However, antipsychotics have various adverse effects
                                                      in the elderly and are associated with an increased risk of death in
                                                      people with dementia.</strong></p>
                                                <ul>
                                                   <li>A meta-analysis found that people with dementia who take atypical
                                                      antipsychotics have an <strong>increased mortality risk
                                                      </strong>compared with people taking placebo. <em>(Ma H, et al,
                                                         2014)</em></li>
      
                                                   <li>A large cohort study of elderly people found that <strong>higher
                                                         doses</strong> of antipsychotics are generally associated with
                                                      <strong>greater risk</strong>. <em>(Huybrechts K, 2012)</em></li>
      
                                                   <li>It also found that of all the antipsychotics studied,
                                                      <strong>haloperidol </strong>has the highest risk associated with its
                                                      use. <em>(Huybrechts K, 2012)</em></li>
      
                                                   <li>Contrary to popular belief, long-term antipsychotic prescriptions in
                                                      people with dementia whose behaviour is now settled, can be
                                                      <strong>withdrawn safely </strong>in the majority of cases. <em>(Van
                                                         Leeuwen, 2018)</em></li>
                                                </ul>
                                             </div>
                                          </div>
                                       </div>
      
      
      
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle31" class="toggle" />
                                             <label class="title" for="toggle31">
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: primary prevention of delirium: this may be the
                                                   most effective treatment strategy</span>
                                             </label>
                                             <div class="content">
                                                <p><strong>A non-randomised trial studying how to reduce risk factors for
                                                      delirium compared a multicomponent strategy with usual care in 852
                                                      elderly patients (over 70 years) in hospital. </strong><em>(Inouye,
                                                      1999)</em></p>
                                                <ul>
                                                   <li>The multicomponent strategy targeted the following 6 risk factors:
                                                      <ul>
                                                         <li>cognitive impairment</li>
                                                         <li>sleep deprivation</li>
                                                         <li>immobility</li>
                                                         <li>visual impairment</li>
                                                         <li>hearing impairment</li>
                                                         <li>dehydration.</li>
                                                      </ul>
                                                   </li>
                                                </ul>
                                                <p>It found: <em>(Inouye, 1999)</em></p>
                                                <ul>
                                                   <li>There were <strong>significantly fewer first episodes of
                                                         delirium</strong> with the <strong>multicomponent strategy
                                                      </strong>vs usual care (44 [9.9%] vs 64 [15%] respectively)</li>
                                                   <li>Matched group analysis found an odds ratio (OR) of 0.60 (95%CI:
                                                      0.39-0.92; p=0.02)</li>
                                                   <li><strong>Total number of days with delirium</strong> was
                                                      <strong>significantly lower </strong>with the <strong>multicomponent
                                                         strategy</strong> vs usual care (105 vs. 161 days respectively,
                                                      p=0.02)</li>
                                                </ul>
                                                <p><strong>Delirium severity and recurrence rates</strong> were <strong>not
                                                      significantly different </strong>in the 2 groups.</p>
                                             </div>
                                          </div>
                                       </div>
      
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Dementia-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Set an escalation plan</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Set an escalation plan for all patients with dementia as early as
                                             possible.</strong></p>
                                       <ul>
                                          <li>This should include: <em>(Fritz Z, et al, 2017):</em>
                                             <ul>
                                                <li><strong>Resuscitation status</strong> (i.e., do not attempt
                                                   cardiopulmonary resuscitation [DNACPR] decision)</li>
                                                <li><strong>Ceiling of care</strong> (e.g., is the patient suitable for
                                                   intubation or intensive care admission)</li>
                                             </ul>
                                          </li>
      
                                          <li>Escalation plans should take account of<strong> advanced care planning</strong>,
                                             including legally-binding advanced directives. <em>(Fritz Z, et al, 2017)</em>
                                          </li>
                                       </ul>
                                       <p><strong>Communicate</strong> all decisions regarding the escalation plan
                                          <strong>with the patient</strong>.<em>(Fritz Z, et al, 2017)</em></p>
                                       <ul>
                                          <li><strong>Assess mental capacity</strong> (the ability to make decisions at a
                                             specific time a decision needs to be made) and document. <em>(NICE, 2018)</em>
                                             Follow the appropriate legislation in your region.</li>
                                          <li>In England and Wales, health professionals must comply with the <strong>2005
                                                Mental Capacity Act</strong>. <em>(Department of Health, 2005)
                                             </em>Assessments should follow the principles in the Act. <em>(Department of
                                                Health, 2005) </em></li>
                                          <li>If a patient is assessed to lack mental capacity, ensure decisions are made in
                                             the <strong>best interests of the patient</strong>. <em>(Department of Health,
                                                2005) (NICE, 2018)</em></li>
                                       </ul>
                                       <p><strong>If the patient is assessed to lack mental capacity, consult with the
                                             patient&rsquo;s next of kin in order to make &lsquo;best interests&rsquo;
                                             decisions. </strong><em>(Department of Health, 2005) </em></p>
                                       <p>According to the 2005 Mental Capacity Act in England and Wales, if a patient is
                                          unbefriended and a decision is not time critical, an independent mental capacity
                                          advocate (IMCA) should be sought to perform this role instead. (<em>Social Care
                                             Institute for Excellence, 2011)</em></p>
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group COPD-como-content Asthma-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Remember to prescribe usual inhalers </span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Patients may not think to tell you about their usual inhalers when asked
                                             about their medication, so remember to check and prescribe these if
                                             appropriate</strong></p>
                                       <ul>
                                          <li>Patients with asthma should continue any inhaled corticosteroid medication they
                                             usually take. These should not be stopped without a clear medical reason.</li>
                                          <li>Many inhalers are combined medications, so check there is no dual prescribing
                                          </li>
                                       </ul>
                                       <p><strong>Temporarily stop inhaled long-acting muscarinic receptor antagonists if your
                                             patient with COPD or asthma usually takes this and develops acute kidney injury
                                             with an eGFR &lt;30.</strong></p>
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group COPD-como-content Asthma-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Nicotene replacement therapy in current
                                                      smokers</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>All current smokers are nicotine dependent</strong></p>
                                       <ul>
                                          <li>Nicotine replacement therapy should be prescribed to prevent withdrawal
                                             regardless of a patient&rsquo;s intention regarding smoking cessation</li>
                                          <li>Please consult your local hospital guidance.</li>
                                       </ul>
                                       <p><br /><strong>Make every contact count:</strong></p>
                                       <ul>
                                          <li>Being in hospital with an acute illness is the ideal time to support someone to
                                             give up smoking</li>
                                          <li>Provide brief advice.</li>
                                       </ul>
                                    </div>
      
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group COPD-como-content Asthma-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Monitor for and manage any acute exacerbation of
                                                      asthma or COPD</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Monitor patient for symptoms and signs of an acute exacerbation of their
                                             COPD or asthma.</strong></p>
                                       <ul>
                                          <li>A patient with airways disease may have an acute exacerbation while in hospital
                                             with a separate another medical or surgical condition.</li>
                                       </ul>
                                       <p><strong>Patients with comorbid COPD may be having an acute exacerbation if there is
                                             an acute worsening of respiratory symptoms that results in the need for
                                             additional therapy.</strong><em>(Global Initiative for Chronic Obstructive Lung
                                             Disease, 2019)</em></p>
                                       <ul>
                                          <li><strong>Differentiate</strong> from other conditions which may present very
                                             similarly, such as <strong>acute coronary syndrome</strong>, <strong>acute heart
                                                failure</strong> and <strong>pneumonia</strong>.</li>
                                          <li>Follow guideline recommendations on <strong>investigations</strong>, including:
                                             <ul>
                                                <li><strong>ABG</strong> measurement</li>
                                                <li><strong>Chest x-ray.</strong> Generally, do a chest x-ray if a patient
                                                   with COPD is admitted with breathlessness or cough, or has worse symptoms
                                                   than usual.</li>
                                             </ul>
                                          </li>
                                          <li>Follow <strong>COPD guideline </strong>recommendations on <strong>initial
                                                management</strong>, including:<ul>
                                                <li><strong>Assessing severity</strong></li>
                                                <li>Increasing dose and/or frequency of <strong>bronchodilator
                                                      therapy</strong>, using nebulisers (driven with air) or spacers</li>
                                                <li>Considering <strong>oral corticosteroids</strong>,
                                                   <strong>antibiotics</strong> and need for <strong>noninvasive
                                                      ventilation</strong>.</li>
                                                <li>See BMJ Best Practice topic on Acute exacerbation in COPD</li>
                                             </ul>
                                          </li>
                                       </ul>
                                       <p><strong>Follow guideline recommendations for assessment of severity and management
                                             of an acute exacerbation of asthma in adults. </strong><em>(</em><em>British
                                             Thoracic Society; Scottish Intercollegiate Guidelines Network, 2016) </em></p>
                                       <ul>
                                          <li>Initial treatment of acute severe asthma includes:<ul>
                                                <li><strong>Supplementary oxygen</strong> if hypoxaemic. Titrate to maintain
                                                   an oxygen saturation level of <strong>94% to 98%</strong></li>
                                                <li><strong>High-dose inhaled beta2 agonists</strong> as early as possible,
                                                   usually via nebuliser (oxygen-driven)</li>
                                                <li><strong>Ipratropium bromide</strong> via nebuliser (oxygen-driven) if
                                                   needed</li>
                                                <li><strong>Corticosteroids</strong> in adequate doses (40 to 50 mg daily for
                                                   at least 5 days)</li>
                                                <li>Other therapies may be required, <strong>follow guideline
                                                      recommendations</strong></li>
                                                <li>See BMJ Best Practice topic on Acute exacerbation of asthma in adults.
                                                </li>
                                             </ul>
                                          </li>
                                       </ul>
                                       <p><strong>Stop long-acting muscarinic receptor antagonists (LAMAs) e.g., tiotropium
                                             temporarily if short-acting muscarinic antagonists (SAMAs) e.g., ipratropium
                                             bromide are prescribed via nebuliser.</strong></p>
                                       <ul>
                                          <li>This is based on expert opinion due to concern over possible anticholinergic
                                             adverse effects.</li>
                                       </ul>
                                       <p><strong>Regular nebulisers should only be prescribed for 24 to 48 hours and then
                                             switched back to the patient&rsquo;s usual inhalers.</strong></p>
      
      
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle32" class="toggle" />
                                             <label class="title" for="toggle32">
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: cardiovascular harm with beta2- agonists.</span>
                                             </label>
                                             <div class="content">
                                                <p><strong>Beta2-agonists increase the risk of myocardial infarction and other
                                                      adverse cardiovascular events</strong></p>
                                                <ul>
                                                   <li>Beta2-agonists increase heart rate and reduce potassium levels.
                                                      <em>(Salpeter SR, et al, 2004) </em>They are absorbed into the systemic
                                                      circulation and there is evidence they are associated with an increased
                                                      risk of myocardial infarction, unable angina, congestive heart failure
                                                      and arrhythmias. <em>(Au DH, et al, 2002) (Salpeter SR, et al, 2004)
                                                         (Baker JG, 2017)</em></li>
                                                </ul>
                                             </div>
                                          </div>
                                       </div>
      
      
                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle33" class="toggle" />
                                             <label class="title" for="toggle33">
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: short duration vs longer duration of
                                                   corticosteroids for acute exacerbation of COPD</span>
                                             </label>
                                             <div class="content">
                                                <p><strong>A systematic review found no difference in outcomes (treatment
                                                      failure, time to next exacerbation, time in hospital, lung function,
                                                      adverse effects, mortality) between short courses (7 days or less) vs
                                                      more conventional longer courses (longer than 7 days) of corticosteroids
                                                      in people with acute exacerbation of COPD </strong><em>(Walters JAE, et
                                                      al, 2018)</em></p>
                                                <ul>
                                                   <li>The randomised controlled trials included in this Cochrane review were
                                                      all in hospital settings and only included people with severe to very
                                                      severe COPD<em> (Walters JAE, et al, 2018)</em></li>
                                                   <li>The review authors concluded that due to the addition of a new trial,
                                                      they have increased confidence that a corticosteroid course of around 5
                                                      days is likely to be sufficient for the treatment of an acute
                                                      exacerbation of COPD. <em>(Walters JAE, et al, 2018)</em></li>
                                                </ul>
                                             </div>
                                          </div>
                                       </div>
      
                                    </div>
                                 </div>
                                 <!--/.panel-body -->
                              </section>
                              <section class="panel-group Diabetes-como-content">
                                 <div class="panel-header">
                                    <p class="panel-title">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                                          role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                          <span class="titles-wrap col-md-12">
                                             <span class="title-02">
                                                <span class="title-03 col-md-1 col-sm-1">
                                                   Plus
                                                   <span class="noShow">&nbsp;–&nbsp;</span>
                                                </span>
                                                <span class="title-04">
                                                   <span class="material-icons"><span></span><span></span></span>
                                                   <span class="txtwrap">Check patient’s feet</span>
                                                </span>
                                                <span class="material-icons">
                                                   
                                                </span>
                                             </span>
                                          </span>
                                       </a>
                                    </p>
                                 </div>
                                 <div class="panel-content col-md-10 col-sm-12" role="tabpanel" aria-labelledby="nested-collapse_0_0_3"
                                    id="nested-collapse_0_0_3" aria-expanded="false" style="display: none;">
      
                                    <div class="poce_drug_msg">
                                       <span class="material-icons">
                                          
                                       </span>
                                       <h3 class="poce_title"></h3>
                                       <p><strong>Check the feet of all adults with diabetes on admission to hospital and
                                             whenever there has been a change in their status. </strong><em>(NICE, 2016)</em>
                                       </p>
                                       <ul>
                                          <li><strong>Why? </strong>
                                             <ul>
                                                <li>To detect <strong>new ulceration </strong>or<strong> infection,
                                                   </strong>which may be<strong> unnoticed</strong> by the patient andmay even
                                                   be the <strong>underlying cause </strong>of their illness (e.g., patient
                                                   presenting with sepsis, spinal abscess or endocarditis where the original
                                                   focus of infection is the foot lesion).</li>
                                                <li>To determine if patient is at<strong> high risk of pressure ulceration
                                                   </strong>and <strong>requires pressure relief</strong>.</li>
                                             </ul>
                                          </li>
                                          <li><strong>Take action </strong>
                                             <ul>
                                                <li>You must <strong>remove any foot dressings</strong> to see if any
                                                   wound/ulcer is<strong> infected. </strong><em>(NICE NG19, 2016)</em></li>
                                                <li><strong>Inspect</strong> the foot for lesions and examine for loss of
                                                   protective <strong>sensation</strong>. Follow your local guidelines, but a
                                                   quick simple test is the <strong>Ipswich Touch Test&copy;️</strong>.
                                                   (Rayman G, et al, 2011)</li>
                                                <li>If your patient has <strong>reduced sensation</strong>, they are at
                                                   <strong>high risk of pressure ulceration</strong>. Inform the nursing staff
                                                   and <strong>provide pressure relieving devices</strong>.</li>
                                                <li>A <strong>daily heel check</strong> for <strong>signs of pressure
                                                      trauma</strong> should be undertaken by nursing or health care assistant
                                                   staff.</li>
                                             </ul>
                                          </li>
                                       </ul>
      
                                    </div>
                                 </div>
                                 <!--/.panel-body -->
                              </section>                           
                           </div>
                           
                        </section>                        


                     </div>
                  </div>

               </div>
         </div>

      </div>

      </div>
      <div class="card-block disclaimer">
         <p><span>Use of this content is subject to our <a href="https://bestpractice.bmj.com/info/disclaimer/"
                  target="_blank">disclaimer</a> </span></p>
      </div>
      <script type="text/javascript">
         //<![CDATA[
         var drugDatabases = ["AHFS", "BNF", "BNFC", "MARTINDALE", "MICROMEDEX"];
         var drugMappings = {
            "b3fb3286-271c-47f6-ae52-1bd3958b1e9b": {
               "BNFC": "844811582",
               "AHFS": "382789",
               "BNF": "844811582",
               "MARTINDALE": "2041-c"
            },
            "46d9672e-3313-452d-9bfd-a4ddf90b32f3": {
               "BNFC": "338844366",
               "AHFS": "382749",
               "BNF": "338844366",
               "MARTINDALE": "9506-x"
            },
            "d4ccd444-8501-447d-848f-bc97c03774ba": {
               "BNFC": "694891763",
               "AHFS": "396006",
               "BNF": "694891763",
               "MARTINDALE": "14676-j"
            },
            "88583afa-6bbd-4755-a21e-c63ab12370f0": {
               "AHFS": "301057",
               "MARTINDALE": "17311-s"
            },
            "4866ce04-4d68-4b50-83f4-66283ea52c07": {
               "BNFC": "347445885",
               "AHFS": "382826",
               "BNF": "347445885",
               "MARTINDALE": "11401-s"
            },
            "0f8c4ada-cd84-4c04-8860-01a81e07c1f9": {
               "AHFS": "312005",
               "BNF": "758974083",
               "MARTINDALE": "22005-r"
            },
            "3984222a-c42a-4f8a-bff1-f99645ade85d": {
               "BNFC": "190424995",
               "AHFS": "393016",
               "BNF": "190424995",
               "MARTINDALE": "13424-s"
            },
            "4b33f194-29da-4239-aae9-c1746e2bda94": {
               "AHFS": "315041",
               "BNF": "142886536",
               "MARTINDALE": "25433-t"
            },
            "aff9d94e-1579-4f56-acb7-73775d12d818": {
               "AHFS": "313017",
               "BNF": "379487049",
               "MARTINDALE": "24489-b"
            },
            "1f043ef5-6686-4b38-a018-9dea67de1e36": {
               "BNFC": "107604022",
               "AHFS": "382277",
               "BNF": "107604022",
               "MARTINDALE": "21515-l"
            },
            "6402d40a-aa86-4def-a6af-9d56b0e8ef3e": {
               "AHFS": "311009",
               "BNF": "860832161",
               "MARTINDALE": "20786-b"
            },
            "89dc308c-7daa-4c1f-a0c4-829a581f1936": {
               "BNFC": "169791712",
               "AHFS": "389001",
               "BNF": "169791712",
               "MARTINDALE": "16956-z"
            },
            "a37dcf97-a50b-4776-ad01-6fd4a31bb295": {
               "BNFC": "829952202",
               "AHFS": "382861",
               "BNF": "829952202",
               "MARTINDALE": "2052-t"
            },
            "a4adb6a6-1e28-4057-9789-361aa3c914b8": {
               "AHFS": "302012",
               "BNF": "724890658",
               "MARTINDALE": "20172-x"
            }
         };
         //]]>
      </script>
   </main>
   <!-- set the messages country code variable from region to be used from i18 plugin. Setting here so it's available in all pages -->
   <script>
      /*<![CDATA[*/

      var messagesCountryCode = "en_GB";
      /*]]>*/
   </script>
   <aside id="panel-nhs" class="card-block">
      <div id="access" class="col-sm-6">
         <div class="row">
            <div class="col-md-6">
               <p>Access provided by:</p>
            </div>
            <div class="col-md-6">
               <img src="../images/bmj-logo.png" alt="BMJ Group (Online access from BMA House)">
            </div>
         </div>
      </div>
   </aside>
   <footer id="footer">
      <div class="container">
         <div class="row">
            <nav class="col-md-9" role="navigation">
               <div class="row">
                  <dl class="col-md-4" role="menu">
                     <dt>Browse</dt>
                     <dd><a href="https://bestpractice.bmj.com/">Home</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/recent-updates">Recent updates</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/specialties">Specialties</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/calculators">Calculators</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/patient-leaflets">Patient leaflets</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/procedural-videos">Procedural videos</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/evidence">Evidence</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/drugs">Drugs</a></dd>
                  </dl>
                  <!-- logged-in individual or institutional user -->
                  <!-- unknown user -->
                  <!--institutional user not logged in-->
                  <dl class="col-md-4" role="menu">
                     <dt>Services</dt>
                     <dd><a href="https://bestpractice.bmj.com/login">Log in</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/registration">Create an account</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/info/getting-started/" target="_blank">Getting
                           started</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/info/faq/" target="_blank">FAQs</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/info/benefits-features/earn-cme-points/"
                           target="_blank">About CME/CPD</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/info/benefits-features/" target="_blank">About us</a>
                     </dd>
                     <dd><a href="https://bestpractice.bmj.com/info/app/" target="_blank">Mobile app</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/info/contact-us/" target="_blank">Contact us</a></dd>
                     <dd>
                        <a
                           href="https://myaccount.bmj.com/myaccount/registration.html?regService=bestpractice-email-alert&amp;fwdUrl=https://bestpractice.bmj.com">
                           Sign up for email alerts
                        </a>
                     </dd>
                  </dl>
                  <dl class="col-md-4" role="menu">
                     <dt>Legal</dt>
                     <dd><a href="https://bestpractice.bmj.com/info/disclaimer/" target="_blank">Disclaimer</a></dd>
                     <dd><a href="https://www.bmj.com/company/legal-information/" target="_blank">Terms and
                           conditions</a></dd>
                     <dd><a href="https://www.bmj.com/company/your-privacy/" target="_blank">Privacy notice</a></dd>
                     <dd><a href="https://www.bmj.com/company/your-privacy/cookies-policy/" target="_blank">Cookie
                           policy</a></dd>
                  </dl>
               </div>
               <!-- row -->
            </nav>
            <div class="col-md-3">
               <ul>
                  <li><a target="_blank" href="https://www.facebook.com/BMJBestPractice"><img alt="Facebook Logo"
                           title="Facebook" src="../images/facebook-64.png" width="60" height="60"></a></li>
                  <li><a target="_blank" href="https://twitter.com/BMJBestPractice"><img alt="Twiter Logo"
                           title="Twitter" src="../images/twitter-64.png" width="60" height="60"></a></li>
                  <li><a target="_blank" href="https://www.linkedin.com/showcase/15218227/"><img alt="LinkedIn Logo"
                           title="LinkedIn" src="../images/linkedIn_logo_circle.png" width="60" height="60"></a></li>
                  <li><a target="_blank" href="https://www.youtube.com/channel/UCt72GZ0cPXpk4EzgFhdWYdQ"><img
                           alt="Youtube Logo" title="YouTube" src="../images/youtube-64.png" width="60" height="60"></a>
                  </li>
               </ul>
               <p class="copyright mt-3"><small>© BMJ Publishing Group 2018</small></p>
               <p class="issn"><small>ISSN 2515-9615</small></p>
            </div>
         </div>
         <!-- row -->
      </div>
      <!-- container -->
   </footer>
   <div class="container modal-registration-form" aria-hidden="true">

      <div id="feedbackContainer" class="modal fade" tabindex="-1" role="dialog" aria-labelledby="ModalFeedbackLabel"
         aria-hidden="true">
         <div class="modal-dialog modal-lg" role="document">
            <div class="modal-content pb-3">
               <div class="modal-header">
                  <div class="row">
                     <div class="col-md-12">
                        <h2>Help us improve <abbr>BMJ</abbr> Best Practice</h2>
                        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                           <span aria-hidden="true">×</span>
                        </button>
                     </div>
                     <div class="col-md-12">
                        <p>Please complete all fields.</p>
                     </div>
                  </div>
               </div>
               <div class="modal-body">
                  <div class="row">
                     <div class="col-md-12">
                        <form id="feedbackForm"
                           action="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"
                           novalidate="novalidate">
                           <div class="row">
                              <div class="col-md-6">
                                 <div class="form-group floating-label">
                                    <label for="feedbackName">Name</label>
                                    <input id="feedbackName" class="form-control" name="feedbackName" type="text">
                                 </div>
                              </div>
                              <div class="col-md-6">
                                 <div class="form-group floating-label">
                                    <label for="feedbackEmail">Email</label>
                                    <input id="feedbackEmail" class="form-control" name="feedbackEmail" type="email"
                                       value="">
                                 </div>
                              </div>
                           </div>
                           <div class="row">
                              <div class="col-md-12">
                                 <h2 id="feedbackPageTitle" class="h3">Page: Pulmonary embolism - Treatment algorithm |
                                    BMJ Best Practice</h2>
                              </div>
                           </div>
                           <input id="feedbackPage" name="feedbackPage" type="hidden"
                              value="Pulmonary embolism - Treatment algorithm | BMJ Best Practice">
                           <div class="row">
                              <div class="col-md-4">
                                 <p>I have some feedback on:</p>
                                 <fieldset class="form-group" role="radiogroup">
                                    <legend>Feedback on: </legend>
                                    <label for="feedOn01"><input id="feedOn01" type="radio" name="feedbackOn"
                                          value="This page" checked="checked">&nbsp;This page</label>
                                    <label for="feedOn02"><input id="feedOn02" type="radio" name="feedbackOn"
                                          value="This website">&nbsp;The website in general</label>
                                    <label for="feedOn03"><input id="feedOn03" type="radio" name="feedbackOn"
                                          value="Something else">&nbsp;Something else</label>
                                 </fieldset>
                              </div>
                              <div class="col-md-8">
                                 <div class="form-group floating-label textarea">
                                    <label for="feedbackContent">I have some feedback on:</label>
                                    <textarea id="feedbackContent" name="feedbackContent"></textarea>
                                 </div>
                              </div>
                           </div>
                           <div class="row">
                              <div class="col-md-12">
                                 <p>We will respond to all feedback.</p>
                              </div>
                           </div>
                           <div class="row">
                              <div class="col-md-12">
                                 <button id="feedbackSubmit" type="submit" class="btn btn-secondary btn-lg">
                                    <span id="spinner2" class="progress-circular-inner progress-circular-left"></span>
                                    <span id="btnText2">Submit Feedback</span>
                                 </button>
                              </div>
                           </div>
                           <div class="row smTxt">
                              <div class="col-md-12">
                                 <p>For any urgent enquiries please contact our customer services team who are ready to
                                    help with any problems.</p>
                              </div>
                           </div>
                           <div class="row smTxt">
                              <div class="col-md-3">
                                 <p><b>Phone:</b> +44 (0) 207 111 1105</p>
                              </div>
                              <div class="col-md-3">
                                 <p><b>Email: </b> <a href="mailto:support@bmj.com">support@bmj.com</a></p>
                              </div>
                           </div>
                        </form>
                     </div>
                  </div>
               </div>
            </div>
         </div>
      </div>

      <!-- COMO MODAL -->
      <div class="modal fade" id="editComo" tabindex="-1" role="dialog" aria-labelledby="editComo" aria-hidden="true"
         style="display: none;">
         <div class="modal-dialog" role="document" style="max-width: 50rem;">
            <div class="modal-content">
               <div class="modal-header" style="background: #fff; margin-top: 1rem;">
                  <h2 class="modal-title" id="exampleModalLabel" style="color: #333;">
                     <span style="font-size: 50px;" class="material-icons">
                     </span> Add your patient's comorbidities</h2>
                  <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                     <span aria-hidden="true" style="color: #333 !important; font-size: 28px;">×</span>
                  </button>
               </div>
               <div class="modal-body">
                  <p>Treatment recommendations for <strong>Pulmonary embolism</strong> will change dependent on your
                     <strong>patient's comorbitities</strong></p>
                  <div class="row">
                     <div class="col-md-12" style="margin-bottom: 0.75rem;">
                        <h3>Select comorbidities</h3>
                     </div>
                     <div class="col-md-6">
                        <div class="card">
                           <ul class="list-group list-group-flush">
                              <li class="list-group-item"><label for="Hypertension"
                                    class="custom-control custom-checkbox">
                                    <input type="checkbox" name="comorbidity" id="Hypertension"
                                       class="comotype custom-control-input" value="Hypertension">
                                    <span class="custom-control-indicator"></span>
                                    <span class="custom-control-description">Hypertension</span>
                                 </label>
                              </li>
                              <li class="list-group-item"><label for="CAD"
                                    class="comotype custom-control custom-checkbox">
                                    <input type="checkbox" name="comorbidity" id="CAD" class="custom-control-input"
                                       value="Coronary artery disease">
                                    <span class="custom-control-indicator"></span>
                                    <span class="custom-control-description">Coronary artery disease</span>
                                 </label>
                              </li>
                              <li class="list-group-item"><label for="HeartFailure"
                                    class="custom-control custom-checkbox">
                                    <input type="checkbox" name="comorbidity" id="HeartFailure"
                                       class="comotype custom-control-input" value="Heart failure">
                                    <span class="custom-control-indicator"></span>
                                    <span class="custom-control-description">Heart failure</span>
                                 </label>
                              </li>
                              <li class="list-group-item"><label for="Stroke"
                                    class="comotype custom-control custom-checkbox">
                                    <input type="checkbox" name="comorbidity" id="Stroke" class="custom-control-input"
                                       value="Stroke">
                                    <span class="custom-control-indicator"></span>
                                    <span class="custom-control-description">Stroke</span>
                                 </label>
                              </li>
                              <li class="list-group-item"><label for="Depression"
                                    class="comotype custom-control custom-checkbox">
                                    <input type="checkbox" name="comorbidity" id="Depression"
                                       class="custom-control-input" value="Depression">
                                    <span class="custom-control-indicator"></span>
                                    <span class="custom-control-description">Depression</span>
                                 </label>
                              </li>
                           </ul>
                        </div>
                     </div>
                     <div class="col-md-6">
                        <div class="card">
                           <ul class="list-group list-group-flush">
                              <li class="list-group-item"><label for="Diabetes" class="custom-control custom-checkbox">
                                    <input type="checkbox" name="comorbidity" id="Diabetes"
                                       class="comotype custom-control-input" value="Diabetes">
                                    <span class="custom-control-indicator"></span>
                                    <span class="custom-control-description">Diabetes</span>
                                 </label>
                              </li>
                              <li class="list-group-item">
                                 <label for="Asthma" class="custom-control custom-checkbox">
                                    <input type="checkbox" name="comorbidity" id="Asthma" class="comotype custom-control-input" value="Asthma">
                                    <span class="custom-control-indicator"></span>
                                    <span class="custom-control-description">Asthma</span>
                                 </label>
                                 <!-- WARNING BOX FOR ASTHMA & COPD -->
                                 <div class="warning-asthma" style="display:none" role="dialog">

                                    <button type="button" class="close close-warning" data-dismiss="warning-asthma" aria-label="Close">
                                       <span aria-hidden="true" style="color: #333 !important; font-size: 28px;">×</span>
                                    </button>
                                    <p>If your patient has <strong>both</strong> Asthma <strong>and</strong> COPD, select the <strong>predominant condition</strong> and tailor your management to the individual.</p>
                                 </div>
                                 <!-- WARNING BOX FOR ASTHMA & COPD ENDS -->
                              </li>
                              <li class="list-group-item"><label for="COPD"
                                    class="comotype custom-control custom-checkbox">
                                    <input type="checkbox" name="comorbidity" id="COPD" class="custom-control-input"
                                       value="COPD">
                                    <span class="custom-control-indicator"></span>
                                    <span class="custom-control-description">COPD</span>
                                 </label>
                              </li>
                              <li class="list-group-item"><label for="CKD"
                                    class="comotype custom-control custom-checkbox">
                                    <input type="checkbox" name="comorbidity" id="CKD" class="custom-control-input"
                                       value="Chronic kidney disease (CKD)">
                                    <span class="custom-control-indicator"></span>
                                    <span class="custom-control-description">Chronic kidney disease (CKD)</span>
                                 </label>
                              </li>
                              <li class="list-group-item"><label for="Dementia"
                                    class="comotype custom-control custom-checkbox">
                                    <input type="checkbox" name="comorbidity" id="Dementia" class="custom-control-input"
                                       value="Dementia">
                                    <span class="custom-control-indicator"></span>
                                    <span class="custom-control-description">Dementia</span>
                                 </label>
                              </li>
                           </ul>
                        </div>
                     </div>
                  </div>

                  <p style="margin-top: 1rem;">Please remember that treatment regimes may change for comorbidities not
                     yet covered by this list.</p>
                  <button type="button" class="btn btn-secondary showalg not-ticked" data-dismiss="modal"
                     aria-label="Close">CLOSE</button>
                  <button type="button" class="btn btn-secondary showalg ticked" data-dismiss="modal"
                     aria-label="Show treatment algorithm">Show treatment algorithm</button>

               </div>
            </div>
         </div>
      </div>
      <!-- COMO MODAL ENDS -->
      
      <div id="feedbackSuccess" class="modal fade" tabindex="-1" role="dialog"
         aria-labelledby="ModalFeedbackConfirmedLabel" aria-hidden="true">
         <div class="modal-dialog modal-lg" role="document">
            <div class="modal-content pb-3">
               <div class="modal-body">
                  <div class="row">
                     <div class="col-md-12">
                        <h2>Thank you</h2>
                        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                           <span aria-hidden="true">×</span>
                        </button>
                     </div>
                  </div>
                  <div class="row">
                     <div class="col-md-12">
                        <p>Your feedback has been submitted successfully.</p>
                     </div>
                  </div>
               </div>
            </div>
         </div>
      </div>
      <div id="feedBackBtn">
         <p role="button"><a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"><span
                  class="material-icons"></span>&nbsp;FEEDBACK</a></p>
      </div>
   </div>
   <script type="text/javascript" src="../js/common.js"></script>
   <script type="text/javascript" src="../js/main.js"></script>        
      <script type="text/javascript" src="../js/comorbidities.js"></script>
   <script>
      // Code for the recently viewed topics suggestion, needs to be inlined to use the Java values
      /*<![CDATA[*/
      function dedupe(array) {
         var seen = {};
         return array.filter(function (item) {
            return seen.hasOwnProperty(item.id) ? false : (seen[item.id] = true);
         });
      }

      function TopicViewed(id, title, lang) {
         this.id = id;
         this.title = title;
         this.lang = lang;
      }
      jQuery(document).ready(function () {
         var topicId = 116;
         var topicLang = "en-gb";
         var topicTitle = "Pulmonary embolism";
         if (topicId) {

            var topicsViewed = [];
            if (localStorage.getItem("topicsViewed") !== null) {
               topicsViewed = JSON.parse(localStorage.topicsViewed);
            }

            topicsViewed.unshift(new TopicViewed(topicId, topicTitle,
            topicLang)); // Add new topics at the beginning
            topicsViewed = dedupe(topicsViewed); // Remove duplicates
            if (topicsViewed.length > 15) { // Drop if size is bigger than 15
               topicsViewed = topicsViewed.slice(0, 14);
            }

            localStorage.topicsViewed = JSON.stringify(topicsViewed);
         }
      });
      /*]]>*/
   </script>

</body>

</html>